<SEC-DOCUMENT>0001193125-25-185388.txt : 20250821
<SEC-HEADER>0001193125-25-185388.hdr.sgml : 20250821
<ACCEPTANCE-DATETIME>20250821170420
ACCESSION NUMBER:		0001193125-25-185388
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		21
CONFORMED PERIOD OF REPORT:	20250818
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250821
DATE AS OF CHANGE:		20250821

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolent Health, Inc.
		CENTRAL INDEX KEY:			0001628908
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT SERVICES [8741]
		ORGANIZATION NAME:           	07 Trade & Services
		EIN:				320454912
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37415
		FILM NUMBER:		251241530

	BUSINESS ADDRESS:	
		STREET 1:		1812 NORTH MOORE ST, SUITE 1705
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22209
		BUSINESS PHONE:		571-389-6000

	MAIL ADDRESS:	
		STREET 1:		1812 NORTH MOORE ST, SUITE 1705
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22209
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d72742d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:evh="http://www.evolenthealth.com/20250818" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-300">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-08-18_to_2025-08-18">0001628908</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="evh-20250818.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-08-18_to_2025-08-18"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-08-18</xbrli:startDate> <xbrli:endDate>2025-08-18</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-311">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-08-18_to_2025-08-18" format="ixt:datemonthdayyearen" id="ixv-312">August&#160;18, 2025</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-313">Evolent Health, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-08-18_to_2025-08-18" format="ixt-sec:stateprovnameen" id="ixv-314">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-315">001-37415</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-316">32-0454912</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction of</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">incorporation or organization)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-317">1812 North Moore Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-318">Suite 1705</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-319">Arlington</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-08-18_to_2025-08-18" format="ixt-sec:stateprovnameen" id="ixv-320">Virginia</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-321">22209</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices)(zip code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-322">(571)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-323">389-6000</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name, former address and former fiscal year, if changed since last report.)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-08-18_to_2025-08-18" format="ixt-sec:boolballotbox" id="ixv-324">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-08-18_to_2025-08-18" format="ixt-sec:boolballotbox" id="ixv-325">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-08-18_to_2025-08-18" format="ixt-sec:boolballotbox" id="ixv-326">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-08-18_to_2025-08-18" format="ixt-sec:boolballotbox" id="ixv-327">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-328">Class&#160;A Common Stock of Evolent Health, Inc., par value $0.01 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-329">EVH</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-08-18_to_2025-08-18" format="ixt-sec:exchnameen" id="ixv-330">New York Stock Exchange</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-08-18_to_2025-08-18" format="ixt-sec:boolballotbox" id="ixv-331">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry Into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Purchase Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;18, 2025, Evolent Health, Inc. (the &#8220;Company&#8221; or &#8220;we&#8221;) entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) with Oppenheimer&#160;&amp; Co. Inc., as representative of the several initial purchasers listed therein (collectively, the &#8220;Purchasers&#8221;), relating to the issuance and sale of $145.0&#160;million aggregate principal amount of its 4.50% convertible senior notes due 2031 (the &#8220;notes&#8221;) in a private placement (the &#8220;Private Placement&#8221;) to persons reasonably believed to be qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), pursuant to an exemption from the registration requirements of the Securities Act afforded by Section&#160;4(a)(2) of the Securities Act. The Company granted the Purchasers an option to purchase up to an additional $21.75&#160;million aggregate principal amount of notes, which the Purchasers exercised in full on August&#160;19, 2025. The closing of the Private Placement of the notes occurred on August&#160;21, 2025 and a total of $166.75&#160;million aggregate principal amount of notes were issued at an issue price of 100.00% of par for net proceeds of approximately $161.2&#160;million, after deducting fees and estimated expenses. On August&#160;21, 2025, using proceeds from the Private Placement plus available liquidity, the Company repurchased approximately $167.4&#160;million aggregate principal amount of its 1.50% convertible senior notes due 2025 for approximately $167.6&#160;million in cash in note repurchases entered into concurrently with the pricing of the Private Placement. The Company also repurchased approximately $40.0&#160;million of shares of the Company&#8217;s Class&#160;A common stock concurrently with the Private Placement in privately negotiated transactions effected with or through one of the Purchasers or its affiliate at a purchase price per share equal to the last reported sale price of the Company&#8217;s Class&#160;A common stock on August&#160;18, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchase Agreement contains customary representations, warranties and agreements of the Company and customary indemnification rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Purchase Agreement is qualified in its entirety by reference to the full text of the Purchase Agreement, a copy of which is filed as Exhibit 10.1 hereto and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Indenture </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes were issued under an Indenture (the &#8220;Indenture&#8221;) dated as of August&#160;21, 2025 between the Company and U.S. Bank Trust Company, National Association, as trustee (the &#8220;Trustee&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Indenture, interest on the notes is payable semiannually in arrears on February&#160;15 and August&#160;15 of each year, beginning on February&#160;15, 2026, at a rate equal to 4.50% per annum. The notes will mature on August&#160;15, 2031, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes will be convertible, upon satisfaction of certain conditions, at an initial conversion rate of 73.9098 shares of the Company&#8217;s Class&#160;A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $13.53 per share of the Company&#8217;s Class&#160;A common stock. The initial conversion price represents a premium of approximately 50.0% over the closing price of the Company&#8217;s Class&#160;A common stock on the New York Stock Exchange on August&#160;18, 2025. In the aggregate, the notes are initially convertible into 18,486,688 shares of the Company&#8217;s Class&#160;A common stock (including the maximum number of any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of termination of conversion rights as described in the Indenture). The conversion rate may be adjusted under certain </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company&#8217;s Class&#160;A common stock or a combination of cash and shares of the Company&#8217;s Class&#160;A common stock, at the Company&#8217;s election. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to satisfaction of certain conditions and subject to the Company&#8217;s ability to terminate the conversion rights of holders of the notes on or after August&#160;20, 2026 as described below, the notes will be convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding the maturity date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On or after August&#160;20, 2026, the Company may terminate the conversion rights of the notes if (i)&#160;for any conversion rights termination date (as defined in the Indenture) occurring on or after August&#160;20, 2026 and prior to, but not including, August&#160;21, 2028, the last reported sale price of the Company&#8217;s Class&#160;A common stock has been at least 150% of the conversion price for at least 20 trading days during the 30 consecutive trading day period (including the last trading day of such period) prior to the Company&#8217;s delivery of notice of such termination of conversion rights or (ii)&#160;for any conversion rights termination date occurring on or after August&#160;21, 2028, the last reported sale price of the Company&#8217;s Class&#160;A common stock has been at least 130% of the conversion price for at least 20 days during the 30 consecutive trading day period (including the last trading day of such period) prior to the Company&#8217;s delivery of notice of such termination of conversion rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of the notes may require the Company to repurchase their notes upon the occurrence of a fundamental change at a price equal to 100% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the notes unless and until holders&#8217; conversion rights have been terminated at its election. However, if holders&#8217; conversion rights have been terminated, the Company may redeem for cash all or a portion of the notes, at its option, at a redemption price equal to 100% of the principal amount of the notes being redeemed, plus any accrued and unpaid interest to, but excluding, the redemption date. No &#8220;sinking fund&#8221; is provided for the notes. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Indenture and the notes does not purport to be complete and is qualified in its entirety by reference to the full text of the Indenture and the form of note, copies of which are filed as Exhibit 4.1 and Exhibit 4.2 hereto, respectively. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;2.03</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Creation of a Direct Financial Obligation. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth in Item 1.01 of this report is incorporated by reference into this Item 2.03. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;3.02</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Unregistered Sales of Equity Securities. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth under Item 1.01 of this report is incorporated by reference into this Item 3.02. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br/>No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d72742dex41.htm">Indenture, dated as of August&#160;21, 2025, between Evolent Health, Inc. and U.S. Bank Trust Company, National Association, as trustee. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;4.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d72742dex41.htm">Form of 4.50% Convertible Senior Notes due 2031 (included as Exhibit A to Exhibit 4.1) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d72742dex101.htm">Purchase Agreement, dated August&#160;18, 2025, by and between Evolent Health, Inc. and Oppenheimer&#160;&amp; Co. Inc. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The cover page from this Current Report on Form <span style="white-space:nowrap">8-K,</span> formatted as Inline XBRL</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:44%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">EVOLENT HEALTH, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: August&#160;21, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan D. Weinberg</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Jonathan D. Weinberg</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">General Counsel and Secretary</span></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>d72742dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EVOLENT HEALTH, INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AND </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">U.S. BANK TRUST COMPANY,
NATIONAL ASSOCIATION, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">as Trustee </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">INDENTURE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated as of August 21,
2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4.50% Convertible Senior Notes due 2031 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">D<SMALL>EFINITIONS</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Definitions</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>References to Interest</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">I<SMALL>SSUE</SMALL>, D<SMALL>ESCRIPTION</SMALL>,
E<SMALL>XECUTION</SMALL>, R<SMALL>EGISTRATION</SMALL> <SMALL>AND</SMALL> E<SMALL>XCHANGE</SMALL> <SMALL>OF</SMALL> N<SMALL>OTES</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Designation and Amount</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Form of Notes</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Date and Denomination of Notes; Payments of Interest and Defaulted Amounts</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Execution, Authentication and Delivery of Notes</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.05.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Exchange and Registration of Transfer of Notes; Restrictions on Transfer;
Depositary</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.06.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Mutilated, Destroyed, Lost or Stolen Notes</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.07.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Temporary Notes</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.08.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Cancellation of Notes Paid, Converted, Etc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.09.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>CUSIP Numbers</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Additional Notes; Repurchases</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>ATISFACTION</SMALL> <SMALL>AND</SMALL>
D<SMALL>ISCHARGE</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Satisfaction and Discharge</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">P<SMALL>ARTICULAR</SMALL> C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL>
<SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Payment of Principal and Interest</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Maintenance of Office or Agency</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Appointments to Fill Vacancies in Trustee&#8217;s Office</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Provisions as to Paying Agent</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.05.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>[Intentionally Omitted]</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.06.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Rule 144A Information Requirement and Annual Reports</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.07.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Stay, Extension and Usury Laws</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.08.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Compliance Certificate; Statements as to Defaults</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.09.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Further Instruments and Acts</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">L<SMALL>ISTS</SMALL> <SMALL>OF</SMALL> H<SMALL>OLDERS</SMALL>
<SMALL>AND</SMALL> R<SMALL>EPORTS</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL> <SMALL>AND</SMALL> <SMALL>THE</SMALL> T<SMALL>RUSTEE</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.01.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Lists of Holders</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.02.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Preservation and Disclosure of Lists</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">D<SMALL>EFAULTS</SMALL> <SMALL>AND</SMALL>
R<SMALL>EMEDIES</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;6.01.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Events of Default</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;6.02.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Acceleration; Rescission and Annulment</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;6.03.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Additional Interest</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;6.04.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Payments of Notes on Default; Suit Therefor</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;6.05.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Application of Monies Collected by Trustee</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;6.06.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Proceedings by Holders</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;6.07.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Proceedings by Trustee</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;6.08.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Remedies Cumulative and Continuing</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;6.09.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Direction of Proceedings and Waiver of Defaults by Majority of Holders</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;6.10.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Notice of Defaults</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;6.11.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Undertaking to Pay Costs</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">C<SMALL>ONCERNING</SMALL> <SMALL>THE</SMALL>
T<SMALL>RUSTEE</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;7.01.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Duties and Responsibilities of Trustee</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;7.02.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Reliance on Documents, Opinions, Etc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;7.03.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>No Responsibility for Recitals, Etc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;7.04.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Trustee, Paying Agents, Conversion Agents, Bid Solicitation Agent or Note Registrar May Own
Notes</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;7.05.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Monies and Shares of Class&nbsp;A Common Stock to Be Held in Trust</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;7.06.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Compensation and Expenses of Trustee</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;7.07.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Officer&#8217;s Certificate as Evidence</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;7.08.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Eligibility of Trustee</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;7.09.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Resignation or Removal of Trustee</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;7.10.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Acceptance by Successor Trustee</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;7.11.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Succession by Merger, Etc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;7.12.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Trustee&#8217;s Application for Instructions from the Company</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">C<SMALL>ONCERNING</SMALL> <SMALL>THE</SMALL>
H<SMALL>OLDERS</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;8.01.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Action by Holders</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;8.02.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Proof of Execution by Holders</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;8.03.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Persons Who Are Deemed Absolute Owners</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;8.04.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Company-Owned Notes Disregarded</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;8.05.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Revocation of Consents; Future Holders Bound</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">H<SMALL>OLDERS</SMALL>&#8217; M<SMALL>EETINGS</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;9.01.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Purpose of Meetings</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;9.02.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Call of Meetings by Trustee</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;9.03.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Call of Meetings by Company or Holders</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;9.04.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Qualifications for Voting</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;9.05.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Regulations</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;9.06.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Voting</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;9.07.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>No Delay of Rights by Meeting</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>UPPLEMENTAL</SMALL> I<SMALL>NDENTURES</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;10.01.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Supplemental Indentures Without Consent of Holders</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;10.02.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Supplemental Indentures with Consent of Holders</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;10.03.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Effect of Supplemental Indentures</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;10.04.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Notation on Notes</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;10.05.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Evidence of Compliance of Supplemental Indenture to Be Furnished Trustee</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">C<SMALL>ONSOLIDATION</SMALL>, M<SMALL>ERGER</SMALL>,
S<SMALL>ALE</SMALL>, C<SMALL>ONVEYANCE</SMALL> <SMALL>AND</SMALL> L<SMALL>EASE</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;11.01.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Company May Consolidate, Etc. on Certain Terms</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;11.02.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Successor Corporation to Be Substituted</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;11.03.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Opinion of Counsel to Be Given to Trustee</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">I<SMALL>MMUNITY</SMALL> <SMALL>OF</SMALL>
I<SMALL>NCORPORATORS</SMALL>, S<SMALL>TOCKHOLDERS</SMALL>, O<SMALL>FFICERS</SMALL> <SMALL>AND</SMALL> D<SMALL>IRECTORS</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;12.01.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Indenture and Notes Solely Corporate Obligations</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[I<SMALL>NTENTIONALLY</SMALL> O<SMALL>MITTED</SMALL>]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">C<SMALL>ONVERSION</SMALL> <SMALL>OF</SMALL>
N<SMALL>OTES</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;14.01.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Conversion Privilege</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;14.02.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Conversion Procedure; Settlement Upon Conversion</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;14.03.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Increased Conversion Rate Applicable to Certain Notes Surrendered in Connection with Make-Whole
Fundamental Changes or During a Conversion Rights Termination Period</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;14.04.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Adjustment of Conversion Rate</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;14.05.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Adjustments of Prices</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;14.06.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Shares to Be Fully Paid</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;14.07.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Effect of Recapitalizations, Reclassifications and Changes of the Class&nbsp;A Common
Stock</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;14.08.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Certain Covenants</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;14.09.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Responsibility of Trustee</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;14.10.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Notice to Holders Prior to Certain Actions</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;14.11.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Stockholder Rights Plans</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;14.12.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Limitation on Beneficial Ownership</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">R<SMALL>EPURCHASE</SMALL> <SMALL>OF</SMALL> N<SMALL>OTES</SMALL>
<SMALL>AT</SMALL> O<SMALL>PTION</SMALL> <SMALL>OF</SMALL> H<SMALL>OLDERS</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;15.01.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[<I>Intentionally Omitted</I>]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;15.02.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Repurchase at Option of Holders Upon a Fundamental Change</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;15.03.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Withdrawal of Fundamental Change Repurchase Notice</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;15.04.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Deposit of Fundamental Change Repurchase Price</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;15.05.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Covenant to Comply with Applicable Laws Upon Repurchase of Notes</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">O<SMALL>PTIONAL</SMALL> R<SMALL>EDEMPTION</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;16.01.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Optional Redemption</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;16.02.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Notice of Optional Redemption; Selection of Notes</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;16.03.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Payment of Notes Called for Redemption</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;16.04.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Restrictions on Redemption</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 17</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">M<SMALL>ISCELLANEOUS</SMALL> P<SMALL>ROVISIONS</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;17.01.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Provisions Binding on Company&#8217;s Successors</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;17.02.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Official Acts by Successor Corporation</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;17.03.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Addresses for Notices, Etc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;17.04.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Governing Law; Jurisdiction</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;17.05.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Evidence of Compliance with Conditions Precedent; Certificates and Opinions of Counsel to
Trustee</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;17.06.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Legal Holidays</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;17.07.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>No Security Interest Created</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;17.08.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Benefits of Indenture</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;17.09.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Table of Contents, Headings, Etc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;17.10.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Authenticating Agent</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;17.11.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Execution in Counterparts</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;17.12.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Severability</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;17.13.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Waiver of Jury Trial</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;17.14.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Force Majeure</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;17.15.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Calculations</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;17.16.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>USA PATRIOT Act</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-1</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">v </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">INDENTURE dated as of August 21, 2025 between EVOLENT HEALTH, INC., a Delaware corporation,
as issuer (the &#8220;<B>Company</B>,&#8221; as more fully set forth in Section&nbsp;1.01) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking association, as trustee (the &#8220;<B>Trustee</B>,&#8221; as more fully set forth in
Section&nbsp;1.01). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">W I T N E S S E T H: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, for its lawful corporate purposes, the Company has duly authorized the issuance of its 4.50% Convertible Senior Notes due 2031 (the
&#8220;<B>Notes</B>&#8221;), initially in an aggregate principal amount not to exceed $166,750,000, and in order to provide the terms and conditions upon which the Notes are to be authenticated, issued and delivered, the Company has duly authorized
the execution and delivery of this Indenture; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Form of Note, the certificate of authentication to be borne by each Note,
the Form of Notice of Conversion, the Form of Fundamental Change Repurchase Notice and the Form of Assignment and Transfer to be borne by the Notes are to be substantially in the forms hereinafter provided; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, all acts and things necessary to make the Notes, when executed by the Company and authenticated and delivered by the Trustee or a
duly authorized authenticating agent, as in this Indenture provided, the valid, binding and legal obligations of the Company, and this Indenture a valid agreement according to its terms, have been done and performed, and the execution of this
Indenture and the issuance hereunder of the Notes have in all respects been duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, THIS INDENTURE WITNESSETH:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">That in order to declare the terms and conditions upon which the Notes are, and are to be, authenticated, issued and delivered, and in
consideration of the premises and of the purchase and acceptance of the Notes by the Holders thereof, the Company covenants and agrees with the Trustee for the benefit of each other and for the equal and proportionate benefit of the respective
Holders from time to time of the Notes (except as otherwise provided below), as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 1 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D<SMALL>EFINITIONS</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.01<I>. Definitions</I><I>.</I> The terms defined in this Section&nbsp;1.01 (except as herein otherwise expressly provided or
unless the context otherwise requires) for all purposes of this Indenture and of any indenture supplemental hereto shall have the respective meanings specified in this Section&nbsp;1.01. The words &#8220;herein,&#8221; &#8220;hereof,&#8221;
&#8220;hereunder&#8221; and words of similar import refer to this Indenture as a whole and not to any particular Article, Section or other subdivision. The word &#8220;or&#8221; shall not be construed as being exclusive. The terms defined in this
Article include the plural as well as the singular. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Additional Interest</B>&#8221; means all amounts, if any, payable pursuant
to Section&nbsp;4.06(d), Section&nbsp;4.06(e) and Section&nbsp;6.03, as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Additional Shares</B>&#8221; shall have the meaning specified in
Section&nbsp;14.03(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Affiliate</B>&#8221; of any specified Person means any other Person directly or indirectly controlling
or controlled by or under direct or indirect common control with such specified Person. For the purposes of this definition, &#8220;control,&#8221; when used with respect to any specified Person means the power to direct or cause the direction of
the management and policies of such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise; and the terms &#8220;controlling&#8221; and &#8220;controlled&#8221; have meanings correlative to the
foregoing. Notwithstanding anything to the contrary herein, the determination of whether one Person is an &#8220;<B>Affiliate</B>&#8221; of another Person for purposes of this Indenture shall be made based on the facts at the time such determination
is made or required to be made, as the case may be, hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Beneficial Owner</B>&#8221; shall have the meaning specified in
Section&nbsp;14.12(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Beneficial Ownership Limit</B>&#8221; shall have the meaning specified in Section&nbsp;14.12(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Bid Solicitation Agent</B>&#8221; means the Company or the Person appointed by the Company to solicit bids for the Trading Price of
the Notes in accordance with Section&nbsp;14.01(b)(i). The Company shall initially act as the Bid Solicitation Agent. The Company may, however, appoint another person as the Bid Solicitation Agent without prior notice to the Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Board of Directors</B>&#8221; means the board of directors of the Company or a committee of such board duly authorized to act for it
hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Board Resolution</B>&#8221; means a copy of a resolution certified by the Secretary or an Assistant Secretary of the
Company to have been duly adopted by the Board of Directors or pursuant to authorization by the Board of Directors, and to be in full force and effect on the date of such certification, and delivered to the Trustee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Business Day</B>&#8221; means, with respect to any Note, any day other than a Saturday, a Sunday or a day on which the Federal
Reserve Bank of New York is authorized or required by law or executive order to close or be closed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Capital Stock</B>&#8221;
means, for any entity, any and all shares, interests, rights to purchase, warrants, options, participations or other equivalents of or interests in (however designated) stock issued by that entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Cash Settlement</B>&#8221; shall have the meaning specified in Section&nbsp;14.02(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Class</B><B></B><B>&nbsp;A</B> <B>Common Stock</B>&#8221; means the Class&nbsp;A common stock of the Company, par value $0.01 per
share, subject to Section&nbsp;14.07. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Class</B><B></B><B>&nbsp;B Common Stock</B>&#8221; means the Class&nbsp;B common stock of
the Company, par value $0.01 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Class</B><B></B><B>&nbsp;B Common Units</B>&#8221; means the Class&nbsp;B common units
of Evolent Health LLC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Clause A Distribution</B>&#8221; shall have the meaning specified in
Section&nbsp;14.04(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Clause B Distribution</B>&#8221; shall have the meaning specified in Section&nbsp;14.04(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Clause C Distribution</B>&#8221; shall have the meaning specified in Section&nbsp;14.04(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>close of business</B>&#8221; means 5:00 p.m. (New York City time). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Combination Settlement</B>&#8221; shall have the meaning specified in Section&nbsp;14.02(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Commission</B>&#8221; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Common Equity</B>&#8221; of any Person means Capital Stock of such Person that is generally entitled (a)&nbsp;to vote in the
election of directors of such Person or (b)&nbsp;if such Person is not a corporation, to vote or otherwise participate in the selection of the governing body, partners, managers or others that will control the management or policies of such Person.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Company</B>&#8221; shall have the meaning specified in the first paragraph of this Indenture, and subject to the provisions of
Article 11, shall include its successors and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Company Order</B>&#8221; means a written order of the Company, signed by
(a)&nbsp;the Company&#8217;s Chief Executive Officer, Chief Financial Officer, President, Controller, Executive or Senior Vice President or any Vice President (whether or not designated by a number or numbers or word or words added before or after
the title &#8220;Vice President&#8221;) and (b)&nbsp;any such other Officer designated in clause (a)&nbsp;of this definition or the Company&#8217;s Treasurer or Assistant Treasurer or Secretary or any Assistant Secretary, and delivered to the
Trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Conversion Agent</B>&#8221; shall have the meaning specified in Section&nbsp;4.02. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Conversion Date</B>&#8221; shall have the meaning specified in Section&nbsp;14.02(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Conversion Obligation</B>&#8221; shall have the meaning specified in Section&nbsp;14.01. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Conversion Price</B>&#8221; means as of any time, $1,000, <I>divided by</I> the Conversion Rate as of such time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Conversion Rate</B>&#8221; shall have the meaning specified in Section&nbsp;14.01. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Conversion Rights Termination Date</B>&#8221; shall have the meaning specified in Section&nbsp;14.01(c)(ii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Conversion Rights Termination Period</B>&#8221; shall have the meaning specified in Section&nbsp;14.01(b)(v). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Conversion Rights Termination Price Trigger</B>&#8221; means, for any Trading Day and in respect of any Conversion Rights
Termination Date, (a)&nbsp;if the Conversion Rights Termination Date is on or after August&nbsp;20, 2026 and prior to, but not including, August&nbsp;21, 2028, 150% of the Conversion Price then in effect on such Trading Day and (b)&nbsp;if the
Conversion Rights Termination Date is on or after August&nbsp;21, 2028, 130% of the Conversion Price then in effect on such Trading Day. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Corporate Event</B>&#8221; shall have the meaning specified in
Section&nbsp;14.01(b)(iii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Corporate Trust Office</B>&#8221; means the principal office of the Trustee at which at any time
its corporate trust business shall be administered, which office at the date hereof is located at 1051 East Cary Street, Suite 600, Richmond, Virginia 23219, Attn: Global Corporate Trust Services, or such other address as the Trustee may designate
from time to time by notice to the Holders and the Company, or the principal corporate trust office of any successor trustee (or such other address as such successor trustee may designate from time to time by notice to the Holders and the Company).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Custodian</B>&#8221; means the Trustee, as custodian for The Depository Trust Company, with respect to the Global Notes, or any
successor entity thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Daily Conversion Value</B>&#8221; means, for each of the 40 consecutive Trading Days during the
relevant Observation Period, 2.5% of the product of (a)&nbsp;the Conversion Rate on such Trading Day and (b)&nbsp;the Daily VWAP for such Trading Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Daily Measurement Value</B>&#8221;<B> </B>means the Specified Dollar Amount (if any)<I> divided by</I> 40. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Daily Settlement Amount</B>&#8221; for each of the 40 consecutive Trading Days during the relevant Observation Period, shall consist
of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) cash in an amount equal to the lesser of (i)&nbsp;the Daily Measurement Value and (ii)&nbsp;the Daily Conversion Value on such
Trading Day; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) if the Daily Conversion Value on such Trading Day exceeds the Daily Measurement Value, a number of shares of
Class&nbsp;A Common Stock equal to (i)&nbsp;the difference between the Daily Conversion Value and the Daily Measurement Value, <I>divided by</I>, (ii)&nbsp;the Daily VWAP for such Trading Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Daily VWAP</B>&#8221; means, for each of the 40 consecutive Trading Days during the relevant Observation Period, the per share
volume-weighted average price as displayed under the heading &#8220;Bloomberg VWAP&#8221; on Bloomberg page &#8220;EVH &lt;equity&gt; AQR&#8221; (or its equivalent successor if such page is not available) in respect of the period from the scheduled
open of trading until the scheduled close of trading of the primary trading session on such Trading Day (or if such volume-weighted average price is unavailable, the market value of one share of Class&nbsp;A Common Stock on such Trading Day
determined, using a volume-weighted average method, by a nationally recognized independent investment banking firm retained by the Company for this purpose). The &#8220;Daily VWAP&#8221; shall be determined without regard to after-hours trading or
any other trading outside of the regular trading session trading hours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Default</B>&#8221; means any event that is, or after
notice or passage of time, or both, would be, an Event of Default. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Default Settlement Method</B>&#8221; means, initially, (i)&nbsp;in the case of any
conversion that occurs during the Conversion Rights Termination Period pursuant to Section&nbsp;14.01(b)(v), Physical Settlement, and (ii)&nbsp;in all other cases, Combination Settlement with a Specified Dollar Amount of $1,000 per $1,000 principal
amount of Notes; <I>provided</I> that the Company may, from time to time, change the Default Settlement Method as set forth in clause (ii)&nbsp;herein by sending notice of the new Default Settlement Method pursuant to clause (ii)&nbsp;herein to the
Holders, the Trustee and the Conversion Agent (if other than the Trustee) prior to May&nbsp;15, 2031, all in accordance with, and subject to, the last paragraph of Section&nbsp;14.02(a)(iii). For the avoidance of doubt, the Company is not permitted
to change the Default Settlement Method set forth in clause (i)&nbsp;herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Defaulted Amounts</B>&#8221; means any amounts on
any Note (including, without limitation, the Redemption Price, the Fundamental Change Repurchase Price, principal and interest) that are payable but are not punctually paid or duly provided for. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Depositary</B>&#8221; means, with respect to each Global Note, the Person specified in Section&nbsp;2.05(c) as the Depositary with
respect to such Notes, until a successor shall have been appointed and become such pursuant to the applicable provisions of this Indenture, and thereafter, &#8220;<B>Depositary</B>&#8221; shall mean or include such successor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Distributed Property</B>&#8221; shall have the meaning specified in Section&nbsp;14.04(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Effective Date</B>&#8221; shall have the meaning specified in Section&nbsp;14.03(c), except that, as used in Section&nbsp;14.04 and
Section&nbsp;14.05, &#8220;<B>Effective Date</B>&#8221; means the first date on which shares of the Class&nbsp;A Common Stock trade on the applicable exchange or in the applicable market, regular way, reflecting the relevant share split or share
combination, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Event of Default</B>&#8221; shall have the meaning specified in Section&nbsp;6.01. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Exchange Act</B>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date</B>&#8221; means the first date on which shares of the Class&nbsp;A
Common Stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive the issuance, dividend or distribution in question, from the Company or, if applicable, from the seller of Class&nbsp;A Common Stock
on such exchange or market (in the form of due bills or otherwise) as determined by such exchange or market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Form of Assignment
and Transfer</B>&#8221; means the &#8220;Form of Assignment and Transfer&#8221; attached as Attachment 3 to the Form of Note attached hereto as Exhibit A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Form of Fundamental Change Repurchase Notice</B>&#8221; means the &#8220;Form of Fundamental Change Repurchase Notice&#8221;
attached as Attachment 2 to the Form of Note attached hereto as Exhibit A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Form of Note</B>&#8221; means the &#8220;Form of
Note&#8221; attached hereto as Exhibit A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Form of Notice of Conversion</B>&#8221; means the &#8220;Form of Notice of
Conversion&#8221; attached as Attachment 1 to the Form of Note attached hereto as Exhibit A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#8220;<B>Fundamental Change</B>&#8221;
shall be deemed to have occurred at the time after the Notes are originally issued if any of the following occurs: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
except as described in clause (b)&nbsp;below, (1) a &#8220;person&#8221; or &#8220;group&#8221; within the meaning of Section&nbsp;13(d) of the Exchange Act, other than the Company, its Wholly Owned Subsidiaries and the employee benefit plans of the
Company and its Wholly Owned Subsidiaries, has become the direct or indirect &#8220;beneficial owner,&#8221; as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act, of the Company&#8217;s Common Equity representing
more than 50% of the voting power of the Company&#8217;s Common Equity; <I>provided</I>,<I> however</I>, that a &#8220;person&#8221; or &#8220;group&#8221; shall not be deemed a beneficial owner of, or to own beneficially, (x)&nbsp;any securities
tendered pursuant to a tender or exchange offer made by or on behalf of such &#8220;person&#8221; or &#8220;group&#8221; pursuant to a Schedule TO (or any successor form) until such tendered securities are accepted for purchase or exchange
thereunder or (y)&nbsp;any securities to the extent such beneficial ownership (i)&nbsp;arises solely as a result of a revocable proxy delivered to such &#8220;person&#8221; or &#8220;group&#8221; by a shareholder that is not, for the avoidance of
doubt, a member of such &#8220;group&#8221; in response to a proxy or consent solicitation made pursuant to, and disclosed in accordance with, the applicable rules and regulations under the Exchange Act, and (ii)&nbsp;is not also then reportable on
Schedule 13D or Schedule 13G (or any successor schedule) under the Exchange Act; and (2)&nbsp;such &#8220;person&#8221; or &#8220;group&#8221; files, or the Company files, a Schedule TO or any schedule, form or report under the Exchange Act
disclosing that such an event described in the immediately preceding clause (1)&nbsp;has occurred; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the consummation of
(A)&nbsp;any recapitalization, reclassification or change of the Class&nbsp;A Common Stock (other than changes resulting from a subdivision or combination) as a result of which the Class&nbsp;A Common Stock would be converted into, or exchanged for,
stock, other securities, other property or assets; (B)&nbsp;any share exchange, consolidation or merger of the Company pursuant to which the Class&nbsp;A Common Stock will be converted into cash, securities or other property or assets; or
(C)&nbsp;any sale, lease or other transfer in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its Subsidiaries, taken as a whole, to any Person other than one of the
Company&#8217;s Subsidiaries; <I>provided, however</I>, that a transaction described in clause (B)&nbsp;in which the holders of all classes of the Company&#8217;s Common Equity immediately prior to such transaction hold, directly or indirectly, more
than 50% of the voting power of all classes of Common Equity of the continuing or surviving corporation or transferee or the parent thereof immediately after such transaction in substantially the same proportions as such holders held, directly or
indirectly, immediately prior to such transaction shall not be a Fundamental Change pursuant to this clause (b); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the
stockholders of the Company approve any plan or proposal for the liquidation or dissolution of the Company; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) the Class&nbsp;A Common Stock (or other common stock or American
depositary receipts underlying the Notes) ceases to be listed or quoted on any of The New York Stock Exchange, The Nasdaq Global Select Market or The Nasdaq Global Market (or any of their respective successors); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I>, <I>however</I>, that a transaction or transactions described in clause (b)&nbsp;above shall not constitute a Fundamental Change, if at least
90% of the consideration received or to be received by the holders of the Class&nbsp;A Common Stock, excluding cash payments for fractional shares, in connection with such transaction or transactions consists of shares of common stock or American
depositary receipts in respect thereof that are listed or quoted on any of The New York Stock Exchange, The Nasdaq Global Select Market or The Nasdaq Global Market (or any of their respective successors) or will be so listed or quoted when issued or
exchanged in connection with such transaction or transactions and as a result of such transaction or transactions the Notes become convertible into such consideration, excluding cash payments for fractional shares (subject to the provisions of
Section&nbsp;14.02(a)). For the avoidance of doubt, if a transaction constitutes a Fundamental Change pursuant to both clause (a)&nbsp;and clause (b)&nbsp;above, such transaction shall be treated as a Fundamental Change solely pursuant to clause
(b)&nbsp;above for purposes of the exclusion described in this paragraph. If any transaction in which the Class&nbsp;A Common Stock is replaced by the securities of another entity occurs, following completion of any related Make-Whole Fundamental
Change Period (or, in the case of a transaction that would have been a Fundamental Change or a Make-Whole Fundamental Change but for the proviso immediately following clause (d)&nbsp;of this definition, following the effective date of such
transaction) references to the Company in this definition shall instead be references to such other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Fundamental Change
Company Notice</B>&#8221; shall have the meaning specified in Section&nbsp;15.02(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Fundamental Change Repurchase
Date</B>&#8221; shall have the meaning specified in Section&nbsp;15.02(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Fundamental Change Repurchase Notice</B>&#8221;
shall have the meaning specified in Section&nbsp;15.02(b)(i). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Fundamental Change Repurchase Price</B>&#8221; shall have the
meaning specified in Section&nbsp;15.02(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Global Note</B>&#8221; shall have the meaning specified in Section&nbsp;2.05(b).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Holder</B>,&#8221; as applied to any Note, or other similar terms (but excluding the term &#8220;beneficial holder&#8221;),
means any Person in whose name at the time a particular Note is registered on the Note Register. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Indenture</B>&#8221; means
this instrument as originally executed or, if amended or supplemented as herein provided, as so amended or supplemented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Interest Payment Date</B>&#8221; means each February&nbsp;15 and August&nbsp;15 of each year, beginning on February&nbsp;15, 2026.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Last Reported Sale Price</B>&#8221; of the Class&nbsp;A Common Stock (or other
security for which a closing sale price must be determined) on any date means the closing sale price per share (or if no closing sale price is reported, the average of the bid and ask prices or, if more than one in either case, the average of the
average bid and the average ask prices) on that date as reported in composite transactions for the principal U.S. national or regional securities exchange on which the Class&nbsp;A Common Stock (or such other security) is traded. If the Class&nbsp;A
Common Stock (or such other security) is not listed for trading on a U.S. national or regional securities exchange on the relevant date, the &#8220;<B>Last Reported Sale Price</B>&#8221; shall be the last quoted bid price for the Class&nbsp;A Common
Stock (or such other security) in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the relevant date as reported by OTC Markets Group Inc. or a similar organization. If the Class&nbsp;A
Common Stock (or such other security) is not so quoted, the &#8220;<B>Last Reported Sale Price</B>&#8221; shall be the average of the <FONT STYLE="white-space:nowrap">mid-point</FONT> of the last bid and ask prices for the Class&nbsp;A Common Stock
(or such other security) on the relevant date from a nationally recognized independent investment banking firm selected by the Company for this purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Make-Whole Fundamental Change</B>&#8221; means any transaction or event that constitutes a Fundamental Change (as defined above and
determined after giving effect to any exceptions to or exclusions from such definition, but without regard to the <I>proviso</I> in clause (b)&nbsp;of the definition thereof). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Make-Whole Fundamental Change Period</B>&#8221; shall have the meaning specified in Section&nbsp;14.03(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Market Disruption Event</B>&#8221; means, for the purposes of determining amounts due upon conversion (a)&nbsp;a failure by the
primary U.S. national or regional securities exchange or market on which the Class&nbsp;A Common Stock is listed or admitted for trading to open for trading during its regular trading session or (b)&nbsp;the occurrence or existence prior to 1:00
p.m., New York City time, on any Scheduled Trading Day for the Class&nbsp;A Common Stock for more than one half-hour period in the aggregate during regular trading hours of any suspension or limitation imposed on trading (by reason of movements in
price exceeding limits permitted by the relevant stock exchange or otherwise) in the Class&nbsp;A Common Stock or in any options contracts or futures contracts relating to the Class&nbsp;A Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Maturity Date</B>&#8221; means August&nbsp;15, 2031. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Measurement Period</B>&#8221; shall have the meaning specified in Section&nbsp;14.01(b)(i). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Note</B>&#8221; or &#8220;<B>Notes</B>&#8221; shall have the meaning specified in the first paragraph of the recitals of this
Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Note Register</B>&#8221; shall have the meaning specified in Section&nbsp;2.05(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Note Registrar</B>&#8221; shall have the meaning specified in Section&nbsp;2.05(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Notice of Conversion</B>&#8221; shall have the meaning specified in Section&nbsp;14.02(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Notice of Redemption</B>&#8221; shall have the meaning specified in Section&nbsp;16.02(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Notice of Termination of Conversion Rights</B>&#8221; shall have the meaning
specified in Section&nbsp;14.01(c)(ii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Observation Period</B>&#8221; with respect to any Note surrendered for conversion
means: (i)&nbsp;if the relevant Conversion Date occurs prior to May&nbsp;15, 2031, the 40 consecutive Trading Day period beginning on, and including, the second Trading Day immediately succeeding such Conversion Date and (ii)&nbsp;if the relevant
Conversion Date occurs on or after May&nbsp;15, 2031, the 40 consecutive Trading Days beginning on, and including, the 41st Scheduled Trading Day immediately preceding the Maturity Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Offering Memorandum</B>&#8221; means the preliminary offering memorandum dated August&nbsp;18, 2025, as supplemented by the related
pricing term sheet dated August&nbsp;18, 2025, relating to the offering and sale of the Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Officer</B>&#8221; means, with
respect to the Company, the President, the Chief Executive Officer, the Treasurer, the Secretary, any Executive or Senior Vice President or any Vice President (whether or not designated by a number or numbers or word or words added before or after
the title &#8220;Vice President&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Officer&#8217;s Certificate</B>,&#8221; when used with respect to the Company, means a
certificate that is delivered to the Trustee and that is signed by one Officer of the Company. Each such certificate shall include the statements provided for in Section&nbsp;17.05 if and to the extent required by the provisions of such Section.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>open of business</B>&#8221; means 9:00 a.m. (New York City time). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Opinion of Counsel</B>&#8221; means an opinion in writing signed by legal counsel, who may be an employee of or counsel to the
Company, or other counsel acceptable to the Trustee, that is delivered to the Trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Optional Redemption</B>&#8221; shall
have the meaning specified in Section&nbsp;16.01. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>outstanding</B>,&#8221; when used with reference to Notes, shall, subject to
the provisions of Section&nbsp;8.04, mean, as of any particular time, all Notes authenticated and delivered by the Trustee under this Indenture, except: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Notes theretofore canceled by the Trustee or accepted by the Trustee for cancellation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notes, or portions thereof, that have become due and payable and in respect of which monies in the necessary amount shall
have been deposited in trust with the Trustee or with any Paying Agent (other than the Company) or shall have been set aside and segregated in trust by the Company (if the Company shall act as its own Paying Agent); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Notes that have been paid pursuant to Section&nbsp;2.06 or Notes in lieu of which, or in substitution for which, other
Notes shall have been authenticated and delivered pursuant to the terms of Section&nbsp;2.06 unless proof satisfactory to the Trustee is presented that any such Notes are held by protected purchasers in due course; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Notes converted pursuant to Article 14 and required to be cancelled
pursuant to Section&nbsp;2.08; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Notes redeemed pursuant to Article 16; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Notes repurchased by the Company pursuant to the penultimate sentence of Section&nbsp;2.10 and required to be canceled
pursuant to the last sentence thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Paying Agent</B>&#8221; shall have the meaning specified in Section&nbsp;4.02. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Person</B>&#8221; means an individual, a corporation, a limited liability company, an association, a partnership, a joint venture, a
joint stock company, a trust, an unincorporated organization or a government or an agency or a political subdivision thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Physical Notes</B>&#8221; means permanent certificated Notes in registered form issued in denominations of $1,000 principal amount
and integral multiples thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Physical Settlement</B>&#8221; shall have the meaning specified in Section&nbsp;14.02(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Predecessor Note</B>&#8221; of any particular Note means every previous Note evidencing all or a portion of the same debt as that
evidenced by such particular Note; and, for the purposes of this definition, any Note authenticated and delivered under Section&nbsp;2.06 in lieu of or in exchange for a mutilated, lost, destroyed or stolen Note shall be deemed to evidence the same
debt as the mutilated, lost, destroyed or stolen Note that it replaces. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Record Date</B>&#8221; means, with respect to any
dividend, distribution or other transaction or event in which the holders of the Class&nbsp;A Common Stock (or other applicable security) have the right to receive any cash, securities or other property or in which the Class&nbsp;A Common Stock (or
such other security) is exchanged for or converted into any combination of cash, securities or other property, the date fixed for determination of holders of the Class&nbsp;A Common Stock (or such other security) entitled to receive such cash,
securities or other property (whether such date is fixed by the Board of Directors, by statute, by contract or otherwise). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Redemption Date</B>&#8221; shall have the meaning specified in Section&nbsp;16.02(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Redemption Price&#8221; </B>means, for any Notes to be redeemed pursuant to Section&nbsp;16.01, 100% of the principal amount of such
Notes, <I>plus </I>accrued and unpaid interest, if any, to, but excluding, the Redemption Date (unless the Redemption Date falls after a Regular Record Date but on or prior to the immediately succeeding Interest Payment Date, in which case interest
accrued to the Interest Payment Date will be paid to Holders of record of such Notes as of the close of business on such Regular Record Date, and the Redemption Price will be equal to 100% of the principal amount of such Notes). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Reference Property</B>&#8221; shall have the meaning specified in Section&nbsp;14.07(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Regular Record Date</B>,&#8221; with respect to any Interest Payment Date, means
the February&nbsp;1 or August&nbsp;1 (whether or not such day is a Business Day) immediately preceding the applicable February&nbsp;15 or August&nbsp;15 Interest Payment Date, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Resale Restriction Termination Date</B>&#8221; shall have the meaning specified in Section&nbsp;2.05(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Responsible Officer</B>&#8221; means, when used with respect to the Trustee, any officer within the corporate trust department of
the Trustee, including any vice president, assistant vice president, assistant secretary, assistant treasurer, trust officer or any other officer of the Trustee who customarily performs functions similar to those performed by the Persons who at the
time shall be such officers, respectively, or to whom any corporate trust matter is referred because of such person&#8217;s knowledge of and familiarity with the particular subject and who shall have direct responsibility for the administration of
this Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Restricted Securities</B>&#8221; shall have the meaning specified in Section&nbsp;2.05(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Rule 144</B>&#8221; means Rule 144 as promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Rule 144A</B>&#8221; means Rule 144A as promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Scheduled Trading Day</B>&#8221; means a day that is scheduled to be a Trading Day on the principal U.S. national or regional
securities exchange or market on which the Class&nbsp;A Common Stock is listed or admitted for trading. If the Class&nbsp;A Common Stock is not so listed or admitted for trading, &#8220;<B>Scheduled Trading Day</B>&#8221; means a Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Securities Act</B>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Settlement Amount</B>&#8221; has the meaning specified in Section&nbsp;14.02(a)(iv). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Settlement Method</B>&#8221; means, with respect to any conversion of Notes, Physical Settlement, Cash Settlement or Combination
Settlement, as elected (or deemed to have been elected) by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Settlement Notice</B>&#8221; has the meaning specified
in Section&nbsp;14.02(a)(iii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Share Exchange Event</B>&#8221; shall have the meaning specified in Section&nbsp;14.07(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Significant Subsidiary</B>&#8221; means a Subsidiary of the Company that meets the definition of &#8220;significant
subsidiary&#8221; in Article 1, Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Specified Dollar Amount</B>&#8221; means the maximum cash amount per $1,000 principal amount of Notes to be received upon conversion
as specified in the Settlement Notice related to any converted Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><FONT STYLE="white-space:nowrap">Spin-Off</FONT></B>&#8221; shall have the meaning specified in Section&nbsp;14.04(c). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Stock Price</B>&#8221; shall have the meaning specified in Section&nbsp;14.03(c).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Subsidiary</B>&#8221; means, with respect to any Person, any corporation, association, partnership or other business entity of
which more than 50% of the total voting power of shares of Capital Stock or other interests (including partnership interests) entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers, general
partners or trustees thereof is at the time owned or controlled, directly or indirectly, by (i)&nbsp;such Person; (ii)&nbsp;such Person and one or more Subsidiaries of such Person; or (iii)&nbsp;one or more Subsidiaries of such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Successor Company</B>&#8221; shall have the meaning specified in Section&nbsp;11.01(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Termination of Conversion Rights</B>&#8221; shall have the meaning specified in Section&nbsp;14.01(c)(i). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Trading Day</B>&#8221; means, except for purposes of determining amounts due upon conversion, a day on which (i)&nbsp;trading in the
Class&nbsp;A Common Stock (or other security for which a closing sale price must be determined) generally occurs on The New York Stock Exchange or, if the Class&nbsp;A Common Stock (or such other security) is not then listed on The New York Stock
Exchange, on the principal other U.S. national or regional securities exchange on which the Class&nbsp;A Common Stock (or such other security) is then listed or, if the Class&nbsp;A Common Stock (or such other security) is not then listed on a U.S.
national or regional securities exchange, on the principal other market on which the Class&nbsp;A Common Stock (or such other security) is then traded and (ii)&nbsp;a Last Reported Sale Price for the Class&nbsp;A Common Stock (or such other
security) is available on such securities exchange or market; <I>provided</I> that if the Class&nbsp;A Common Stock (or such other security) is not so listed or traded, &#8220;<B>Trading Day</B>&#8221; means a Business Day; and <I>provided,
further</I>, that for purposes of determining amounts due upon conversion only, &#8220;<B>Trading Day</B>&#8221; means a day on which (x)&nbsp;there is no Market Disruption Event and (y)&nbsp;trading in the Class&nbsp;A Common Stock generally occurs
on The New York Stock Exchange or, if the Class&nbsp;A Common Stock is not then listed on The New York Stock Exchange, on the principal other U.S. national or regional securities exchange on which the Class&nbsp;A Common Stock is then listed or, if
the Class&nbsp;A Common Stock is not then listed on a U.S. national or regional securities exchange, on the principal other market on which the Class&nbsp;A Common Stock is then listed or admitted for trading. If the Class&nbsp;A Common Stock is not
so listed or admitted for trading, &#8220;<B>Trading Day</B>&#8221; means a Business Day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Trading Price</B>&#8221; of the Notes
on any date of determination means the average of the secondary market bid quotations obtained by the Bid Solicitation Agent for $2,000,000 principal amount of Notes at approximately 3:30 p.m., New York City time, on such determination date from
three independent nationally recognized securities dealers the Company selects for this purpose; <I>provided</I> that if three such bids cannot reasonably be obtained by the Bid Solicitation Agent but two such bids are obtained, then the average of
the two bids shall be used, and if only one such bid can reasonably be obtained by the Bid Solicitation Agent, that one bid shall be used. If the Bid Solicitation Agent cannot reasonably obtain at least one bid for $2,000,000 principal amount of
Notes from a nationally recognized securities dealer on any determination date, then the Trading Price per $1,000 principal amount of Notes on such determination date shall be deemed to be less than 98% of the product of the Last Reported Sale Price
of the Class&nbsp;A Common Stock and the Conversion Rate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>transfer</B>&#8221; shall have the meaning specified in Section&nbsp;2.05(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Trigger Event</B>&#8221; shall have the meaning specified in Section&nbsp;14.04(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Trust Indenture Act</B>&#8221; means the Trust Indenture Act of 1939, as amended, as it was in force at the date of execution of
this Indenture; <I>provided</I>, <I>however</I>, that in the event the Trust Indenture Act of 1939 is amended after the date hereof, the term &#8220;Trust Indenture Act&#8221; shall mean, to the extent required by such amendment, the Trust Indenture
Act of 1939, as so amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Trustee</B>&#8221; means the Person named as the &#8220;<B>Trustee</B>&#8221; in the first
paragraph of this Indenture until a successor trustee shall have become such pursuant to the applicable provisions of this Indenture, and thereafter &#8220;<B>Trustee</B>&#8221; shall mean or include each Person who is then a Trustee hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>unit of Reference Property</B>&#8221; shall have the meaning specified in Section&nbsp;14.07(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Valuation Period</B>&#8221; shall have the meaning specified in Section&nbsp;14.04(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Wholly Owned Subsidiary</B>&#8221; means, with respect to any Person, any Subsidiary of such Person, except that, solely for
purposes of this definition, the reference to &#8220;more than 50%&#8221; in the definition of &#8220;Subsidiary&#8221; shall be deemed replaced by a reference to &#8220;100%&#8221;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.02<I>. References to Interest.</I> Unless the context otherwise requires, any reference to interest on, or in respect of, any
Note in this Indenture shall be deemed to include Additional Interest if, in such context, Additional Interest is, was or would be payable pursuant to any of Section&nbsp;4.06(d), Section&nbsp;4.06(e) and Section&nbsp;6.03. Unless the context
otherwise requires, any express mention of Additional Interest in any provision hereof shall not be construed as excluding Additional Interest in those provisions hereof where such express mention is not made. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 2 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I<SMALL>SSUE</SMALL>,
D<SMALL>ESCRIPTION</SMALL>, E<SMALL>XECUTION</SMALL>, R<SMALL>EGISTRATION</SMALL> <SMALL>AND</SMALL> E<SMALL>XCHANGE</SMALL> <SMALL>OF</SMALL> N<SMALL>OTES</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.01<I>. Designation and Amount.</I> The Notes shall be designated as the &#8220;4.50% Convertible Senior Notes due 2031.&#8221;
The aggregate principal amount of Notes that may be authenticated and delivered under this Indenture is initially limited to $166,750,000, subject to Section&nbsp;2.10 and except for Notes authenticated and delivered upon registration or transfer
of, or in exchange for, or in lieu of other Notes to the extent expressly permitted hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.02<I>. Form of Notes.</I>
The Notes and the Trustee&#8217;s certificate of authentication to be borne by such Notes shall be substantially in the respective forms set forth in Exhibit A, the terms and provisions of which shall constitute, and are hereby expressly
incorporated in and made a part of this Indenture. To the extent applicable, the Company and the Trustee, by their execution and delivery of this Indenture, expressly agree to such terms and provisions and to be bound thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Global Note may be endorsed with or have incorporated in the text thereof such legends
or recitals or changes not inconsistent with the provisions of this Indenture as may be required by the Custodian or the Depositary, or as may be required to comply with any applicable law or any regulation thereunder or with the rules and
regulations of any securities exchange or automated quotation system upon which the Notes may be listed or traded or designated for issuance or to conform with any usage with respect thereto, or to indicate any special limitations or restrictions to
which any particular Notes are subject. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the Notes may have such letters, numbers or other marks of identification and such
notations, legends or endorsements as the Officer executing the same may approve (execution thereof to be conclusive evidence of such approval) and as are not inconsistent with the provisions of this Indenture, or as may be required to comply with
any law or with any rule or regulation made pursuant thereto or with any rule or regulation of any securities exchange or automated quotation system on which the Notes may be listed or designated for issuance, or to conform to usage or to indicate
any special limitations or restrictions to which any particular Notes are subject. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Global Note shall represent such principal amount
of the outstanding Notes as shall be specified therein and shall provide that it shall represent the aggregate principal amount of outstanding Notes from time to time endorsed thereon and that the aggregate principal amount of outstanding Notes
represented thereby may from time to time be increased or reduced to reflect redemptions, repurchases, cancellations, conversions, transfers or exchanges permitted hereby. Any endorsement of a Global Note to reflect the amount of any increase or
decrease in the amount of outstanding Notes represented thereby shall be made by the Trustee or the Custodian, at the direction of the Trustee, in such manner and upon instructions given by the Holder of such Notes in accordance with this Indenture.
Payment of principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, and accrued and unpaid interest on, a Global Note shall be made to the Holder of such Note on the date of payment, unless a record
date or other means of determining Holders eligible to receive payment is provided for herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.03<I>. Date and
Denomination of Notes; Payments of Interest and Defaulted Amounts.</I> (a)&nbsp;The Notes shall be issuable in registered form without coupons in denominations of $1,000 principal amount and integral multiples thereof. Each Note shall be dated the
date of its authentication and shall bear interest from the date specified on the face of such Note. Accrued interest on the Notes shall be computed on the basis of a <FONT STYLE="white-space:nowrap">360-day</FONT> year composed of twelve <FONT
STYLE="white-space:nowrap">30-day</FONT> months and, for partial months, on the basis of the number of days actually elapsed in a <FONT STYLE="white-space:nowrap">30-day</FONT> month. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Person in whose name any Note (or its Predecessor Note) is registered on the Note Register at the close of business on any Regular
Record Date with respect to any Interest Payment Date shall be entitled to receive the interest payable on such Interest Payment Date. The principal amount of any Note (x)&nbsp;in the case of any Physical Note, shall be payable at the office or
agency of the Company maintained by the Company for such purposes in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contiguous United States, which shall initially be the Corporate Trust Office and (y)&nbsp;in the case of any Global Note, shall be payable by wire transfer of immediately available funds to the
account of the Depositary or its nominee. The Company shall pay interest (i)&nbsp;on any Physical Notes (A)&nbsp;to Holders holding Physical Notes having an aggregate principal amount of $5,000,000 or less, by check mailed to the Holders of these
Notes at their address as it appears in the Note Register and (B)&nbsp;to Holders holding Physical Notes having an aggregate principal amount of more than $5,000,000, either by check mailed to each Holder or, upon application by such a Holder to the
Note Registrar not later than the relevant Regular Record Date, by wire transfer in immediately available funds to that Holder&#8217;s account within the United States, which application shall remain in effect until the Holder notifies, in writing,
the Note Registrar to the contrary or (ii)&nbsp;on any Global Note by wire transfer of immediately available funds to the account of the Depositary or its nominee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Any Defaulted Amounts shall forthwith cease to be payable to the Holder on the relevant payment date but shall accrue interest per annum
at the rate borne by the Notes <I>plus</I> one percent, subject to the enforceability thereof under applicable law, from, and including, such relevant payment date, and such Defaulted Amounts together with such interest thereon shall be paid by the
Company, at its election in each case, as provided in clause (i)&nbsp;or (ii) below: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company may elect to make
payment of any Defaulted Amounts to the Persons in whose names the Notes (or their respective Predecessor Notes) are registered at the close of business on a special record date for the payment of such Defaulted Amounts, which shall be fixed in the
following manner. The Company shall notify the Trustee in writing of the amount of the Defaulted Amounts proposed to be paid on each Note and the date of the proposed payment (which shall be not less than 25 days after the receipt by the Trustee of
such notice, unless the Trustee shall consent to an earlier date), and at the same time the Company shall deposit with the Trustee an amount of money equal to the aggregate amount to be paid in respect of such Defaulted Amounts or shall make
arrangements satisfactory to the Trustee for such deposit on or prior to the date of the proposed payment, such money when deposited to be held in trust for the benefit of the Persons entitled to such Defaulted Amounts as in this clause provided.
Thereupon the Company shall fix a special record date for the payment of such Defaulted Amounts which shall be not more than 15 days and not less than 10 days prior to the date of the proposed payment, and not less than 10 days after the receipt by
the Trustee of the notice of the proposed payment. The Company shall promptly notify the Trustee of such special record date and the Trustee, in the name and at the expense of the Company, shall cause notice of the proposed payment of such Defaulted
Amounts and the special record date therefor to be delivered to each Holder not less than 10 days prior to such special record date. Notice of the proposed payment of such Defaulted Amounts and the special record date therefor having been so
delivered, such Defaulted Amounts shall be paid to the Persons in whose names the Notes (or their respective Predecessor Notes) are registered at the close of business on such special record date and shall no longer be payable pursuant to the
following clause (ii)&nbsp;of this Section&nbsp;2.03(c). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Company may make payment of any Defaulted Amounts in any other
lawful manner not inconsistent with the requirements of any securities exchange or automated quotation system on which the Notes may be listed or designated for trading, and upon such notice as may be required by such exchange or automated quotation
system, if, after notice given by the Company to the Trustee of the proposed payment pursuant to this clause, such manner of payment shall be deemed practicable by the Trustee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.04<I>. </I><I>Execution, Authentication and Delivery of Notes.</I> The Notes shall be signed in the name and on behalf of the
Company by the manual, facsimile or .pdf signature of any Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time and from time to time after the execution and delivery of
this Indenture, the Company may deliver Notes executed by the Company to the Trustee for authentication, together with a Company Order for the authentication and delivery of such Notes, and the Trustee in accordance with such Company Order shall
authenticate and deliver such Notes, without any further action by the Company hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only such Notes as shall bear thereon a
certificate of authentication substantially in the form set forth on the Form of Note attached as Exhibit A hereto, executed manually by an authorized officer of the Trustee (or an authenticating agent appointed by the Trustee as provided by
Section&nbsp;17.10), shall be entitled to the benefits of this Indenture or be valid or obligatory for any purpose. Such certificate by the Trustee (or such an authenticating agent) upon any Note executed by the Company shall be conclusive evidence
that the Note so authenticated has been duly authenticated and delivered hereunder and that the Holder is entitled to the benefits of this Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case any Officer of the Company who shall have signed any of the Notes shall cease to be such Officer before the Notes so signed shall have
been authenticated and delivered by the Trustee, or disposed of by the Company, such Notes nevertheless may be authenticated and delivered or disposed of as though the person who signed such Notes had not ceased to be such Officer of the Company;
and any Note may be signed on behalf of the Company by such persons as, at the actual date of the execution of such Note, shall be the Officers of the Company, although at the date of the execution of this Indenture any such person was not such an
Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.05<I>. Exchange and Registration of Transfer of Notes; Restrictions on Transfer; Depositary.</I> (a)&nbsp;The
Company shall cause to be kept at the Corporate Trust Office a register (the register maintained in such office or in any other office or agency of the Company designated pursuant to Section&nbsp;4.02, the &#8220;<B>Note Register</B>&#8221;) in
which, subject to such reasonable regulations as it may prescribe, the Company shall provide for the registration of Notes and of transfers of Notes. Such register shall be in written form or in any form capable of being converted into written form
within a reasonable period of time. The Trustee is hereby initially appointed the &#8220;<B>Note Registrar</B>&#8221; for the purpose of registering Notes and transfers of Notes as herein provided. The Company may appoint one or more <FONT
STYLE="white-space:nowrap">co-Note</FONT> Registrars in accordance with Section&nbsp;4.02. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon surrender for registration of transfer of
any Note to the Note Registrar or any <FONT STYLE="white-space:nowrap">co-Note</FONT> Registrar, and satisfaction of the requirements for such transfer set forth in this Section&nbsp;2.05, the Company shall execute, and the Trustee shall
authenticate and deliver, in the name of the designated transferee or transferees, one or more new Notes of any authorized denominations and of a like aggregate principal amount and bearing such restrictive legends as may be required by this
Indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notes may be exchanged for other Notes of any authorized denominations and of a like
aggregate principal amount, upon surrender of the Notes to be exchanged at any such office or agency maintained by the Company pursuant to Section&nbsp;4.02. Whenever any Notes are so surrendered for exchange, the Company shall execute, and the
Trustee shall authenticate and deliver, the Notes that the Holder making the exchange is entitled to receive, bearing registration numbers not contemporaneously outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All Notes presented or surrendered for registration of transfer or for exchange, repurchase, or conversion shall (if so required by the
Company, the Trustee, the Note Registrar or any <FONT STYLE="white-space:nowrap">co-Note</FONT> Registrar) be duly endorsed, or be accompanied by a written instrument or instruments of transfer in form satisfactory to the Company and duly executed,
by the Holder thereof or its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> duly authorized in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No service charge shall be imposed by the Company, the Trustee, the Note Registrar, any <FONT STYLE="white-space:nowrap">co-Note</FONT>
Registrar or the Paying Agent for any exchange or registration of transfer of Notes, but the Company may require a Holder to pay a sum sufficient to cover any documentary, stamp or similar issue or transfer tax required in connection therewith as a
result of the name of the Holder of new Notes issued upon such exchange or registration of transfer being different from the name of the Holder of the old Notes surrendered for exchange or registration of transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the Company, the Trustee, the Note Registrar or any <FONT STYLE="white-space:nowrap">co-Note</FONT> Registrar shall be required to
exchange or register a transfer of (i)&nbsp;any Notes surrendered for conversion or, if a portion of any Note is surrendered for conversion, such portion thereof surrendered for conversion, (ii)&nbsp;any Notes, or a portion of any Note, surrendered
for repurchase (and not withdrawn) in accordance with Article 15 or (iii)&nbsp;any Notes selected for redemption in accordance with Article 16, except the unredeemed portion of any Note being redeemed in part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All Notes issued upon any registration of transfer or exchange of Notes in accordance with this Indenture shall be the valid obligations of
the Company, evidencing the same debt, and entitled to the same benefits under this Indenture as the Notes surrendered upon such registration of transfer or exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) So long as the Notes are eligible for book-entry settlement with the Depositary, unless otherwise required by law, subject to the fourth
paragraph from the end of Section&nbsp;2.05(c) all Notes shall be represented by one or more Notes in global form (each, a &#8220;<B>Global Note</B>&#8221;) registered in the name of the Depositary or the nominee of the Depositary. Each Global Note
shall bear the legend required on a Global Note set forth in Exhibit A hereto. The transfer and exchange of beneficial interests in a Global Note that does not involve the issuance of a Physical Note shall be effected through the Depositary (but not
the Trustee or the Custodian) in accordance with this Indenture (including the restrictions on transfer set forth herein) and the procedures of the Depositary therefor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Every Note that bears or is required under this Section&nbsp;2.05(c) to bear the legend
set forth in this Section&nbsp;2.05(c) (together with any Class&nbsp;A Common Stock issued upon conversion of the Notes that is required to bear the legend set forth in Section&nbsp;2.05(d), collectively, the &#8220;<B>Restricted
Securities</B>&#8221;) shall be subject to the restrictions on transfer set forth in this Section&nbsp;2.05(c) (including the legend set forth below), unless such restrictions on transfer shall be eliminated or otherwise waived by written consent of
the Company, and the Holder of each such Restricted Security, by such Holder&#8217;s acceptance thereof, agrees to be bound by all such restrictions on transfer. As used in this Section&nbsp;2.05(c) and Section&nbsp;2.05(d), the term
&#8220;<B>transfer</B>&#8221; encompasses any sale, pledge, transfer or other disposition whatsoever of any Restricted Security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until
the date (the &#8220;<B>Resale Restriction Termination Date</B>&#8221;) that is the later of (1)&nbsp;the date that is one year after the last date of original issuance of the Notes, or such shorter period of time as permitted by Rule 144 or any
successor provision thereto, and (2)&nbsp;such later date, if any, as may be required by applicable law, any certificate evidencing such Note (and all securities issued in exchange therefor or substitution thereof, other than Class&nbsp;A Common
Stock, if any, issued upon conversion thereof, which shall bear the legend set forth in Section&nbsp;2.05(d), if applicable) shall bear a legend in substantially the following form (unless such Notes have been transferred pursuant to a registration
statement that has become or been declared effective under the Securities Act and that continues to be effective at the time of such transfer, or sold pursuant to the exemption from registration provided by Rule 144 or any similar provision then in
force under the Securities Act, or unless otherwise agreed by the Company in writing, with notice thereof to the Trustee): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS SECURITY
AND THE CLASS A COMMON STOCK, IF ANY, ISSUABLE UPON CONVERSION OF THIS SECURITY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;<B>SECURITIES ACT</B>&#8221;), AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE
TRANSFERRED EXCEPT IN ACCORDANCE WITH THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF OR OF A BENEFICIAL INTEREST HEREIN, THE ACQUIRER: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) REPRESENTS THAT IT AND ANY ACCOUNT FOR WHICH IT IS ACTING IS A &#8220;QUALIFIED INSTITUTIONAL BUYER&#8221; (WITHIN THE
MEANING OF RULE 144A UNDER THE SECURITIES ACT) AND THAT IT EXERCISES SOLE INVESTMENT DISCRETION WITH RESPECT TO EACH SUCH ACCOUNT, AND </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) AGREES FOR THE BENEFIT OF EVOLENT HEALTH, INC. (THE &#8220;<B>COMPANY</B>&#8221;) THAT IT WILL NOT OFFER, SELL, PLEDGE OR
OTHERWISE TRANSFER THIS SECURITY OR ANY BENEFICIAL INTEREST HEREIN PRIOR TO THE DATE THAT IS THE LATER OF (X)&nbsp;ONE YEAR AFTER THE LAST ORIGINAL ISSUE DATE HEREOF OR SUCH SHORTER PERIOD OF TIME AS PERMITTED BY RULE 144 UNDER THE SECURITIES ACT OR
ANY SUCCESSOR PROVISION THERETO AND (Y)&nbsp;SUCH LATER DATE, IF ANY, AS MAY BE REQUIRED BY APPLICABLE LAW, EXCEPT: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) TO
THE COMPANY OR ANY SUBSIDIARY THEREOF, OR </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) PURSUANT TO A REGISTRATION STATEMENT WHICH HAS BECOME EFFECTIVE UNDER THE
SECURITIES ACT, OR </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) TO A PERSON REASONABLY BELIEVED TO BE A QUALIFIED INSTITUTIONAL BUYER IN
COMPLIANCE WITH RULE 144A UNDER THE SECURITIES ACT, OR </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144
UNDER THE SECURITIES ACT OR ANY OTHER AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PRIOR TO THE
REGISTRATION OF ANY TRANSFER IN ACCORDANCE WITH CLAUSE (2)(D) ABOVE, THE COMPANY AND THE TRUSTEE RESERVE THE RIGHT TO REQUIRE THE DELIVERY OF SUCH LEGAL OPINIONS, CERTIFICATIONS OR OTHER EVIDENCE AS MAY REASONABLY BE REQUIRED IN ORDER TO DETERMINE
THAT THE PROPOSED TRANSFER IS BEING MADE IN COMPLIANCE WITH THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. NO REPRESENTATION IS MADE AS TO THE AVAILABILITY OF ANY EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No transfer of any Note prior to the Resale Restriction Termination Date will be registered by the Note Registrar unless the applicable box on
the Form of Assignment and Transfer has been checked. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Note (or security issued in exchange or substitution therefor)&nbsp;(i) as to
which such restrictions on transfer shall have expired in accordance with their terms, (ii)&nbsp;that has been transferred pursuant to a registration statement that has become effective or been declared effective under the Securities Act and that
continues to be effective at the time of such transfer or (iii)&nbsp;that has been sold pursuant to the exemption from registration provided by Rule 144 or any similar provision then in force under the Securities Act, may, upon surrender of such
Note for exchange to the Note Registrar in accordance with the provisions of this Section&nbsp;2.05, be exchanged for a new Note or Notes, of like tenor and aggregate principal amount, which shall not bear the restrictive legend required by this
Section&nbsp;2.05(c) and shall not be assigned a restricted CUSIP number. The Company shall be entitled to instruct the Custodian in writing to so surrender any Global Note as to which any of the conditions set forth in clause (i)&nbsp;through (iii)
of the immediately preceding sentence have been satisfied, and, upon such instruction, the Custodian shall so surrender such Global Note for exchange; and any new Global Note so exchanged therefor shall not bear the restrictive legend specified in
this Section&nbsp;2.05(c) and shall not be assigned a restricted CUSIP number. The Company shall promptly notify the Trustee upon the occurrence of the Resale Restriction Termination Date and promptly after a registration statement, if any, with
respect to the Notes or any Class&nbsp;A Common Stock issued upon conversion of the Notes has been declared effective under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provisions of this Indenture (other than the provisions set forth in this Section&nbsp;2.05(c)), a Global Note may
not be transferred as a whole or in part except (i)&nbsp;by the Depositary to a nominee of the Depositary or by a nominee of the Depositary to the Depositary or another nominee of the Depositary or by the Depositary or any such nominee to a
successor Depositary or a nominee of such successor Depositary and (ii)&nbsp;for exchange of a Global Note or a portion thereof for one or more Physical Notes in accordance with the second immediately succeeding paragraph. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Depositary shall be a clearing agency registered under the Exchange Act. The Company
initially appoints The Depository Trust Company to act as Depositary with respect to each Global Note. Initially, each Global Note shall be issued to the Depositary, registered in the name of Cede&nbsp;&amp; Co., as the nominee of the Depositary,
and deposited with the Trustee as custodian for Cede&nbsp;&amp; Co. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If (i)&nbsp;the Depositary notifies the Company at any time that the
Depositary is unwilling or unable to continue as depositary for the Global Notes and a successor depositary is not appointed within 90 days, (ii)&nbsp;the Depositary ceases to be registered as a clearing agency under the Exchange Act and a successor
depositary is not appointed within 90 days or (iii)&nbsp;an Event of Default with respect to the Notes has occurred and is continuing and a beneficial owner of any Note requests through the Trustee that its beneficial interest therein be issued as a
Physical Note, the Company shall execute, and the Trustee, upon receipt of an Officer&#8217;s Certificate and a Company Order for the authentication and delivery of Notes, shall authenticate and deliver (x)&nbsp;in the case of clause (iii), a
Physical Note to such beneficial owner in a principal amount equal to the principal amount of such Note corresponding to such beneficial owner&#8217;s beneficial interest and (y)&nbsp;in the case of clause (i)&nbsp;or (ii), Physical Notes to each
beneficial owner of the related Global Notes (or a portion thereof) in an aggregate principal amount equal to the aggregate principal amount of such Global Notes in exchange for such Global Notes, and upon delivery of the Global Notes to the Trustee
such Global Notes shall be canceled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Physical Notes issued in exchange for all or a part of the Global Note pursuant to this
Section&nbsp;2.05(c) shall be registered in such names and in such authorized denominations as the Depositary, pursuant to instructions from its direct or indirect participants or otherwise, or, in the case of clause (iii)&nbsp;of the immediately
preceding paragraph, the relevant beneficial owner, shall instruct the Trustee. Upon execution and authentication, the Trustee shall deliver such Physical Notes to the Persons in whose names such Physical Notes are so registered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At such time as all interests in a Global Note have been converted, canceled, repurchased, redeemed or transferred, such Global Note shall be,
upon receipt thereof, canceled by the Trustee in accordance with standing procedures and existing instructions between the Depositary and the Custodian. At any time prior to such cancellation, if any interest in a Global Note is exchanged for
Physical Notes, converted, canceled, repurchased, redeemed or transferred to a transferee who receives Physical Notes therefor or any Physical Note is exchanged or transferred for part of such Global Note, the principal amount of such Global Note
shall, in accordance with the standing procedures and instructions existing between the Depositary and the Custodian, be appropriately reduced or increased, as the case may be, and an endorsement shall be made on such Global Note, by the Trustee or
the Custodian, at the direction of the Trustee, to reflect such reduction or increase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the Company, the Trustee or any agent of
the Company or the Trustee shall have any responsibility or liability for any aspect of the records relating to or payments made on account of beneficial ownership interests of a Global Note or maintaining, supervising or reviewing any records
relating to such beneficial ownership interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Until the Resale Restriction Termination Date, any stock certificate representing
Class&nbsp;A Common Stock issued upon conversion of a Note shall bear a legend in substantially the following form (unless such Class&nbsp;A Common Stock has been transferred pursuant to a registration statement that has become or been declared
effective under the Securities Act and that continues to be effective at the time of such transfer, or pursuant to the exemption from registration provided by Rule 144 or any similar provision then in force under the Securities Act, or such
Class&nbsp;A Common Stock has been issued upon conversion of a Note that has been transferred pursuant to a registration statement that has become or been declared effective under the Securities Act and that continues to be effective at the time of
such transfer, or pursuant to the exemption from registration provided by Rule 144 or any similar provision then in force under the Securities Act, or unless otherwise agreed by the Company with written notice thereof to the Trustee and any transfer
agent for the Class&nbsp;A Common Stock): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
&#8220;<B>SECURITIES ACT</B>&#8221;), AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF OR OF A BENEFICIAL INTEREST HEREIN, THE ACQUIRER: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) REPRESENTS THAT IT AND ANY ACCOUNT FOR WHICH IT IS ACTING IS A &#8220;QUALIFIED INSTITUTIONAL BUYER&#8221; (WITHIN THE
MEANING OF RULE 144A UNDER THE SECURITIES ACT) AND THAT IT EXERCISES SOLE INVESTMENT DISCRETION WITH RESPECT TO EACH SUCH ACCOUNT, AND </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) AGREES FOR THE BENEFIT OF EVOLENT HEALTH, INC. (THE &#8220;<B>COMPANY</B>&#8221;) THAT IT WILL NOT OFFER, SELL, PLEDGE OR
OTHERWISE TRANSFER THIS SECURITY OR ANY BENEFICIAL INTEREST HEREIN PRIOR TO THE DATE THAT IS THE LATER OF (X)&nbsp;ONE YEAR AFTER THE LAST ORIGINAL ISSUE DATE OF THE SERIES OF NOTES UPON THE CONVERSION OF WHICH THIS SECURITY WAS ISSUED OR SUCH
SHORTER PERIOD OF TIME AS PERMITTED BY RULE 144 UNDER THE SECURITIES ACT OR ANY SUCCESSOR PROVISION THERETO AND (Y)&nbsp;SUCH LATER DATE, IF ANY, AS MAY BE REQUIRED BY APPLICABLE LAW, EXCEPT: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF, OR </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) PURSUANT TO A REGISTRATION STATEMENT WHICH HAS BECOME EFFECTIVE UNDER THE SECURITIES ACT, OR </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) TO A PERSON IT REASONABLY BELIEVED TO BE A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER THE SECURITIES
ACT, OR </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144 UNDER THE SECURITIES ACT OR ANY OTHER
AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PRIOR TO THE REGISTRATION OF ANY TRANSFER IN ACCORDANCE WITH CLAUSE (2)(D) ABOVE, THE
COMPANY AND THE TRANSFER AGENT FOR THE COMPANY&#8217;S CLASS A COMMON STOCK RESERVE THE RIGHT TO REQUIRE THE DELIVERY OF SUCH LEGAL OPINIONS, CERTIFICATIONS OR OTHER EVIDENCE AS MAY REASONABLY BE REQUIRED IN ORDER TO DETERMINE THAT THE PROPOSED
TRANSFER IS BEING MADE IN COMPLIANCE WITH THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. NO REPRESENTATION IS MADE AS TO THE AVAILABILITY OF ANY EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any such Class&nbsp;A Common Stock (i)&nbsp;as to which such restrictions on transfer shall have expired in accordance with their terms,
(ii)&nbsp;that has been transferred pursuant to a registration statement that has become or been declared effective under the Securities Act and that continues to be effective at the time of such transfer or (iii)&nbsp;that has been sold pursuant to
the exemption from registration provided by Rule 144 or any similar provision then in force under the Securities Act, may, upon surrender of the certificates representing such shares of Class&nbsp;A Common Stock for exchange in accordance with the
procedures of the transfer agent for the Class&nbsp;A Common Stock, be exchanged for a new certificate or certificates for a like aggregate number of shares of Class&nbsp;A Common Stock, which shall not bear the restrictive legend required by this
Section&nbsp;2.05(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Any Note or Class&nbsp;A Common Stock issued upon the conversion or exchange of a Note that is repurchased or
owned by any Affiliate of the Company (or any Person who was an Affiliate of the Company at any time during the three months immediately preceding) may not be resold by such Affiliate (or such Person, as the case may be) unless registered under the
Securities Act or resold pursuant to an exemption from the registration requirements of the Securities Act in a transaction that results in such Note or Class&nbsp;A Common Stock, as the case may be, no longer being a &#8220;restricted
security&#8221; (as defined under Rule 144). The Company shall cause any Note that is repurchased, redeemed or owned by it to be surrendered to the Trustee for cancellation in accordance with Section&nbsp;2.08. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.06<I>. Mutilated, Destroyed, Lost or Stolen Notes.</I> In case any Note shall become mutilated or be destroyed, lost or stolen,
the Company in its discretion may execute, and upon its written request the Trustee or an authenticating agent appointed by the Trustee shall authenticate and deliver, a new Note, bearing a registration number not contemporaneously outstanding, in
exchange and substitution for the mutilated Note, or in lieu of and in substitution for the Note so destroyed, lost or stolen. In every case the applicant for a substituted Note shall furnish to the Company, to the Trustee and, if applicable, to
such authenticating agent such security or indemnity as may be required by them to save each of them harmless from any loss, liability, cost or expense caused by or connected with such substitution, and, in every case of destruction, loss or theft,
the applicant shall also furnish to the Company, to the Trustee and, if applicable, to such authenticating agent evidence to their satisfaction of the destruction, loss or theft of such Note and of the ownership thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Trustee or such authenticating agent may authenticate any such substituted Note and
deliver the same upon the receipt of such security or indemnity as the Trustee, the Company and, if applicable, such authenticating agent may require. No service charge shall be imposed by the Company, the Trustee, the Note Registrar, any <FONT
STYLE="white-space:nowrap">co-Note</FONT> Registrar or the Paying Agent upon the issuance of any substitute Note, but the Company may require a Holder to pay a sum sufficient to cover any documentary, stamp or similar issue or transfer tax required
in connection therewith as a result of the name of the Holder of the new substitute Note being different from the name of the Holder of the old Note that became mutilated or was destroyed, lost or stolen. In case any Note that has matured or is
about to mature or has been surrendered for required repurchase or redemption or is about to be converted in accordance with Article 14 shall become mutilated or be destroyed, lost or stolen, the Company may, in its sole discretion, instead of
issuing a substitute Note, pay or authorize the payment of or convert or authorize the conversion of the same (without surrender thereof except in the case of a mutilated Note), as the case may be, if the applicant for such payment or conversion
shall furnish to the Company, to the Trustee and, if applicable, to such authenticating agent such security or indemnity as may be required by them to save each of them harmless for any loss, liability, cost or expense caused by or connected with
such substitution, and, in every case of destruction, loss or theft, evidence satisfactory to the Company, the Trustee and, if applicable, any Paying Agent or Conversion Agent evidence of their satisfaction of the destruction, loss or theft of such
Note and of the ownership thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Every substitute Note issued pursuant to the provisions of this Section&nbsp;2.06 by virtue of the
fact that any Note is destroyed, lost or stolen shall constitute an additional contractual obligation of the Company, whether or not the destroyed, lost or stolen Note shall be found at any time, and shall be entitled to all the benefits of (but
shall be subject to all the limitations set forth in) this Indenture equally and proportionately with any and all other Notes duly issued hereunder. To the extent permitted by law, all Notes shall be held and owned upon the express condition that
the foregoing provisions are exclusive with respect to the replacement, payment, redemption, conversion or repurchase of mutilated, destroyed, lost or stolen Notes and shall preclude any and all other rights or remedies notwithstanding any law or
statute existing or hereafter enacted to the contrary with respect to the replacement, payment, redemption, conversion or repurchase of negotiable instruments or other securities without their surrender. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.07<I>. Temporary Notes.</I> Pending the preparation of Physical Notes, the Company may execute and the Trustee or an
authenticating agent appointed by the Trustee shall, upon written request of the Company, authenticate and deliver temporary Notes (printed or lithographed). Temporary Notes shall be issuable in any authorized denomination, and substantially in the
form of the Physical Notes but with such omissions, insertions and variations as may be appropriate for temporary Notes, all as may be determined by the Company. Every such temporary Note shall be executed by the Company and authenticated by the
Trustee or such authenticating agent upon the same conditions and in substantially the same manner, and with the same effect, as the Physical Notes. Without unreasonable delay, the Company shall execute and deliver to the Trustee or such
authenticating agent Physical Notes (other than any Global Note) and thereupon any or all temporary Notes (other than any Global Note) may be surrendered in exchange therefor, at each office or agency maintained by the Company pursuant to
Section&nbsp;4.02 and the Trustee or such authenticating agent shall authenticate and deliver in exchange for such temporary Notes an equal aggregate principal amount of Physical Notes. Such exchange shall be made by the Company at its own expense
and without any charge therefor. Until so exchanged, the temporary Notes shall in all respects be entitled to the same benefits and subject to the same limitations under this Indenture as Physical Notes authenticated and delivered hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.08<I>. Cancellation</I> <I>of Notes Paid, Converted, Etc. </I>The Company
shall cause all Notes surrendered for the purpose of payment, repurchase (including as described in Section&nbsp;2.10 below, but excluding Notes repurchased pursuant to cash-settled swaps or other derivatives), redemption, registration of transfer
or exchange or conversion, if surrendered to any Person other than the Trustee (including any of the Company&#8217;s agents, Subsidiaries or Affiliates), to be surrendered to the Trustee for cancellation. All Notes delivered to the Trustee shall be
canceled promptly by it, and, except for any Notes surrendered for registration of transfer or exchange, no Notes shall be authenticated in exchange thereof except as expressly permitted by any of the provisions of this Indenture. The Trustee shall
dispose of canceled Notes in accordance with its customary procedures and, after such disposition, shall deliver a certificate of such disposition to the Company, at the Company&#8217;s written request in a Company Order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.09<I>. CUSIP Numbers.</I> The Company in issuing the Notes may use &#8220;CUSIP&#8221; numbers (if then generally in use), and,
if so, the Trustee shall use &#8220;CUSIP&#8221; numbers in all notices issued to Holders as a convenience to such Holders; <I>provided</I> that any such notice may state that no representation is made as to the correctness of such numbers either as
printed on the Notes or on such notice and that reliance may be placed only on the other identification numbers printed on the Notes. The Company shall promptly notify the Trustee in writing of any change in the &#8220;CUSIP&#8221; numbers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.10<I>. Additional Notes; Repurchases.</I> The Company may, without the consent of the Holders and notwithstanding
Section&nbsp;2.01, reopen this Indenture and issue additional Notes hereunder with the same terms as the Notes initially issued hereunder (other than differences in the issue date, the issue price and interest accrued prior to the issue date, if
any, of such additional Notes) in an unlimited aggregate principal amount; <I>provided</I> that if any such additional Notes are not fungible with the Notes initially issued hereunder for U.S. federal securities law or income tax purposes, such
additional Notes shall have a separate CUSIP number. Prior to the issuance of any such additional Notes, the Company shall deliver to the Trustee a Company Order, an Officer&#8217;s Certificate and an Opinion of Counsel, such Officer&#8217;s
Certificate and Opinion of Counsel to cover such matters, in addition to those required by Section&nbsp;17.05, as the Trustee shall reasonably request. In addition, the Company may, to the extent permitted by law, and directly or indirectly
(regardless of whether such Notes are surrendered to the Company), repurchase Notes in the open market or otherwise, whether by the Company or its Subsidiaries or through a private or public tender or exchange offer or through counterparties to
private agreements, including by cash-settled swaps or other derivatives. The Company shall cause any Notes so repurchased (other than Notes effectively repurchased pursuant to cash-settled swaps or other derivatives) to be surrendered to the
Trustee for cancellation in accordance with Section&nbsp;2.08 and such Notes shall no longer be considered outstanding under this Indenture upon their repurchase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 3 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>ATISFACTION</SMALL> <SMALL>AND</SMALL> D<SMALL>ISCHARGE</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.01<I>. Satisfaction and Discharge.</I> This Indenture shall upon request of the Company contained in an Officer&#8217;s
Certificate cease to be of further effect, and the Trustee, at the expense of the Company, shall execute proper instruments acknowledging satisfaction and discharge of this Indenture, when (a)&nbsp;(i) all Notes theretofore authenticated and
delivered (other than Notes which have been destroyed, lost or stolen and which have been replaced, paid or converted as provided in Section&nbsp;2.06) have been delivered to the Trustee for cancellation; or (ii)&nbsp;the Company has deposited with
the Trustee or delivered to Holders, as applicable, after the Notes have become due and payable, whether on the Maturity Date, on any Fundamental Change Repurchase Date, on any Redemption Date, upon conversion or otherwise, cash and/or shares of
Class&nbsp;A Common Stock solely to satisfy the Company&#8217;s Conversion Obligation (in the case of amounts due upon conversion), as applicable, sufficient to pay all of the outstanding Notes or satisfy all outstanding conversions, as the case may
be, and paying all other sums due and payable under this Indenture by the Company; and (b)&nbsp;the Company has delivered to the Trustee an Officer&#8217;s Certificate and an Opinion of Counsel, each stating that all conditions precedent herein
provided for relating to the satisfaction and discharge of this Indenture have been complied with. Notwithstanding the satisfaction and discharge of this Indenture, the obligations of the Company to the Trustee under Section&nbsp;7.06 shall survive.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 4 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">P<SMALL>ARTICULAR</SMALL> C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.01<I>. Payment of Principal and Interest.</I> The Company covenants and agrees that it will cause to be paid the principal
(including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, and accrued and unpaid interest on, each of the Notes at the places, at the respective times and in the manner provided herein and in the Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.02<I>. Maintenance of Office or Agency.</I> The Company will maintain in the contiguous United States an office or agency where
the Notes may be surrendered for registration of transfer or exchange or for presentation for payment, repurchase or redemption (&#8220;<B>Paying Agent</B>&#8221;) or for conversion (&#8220;<B>Conversion Agent</B>&#8221;) and where notices and
demands to or upon the Company in respect of the Notes and this Indenture may be served. The Company will give prompt written notice to the Trustee of the location, and any change in the location, of such office or agency. If at any time the Company
shall fail to maintain any such required office or agency or shall fail to furnish the Trustee with the address thereof, such presentations, surrenders, notices and demands may be made or served at the Corporate Trust Office or the office or agency
of the Trustee in the contiguous United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may also from time to time designate as
<FONT STYLE="white-space:nowrap">co-Note</FONT> Registrars one or more other offices or agencies where the Notes may be presented or surrendered for any or all such purposes and may from time to time rescind such designations; <I>provided</I> that
no such designation or rescission shall in any manner relieve the Company of its obligation to maintain an office or agency in the contiguous United States for such purposes. The Company will give prompt written notice to the Trustee of any such
designation or rescission and of any change in the location of any such other office or agency. The terms &#8220;<B>Paying Agent</B>&#8221; and &#8220;<B>Conversion Agent</B>&#8221; include any such additional or other offices or agencies, as
applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby initially designates the Trustee as the Paying Agent, Note Registrar, Custodian and Conversion Agent and
the Corporate Trust Office as the office or agency in the contiguous United States where Notes may be surrendered for registration of transfer or exchange or for presentation for payment or repurchase or for conversion and where notices and demands
to or upon the Company in respect of the Notes and this Indenture may be served. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.03<I>. Appointments to Fill Vacancies in Trustee</I><I>&#8217;</I><I>s
Office.</I> The Company, whenever necessary to avoid or fill a vacancy in the role of Trustee, will appoint, in the manner provided in Section&nbsp;7.09, a Trustee, so that there shall at all times be a Trustee hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.04<I>. Provisions as to Paying Agent.</I> (a)&nbsp;If the Company shall appoint a Paying Agent other than the Trustee, the
Company will cause such Paying Agent to execute and deliver to the Trustee an instrument in which such agent shall agree with the Trustee, subject to the provisions of this Section&nbsp;4.04: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) that it will hold all sums held by it as such agent for the payment of the principal (including the Redemption Price and
the Fundamental Change Repurchase Price, if applicable) of, and accrued and unpaid interest on, the Notes in trust for the benefit of the Holders of the Notes; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) that it will give the Trustee prompt notice of any failure by the Company to make any payment of the principal (including
the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, and accrued and unpaid interest on, the Notes when the same shall be due and payable; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) that at any time during the continuance of an Event of Default, upon request of the Trustee, it will forthwith pay to the
Trustee all sums so held in trust. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall, on or before each due date of the principal (including the Redemption Price and the
Fundamental Change Repurchase Price, if applicable) of, or accrued and unpaid interest on, the Notes, deposit with the Paying Agent a sum sufficient to pay such principal (including the Redemption Price and the Fundamental Change Repurchase Price,
if applicable) or accrued and unpaid interest, and (unless such Paying Agent is the Trustee) the Company will promptly notify the Trustee of any failure to take such action; <I>provided</I> that if such deposit is made on the due date, such deposit
must be received by the Paying Agent by 10:00 a.m., New York City time, on such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If the Company shall act as its own Paying
Agent, it will, on or before each due date of the principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, and accrued and unpaid interest on, the Notes, set aside, segregate and hold in trust for the
benefit of the Holders of the Notes a sum sufficient to pay such principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) and accrued and unpaid interest so becoming due and will promptly notify the
Trustee in writing of any failure to take such action and of any failure by the Company to make any payment of the principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, or accrued and unpaid
interest on, the Notes when the same shall become due and payable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Anything in this Section&nbsp;4.04 to the contrary notwithstanding, the Company may, at
any time, for the purpose of obtaining a satisfaction and discharge of this Indenture, or for any other reason, pay, cause to be paid or deliver to the Trustee all sums or amounts held in trust by the Company or any Paying Agent hereunder as
required by this Section&nbsp;4.04, such sums or amounts to be held by the Trustee upon the trusts herein contained and upon such payment or delivery by the Company or any Paying Agent to the Trustee, the Company or such Paying Agent shall be
released from all further liability but only with respect to such sums or amounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Any money and shares of Class&nbsp;A Common Stock
deposited with the Trustee or any Paying Agent, or then held by the Company, in trust for the payment of the principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, accrued and unpaid interest on and
the consideration due upon conversion of any Note and remaining unclaimed for two years after such principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable), interest or consideration due upon conversion
has become due and payable shall be paid to the Company on request of the Company contained in an Officer&#8217;s Certificate, or (if then held by the Company) shall be discharged from such trust; and the Holder of such Note shall thereafter, as an
unsecured general creditor, look only to the Company for payment thereof, and all liability of the Trustee or such Paying Agent with respect to such trust money and shares of Class&nbsp;A Common Stock, and all liability of the Company as trustee
thereof, shall thereupon cease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.05<I>. [Intentionally Omitted]</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.06<I>. Rule 144A Information Requirement and Annual Reports.</I> (a)&nbsp;At any time the Company is not subject to
Section&nbsp;13 or 15(d) of the Exchange Act, the Company shall, so long as any of the Notes or any shares of Class&nbsp;A Common Stock issuable upon conversion thereof shall, at such time, constitute &#8220;restricted securities&#8221; within the
meaning of Rule 144(a)(3) under the Securities Act, promptly provide to the Trustee and, upon written request, any Holder, beneficial owner or prospective purchaser of such Notes or any shares of Class&nbsp;A Common Stock issuable upon conversion of
such Notes, the information required to be delivered pursuant to Rule 144A(d)(4) under the Securities Act to facilitate the resale of such Notes or shares of the Class&nbsp;A Common Stock pursuant to Rule 144A. During the period and subject to the
conditions described in the immediately preceding sentence, the Company shall take such further action as any Holder or beneficial owner of such Notes or such Class&nbsp;A Common Stock may reasonably request to the extent from time to time required
to enable such Holder or beneficial owner to sell such Notes or shares of Class&nbsp;A Common Stock in accordance with Rule 144A, as such rule may be amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company shall file with the Trustee, within 15 days after the same are required to be filed with the Commission, copies of any
documents or reports that the Company is required to file with the Commission pursuant to Section&nbsp;13 or 15(d) of the Exchange Act (giving effect to any grace period provided by Rule <FONT STYLE="white-space:nowrap">12b-25</FONT> under the
Exchange Act). Any such document or report that the Company files with the Commission via the Commission&#8217;s EDGAR system shall be deemed to be filed with the Trustee for purposes of this Section&nbsp;4.06(b) at the time such documents are filed
via the EDGAR system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Delivery of the reports and documents described in subsection (b)&nbsp;above to the Trustee is for
informational purposes only, and the Trustee&#8217;s receipt of such shall not constitute constructive notice of any information contained therein or determinable from information contained therein, including the Company&#8217;s compliance with any
of its covenants hereunder (as to which the Trustee is entitled to conclusively rely on an Officer&#8217;s Certificate). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) If, at any time during the <FONT STYLE="white-space:nowrap">six-month</FONT> period
beginning on, and including, the date that is six months after the last date of original issuance of the Notes, the Company fails to timely file any document or report that it is required to file with the Commission pursuant to Section&nbsp;13 or
15(d) of the Exchange Act, as applicable (after giving effect to all applicable grace periods thereunder and other than current reports on Form <FONT STYLE="white-space:nowrap">8-K),</FONT> or the Notes are not otherwise freely tradable pursuant to
Rule 144 by Holders other than the Company&#8217;s Affiliates or Holders that were the Company&#8217;s Affiliates at any time during the three months immediately preceding (as a result of restrictions pursuant to U.S. securities laws or the terms of
this Indenture or the Notes), the Company shall pay Additional Interest on such Notes. Such Additional Interest shall accrue on such Notes at the rate of 0.50% per annum of the principal amount of the Notes outstanding for each day during such
period for which the Company&#8217;s failure to file has occurred and is continuing or the Notes are not otherwise freely tradable pursuant to Rule 144 by Holders other than the Company&#8217;s Affiliates (or Holders that were the Company&#8217;s
Affiliates at any time during the three months immediately preceding). As used in this Section&nbsp;4.06(d), documents or reports that the Company is required to &#8220;file&#8221; with the Commission pursuant to Section&nbsp;13 or 15(d) of the
Exchange Act does not include documents or reports that the Company furnishes to the Commission pursuant to Section&nbsp;13 or 15(d) of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) If, and for so long as, the restrictive legend on any Notes specified in Section&nbsp;2.05(c) has not been removed, any Notes are assigned
a restricted CUSIP number or any Notes are not otherwise freely tradable pursuant to Rule 144 by Holders other than the Company&#8217;s Affiliates or Holders that were the Company&#8217;s Affiliates at any time during the three months immediately
preceding (without restrictions pursuant to U.S. securities laws or the terms of this Indenture or the Notes) as of the 380th day (or, if such day is not a Business Day, the immediately following Business Day) after the last date of original
issuance of the Notes, the Company shall pay Additional Interest on such Notes at a rate equal to 0.50% per annum of the principal amount of Notes outstanding until the restrictive legend on such Notes has been removed in accordance with
Section&nbsp;2.05(c), such Notes are assigned an unrestricted CUSIP number and such Notes are freely tradable pursuant to Rule 144 by Holders other than the Company&#8217;s Affiliates (or Holders that were the Company&#8217;s Affiliates at any time
during the three months immediately preceding) (without restrictions pursuant to U.S. securities laws or the terms of this Indenture or the Notes); <I>provided, however</I>, that no Additional Interest shall accrue or be owed pursuant to this
Section&nbsp;4.06(e) until the fifteenth Business Day following written notification to the Company (with a copy to the Trustee and the Conversion Agent (if other than the Trustee)) by any Holder or beneficial owner of the Notes requesting that the
Company comply with its obligations described in this Section&nbsp;4.06(e) (which notice may be given at any time after the 330th day after the last date of original issuance of the Notes), it being understood and agreed that in no event shall
Additional Interest accrue or be owed pursuant to this Section&nbsp;4.06(e) for any period prior to the 380th day (or, if such day is not a Business Day, the immediately following Business Day) after the last date of original issuance of the Notes.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Additional Interest will be payable in arrears on each Interest Payment Date following accrual in the same manner as regular interest
on the Notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Additional Interest that is payable in accordance with Section&nbsp;4.06(d) or
Section&nbsp;4.06(e) shall be in addition to, and not in lieu of, any Additional Interest that may be payable as a result of the Company&#8217;s election pursuant to Section&nbsp;6.03. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) If Additional Interest is payable by the Company pursuant to Section&nbsp;4.06(d) or Section&nbsp;4.06(e), the Company shall deliver to
the Trustee an Officer&#8217;s Certificate to that effect stating (i)&nbsp;the amount of such Additional Interest that is payable and (ii)&nbsp;the date on which such Additional Interest is payable. Unless and until a Responsible Officer of the
Trustee receives at the Corporate Trust Office such a certificate, the Trustee may assume without inquiry that no such Additional Interest is payable. If the Company has paid Additional Interest directly to the Persons entitled to it, the Company
shall deliver to the Trustee an Officer&#8217;s Certificate setting forth the particulars of such payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.07<I>. Stay,
Extension and Usury Laws.</I> The Company covenants (to the extent that it may lawfully do so) that it shall not at any time insist upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law
or other law that would prohibit or forgive the Company from paying all or any portion of the principal of or interest on the Notes as contemplated herein, wherever enacted, now or at any time hereafter in force, or that may affect the covenants or
the performance of this Indenture; and the Company (to the extent it may lawfully do so) hereby expressly waives all benefit or advantage of any such law, and covenants that it will not, by resort to any such law, hinder, delay or impede the
execution of any power herein granted to the Trustee, but will suffer and permit the execution of every such power as though no such law had been enacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.08<I>. Compliance Certificate; Statements as to Defaults.</I> The Company shall deliver to the Trustee within 120 days after
the end of each fiscal year of the Company (beginning with the fiscal year ending on December&nbsp;31, 2025) an Officer&#8217;s Certificate stating whether the signers thereof have knowledge of any failure by the Company to comply with all
conditions and covenants then required to be performed under this Indenture and, if so, specifying each such failure and the nature thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company shall deliver to the Trustee, as soon as possible, and in any event within 30 days after the Company has knowledge of
any Event of Default or Default, an Officer&#8217;s Certificate setting forth the details of such Event of Default or Default, its status and the action that the Company is taking or proposing to take in respect thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.09<I>. Further Instruments and Acts.</I> Upon request of the Trustee, the Company shall execute and deliver such further
instruments and do such further acts as may be reasonably necessary or proper to carry out more effectively the purposes of this Indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 5 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L<SMALL>ISTS</SMALL> <SMALL>OF</SMALL> H<SMALL>OLDERS</SMALL> <SMALL>AND</SMALL> R<SMALL>EPORTS</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL>
C<SMALL>OMPANY</SMALL> <SMALL>AND</SMALL> <SMALL>THE</SMALL> T<SMALL>RUSTEE</SMALL> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.01<I>. Lists of Holders.</I> The
Company covenants and agrees that it will furnish or cause to be furnished to the Trustee, semiannually, not more than 15 days after each February&nbsp;1 and August&nbsp;1 in each year beginning with February&nbsp;1, 2026, and at such other times as
the Trustee may request in writing, within 30 days after receipt by the Company of any such request (or such lesser time as the Trustee may reasonably request in order to enable it to timely provide any notice to be provided by it hereunder), a list
in such form as the Trustee may reasonably require of the names and addresses of the Holders as of a date not more than 15 days (or such other date as the Trustee may reasonably request in order to so provide any such notices) prior to the time such
information is furnished, except that no such list need be furnished so long as the Trustee is acting as Note Registrar. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.02<I>. Preservation and Disclosure of Lists.</I> The Trustee shall preserve, in as current a form as is reasonably practicable,
all information as to the names and addresses of the Holders contained in the most recent list furnished to it as provided in Section&nbsp;5.01 or maintained by the Trustee in its capacity as Note Registrar, if so acting. The Trustee may destroy any
list furnished to it as provided in Section&nbsp;5.01 upon receipt of a new list so furnished. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 6 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D<SMALL>EFAULTS</SMALL> <SMALL>AND</SMALL> R<SMALL>EMEDIES</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.01<I>. Events of Default.</I> Each of the following events shall be an &#8220;<B>Event of Default</B>&#8221; with respect to
the Notes: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) default in any payment of interest on any Note when due and payable, and the default continues for a period of 30 days;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) default in the payment of principal of any Note when due and payable on the Maturity Date, upon any Optional Redemption, upon any
required repurchase, upon declaration of acceleration or otherwise; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) failure by the Company to comply with its obligation to convert
the Notes in accordance with this Indenture upon exercise of a Holder&#8217;s conversion right and the failure continues for a period of three Business Days; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) failure by the Company to issue a Fundamental Change Company Notice in accordance with Section&nbsp;15.02(c), notice of a Make-Whole
Fundamental Change in accordance with Section&nbsp;14.03(b) or notice of a specified corporate event in accordance with Section&nbsp;14.01(b)(ii) or Section&nbsp;14.01(b)(iii), in each case when due, and the failure continues for a period of five
Business Days; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) failure by the Company to comply with its obligations under Article 11; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) failure by the Company for 60 days after written notice from the Trustee or the Holders of at least 25% in principal amount of the Notes
then outstanding has been received by the Company to comply with any of its other agreements contained in the Notes or this Indenture; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) default by the Company or any Subsidiary of the Company with respect to any mortgage,
agreement or other instrument under which there may be outstanding, or by which there may be secured or evidenced, any indebtedness for money borrowed in excess of $20,000,000 (or its foreign currency equivalent) in the aggregate of the Company
and/or any such Subsidiary, whether such indebtedness exists as of the date of this Indenture or shall thereafter be created (i)&nbsp;resulting in such indebtedness becoming or being declared due and payable or (ii)&nbsp;constituting a failure to
pay the principal or interest of any such debt when due and payable at its stated maturity, upon any required repurchase, upon declaration of acceleration or otherwise; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) a final judgment or judgments for the payment of $20,000,000 (or its foreign currency equivalent) or more (excluding any amounts covered
by insurance) in the aggregate rendered against the Company or any Subsidiary of the Company, which judgment is not discharged, bonded, paid, waived or stayed within 60 days after (i)&nbsp;the date on which the right to appeal thereof has expired if
no such appeal has commenced, or (ii)&nbsp;the date on which all rights to appeal have been extinguished; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the Company or any
Significant Subsidiary shall commence a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to the Company or any such Significant Subsidiary or its debts under any bankruptcy, insolvency or other
similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of the Company or any such Significant Subsidiary or any substantial part of its property, or shall consent to
any such relief or to the appointment of or taking possession by any such official in an involuntary case or other proceeding commenced against it, or shall make a general assignment for the benefit of creditors, or shall fail generally to pay its
debts as they become due; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) an involuntary case or other proceeding shall be commenced against the Company or any Significant
Subsidiary seeking liquidation, reorganization or other relief with respect to the Company or such Significant Subsidiary or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a
trustee, receiver, liquidator, custodian or other similar official of the Company or such Significant Subsidiary or any substantial part of its property, and such involuntary case or other proceeding shall remain undismissed and unstayed for a
period of 30 consecutive days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.02. <I>Acceleration; Rescission and Annulment</I>. If one or more Events of Default shall
have occurred and be continuing (whatever the reason for such Event of Default and whether it shall be voluntary or involuntary or be effected by operation of law or pursuant to any judgment, decree or order of any court or any order, rule or
regulation of any administrative or governmental body), then, and in each and every such case (other than an Event of Default specified in Section&nbsp;6.01(i) or Section&nbsp;6.01(j) with respect to the Company or any of its Significant
Subsidiaries), unless the principal of all of the Notes shall have already become due and payable, either the Trustee or the Holders of at least 25% in aggregate principal amount of the Notes then outstanding determined in accordance with
Section&nbsp;8.04, by notice in writing to the Company (and to the Trustee if given by Holders), may, and the Trustee at the request of such Holders shall, declare 100% of the principal of, and accrued and unpaid interest on, all the Notes to be due
and payable immediately, and upon any such declaration the same shall become and shall automatically be immediately due and payable, anything contained in this Indenture or in the Notes to the contrary notwithstanding. If an Event of Default
specified in Section&nbsp;6.01(i) or Section&nbsp;6.01(j) with respect to the Company or any of its Significant Subsidiaries occurs and is continuing, 100% of the principal of, and accrued and unpaid interest, if any, on, all Notes shall become and
shall automatically be immediately due and payable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The immediately preceding paragraph, however, is subject to the conditions that if, at any
time after the principal of the Notes shall have been so declared due and payable, and before any judgment or decree for the payment of the monies due shall have been obtained or entered as hereinafter provided, the Company shall pay or shall
deposit with the Trustee a sum sufficient to pay installments of accrued and unpaid interest upon all Notes and the principal of any and all Notes that shall have become due otherwise than by acceleration (with interest on overdue installments of
accrued and unpaid interest to the extent that payment of such interest is enforceable under applicable law, and on such principal at the rate borne by the Notes at such time, <I>plus</I> one percent) and amounts due to the Trustee pursuant to
Section&nbsp;7.06, and if (1)&nbsp;rescission would not conflict with any judgment or decree of a court of competent jurisdiction and (2)&nbsp;any and all existing Events of Default under this Indenture, other than the nonpayment of the principal of
and accrued and unpaid interest, if any, on Notes that shall have become due solely by such acceleration, shall have been cured or waived pursuant to Section&nbsp;6.09, then and in every such case (except as provided in the immediately succeeding
sentence) the Holders of a majority in aggregate principal amount of the Notes then outstanding, by written notice to the Company and to the Trustee, may waive all Defaults or Events of Default with respect to the Notes and rescind and annul such
declaration and its consequences and such Default shall cease to exist, and any Event of Default arising therefrom shall be deemed to have been cured for every purpose of this Indenture; but no such waiver or rescission and annulment shall extend to
or shall affect any subsequent Default or Event of Default, or shall impair any right consequent thereon. Notwithstanding anything to the contrary herein, no such waiver or rescission and annulment shall extend to or shall affect any Default or
Event of Default resulting from (i)&nbsp;the nonpayment of the principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, or accrued and unpaid interest on, any Notes, (ii)&nbsp;a failure to repurchase
any Notes when required or (iii)&nbsp;a failure to pay or deliver, as the case may be, the consideration due upon conversion of the Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.03. <I>Additional Interest</I>. Notwithstanding anything in this Indenture or in the Notes to the contrary, to the extent the
Company elects, the sole remedy for an Event of Default relating to the Company&#8217;s failure to comply with its obligations as set forth in Section&nbsp;4.06(b) shall, for the first 180 days after the occurrence of such an Event of Default,
consist exclusively of the right to receive Additional Interest on the Notes at a rate equal to (1) 0.25% per annum of the principal amount of the Notes outstanding for each day during the first 90 days during which such Event of Default is
continuing beginning on, and including, the date on which such Event of Default first occurs and (2) 0.50% per annum of the principal amount of the Notes outstanding for each day during the next 90 days during which such Event of Default is
continuing. Additional Interest payable pursuant to this Section&nbsp;6.03 shall be in addition to, not in lieu of, any Additional Interest payable pursuant to Section&nbsp;4.06(d) or Section&nbsp;4.06(e). If the Company so elects, such Additional
Interest shall be payable in the same manner and on the same dates as the stated interest payable on the Notes. On the 181st day after such Event of Default (if the Event of Default relating to the Company&#8217;s failure to comply with its
obligations set forth in Section&nbsp;4.06(b) is not cured or waived prior to such 181st day), the Notes shall be subject to acceleration as provided in Section&nbsp;6.02 and Additional Interest pursuant to this Section&nbsp;6.03 shall cease to
accrue. The provisions of this paragraph will not affect the rights of Holders of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Notes in the event of the occurrence of any Event of Default other than the Company&#8217;s failure to comply with its obligations as set forth in Section&nbsp;4.06(b). In the event the Company
does not elect to pay Additional Interest following an Event of Default in accordance with this Section&nbsp;6.03 or the Company elected to make such payment but does not pay the Additional Interest when due, the Notes shall be immediately subject
to acceleration as provided in Section&nbsp;6.02. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to elect to pay Additional Interest as the sole remedy during the first 180
days after the occurrence of any Event of Default described in the immediately preceding paragraph, the Company must notify all Holders of the Notes, the Trustee and the Paying Agent of such election prior to the beginning of such <FONT
STYLE="white-space:nowrap">180-day</FONT> period. Upon the failure to timely give such notice, the Notes shall be immediately subject to acceleration as provided in Section&nbsp;6.02. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.04<I>. Payments of Notes on Default; Suit Therefor.</I> If an Event of Default described in clause (a)&nbsp;or (b) of
Section&nbsp;6.01 shall have occurred, the Company shall, upon demand of the Trustee, pay to the Trustee, for the benefit of the Holders of the Notes, the whole amount then due and payable on the Notes for principal and interest, if any, with
interest on any overdue principal and interest, if any, at the rate borne by the Notes at such time, <I>plus</I> one percent, and, in addition thereto, such further amount as shall be sufficient to cover any amounts due to the Trustee under
Section&nbsp;7.06. If the Company shall fail to pay such amounts forthwith upon such demand, the Trustee, in its own name and as trustee of an express trust, may institute a judicial proceeding for the collection of the sums so due and unpaid, may
prosecute such proceeding to judgment or final decree and may enforce the same against the Company or any other obligor upon the Notes and collect the moneys adjudged or decreed to be payable in the manner provided by law out of the property of the
Company or any other obligor upon the Notes, wherever situated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event there shall be pending proceedings for the bankruptcy or for
the reorganization of the Company or any other obligor on the Notes under Title 11 of the United States Code, or any other applicable law, or in case a receiver, assignee or trustee in bankruptcy or reorganization, liquidator, sequestrator or
similar official shall have been appointed for or taken possession of the Company or such other obligor, the property of the Company or such other obligor, or in the event of any other judicial proceedings relative to the Company or such other
obligor upon the Notes, or to the creditors or property of the Company or such other obligor, the Trustee, irrespective of whether the principal of the Notes shall then be due and payable as therein expressed or by declaration or otherwise and
irrespective of whether the Trustee shall have made any demand pursuant to the provisions of this Section&nbsp;6.04, shall be entitled and empowered, by intervention in such proceedings or otherwise, to file and prove a claim or claims for the whole
amount of principal and accrued and unpaid interest, if any, in respect of the Notes, and, in case of any judicial proceedings, to file such proofs of claim and other papers or documents and to take such other actions as it may deem necessary or
advisable in order to have the claims of the Trustee (including any claim for the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel) and of the Holders allowed in such judicial proceedings relative
to the Company or any other obligor on the Notes, its or their creditors, or its or their property, and to collect and receive any monies or other property payable or deliverable on any such claims, and to distribute the same after the deduction of
any amounts due to the Trustee hereunder; and any receiver, assignee or trustee in bankruptcy or reorganization, liquidator, custodian or similar official is hereby authorized by each of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Holders to make such payments to the Trustee, as administrative expenses, and, in the event that the Trustee shall consent to the making of such payments directly to the Holders, to pay to the
Trustee any amount due it for reasonable compensation, expenses, advances and disbursements, including agents and counsel fees, and including any other amounts due to the Trustee hereunder, incurred by it up to the date of such distribution. To the
extent that such payment of reasonable compensation, expenses, advances and disbursements out of the estate in any such proceedings shall be denied for any reason, payment of the same shall be secured by a lien on, and shall be paid out of, any and
all distributions, dividends, monies, securities and other property that the Holders of the Notes may be entitled to receive in such proceedings, whether in liquidation or under any plan of reorganization or arrangement or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Holder any
plan of reorganization, arrangement, adjustment or composition affecting such Holder or the rights of any Holder thereof, or to authorize the Trustee to vote in respect of the claim of any Holder in any such proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All rights of action and of asserting claims under this Indenture, or under any of the Notes, may be enforced by the Trustee without the
possession of any of the Notes, or the production thereof at any trial or other proceeding relative thereto, and any such suit or proceeding instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery
of judgment shall, after provision for the payment of the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel, be for the ratable benefit of the Holders of the Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any proceedings brought by the Trustee (and in any proceedings involving the interpretation of any provision of this Indenture to which the
Trustee shall be a party) the Trustee shall be held to represent all the Holders of the Notes, and it shall not be necessary to make any Holders of the Notes parties to any such proceedings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case the Trustee shall have proceeded to enforce any right under this Indenture and such proceedings shall have been discontinued or
abandoned because of any waiver pursuant to Section&nbsp;6.09 or any rescission and annulment pursuant to Section&nbsp;6.02 or for any other reason or shall have been determined adversely to the Trustee, then and in every such case the Company, the
Holders and the Trustee shall, subject to any determination in such proceeding, be restored respectively to their several positions and rights hereunder, and all rights, remedies and powers of the Company, the Holders and the Trustee shall continue
as though no such proceeding had been instituted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.05<I>. Application of Monies Collected by Trustee.</I> Any monies
collected by the Trustee pursuant to this Article 6 with respect to the Notes shall be applied in the following order, at the date or dates fixed by the Trustee for the distribution of such monies, upon presentation of the several Notes, and
stamping thereon the payment, if only partially paid, and upon surrender thereof, if fully paid: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>First</B>, to the payment of all
amounts due the Trustee (acting in any capacity hereunder); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Second</B>, in case the principal of the outstanding Notes shall not have become due and
be unpaid, to the payment of interest on, and any cash due upon conversion of, the Notes in default in the order of the date due of the payments of such interest and cash due upon conversion, as the case may be, with interest (to the extent that
such interest has been collected by the Trustee) upon such overdue payments at the rate borne by the Notes at such time, <I>plus</I> one percent, such payments to be made ratably to the Persons entitled thereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Third</B>, in case the principal of the outstanding Notes shall have become due, by declaration or otherwise, and be unpaid to the payment
of the whole amount (including, if applicable, the payment of the Redemption Price and the Fundamental Change Repurchase Price and any cash due upon conversion) then owing and unpaid upon the Notes for principal and interest, if any, with interest
on the overdue principal and, to the extent that such interest has been collected by the Trustee, upon overdue installments of interest at the rate borne by the Notes at such time <I>plus</I> one percent, and in case such monies shall be
insufficient to pay in full the whole amounts so due and unpaid upon the Notes, then to the payment of such principal (including, if applicable, the Redemption Price and the Fundamental Change Repurchase Price and the cash due upon conversion) and
interest without preference or priority of principal over interest, or of interest over principal or of any installment of interest over any other installment of interest, or of any Note over any other Note, ratably to the aggregate of such
principal (including, if applicable, the Redemption Price and the Fundamental Change Repurchase Price and any cash due upon conversion) and accrued and unpaid interest; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Fourth</B>, to the payment of the remainder, if any, to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.06<I>. Proceedings by Holders.</I> Except to enforce the right to receive payment of principal (including, if applicable, the
Redemption Price and the Fundamental Change Repurchase Price) or interest when due, or the right to receive payment or delivery of the consideration due upon conversion, no Holder of any Note shall have any right by virtue of or by availing of any
provision of this Indenture to institute any suit, action or proceeding in equity or at law upon or under or with respect to this Indenture, or for the appointment of a receiver, trustee, liquidator, custodian or other similar official, or for any
other remedy hereunder, unless: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) such Holder previously shall have given to the Trustee written notice of an Event of Default and of
the continuance thereof, as herein provided; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Holders of at least 25% in aggregate principal amount of the Notes then outstanding
shall have made written request upon the Trustee to institute such action, suit or proceeding in its own name as Trustee hereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
such Holders shall have offered to the Trustee such security or indemnity reasonably satisfactory to the Trustee against any loss, liability or expense to be incurred therein or thereby; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) the Trustee for 60 days after its receipt of such notice, request and offer of such security or indemnity, shall have neglected or refused
to institute any such action, suit or proceeding; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) no direction that, in the opinion of the Trustee, is inconsistent with such written
request shall have been given to the Trustee by the Holders of a majority of the aggregate principal amount of the Notes then outstanding within such <FONT STYLE="white-space:nowrap">60-day</FONT> period pursuant to Section&nbsp;6.09, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">it being understood and intended, and being expressly covenanted by the taker and Holder of every Note with every other taker and Holder and the Trustee that
no one or more Holders shall have any right in any manner whatever by virtue of or by availing of any provision of this Indenture to affect, disturb or prejudice the rights of any other Holder, or to obtain or seek to obtain priority over or
preference to any other such Holder, or to enforce any right under this Indenture, except in the manner herein provided and for the equal, ratable and common benefit of all Holders (except as otherwise provided herein). For the protection and
enforcement of this Section&nbsp;6.06, each and every Holder and the Trustee shall be entitled to such relief as can be given either at law or in equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision of this Indenture and any provision of any Note, each Holder shall have the right to receive payment or
delivery, as the case may be, of (x)&nbsp;the principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, (y)&nbsp;accrued and unpaid interest, if any, on, and (z)&nbsp;the consideration due upon
conversion of, such Note, on or after the respective due dates expressed or provided for in such Note or in this Indenture, or to institute suit for the enforcement of any such payment or delivery, as the case may be. Notwithstanding the foregoing
and for the avoidance of doubt, no amendment to, or deletion or waiver of any of, the provisions set forth in this Indenture or any action taken by the Company not prohibited by this Indenture (other than any action pursuant to Section&nbsp;10.02
that requires the consent of each Holder of an outstanding Note affected) shall be deemed to impair or affect any rights of any Holder to receive such payment or delivery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.07<I>. Proceedings by Trustee.</I> In case of an Event of Default, the Trustee may in its discretion proceed to protect and
enforce the rights vested in it by this Indenture by such appropriate judicial proceedings as are necessary to protect and enforce any of such rights, either by suit in equity or by action at law or by proceeding in bankruptcy or otherwise, whether
for the specific enforcement of any covenant or agreement contained in this Indenture or in aid of the exercise of any power granted in this Indenture, or to enforce any other legal or equitable right vested in the Trustee by this Indenture or by
law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.08<I>. Remedies Cumulative and Continuing.</I> Except as provided in the last paragraph of Section&nbsp;2.06, all
powers and remedies given by this Article 6 to the Trustee or to the Holders shall, to the extent permitted by law, be deemed cumulative and not exclusive of any thereof or of any other powers and remedies available to the Trustee or the Holders of
the Notes, by judicial proceedings or otherwise, to enforce the performance or observance of the covenants and agreements contained in this Indenture, and no delay or omission of the Trustee or of any Holder of any of the Notes to exercise any right
or power accruing upon any Default or Event of Default shall impair any such right or power, or shall be construed to be a waiver of any such Default or Event of Default or any acquiescence therein; and, subject to the provisions of
Section&nbsp;6.06, every power and remedy given by this Article 6 or by law to the Trustee or to the Holders may be exercised from time to time, and as often as shall be deemed expedient, by the Trustee or by the Holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.09<I>. Direction of Proceedings and Waiver of Defaults by Majority of
Holders.</I> The Holders of a majority of the aggregate principal amount of the Notes at the time outstanding determined in accordance with Section&nbsp;8.04 shall have the right to direct the time, method and place of conducting any proceeding for
any remedy available to the Trustee or exercising any trust or power conferred on the Trustee with respect to the Notes; <I>provided</I>, <I>however</I>, that (a)&nbsp;such direction shall not be in conflict with any rule of law or with this
Indenture, and (b)&nbsp;the Trustee may take any other action deemed proper by the Trustee that is not inconsistent with such direction. The Trustee may refuse to follow any direction that it determines is unduly prejudicial to the rights of any
other Holder or that would involve the Trustee in personal liability. The Holders of a majority in aggregate principal amount of the Notes at the time outstanding determined in accordance with Section&nbsp;8.04 may on behalf of the Holders of all of
the Notes waive any past Default or Event of Default hereunder and its consequences except (i)&nbsp;a default in the payment of accrued and unpaid interest, if any, on, or the principal (including any Redemption Price and any Fundamental Change
Repurchase Price) of, the Notes when due that has not been cured, (ii)&nbsp;a failure by the Company to pay or deliver, as the case may be, the consideration due upon conversion of the Notes or (iii)&nbsp;a default in respect of a covenant or
provision hereof which under Article 10 cannot be modified or amended without the consent of each Holder of an outstanding Note affected. Upon any such waiver the Company, the Trustee and the Holders of the Notes shall be restored to their former
positions and rights hereunder; but no such waiver shall extend to any subsequent or other Default or Event of Default or impair any right consequent thereon. Whenever any Default or Event of Default hereunder shall have been waived as permitted by
this Section&nbsp;6.09, said Default or Event of Default shall for all purposes of the Notes and this Indenture be deemed to have been cured and to be not continuing; but no such waiver shall extend to any subsequent or other Default or Event of
Default or impair any right consequent thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.10<I>. Notice of Defaults.</I> The Trustee shall, within 90 days after the
occurrence and continuance of a Default of which a Responsible Officer has actual knowledge, deliver to all Holders notice of all Defaults known to a Responsible Officer, unless such Defaults shall have been cured or waived before the giving of such
notice; <I>provided</I> that, except in the case of a Default in the payment of the principal of (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable), or accrued and unpaid interest on, any of the Notes or a
Default in the payment or delivery of the consideration due upon conversion, the Trustee shall be protected in withholding such notice if and so long it determines that the withholding of such notice is in the interests of the Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.11<I>. Undertaking to Pay Costs.</I> All parties to this Indenture agree, and each Holder of any Note by its acceptance thereof
shall be deemed to have agreed, that any court may, in its discretion, require, in any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action taken or omitted by it as Trustee, the
filing by any party litigant in such suit of an undertaking to pay the costs of such suit and that such court may in its discretion assess reasonable costs, including reasonable attorneys&#8217; fees and expenses, against any party litigant in such
suit, having due regard to the merits and good faith of the claims or defenses made by such party litigant; <I>provided</I> that the provisions of this Section&nbsp;6.11 (to the extent permitted by law) shall not apply to any suit instituted by the
Trustee, to any suit instituted by any Holder, or group of Holders, holding in the aggregate more than 10% in principal amount of the Notes at the time outstanding determined in accordance with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Section 8.04, or to any suit instituted by any Holder for the enforcement of the payment of the principal of or accrued and unpaid interest, if any, on any Note (including, but not limited to,
the Redemption Price and the Fundamental Change Repurchase Price, if applicable) on or after the due date expressed or provided for in such Note or to any suit for the enforcement of the right to convert any Note, or receive the consideration due
upon conversion, in accordance with the provisions of Article 14. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 7 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C<SMALL>ONCERNING</SMALL> <SMALL>THE</SMALL> T<SMALL>RUSTEE</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.01<I>. Duties and Responsibilities of Trustee.</I> The Trustee, prior to the occurrence of an Event of Default and after the
curing or waiver of all Events of Default that may have occurred, undertakes to perform such duties and only such duties as are specifically set forth in this Indenture. In the event an Event of Default has occurred and is continuing, the Trustee
shall exercise such of the rights and powers vested in it by this Indenture, and use the same degree of care and skill in its exercise, as a prudent person would exercise or use under the circumstances in the conduct of such person&#8217;s own
affairs; <I>provided</I> that if an Event of Default occurs and is continuing, the Trustee will be under no obligation to exercise any of the rights or powers under this Indenture at the request or direction of any of the Holders unless such Holders
have offered to the Trustee indemnity or security reasonably satisfactory to the Trustee against any loss, liability or expense that might be incurred by it in compliance with such request or direction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No provision of this Indenture shall be construed to relieve the Trustee from liability for its own grossly negligent action, its own grossly
negligent failure to act or its own willful misconduct, except that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) prior to the occurrence of an Event of Default and after the
curing or waiving of all Events of Default that may have occurred: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the duties and obligations of the Trustee shall be
determined solely by the express provisions of this Indenture, and the Trustee shall not be liable except for the performance of such duties and obligations as are specifically set forth in this Indenture and no implied covenants or obligations
shall be read into this Indenture against the Trustee; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) in the absence of gross negligence and willful misconduct
on the part of the Trustee, the Trustee may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon any certificates or opinions furnished to the Trustee and conforming to the requirements of
this Indenture; but, in the case of any such certificates or opinions that by any provisions hereof are specifically required to be furnished to the Trustee, the Trustee shall be under a duty to examine the same to determine whether or not they
conform to the requirements of this Indenture (but need not confirm or investigate the accuracy of any mathematical calculations or other facts stated therein); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the Trustee shall not be liable for any error of judgment made in good faith by a
Responsible Officer or Officers of the Trustee, unless it shall be proved that the Trustee was grossly negligent in ascertaining the pertinent facts; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the Trustee shall not be liable with respect to any action taken or omitted to be taken by it in good faith in accordance with the
direction of the Holders of not less than a majority of the aggregate principal amount of the Notes at the time outstanding determined as provided in Section&nbsp;8.04 relating to the time, method and place of conducting any proceeding for any
remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee, under this Indenture; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) whether or not
therein provided, every provision of this Indenture relating to the conduct or affecting the liability of, or affording protection to, the Trustee shall be subject to the provisions of this Section; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the Trustee shall not be liable in respect of any payment (as to the correctness of amount, entitlement to receive or any other matters
relating to payment) or notice effected by the Company or any Paying Agent or any records maintained by any <FONT STYLE="white-space:nowrap">co-Note</FONT> Registrar with respect to the Notes; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) if any party fails to deliver a notice relating to an event the fact of which, pursuant to this Indenture, requires notice to be sent to
the Trustee, the Trustee may conclusively rely on its failure to receive such notice as reason to act as if no such event occurred, unless a Responsible Officer of the Trustee had actual knowledge of such event; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) in the absence of written investment direction from the Company, all cash received by the Trustee shall be placed in a <FONT
STYLE="white-space:nowrap">non-interest</FONT> bearing trust account, and in no event shall the Trustee be liable for the selection of investments or for investment losses incurred thereon or for losses incurred as a result of the liquidation of any
such investment prior to its maturity date or the failure of the party directing such investments prior to its maturity date or the failure of the party directing such investment to provide timely written investment direction, and the Trustee shall
have no obligation to invest or reinvest any amounts held hereunder in the absence of such written investment direction from the Company; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) in the event that the Trustee is also acting as Custodian, Note Registrar, Paying Agent, Conversion Agent, Bid Solicitation Agent or
transfer agent hereunder, the rights and protections afforded to the Trustee pursuant to this Article 7 shall also be afforded to such Custodian, Note Registrar, Paying Agent, Conversion Agent, Bid Solicitation Agent or transfer agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the provisions contained in this Indenture shall require the Trustee to expend or risk its own funds or otherwise incur personal
financial liability in the performance of any of its duties or in the exercise of any of its rights or powers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.02<I>. Reliance on Documents, Opinions, Etc.</I> Except as otherwise provided
in Section&nbsp;7.01: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the Trustee may conclusively rely and shall be fully protected in acting upon any resolution, certificate,
statement, instrument, opinion, report, notice, request, consent, order, bond, note, coupon or other paper or document believed by it in good faith to be genuine and to have been signed or presented by the proper party or parties; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) any request, direction, order or demand of the Company mentioned herein shall be sufficiently evidenced by an Officer&#8217;s Certificate
(unless other evidence in respect thereof be herein specifically prescribed); and any Board Resolution may be evidenced to the Trustee by a copy thereof certified by the Secretary or an Assistant Secretary of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the Trustee may consult with counsel and require an Opinion of Counsel and any advice of such counsel or Opinion of Counsel shall be full
and complete authorization and protection in respect of any action taken or omitted by it hereunder in good faith and in accordance with such advice or Opinion of Counsel; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) the Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement,
instrument, opinion, report, notice, request, direction, consent, order, bond, debenture or other paper or document, but the Trustee, in its discretion, may make such further inquiry or investigation into such facts or matters as it may see fit,
and, if the Trustee shall determine to make such further inquiry or investigation, it shall be entitled to examine the books, records and premises of the Company, personally or by agent or attorney at the expense of the Company and shall incur no
liability of any kind by reason of such inquiry or investigation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the Trustee may execute any of the trusts or powers hereunder or
perform any duties hereunder either directly or by or through agents, custodians, nominees or attorneys and the Trustee shall not be responsible for any misconduct or negligence on the part of any agent, custodian, nominee or attorney appointed by
it with due care hereunder; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) the permissive rights of the Trustee enumerated herein shall not be construed as duties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In no event shall the Trustee be liable for any consequential loss or damage of any kind whatsoever (including but not limited to lost
profits, punitive damages or special damages), even if the Trustee has been advised of the likelihood of such loss or damage and regardless of the form of action. The Trustee shall not be charged with knowledge of any Default or Event of Default
with respect to the Notes other than a Default or Event of Default arising out of a failure to pay the principal of, or interest on, the Notes (including, if applicable, the Fundamental Change Repurchase Price and the Redemption Price), unless
either (1)&nbsp;a Responsible Officer shall have actual knowledge of such Default or Event of Default or (2)&nbsp;written notice of such Default or Event of Default shall have been given to the Trustee by the Company or by any Holder of the Notes.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.03<I>. No Responsibility for Recitals, Etc.</I> The recitals contained herein and in the Notes (except in the
Trustee&#8217;s certificate of authentication) shall be taken as the statements of the Company, and the Trustee assumes no responsibility for the correctness of the same. The Trustee makes no representations as to the validity or sufficiency of this
Indenture or of the Notes. The Trustee shall not be accountable for the use or application by the Company of any Notes or the proceeds of any Notes authenticated and delivered by the Trustee in conformity with the provisions of this Indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.04<I>. Trustee, Paying Agents, Conversion Agents, Bid Solicitation Agent or
Note Registrar May Own Notes.</I> The Trustee, any Paying Agent, any Conversion Agent, the Bid Solicitation Agent (if other than the Company or any Affiliate thereof) or the Note Registrar, in its individual or any other capacity, may become the
owner or pledgee of Notes with the same rights it would have if it were not the Trustee, Paying Agent, Conversion Agent, Bid Solicitation Agent or Note Registrar. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.05<I>. Monies and Shares of Class</I><I></I><I>&nbsp;A Common Stock to Be Held in Trust.</I> All monies and shares of
Class&nbsp;A Common Stock received by the Trustee shall, until used or applied as herein provided, be held in trust for the purposes for which they were received. Money and shares of Class&nbsp;A Common Stock held by the Trustee in trust hereunder
need not be segregated from other funds except to the extent required by law. The Trustee shall be under no liability for interest on any money or shares of Class&nbsp;A Common Stock received by it hereunder except as may be agreed from time to time
by the Company and the Trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.06<I>. Compensation and Expenses of Trustee.</I> The Company covenants and agrees to pay
to the Trustee (in any capacity hereunder) from time to time, and the Trustee shall be entitled to, reasonable compensation for all services rendered by it hereunder in any capacity (which shall not be limited by any provision of law in regard to
the compensation of a trustee of an express trust) as mutually agreed to in writing between the Trustee and the Company, and the Company will pay or reimburse the Trustee upon its request for all reasonable expenses, disbursements and advances
reasonably incurred or made by the Trustee in accordance with any of the provisions of this Indenture in any capacity hereunder (including the reasonable compensation and the expenses and disbursements of its agents and counsel and of all Persons
not regularly in its employ) except any such expense, disbursement or advance as shall have been caused by its gross negligence, willful misconduct or bad faith as determined by a court of competent jurisdiction in a final <FONT
STYLE="white-space:nowrap">non-appealable</FONT> order. The Company also covenants to indemnify the Trustee in any capacity under this Indenture and any other document or transaction entered into in connection herewith and its agents and any
authenticating agent for, and to hold them harmless against, any loss, claim, damage, liability or expense incurred without gross negligence, willful misconduct or bad faith (as determined by a court of competent jurisdiction in a final <FONT
STYLE="white-space:nowrap">non-appealable</FONT> order) on the part of the Trustee, its officers, directors, agents or employees, or such agent or authenticating agent, as the case may be, and arising out of or in connection with the acceptance or
administration of this Indenture or in any other capacity hereunder, including the costs and expenses of defending themselves against any claim of liability in the premises. The obligations of the Company under this Section&nbsp;7.06 to compensate
or indemnify the Trustee and to pay or reimburse the Trustee for expenses, disbursements and advances shall be secured by a senior claim to which the Notes are hereby made subordinate on all money or property held or collected by the Trustee,
except, subject to the effect of Section&nbsp;6.05, funds held in trust herewith for the benefit of the Holders of particular Notes. The Trustee&#8217;s right to receive payment of any amounts due hereunder shall not be subordinate to any other
liability or indebtedness of the Company. The obligation of the Company under this Article 7 shall survive the satisfaction and discharge of this Indenture and the earlier resignation or removal of the Trustee. The Company need not pay for any
settlement made without its consent, which consent shall not be unreasonably withheld. The indemnification provided in this Section&nbsp;7.06 shall extend to the officers, directors, agents and employees of the Trustee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Without prejudice to any other rights available to the Trustee under applicable law, when
the Trustee and its agents and any authenticating agent incur expenses or render services after an Event of Default specified in Section&nbsp;6.01(i) or Section&nbsp;6.01(j) occurs, the expenses and the compensation for the services are intended to
constitute expenses of administration under any bankruptcy, insolvency or similar laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.07<I>.
Officer</I><I>&#8217;</I><I>s Certificate as Evidence. </I>Except as otherwise provided in Section&nbsp;7.01, whenever in the administration of the provisions of this Indenture the Trustee shall deem it necessary or desirable that a matter be proved
or established prior to taking or omitting any action hereunder, such matter (unless other evidence in respect thereof be herein specifically prescribed) may, in the absence of gross negligence, willful misconduct, recklessness and bad faith on the
part of the Trustee, be deemed to be conclusively proved and established by an Officer&#8217;s Certificate delivered to the Trustee, and such Officer&#8217;s Certificate, in the absence of gross negligence, willful misconduct, recklessness and bad
faith on the part of the Trustee, shall be full warrant to the Trustee for any action taken or omitted by it under the provisions of this Indenture upon the faith thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.08<I>. Eligibility of Trustee.</I> There shall at all times be a Trustee hereunder which shall be a Person that is eligible
pursuant to the Trust Indenture Act (as if the Trust Indenture Act were applicable hereto) to act as such and has a combined capital and surplus of at least $50,000,000. If such Person publishes reports of condition at least annually, pursuant to
law or to the requirements of any supervising or examining authority, then for the purposes of this Section, the combined capital and surplus of such Person shall be deemed to be its combined capital and surplus as set forth in its most recent
report of condition so published. If at any time the Trustee shall cease to be eligible in accordance with the provisions of this Section, it shall resign immediately in the manner and with the effect hereinafter specified in this Article. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.09<I>. Resignation or Removal of Trustee.</I> (a)&nbsp;The Trustee may at any time resign by giving written notice of such
resignation to the Company and by delivering notice thereof to the Holders. Upon receiving such notice of resignation, the Company shall promptly appoint a successor trustee by written instrument, in duplicate, executed by order of the Board of
Directors, one copy of which instrument shall be delivered to the resigning Trustee and one copy to the successor trustee. If no successor trustee shall have been so appointed and have accepted appointment within 60 days after the giving of such
notice of resignation to the Holders, the resigning Trustee may, upon ten Business Days&#8217; notice to the Company and the Holders, petition any court of competent jurisdiction for the appointment of a successor trustee, or any Holder who has been
a bona fide holder of a Note or Notes for at least six months (or since the date of this Indenture) may, subject to the provisions of Section&nbsp;6.11, on behalf of himself or herself and all others similarly situated, petition any such court for
the appointment of a successor trustee. Such court may thereupon, after such notice, if any, as it may deem proper and prescribe, appoint a successor trustee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In case at any time any of the following shall occur: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the Trustee shall cease to be eligible in accordance with the provisions of Section&nbsp;7.08 and shall fail to resign
after written request therefor by the Company or by any such Holder, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the Trustee shall become incapable of acting,
or shall be adjudged a bankrupt or insolvent, or a receiver of the Trustee or of its property shall be appointed, or any public officer shall take charge or control of the Trustee or of its property or affairs for the purpose of rehabilitation,
conservation or liquidation, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then, in either case, the Company may by a Board Resolution remove the Trustee and appoint a successor trustee by written
instrument, in duplicate, executed by order of the Board of Directors, one copy of which instrument shall be delivered to the Trustee so removed and one copy to the successor trustee, or, subject to the provisions of Section&nbsp;6.11, any Holder
who has been a bona fide holder of a Note or Notes for at least six months (or since the date of this Indenture) may, on behalf of himself or herself and all others similarly situated, petition any court of competent jurisdiction for the removal of
the Trustee and the appointment of a successor trustee. Such court may thereupon, after such notice, if any, as it may deem proper and prescribe, remove the Trustee and appoint a successor trustee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Holders of a majority in aggregate principal amount of the Notes at the time outstanding, as determined in accordance with
Section&nbsp;8.04, may at any time remove the Trustee and nominate a successor trustee that shall be deemed appointed as successor trustee unless within ten days after notice to the Company of such nomination the Company objects thereto, in which
case the Trustee so removed or any Holder, upon the terms and conditions and otherwise as in Section&nbsp;7.09(a) provided, may petition any court of competent jurisdiction for an appointment of a successor trustee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Any resignation or removal of the Trustee and appointment of a successor trustee pursuant to any of the provisions of this
Section&nbsp;7.09 shall become effective upon acceptance of appointment by the successor trustee as provided in Section&nbsp;7.10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.10<I>. Acceptance by Successor Trustee.</I> Any successor trustee appointed as provided in Section&nbsp;7.09 shall execute,
acknowledge and deliver to the Company and to its predecessor trustee an instrument accepting such appointment hereunder, and thereupon the resignation or removal of the predecessor trustee shall become effective and such successor trustee, without
any further act, deed or conveyance, shall become vested with all the rights, powers, duties and obligations of its predecessor hereunder, with like effect as if originally named as Trustee herein; but, nevertheless, on the written request of the
Company or of the successor trustee, the trustee ceasing to act shall, upon payment of any amounts then due it pursuant to the provisions of Section&nbsp;7.06, execute and deliver an instrument transferring to such successor trustee all the rights
and powers of the trustee so ceasing to act. Upon request of any such successor trustee, the Company shall execute any and all instruments in writing for more fully and certainly vesting in and confirming to such successor trustee all such rights
and powers. Any trustee ceasing to act shall, nevertheless, retain a senior claim to which the Notes are hereby made subordinate on all money or property held or collected by such trustee as such, except for funds held in trust for the benefit of
Holders of particular Notes, to secure any amounts then due it pursuant to the provisions of Section&nbsp;7.06. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No successor trustee shall accept appointment as provided in this Section&nbsp;7.10 unless
at the time of such acceptance such successor trustee shall be eligible under the provisions of Section&nbsp;7.08. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon acceptance of
appointment by a successor trustee as provided in this Section&nbsp;7.10, each of the Company and the successor trustee, at the written direction and at the expense of the Company shall deliver or cause to be delivered notice of the succession of
such trustee hereunder to the Holders. If the Company fails to deliver such notice within ten days after acceptance of appointment by the successor trustee, the successor trustee shall cause such notice to be delivered at the expense of the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.11<I>. Succession by Merger, Etc.</I> Any corporation or other entity into which the Trustee may be merged or converted or
with which it may be consolidated, or any corporation or other entity resulting from any merger, conversion or consolidation to which the Trustee shall be a party, or any corporation or other entity succeeding to all or substantially all of the
corporate trust business of the Trustee (including the administration of this Indenture), shall be the successor to the Trustee hereunder without the execution or filing of any paper or any further act on the part of any of the parties hereto;
<I>provided</I> that in the case of any corporation or other entity succeeding to all or substantially all of the corporate trust business of the Trustee such corporation or other entity shall be eligible under the provisions of Section&nbsp;7.08.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case at the time such successor to the Trustee shall succeed to the trusts created by this Indenture, any of the Notes shall have been
authenticated but not delivered, any such successor to the Trustee may adopt the certificate of authentication of any predecessor trustee or authenticating agent appointed by such predecessor trustee, and deliver such Notes so authenticated; and in
case at that time any of the Notes shall not have been authenticated, any successor to the Trustee or an authenticating agent appointed by such successor trustee may authenticate such Notes either in the name of any predecessor trustee hereunder or
in the name of the successor trustee; and in all such cases such certificates shall have the full force which it is anywhere in the Notes or in this Indenture provided that the certificate of the Trustee shall have; <I>provided</I>, <I>however</I>,
that the right to adopt the certificate of authentication of any predecessor trustee or to authenticate Notes in the name of any predecessor trustee shall apply only to its successor or successors by merger, conversion or consolidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.12<I>. Trustee</I><I>&#8217;</I><I>s Application for Instructions from the Company.</I> Any application by the Trustee for
written instructions from the Company (other than with regard to any action proposed to be taken or omitted to be taken by the Trustee that affects the rights of the Holders of the Notes under this Indenture) may, at the option of the Trustee, set
forth in writing any action proposed to be taken or omitted by the Trustee under this Indenture and the date on and/or after which such action shall be taken or such omission shall be effective. The Trustee shall not be liable to the Company for any
action taken by, or omission of, the Trustee in accordance with a proposal included in such application on or after the date specified in such application (which date shall not be less than three Business Days after the date any officer that the
Company has indicated to the Trustee should receive such application actually receives such application, unless any such officer shall have consented in writing to any earlier date), unless, prior to taking any such action (or the effective date in
the case of any omission), the Trustee shall have received written instructions in accordance with this Indenture in response to such application specifying the action to be taken or omitted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 8 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C<SMALL>ONCERNING</SMALL> <SMALL>THE</SMALL> H<SMALL>OLDERS</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.01<I>. Action by Holders.</I> Whenever in this Indenture it is provided that the Holders of a specified percentage of the
aggregate principal amount of the Notes may take any action (including the making of any demand or request, the giving of any notice, consent or waiver or the taking of any other action), the fact that at the time of taking any such action, the
Holders of such specified percentage have joined therein may be evidenced (a)&nbsp;by any instrument or any number of instruments of similar tenor executed by Holders in person or by agent or proxy appointed in writing, or (b)&nbsp;by the record of
the Holders voting in favor thereof at any meeting of Holders duly called and held in accordance with the provisions of Article 9, or (c)&nbsp;by a combination of such instrument or instruments and any such record of such a meeting of Holders.
Whenever the Company or the Trustee solicits the taking of any action by the Holders of the Notes, the Company or the Trustee may, but shall not be required to, fix in advance of such solicitation, a date as the record date for determining Holders
entitled to take such action. The record date if one is selected shall be not more than fifteen days prior to the date of commencement of solicitation of such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.02<I>. Proof of Execution by Holders.</I> Subject to the provisions of Section&nbsp;7.01, Section&nbsp;7.02 and
Section&nbsp;9.05, proof of the execution of any instrument by a Holder or its agent or proxy shall be sufficient if made in accordance with such reasonable rules and regulations as may be prescribed by the Trustee or in such manner as shall be
satisfactory to the Trustee. The holding of Notes shall be proved by the Note Register or by a certificate of the Note Registrar. The record of any Holders&#8217; meeting shall be proved in the manner provided in Section&nbsp;9.06. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.03<I>. Persons Who Are Deemed Absolute Owners.</I> The Company, the Trustee, any authenticating agent, any Paying Agent, any
Conversion Agent and any Note Registrar may deem the Person in whose name a Note shall be registered upon the Note Register to be, and may treat it as, the absolute owner of such Note (whether or not such Note shall be overdue and notwithstanding
any notation of ownership or other writing thereon made by any Person other than the Company or any Note Registrar) for the purpose of receiving payment of or on account of the principal (including any Redemption Price and any Fundamental Change
Repurchase Price) of and (subject to Section&nbsp;2.03) accrued and unpaid interest on such Note, for conversion of such Note and for all other purposes; and neither the Company nor the Trustee nor any Paying Agent nor any Conversion Agent nor any
Note Registrar shall be affected by any notice to the contrary. All such payments or deliveries so made to any Holder for the time being, or upon its order, shall be valid, and, to the extent of the sums or shares of Class&nbsp;A Common Stock so
paid or delivered, effectual to satisfy and discharge the liability for monies payable or shares deliverable upon any such Note. Notwithstanding anything to the contrary in this Indenture or the Notes following an Event of Default, any holder of a
beneficial interest in a Global Note may directly enforce against the Company, without the consent, solicitation, proxy, authorization or any other action of the Depositary or any other Person, such holder&#8217;s right to exchange such beneficial
interest for a Note in certificated form in accordance with the provisions of this Indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.04<I>. Company-Owned Notes Disregarded.</I> In determining whether the
Holders of the requisite aggregate principal amount of Notes have concurred in any direction, consent, waiver or other action under this Indenture, Notes that are owned by the Company, by any Subsidiary thereof or by any Affiliate of the Company or
any Subsidiary thereof shall be disregarded and deemed not to be outstanding for the purpose of any such determination; <I>provided</I> that for the purposes of determining whether the Trustee shall be protected in relying on any such direction,
consent, waiver or other action only Notes that a Responsible Officer knows are so owned shall be so disregarded. Notes so owned that have been pledged in good faith may be regarded as outstanding for the purposes of this Section&nbsp;8.04 if the
pledgee shall establish to the satisfaction of the Trustee the pledgee&#8217;s right to so act with respect to such Notes and that the pledgee is not the Company, a Subsidiary thereof or an Affiliate of the Company or a Subsidiary thereof. In the
case of a dispute as to such right, any decision by the Trustee taken upon the advice of counsel shall be full protection to the Trustee. Upon request of the Trustee, the Company shall furnish to the Trustee promptly an Officer&#8217;s Certificate
listing and identifying all Notes, if any, known by the Company to be owned or held by or for the account of any of the above described Persons; and, subject to Section&nbsp;7.01, the Trustee shall be entitled to accept such Officer&#8217;s
Certificate as conclusive evidence of the facts therein set forth and of the fact that all Notes not listed therein are outstanding for the purpose of any such determination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.05<I>. Revocation of Consents; Future Holders Bound.</I> At any time prior to (but not after) the evidencing to the Trustee, as
provided in Section&nbsp;8.01, of the taking of any action by the Holders of the percentage of the aggregate principal amount of the Notes specified in this Indenture in connection with such action, any Holder of a Note that is shown by the evidence
to be included in the Notes the Holders of which have consented to such action may, by filing written notice with the Trustee at its Corporate Trust Office and upon proof of holding as provided in Section&nbsp;8.02, revoke such action so far as
concerns such Note. Except as aforesaid, any such action taken by the Holder of any Note shall be conclusive and binding upon such Holder and upon all future Holders and owners of such Note and of any Notes issued in exchange or substitution
therefor or upon registration of transfer thereof, irrespective of whether any notation in regard thereto is made upon such Note or any Note issued in exchange or substitution therefor or upon registration of transfer thereof. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 9 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H<SMALL>OLDERS</SMALL>&#8217; M<SMALL>EETINGS</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.01<I>. Purpose of Meetings.</I> A meeting of Holders may be called at any time and from time to time pursuant to the provisions
of this Article 9 for any of the following purposes: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) to give any notice to the Company or to the Trustee or to give any directions to
the Trustee permitted under this Indenture, or to consent to the waiving of any Default or Event of Default hereunder (in each case, as permitted under this Indenture) and its consequences, or to take any other action authorized to be taken by
Holders pursuant to any of the provisions of Article 6; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) to remove the Trustee and nominate a successor trustee pursuant to the
provisions of Article 7; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) to consent to the execution of an indenture or indentures supplemental hereto pursuant
to the provisions of Section&nbsp;10.02; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) to take any other action authorized to be taken by or on behalf of the Holders of any
specified aggregate principal amount of the Notes under any other provision of this Indenture or under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.02<I>. Call of Meetings by Trustee.</I> The Trustee may at any time call a meeting of Holders to take any action specified in
Section&nbsp;9.01, to be held at such time and at such place as the Trustee shall determine. Notice of every meeting of the Holders, setting forth the time and the place of such meeting and in general terms the action proposed to be taken at such
meeting and the establishment of any record date pursuant to Section&nbsp;8.01, shall be delivered to Holders of such Notes. Such notice shall also be delivered to the Company. Such notices shall be delivered not less than 20 nor more than 90 days
prior to the date fixed for the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any meeting of Holders shall be valid without notice if the Holders of all Notes then
outstanding are present in person or by proxy or if notice is waived before or after the meeting by the Holders of all Notes then outstanding, and if the Company and the Trustee are either present by duly authorized representatives or have, before
or after the meeting, waived notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.03<I>. Call of Meetings by Company or Holders.</I> In case at any time the Company,
pursuant to a Board Resolution, or the Holders of at least 10% of the aggregate principal amount of the Notes then outstanding, shall have requested the Trustee to call a meeting of Holders, by written request setting forth in reasonable detail the
action proposed to be taken at the meeting, and the Trustee shall not have delivered the notice of such meeting within 20 days after receipt of such request, then the Company or such Holders may determine the time and the place for such meeting and
may call such meeting to take any action authorized in Section&nbsp;9.01, by delivering notice thereof as provided in Section&nbsp;9.02. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.04<I>. Qualifications for Voting.</I> To be entitled to vote at any meeting of Holders a Person shall (a)&nbsp;be a Holder of
one or more Notes on the record date pertaining to such meeting or (b)&nbsp;be a Person appointed by an instrument in writing as proxy by a Holder of one or more Notes on the record date pertaining to such meeting. The only Persons who shall be
entitled to be present or to speak at any meeting of Holders shall be the Persons entitled to vote at such meeting and their counsel and any representatives of the Trustee and its counsel and any representatives of the Company and its counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.05<I>. Regulations.</I> Notwithstanding any other provisions of this Indenture, the Trustee may make such reasonable
regulations as it may deem advisable for any meeting of Holders, in regard to proof of the holding of Notes and of the appointment of proxies, and in regard to the appointment and duties of inspectors of votes, the submission and examination of
proxies, certificates and other evidence of the right to vote, and such other matters concerning the conduct of the meeting as it shall think fit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Trustee shall, by an instrument in writing, appoint a temporary chairman of the meeting,
unless the meeting shall have been called by the Company or by Holders as provided in Section&nbsp;9.03, in which case the Company or the Holders calling the meeting, as the case may be, shall in like manner appoint a temporary chairman. A permanent
chairman and a permanent secretary of the meeting shall be elected by vote of the Holders of a majority in aggregate principal amount of the Notes represented at the meeting and entitled to vote at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the provisions of Section&nbsp;8.04, at any meeting of Holders each Holder or proxyholder shall be entitled to one vote for each
$1,000 principal amount of Notes held or represented by him or her; <I>provided</I>, <I>however</I>, that no vote shall be cast or counted at any meeting in respect of any Note challenged as not outstanding and ruled by the chairman of the meeting
to be not outstanding. The chairman of the meeting shall have no right to vote other than by virtue of Notes held by it or instruments in writing as aforesaid duly designating it as the proxy to vote on behalf of other Holders. Any meeting of
Holders duly called pursuant to the provisions of Section&nbsp;9.02 or Section&nbsp;9.03 may be adjourned from time to time by the Holders of a majority of the aggregate principal amount of Notes represented at the meeting, whether or not
constituting a quorum, and the meeting may be held as so adjourned without further notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.06<I>. Voting.</I> The vote
upon any resolution submitted to any meeting of Holders shall be by written ballot on which shall be subscribed the signatures of the Holders or of their representatives by proxy and the outstanding aggregate principal amount of the Notes held or
represented by them. The permanent chairman of the meeting shall appoint two inspectors of votes who shall count all votes cast at the meeting for or against any resolution and who shall make and file with the secretary of the meeting their verified
written reports in duplicate of all votes cast at the meeting. A record in duplicate of the proceedings of each meeting of Holders shall be prepared by the secretary of the meeting and there shall be attached to said record the original reports of
the inspectors of votes on any vote by ballot taken thereat and affidavits by one or more Persons having knowledge of the facts setting forth a copy of the notice of the meeting and showing that said notice was delivered as provided in
Section&nbsp;9.02. The record shall show the aggregate principal amount of the Notes voting in favor of or against any resolution. The record shall be signed and verified by the affidavits of the permanent chairman and secretary of the meeting and
one of the duplicates shall be delivered to the Company and the other to the Trustee to be preserved by the Trustee, the latter to have attached thereto the ballots voted at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any record so signed and verified shall be conclusive evidence of the matters therein stated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.07<I>. No Delay of Rights by Meeting.</I> Nothing contained in this Article 9 shall be deemed or construed to authorize or
permit, by reason of any call of a meeting of Holders or any rights expressly or impliedly conferred hereunder to make such call, any hindrance or delay in the exercise of any right or rights conferred upon or reserved to the Trustee or to the
Holders under any of the provisions of this Indenture or of the Notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 10 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>UPPLEMENTAL</SMALL> I<SMALL>NDENTURES</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.01<I>. Supplemental Indentures Without Consent of Holders.</I> The Company, when authorized by a Board Resolution, at the
Company&#8217;s expense, may from time to time and at any time, without notice to or consent of any Holders, amend this Indenture or the Notes, by entering into an indenture or indentures supplemental hereto for one or more of the following
purposes: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) to cure any ambiguity, omission, defect or inconsistency; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) to provide for the assumption by a Successor Company of the obligations of the Company under this Indenture pursuant to Article 11; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) to add guarantees with respect to the Notes; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) to secure the Notes; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)
to add to the covenants or Events of Default of the Company for the benefit of the Holders or surrender any right or power conferred upon the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) to make any change that does not adversely affect the rights of any Holder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) to irrevocably elect a Settlement Method or Specified Dollar Amount (or a minimum Specified Dollar Amount) or eliminate the
Company&#8217;s right to elect a Settlement Method; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) in connection with any Share Exchange Event, to provide that the Notes are
convertible into Reference Property, subject to the provisions of Section&nbsp;14.02, and make such related changes to the terms of the Notes to the extent expressly required by this Indenture; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) to conform the provisions of this Indenture or the Notes to the &#8220;Description of Notes&#8221; section of the Offering Memorandum; or
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) to evidence the Termination of Conversion Rights with respect to the Notes pursuant to Section&nbsp;14.01(c)(i) in accordance with
the applicable provisions of this Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the written request of the Company, the Trustee is hereby authorized to join with the
Company in the execution of any such supplemental indenture, to make any further appropriate agreements and stipulations that may be therein contained, but the Trustee shall not be obligated to, but may in its discretion, enter into any supplemental
indenture that affects the Trustee&#8217;s own rights, duties or immunities under this Indenture or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any supplemental indenture
authorized by the provisions of this Section&nbsp;10.01 may be executed by the Company and the Trustee without the consent of the Holders of any of the Notes at the time outstanding, notwithstanding any of the provisions of Section&nbsp;10.02. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.02<I>. Supplemental Indentures with Consent of Holders.</I> With the consent (evidenced as provided in Article 8) of the
Holders of at least a majority of the aggregate principal amount of the Notes then outstanding (determined as provided in Section&nbsp;8.04 and including, without limitation, consents obtained in connection with a repurchase of, or tender or
exchange offer for, Notes), the Company, when authorized by a Board Resolution and the Trustee, at the Company&#8217;s expense, may from time to time and at any time enter into an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indenture or indentures supplemental hereto for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Indenture or any supplemental
indenture or of modifying in any manner the rights of the Holders, or waiving the Company&#8217;s compliance with any of the provisions of this Indenture or the Notes; <I>provided</I>, <I>however</I>, that, without the consent of each Holder of an
outstanding Note affected, no such supplemental indenture shall: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) reduce the amount of Notes whose Holders must consent to an
amendment; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) reduce the rate of or extend the stated time for payment of interest on any Note; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) reduce the principal of or extend the Maturity Date of any Note; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) make any change that adversely affects the conversion rights of any Notes (other than with respect to the exercise by the Company of its
Termination of Conversion Rights option pursuant to Section&nbsp;14.01(c)(i)); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) reduce the Redemption Price or the Fundamental Change
Repurchase Price of any Note or amend or modify in any manner adverse to the Holders the Company&#8217;s obligation to make such payments, whether through an amendment or waiver of provisions in the covenants, definitions or otherwise; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) make any Note payable in money, or at a place of payment, other than that stated in the Note; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) change the ranking of the Notes; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) make any change in this Article 10 that requires each Holder&#8217;s consent or in the waiver provisions in Section&nbsp;6.02 or
Section&nbsp;6.09. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the written request of the Company, and upon the filing with the Trustee of evidence of the consent of Holders as
aforesaid and subject to Section&nbsp;10.05, the Trustee shall join with the Company in the execution of such supplemental indenture unless such supplemental indenture affects the Trustee&#8217;s own rights, duties or immunities under this Indenture
or otherwise, in which case the Trustee may in its discretion, but shall not be obligated to, enter into such supplemental indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders do not need under this Section&nbsp;10.02 to approve the particular form of any proposed supplemental indenture. It shall be
sufficient if such Holders approve the substance thereof. After any such supplemental indenture becomes effective, the Company shall deliver to the Holders a notice briefly describing such supplemental indenture. However, the failure to give such
notice to all the Holders, or any defect in the notice, will not impair or affect the validity of the supplemental indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.03<I>. Effect of Supplemental Indentures.</I> Upon the execution of any
supplemental indenture pursuant to the provisions of this Article 10, this Indenture shall be and be deemed to be modified and amended in accordance therewith and the respective rights, limitation of rights, obligations, duties and immunities under
this Indenture of the Trustee, the Company and the Holders shall thereafter be determined, exercised and enforced hereunder subject in all respects to such modifications and amendments and all the terms and conditions of any such supplemental
indenture shall be and be deemed to be part of the terms and conditions of this Indenture for any and all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.04<I>. Notation on Notes.</I> Notes authenticated and delivered after the execution of any supplemental indenture pursuant to
the provisions of this Article 10&nbsp;may, at the Company&#8217;s expense, bear a notation in form approved by the Trustee as to any matter provided for in such supplemental indenture. If the Company or the Trustee shall so determine, new Notes so
modified as to conform, in the opinion of the Trustee and the Board of Directors, to any modification of this Indenture contained in any such supplemental indenture may, at the Company&#8217;s expense, be prepared and executed by the Company,
authenticated by the Trustee (or an authenticating agent duly appointed by the Trustee pursuant to Section&nbsp;17.10) and delivered in exchange for the Notes then outstanding, upon surrender of such Notes then outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.05<I>. Evidence of Compliance of Supplemental Indenture to Be Furnished Trustee.</I> In addition to the documents required by
Section&nbsp;17.05, the Trustee shall receive an Officer&#8217;s Certificate and an Opinion of Counsel as conclusive evidence that any supplemental indenture executed pursuant hereto complies with the requirements of this Article 10 and is permitted
or authorized by this Indenture. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 11 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C<SMALL>ONSOLIDATION</SMALL>, M<SMALL>ERGER</SMALL>, S<SMALL>ALE</SMALL>, C<SMALL>ONVEYANCE</SMALL> <SMALL>AND</SMALL> L<SMALL>EASE</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.01<I>. Company May Consolidate, Etc. on Certain Terms.</I> Subject to the provisions of Section&nbsp;11.02, the Company shall
not consolidate with, merge with or into, or sell, convey, transfer or lease all or substantially all of the consolidated assets of the Company and its Subsidiaries, taken as a whole, to another Person, unless: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the resulting, surviving or transferee Person (the &#8220;<B>Successor Company</B>&#8221;), if not the Company, shall be a corporation
organized and existing under the laws of the United States of America, any State thereof or the District of Columbia, and the Successor Company (if not the Company) shall expressly assume, by supplemental indenture, all of the obligations of the
Company under the Notes and this Indenture; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) immediately after giving effect to such transaction, no Default or Event of Default
shall have occurred and be continuing under this Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;11.01, the sale, conveyance, transfer or
lease of all or substantially all of the properties and assets of one or more Subsidiaries of the Company to another Person, which properties and assets, if held by the Company instead of such Subsidiaries, would constitute all or substantially all
of the properties and assets of the Company on a consolidated basis, shall be deemed to be the sale, conveyance, transfer or lease of all or substantially all of the properties and assets of the Company to another Person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.02<I>. Successor Corporation to Be Substituted.</I> In case of any such
consolidation, merger, sale, conveyance, transfer or lease and upon the assumption by the Successor Company, by supplemental indenture, executed and delivered to the Trustee and satisfactory in form to the Trustee, of the due and punctual payment of
the principal of and accrued and unpaid interest on all of the Notes, the due and punctual delivery or payment, as the case may be, of any consideration due upon conversion of the Notes and the due and punctual performance of all of the covenants
and conditions of this Indenture to be performed by the Company, such Successor Company (if not the Company) shall succeed to and, except in the case of a lease of all or substantially all of the consolidated assets of the Company and its
Subsidiaries, taken as a whole, shall be substituted for the Company, with the same effect as if it had been named herein as the party of the first part. Such Successor Company thereupon may cause to be signed, and may issue either in its own name
or in the name of the Company any or all of the Notes issuable hereunder which theretofore shall not have been signed by the Company and delivered to the Trustee; and, upon the order of such Successor Company instead of the Company and subject to
all the terms, conditions and limitations in this Indenture prescribed, the Trustee shall authenticate and shall deliver, or cause to be authenticated and delivered, any Notes that previously shall have been signed and delivered by the Officers of
the Company to the Trustee for authentication, and any Notes that such Successor Company thereafter shall cause to be signed and delivered to the Trustee for that purpose. All the Notes so issued shall in all respects have the same legal rank and
benefit under this Indenture as the Notes theretofore or thereafter issued in accordance with the terms of this Indenture as though all of such Notes had been issued at the date of the execution hereof. In the event of any such consolidation,
merger, sale, conveyance or transfer (but not in the case of a lease), upon compliance with this Article 11 the Person named as the &#8220;Company&#8221; in the first paragraph of this Indenture (or any successor that shall thereafter have become
such in the manner prescribed in this Article 11) may be dissolved, wound up and liquidated at any time thereafter and, except in the case of a lease, such Person shall be released from its liabilities as obligor and maker of the Notes and from its
obligations under this Indenture and the Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of any such consolidation, merger, sale, conveyance, transfer or lease, such
changes in phraseology and form (but not in substance) may be made in the Notes thereafter to be issued as may be appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.03<I>. Opinion of Counsel to Be Given to Trustee.</I> No such consolidation, merger, sale, conveyance, transfer or lease shall
be effective unless the Trustee shall receive an Officer&#8217;s Certificate and an Opinion of Counsel as conclusive evidence that any such consolidation, merger, sale, conveyance, transfer or lease and any such assumption and, if a supplemental
indenture is required in connection with such transaction, such supplemental indenture, complies with the provisions of this Article 11. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 12 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I<SMALL>MMUNITY</SMALL> <SMALL>OF</SMALL> I<SMALL>NCORPORATORS</SMALL>, S<SMALL>TOCKHOLDERS</SMALL>, O<SMALL>FFICERS</SMALL> <SMALL>AND</SMALL>
D<SMALL>IRECTORS</SMALL> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.01<I>. Indenture and Notes Solely Corporate Obligations.</I> No recourse for the payment of the
principal of or accrued and unpaid interest on any Note, nor for any claim based thereon or otherwise in respect thereof, and no recourse under or upon any obligation, covenant or agreement of the Company in this Indenture or in any supplemental
indenture or in any Note, nor because of the creation of any indebtedness represented thereby, shall be had against any incorporator, stockholder, employee, agent, Officer or director or Subsidiary, as such, past, present or future, of the Company
or of any successor corporation, either directly or through the Company or any successor corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise; it being expressly
understood that all such liability is hereby expressly waived and released as a condition of, and as a consideration for, the execution of this Indenture and the issue of the Notes. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 13 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[I<SMALL>NTENTIONALLY</SMALL> O<SMALL>MITTED</SMALL>] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 14 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C<SMALL>ONVERSION</SMALL> <SMALL>OF</SMALL> N<SMALL>OTES</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.01<I>. Conversion Privilege.</I> (a)&nbsp;Subject to and upon compliance with the provisions of this Article 14, and subject
to Section&nbsp;14.01(c)(i) below, each Holder of a Note shall have the right, at such Holder&#8217;s option, to convert all or any portion (if the portion to be converted is $1,000 principal amount or an integral multiple thereof) of such Note
(i)&nbsp;subject to satisfaction of the conditions described in Section&nbsp;14.01(b), at any time prior to the close of business on the Business Day immediately preceding May&nbsp;15, 2031 under the circumstances and during the periods set forth in
Section&nbsp;14.01(b), and (ii)&nbsp;regardless of the conditions described in Section&nbsp;14.01(b), but for the avoidance of doubt subject to Section&nbsp;14.01(c)(i), on or after May&nbsp;15, 2031 and prior to the close of business on the
Business Day immediately preceding the Maturity Date, in each case, at an initial conversion rate of 73.9098 shares of Class&nbsp;A Common Stock (subject to adjustment as provided in this Article 14, the &#8220;<B>Conversion Rate</B>&#8221;) per
$1,000 principal amount of Notes (subject to, and in accordance with, the settlement provisions of Section&nbsp;14.02, the &#8220;<B>Conversion Obligation</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) (i) Prior to the close of business on the Business Day immediately preceding May&nbsp;15, 2031, but subject to Section&nbsp;14.01(c)(i), a
Holder may surrender all or any portion of its Notes for conversion at any time during the five Business Day period immediately after any five consecutive Trading Day period (the &#8220;<B>Measurement Period</B>&#8221;) in which the Trading Price
per $1,000 principal amount of Notes, as determined following a request by a Holder of Notes in accordance with this subsection (b)(i), for each Trading Day of the Measurement Period was less than 98% of the product of the Last Reported Sale Price
of the Class&nbsp;A Common Stock on each such Trading Day and the Conversion Rate on each such Trading Day. The Trading Prices shall be determined by the Bid Solicitation Agent pursuant to this subsection (b)(i) and the definition of Trading Price
set forth in this Indenture. The Company shall provide notice to the Bid Solicitation Agent (if other than the Company) of three independent nationally recognized securities dealers selected by the Company pursuant to the definition of Trading
Price, along with appropriate contact information for each. The Bid Solicitation Agent (if other than the Company) shall have no obligation to determine the Trading Price per $1,000 principal amount of Notes unless the Company has requested such
determination, and the Company shall have no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obligation to make such request (or, if the Company is acting as Bid Solicitation Agent, the Company shall have no obligation to determine the Trading Price per $1,000 principal amount of Notes)
unless a Holder provides the Company with reasonable evidence that the Trading Price per $1,000 principal amount of Notes on any Trading Day would be less than 98% of the product of the Last Reported Sale Price of the Class&nbsp;A Common Stock on
such Trading Day and the Conversion Rate on such Trading Day, at which time the Company shall instruct the Bid Solicitation Agent (if other than the Company) to determine, or if the Company is acting as Bid Solicitation Agent, the Company shall
determine, the Trading Price per $1,000 principal amount of Notes beginning on the next Trading Day and on each successive Trading Day until the Trading Price per $1,000 principal amount of Notes is greater than or equal to 98% of the product of the
Last Reported Sale Price of the Class&nbsp;A Common Stock and the Conversion Rate. If (x)&nbsp;the Company is not acting as Bid Solicitation Agent, and the Company does not instruct the Bid Solicitation Agent to determine the Trading Price per
$1,000 principal amount of Notes when obligated as provided in the preceding sentence, or if the Company instructs the Bid Solicitation Agent to obtain bids and the Bid Solicitation Agent fails to make such determination, or (y)&nbsp;the Company is
acting as Bid Solicitation Agent and the Company fails to make such determination when obligated as provided in the preceding sentence, then, in either case, the Trading Price per $1,000 principal amount of Notes shall be deemed to be less than 98%
of the product of the Last Reported Sale Price of the Class&nbsp;A Common Stock and the Conversion Rate on each Trading Day of such failure. If the Trading Price condition set forth above has been met, the Company shall so notify the Holders, the
Trustee and the Conversion Agent (if other than the Trustee). Any such determination shall be conclusive absent manifest error. If, at any time after the Trading Price condition set forth above has been met, the Trading Price per $1,000 principal
amount of Notes is greater than or equal to 98% of the product of the Last Reported Sale Price of the Class&nbsp;A Common Stock and the Conversion Rate for such date, the Company shall so notify the Holders of the Notes, the Trustee and the
Conversion Agent (if other than the Trustee). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) If, prior to the close of business on the Business Day immediately
preceding May&nbsp;15, 2031, the Company elects to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) issue to all or substantially all holders of the Class&nbsp;A
Common Stock any rights, options or warrants entitling them, for a period of not more than 45 calendar days after the announcement date of such issuance, to subscribe for or purchase shares of the Class&nbsp;A Common Stock at a price per share that
is less than the average of the Last Reported Sale Prices of the Class&nbsp;A Common Stock for the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of such issuance; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) distribute to all or substantially all holders of the Class&nbsp;A Common Stock the Company&#8217;s assets, securities or
rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the Board of Directors, exceeding 10% of the Last Reported Sale Price of the Class&nbsp;A Common Stock on the Trading Day preceding
the date of announcement for such distribution, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then, in either case, the Company shall notify all Holders of the Notes, the Trustee and the Conversion
Agent (if other than the Trustee) at least 50 Scheduled Trading Days prior to the Ex- Dividend Date for such issuance or distribution. Once the Company has given such notice, and subject to Section&nbsp;14.01(c)(i), a Holder may surrender all or any
portion of its Notes for conversion at any time until the earlier of (1)&nbsp;the close of business on the Business Day immediately preceding the <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date for such issuance or distribution and
(2)&nbsp;the Company&#8217;s announcement that such issuance or distribution will not take place. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) If a transaction
or event that constitutes a Fundamental Change or a Make-Whole Fundamental Change occurs prior to the close of business on the Business Day immediately preceding May&nbsp;15, 2031, regardless of whether a Holder has the right to require the Company
to repurchase the Notes pursuant to Section&nbsp;15.02, or if the Company is a party to a Share Exchange Event that occurs prior to the close of business on the Business Day immediately preceding May&nbsp;15, 2031, (each such Fundamental Change, a
Make-Whole Fundamental Change or Share Exchange Event, a &#8220;<B>Corporate Event</B>&#8221;), and subject to Section&nbsp;14.01(c)(i), all or any portion of a Holder&#8217;s Notes may be surrendered for conversion at any time on or after the date
that is 50 Scheduled Trading Days prior to the anticipated effective date of such Corporate Event (or, if later, the earlier of (x)&nbsp;the Business Day after the Company gives notice of such Corporate Event and (y)&nbsp;the actual effective date
of such Corporate Event) until the earlier of (i) 35 Trading Days after the actual effective date of such Corporate Event, or if such Corporate Event also constitutes a Fundamental Change, until the related Fundamental Change Repurchase Date and
(ii)&nbsp;the close of business on the Business Day immediately preceding the Maturity Date. The Company shall notify Holders, the Trustee and the Conversion Agent (if other than the Trustee)&nbsp;(x) as promptly as practicable following the date
the Company publicly announces such Corporate Event but in no event less than 50 Scheduled Trading Days prior to the anticipated effective date of such Corporate Event, or (y)&nbsp;if the Company does not have knowledge of such Corporate Event at
least 50 Scheduled Trading Days prior to the anticipated effective date of such Corporate Event, within five Business Days of the date upon which the Company receives notice, or otherwise becomes aware, of such Corporate Event, but in no event later
than the actual effective date of such Corporate Event. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Prior to the close of business on the Business Day
immediately preceding May&nbsp;15, 2031, but subject to Section&nbsp;14.01(c)(i), a Holder may surrender all or any portion of its Notes for conversion at any time during any calendar quarter commencing after the calendar quarter ending on
September&nbsp;30, 2025 (and only during such calendar quarter), if the Last Reported Sale Price of the Class&nbsp;A Common Stock for at least 20 Trading Days (whether or not consecutive) during the period of 30 consecutive Trading Days ending on,
and including, the last Trading Day of the immediately preceding calendar quarter is greater than or equal to 130% of the Conversion Price on each applicable Trading Day. The Company shall determine at the beginning of each calendar quarter
commencing after September&nbsp;30, 2025 whether the Notes may be surrendered for conversion in accordance with this clause (iv)&nbsp;and shall notify the Holders, the Trustee and the Conversion Agent (if other than the Trustee) if the Notes become
convertible in accordance with this clause (iv). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) If the Company elects its Termination of Conversion Rights option
pursuant to Section&nbsp;14.01(c)(i), then a Holder may surrender all or any portion of its Notes for conversion at any time prior to the close of business on the Scheduled Trading Day prior to the Conversion Rights Termination Date, even if the
Notes are not otherwise convertible at such time. After that time, the right to convert shall expire. If a Holder elects to convert Notes from, and including, the date the Company delivers a Notice of Termination of Conversion Rights until the close
of business on the Scheduled Trading Day immediately preceding the Conversion Rights Termination Date (any such period, a &#8220;<B>Conversion Rights Termination Period</B>&#8221;), the Company shall, under certain circumstances, increase the
Conversion Rate for the Notes as described under Section&nbsp;14.03. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) (i) On or after August&nbsp;20, 2026, the Company may terminate
the rights of Holders to convert their Notes (the &#8220;<B>Termination of Conversion Rights</B>&#8221;) if the Last Reported Sale Price of the Class&nbsp;A Common Stock has been greater than or equal to the applicable Conversion Rights Termination
Price Trigger for at least 20 Trading Days (whether or not consecutive) during any 30 consecutive Trading Day period (including the last Trading Day of such period) ending on, and including, the Trading Day immediately preceding the date on which
the Company provides the Notice of Termination of Conversion Rights in accordance with Section&nbsp;14.01(c)(ii). For the avoidance of doubt, such Termination of Conversion Rights shall apply to all of the Notes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In case the Company exercises its Termination of Conversion Rights option pursuant to Section&nbsp;14.01(c)(i), it shall
fix a date for the conversion rights to be terminated (the &#8220;<B>Conversion Rights Termination Date</B>&#8221;), which shall not be earlier than August&nbsp;20, 2026, and it or, at its written request received by the Trustee not less than 15
calendar days prior to the date such Notice of Termination of Conversion Rights is to be sent (or such shorter period of time as may be acceptable to the Trustee), the Trustee, in the name of and at the expense of the Company, shall deliver or cause
to be delivered a notice of the Termination of Conversion Rights (a &#8220;<B>Notice of Termination of Conversion Rights</B>&#8221;) not less than 15 nor more than 25 Scheduled Trading Days prior to the Conversion Rights Termination Date to each
Holder; <I>provided, however, </I>that, if the Company shall give such notice, it shall also give written notice of the Conversion Rights Termination Date to the Trustee and the Conversion Agent (if other than the Trustee). Any date on which the
conversion rights are terminated must be a Business Day, and the Company shall not specify a Conversion Rights Termination Date that falls on or after May&nbsp;15, 2031. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The Notice of Termination of Conversion Rights, if delivered in the manner herein provided, shall be conclusively
presumed to have been duly given, whether or not the Holder receives such notice. In any case, failure to give such Notice of Termination of Conversion Rights or any defect in the Notice of Termination of Conversion Rights to the Holder of any Note
shall not affect the validity of the proceedings for the Termination of Conversion Rights of any other Note. A Notice of Termination of Conversion Rights shall be irrevocable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Each Notice of Termination of Conversion Rights shall specify: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) the Conversion Rights Termination Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) that from and after the Conversion Rights Termination Date, the Notes will no longer be convertible; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) that Holders may surrender their Notes for conversion at any time prior to the close of business on the Scheduled Trading
Day immediately preceding the Conversion Rights Termination Date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) that the Company is required to settle all
conversions of Notes with a Conversion Date occurring after the Company&#8217;s issuance of a Notice of Termination of Conversion Rights with respect to the Notes but prior to the Conversion Rights Termination Date, by Physical Settlement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) the procedures a converting Holder must follow to convert its Notes; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(F) the Conversion Rate and, if applicable, the number of Additional Shares to be added to the Conversion Rate in accordance
with Section&nbsp;14.03 as a result of the Company&#8217;s issuance of a Notice of Termination of Conversion Rights; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(G) the CUSIP, ISIN or other similar numbers, if any, assigned to such Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary herein, from and after the Conversion Rights Termination Date, the Notes will no longer be
convertible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.02<I>. Conversion Procedure; Settlement Upon Conversion.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to this Section&nbsp;14.02, Section&nbsp;14.03(b) and Section&nbsp;14.07(a), upon conversion of any Note, the Company shall pay or
deliver, as the case may be, to the converting Holder, in respect of each $1,000 principal amount of Notes being converted, cash (&#8220;<B>Cash Settlement</B>&#8221;), shares of Class&nbsp;A Common Stock, together with cash, if applicable, in lieu
of delivering any fractional share of Class&nbsp;A Common Stock in accordance with subsection (j)&nbsp;of this Section&nbsp;14.02 (&#8220;<B>Physical Settlement</B>&#8221;) or a combination of cash and shares of Class&nbsp;A Common Stock, together
with cash, if applicable, in lieu of delivering any fractional share of Class&nbsp;A Common Stock in accordance with subsection (j)&nbsp;of this Section&nbsp;14.02 (&#8220;<B>Combination Settlement</B>&#8221;), at its election, as set forth in this
Section&nbsp;14.02. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Notwithstanding the foregoing, all conversions for which the relevant Conversion Date occurs after
the Company&#8217;s issuance of a Notice of Termination of Conversion Rights with respect to the Notes and prior to the Conversion Rights Termination Date shall be settled by Physical Settlement. All conversions for which the relevant Conversion
Date occurs on or after May&nbsp;15, 2031, shall be settled using the same Settlement Method. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Except for any conversions for which the relevant Conversion Date
occurs after the Company&#8217;s issuance of a Notice of Termination of Conversion Rights with respect to the Notes but prior to the Conversion Rights Termination Date, and any conversions for which the relevant Conversion Date occurs on or after
May&nbsp;15, 2031, the Company shall use the same Settlement Method for all conversions with the same Conversion Date, but the Company shall not have any obligation to use the same Settlement Method with respect to conversions with different
Conversion Dates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) If, in respect of any Conversion Date (or the period described in the third immediately succeeding
set of parentheses, as the case may be), the Company elects to deliver a notice (the &#8220;<B>Settlement Notice</B>&#8221;) of the relevant Settlement Method in respect of such Conversion Date (or such period, as the case may be), the Company,
through the Trustee, shall deliver such Settlement Notice to converting Holders no later than the close of business on the Trading Day immediately following the relevant Conversion Date (or, in the case of any conversions for which the relevant
Conversion Date occurs (x)&nbsp;after the date of issuance of a Notice of Termination of Conversion Rights with respect to the Notes and prior to the Conversion Rights Termination Date, in such Notice of Termination of Conversion Rights (which
Settlement Method shall be Physical Settlement) or (y)&nbsp;on or after May&nbsp;15, 2031, no later than May&nbsp;15, 2031). If the Company does not elect a Settlement Method by the deadline set forth in the immediately preceding sentence, the
Company shall no longer have the right to elect a Settlement Method and the Company shall be deemed to have elected the Default Settlement Method with respect to such conversion. Any Settlement Notice shall specify the relevant Settlement Method and
in the case of an election of Combination Settlement, the relevant Settlement Notice shall indicate the Specified Dollar Amount per $1,000 principal amount of Notes. If the Company timely elects Combination Settlement with respect to a conversion
but does not timely notify the converting Holder of the applicable Specified Dollar Amount, then the Specified Dollar Amount for such conversion will be deemed to be $1,000 per $1,000 principal amount of Notes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may, by notice to the Holders prior to May&nbsp;15, 2031, irrevocably fix the Settlement Method, to any Settlement
Method that the Company is then permitted to elect, that will apply to all conversions of Notes with a Conversion Date that is on or after the date the Company sends such notice (other than, for the avoidance of doubt, any conversion that occurs
during the Conversion Rights Termination Period, with respect to which Physical Settlement shall apply). Concurrently with providing notice to all Holders of a change in the Default Settlement Method as set forth in clause (ii)&nbsp;of the
definition thereof or an election to irrevocably fix the Settlement Method, the Company shall promptly issue a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or press release announcing that the Company has made such change to
the Default Settlement Method as set forth in clause (ii)&nbsp;of the definition thereof or elected to irrevocably fix the Settlement Method, as the case may be. Notwithstanding the foregoing, no such change in the Default Settlement Method as set
forth in clause (ii)&nbsp;of the definition thereof or irrevocable election shall affect any Settlement Method theretofore elected (or deemed to be elected) with respect to any Note pursuant to this Section&nbsp;14.02. For the avoidance of doubt,
such an irrevocable election, if made, shall be effective without the need to amend this Indenture or the Notes, including pursuant to the provisions described in Section&nbsp;10.01(g). However, the Company may nonetheless choose to execute such an
amendment at the Company&#8217;s option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) The cash, shares of Class&nbsp;A Common Stock or combination of cash
and shares of Class&nbsp;A Common Stock in respect of any conversion of Notes (the &#8220;<B>Settlement Amount</B>&#8221;) shall be computed as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) if the Company elects (or is deemed to have elected) to satisfy its Conversion Obligation in respect of such conversion by
Physical Settlement, the Company shall deliver to the converting Holder in respect of each $1,000 principal amount of Notes being converted a number of shares of Class&nbsp;A Common Stock equal to the Conversion Rate in effect on the Conversion
Date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) if the Company elects to satisfy its Conversion Obligation in respect of such conversion by Cash Settlement, the
Company shall pay to the converting Holder in respect of each $1,000 principal amount of Notes being converted cash in an amount equal to the sum of the Daily Conversion Values for each of the 40 consecutive Trading Days during the related
Observation Period; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) if the Company elects (or is deemed to have elected) to satisfy its Conversion Obligation in
respect of such conversion by Combination Settlement, the Company shall pay or deliver, as the case may be, in respect of each $1,000 principal amount of Notes being converted, a Settlement Amount equal to the sum of the Daily Settlement Amounts for
each of the 40 consecutive Trading Days during the related Observation Period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) The Daily Settlement Amounts (if
applicable) and the Daily Conversion Values (if applicable) shall be determined by the Company promptly following the last day of the related Observation Period. Promptly after such determination of the Daily Settlement Amounts or the Daily
Conversion Values, as the case may be, and the amount of cash payable in lieu of delivering any fractional share of Class&nbsp;A Common Stock, the Company shall notify the Trustee and the Conversion Agent (if other than the Trustee) of the Daily
Settlement Amounts or the Daily Conversion Values, as the case may be, and the amount of cash payable in lieu of delivering fractional shares of Class&nbsp;A Common Stock. The Trustee and the Conversion Agent (if other than the Trustee) shall have
no responsibility for any such determination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Subject to Section&nbsp;14.02(e), before any Holder of a Note shall be entitled to
convert a Note as set forth above, such Holder shall (i)&nbsp;in the case of a Global Note, comply with the procedures of the Depositary in effect at that time and, if required, pay funds equal to interest payable on the next Interest Payment Date
to which such Holder is not entitled as set forth in Section&nbsp;14.02(h) and (ii)&nbsp;in the case of a Physical Note (1)&nbsp;complete, manually sign and deliver an irrevocable notice to the Conversion Agent as set forth in the Form of Notice of
Conversion (or a facsimile thereof) (a &#8220;<B>Notice of Conversion</B>&#8221;) at the office of the Conversion Agent and state in writing therein the principal amount of Notes to be converted and the name or names (with addresses) in which such
Holder wishes the certificate or certificates for any shares of Class&nbsp;A Common Stock to be delivered upon settlement of the Conversion Obligation to be registered, (2)&nbsp;surrender such Notes, duly endorsed to the Company or in blank (and
accompanied by appropriate endorsement and transfer documents), at the office of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Conversion Agent, (3)&nbsp;if required, furnish appropriate endorsements and transfer documents and (4)&nbsp;if required, pay funds equal to interest payable on the next Interest Payment Date to
which such Holder is not entitled as set forth in Section&nbsp;14.02(h). The Trustee (and if different, the Conversion Agent) shall notify the Company of any conversion pursuant to this Article 14 on the Conversion Date for such conversion. No
Notice of Conversion with respect to any Notes may be delivered by a Holder thereof if such Holder has also delivered a Fundamental Change Repurchase Notice to the Company in respect of such Notes and has not validly withdrawn such Fundamental
Change Repurchase Notice in accordance with Section&nbsp;15.03. If a Holder submits its Notes for required repurchase, the Holder&#8217;s right to withdraw the Fundamental Change Repurchase Notice and convert the Notes that are subject to repurchase
will terminate at the close of business on the Business Day immediately preceding the relevant Fundamental Change Repurchase Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
more than one Note shall be surrendered for conversion at one time by the same Holder, the Conversion Obligation with respect to such Notes shall be computed on the basis of the aggregate principal amount of the Notes (or specified portions thereof
to the extent permitted thereby) so surrendered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) A Note shall be deemed to have been converted immediately prior to the close of
business on the date (the &#8220;<B>Conversion Date</B>&#8221;) that the Holder has complied with the requirements set forth in subsection (b)&nbsp;above. Except as set forth in Section&nbsp;14.03(b), Section&nbsp;14.07(a) and Section&nbsp;14.12,
the Company shall pay or deliver, as the case may be, the consideration due in respect of the Conversion Obligation on the second Business Day immediately following the relevant Conversion Date, if the Company elects (or is deemed to have elected)
Physical Settlement, or on the second Business Day immediately following the last Trading Day of the relevant Observation Period, in the case of any other Settlement Method. If any shares of Class&nbsp;A Common Stock are due to a converting Holder,
the Company shall issue or cause to be issued, and deliver (if applicable) to the Conversion Agent or to such Holder, or such Holder&#8217;s nominee or nominees, the full number of shares of Class&nbsp;A Common Stock to which such Holder shall be
entitled, in certificate form or in book-entry format, in satisfaction of the Company&#8217;s Conversion Obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) In case any Note
shall be surrendered for partial conversion, the Company shall execute and the Trustee shall authenticate and deliver to the Holder of the Note so surrendered a new Note or Notes in authorized denominations in an aggregate principal amount equal to
the unconverted portion of the surrendered Note, without payment of any service charge by the converting Holder but, if required by the Company or the Trustee, with payment of a sum sufficient to cover any documentary, stamp or similar issue or
transfer tax or similar governmental charge required by law or that may be imposed in connection therewith as a result of the name of the Holder of the new Notes issued upon such conversion being different from the name of the Holder of the old
Notes surrendered for such conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) If a Holder submits a Note for conversion, the Company shall pay any documentary, stamp or
similar issue or transfer tax due on the issue of any shares of Class&nbsp;A Common Stock upon conversion, unless the tax is due because the Holder requests such shares to be issued in a name other than the Holder&#8217;s name, in which case the
Holder shall pay that tax. The Conversion Agent may refuse to deliver the certificates representing the shares of Class&nbsp;A Common Stock being issued in a name other than the Holder&#8217;s name until the Trustee receives a sum sufficient to pay
any tax that is due by such Holder in accordance with the immediately preceding sentence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Except as provided in Section&nbsp;14.04, no adjustment shall be made for dividends on
any shares of Class&nbsp;A Common Stock issued upon the conversion of any Note as provided in this Article 14. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Upon the conversion of
an interest in a Global Note, the Trustee, or the Custodian at the direction of the Trustee, shall make a notation on such Global Note as to the reduction in the principal amount represented thereby. The Company shall notify the Trustee in writing
of any conversion of Notes effected through any Conversion Agent other than the Trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Upon conversion, a Holder shall not receive
any separate cash payment for accrued and unpaid interest, if any, except as set forth below. The Company&#8217;s settlement of the full Conversion Obligation shall be deemed to satisfy in full its obligation to pay the principal amount of the Note
and accrued and unpaid interest, if any, to, but not including, the relevant Conversion Date. As a result, accrued and unpaid interest, if any, to, but not including, the relevant Conversion Date shall be deemed to be paid in full rather than
cancelled, extinguished or forfeited. Upon conversion of Notes into a combination of cash and shares of Class&nbsp;A Common Stock, accrued and unpaid interest will be deemed to be paid first out of the cash paid upon such conversion. Notwithstanding
the foregoing, if Notes are converted after the close of business on a Regular Record Date, Holders of such Notes as of the close of business on such Regular Record Date will receive the full amount of interest payable on such Notes on the
corresponding Interest Payment Date notwithstanding the conversion. Notes surrendered for conversion during the period from the close of business on any Regular Record Date to the open of business on the immediately following Interest Payment Date
must be accompanied by funds equal to the amount of interest payable on the Notes so converted; <I>provided</I> that no such payment shall be required (1)&nbsp;for conversions following the Regular Record Date immediately preceding the Maturity
Date; (2)&nbsp;if the Company has specified a Conversion Rights Termination Date that is after a Regular Record Date and on or prior to the Business Day immediately following the corresponding Interest Payment Date; (3)&nbsp;if the Company has
specified a Fundamental Change Repurchase Date that is after a Regular Record Date and on or prior to the Business Day immediately following the corresponding Interest Payment Date; or (4)&nbsp;to the extent of any Defaulted Amounts, if any
Defaulted Amounts exists at the time of conversion with respect to such Note. Therefore, for the avoidance of doubt, all Holders of record on the Regular Record Date immediately preceding the Maturity Date shall receive the full interest payment due
on the Maturity Date in cash regardless of whether their Notes have been converted following such Regular Record Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Person in
whose name the shares of Class&nbsp;A Common Stock shall be issuable upon conversion shall be treated as a stockholder of record as of the close of business on the relevant Conversion Date (if the Company elects (or is deemed to have elected) to
satisfy the related Conversion Obligation by Physical Settlement) or the last Trading Day of the relevant Observation Period (if the Company elects to satisfy the related Conversion Obligation by Combination Settlement), as the case may be. Upon a
conversion of Notes, such Person shall no longer be a Holder of such Notes surrendered for conversion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The Company shall not issue any fractional share of Class&nbsp;A Common Stock upon
conversion of the Notes and shall instead pay cash in lieu of delivering any fractional share of Class&nbsp;A Common Stock issuable upon conversion based on the Daily VWAP for the relevant Conversion Date (in the case of Physical Settlement) or
based on the Daily VWAP for the last Trading Day of the relevant Observation Period (in the case of Combination Settlement). For each Note surrendered for conversion if the Company has elected Combination Settlement, the full number of shares that
shall be issued upon conversion thereof shall be computed on the basis of the aggregate Daily Settlement Amounts for the relevant Observation Period and any fractional shares remaining after such computation shall be paid in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.03<I>. Increased Conversion Rate Applicable to Certain Notes Surrendered in Connection with Make-Whole Fundamental Changes or
During a Conversion Rights Termination Period.</I> (a)&nbsp;If (i) the Effective Date of a Make-Whole Fundamental Change occurs prior to the Maturity Date and a Holder elects to convert its Notes in connection with such Make-Whole Fundamental Change
or (ii)&nbsp;the Company issues a Notice of Termination of Conversion Rights and a Holder elects to convert its Notes with a Conversion Date occurring during the Conversion Rights Termination Period, the Company shall, under the circumstances
described below, increase the Conversion Rate for the Notes so surrendered for conversion by a number of additional shares of Class&nbsp;A Common Stock (the &#8220;<B>Additional Shares</B>&#8221;), as described below. A conversion of Notes shall be
deemed for these purposes to be &#8220;in connection with&#8221; such Make-Whole Fundamental Change if the relevant Notice of Conversion is received by the Conversion Agent from, and including, the Effective Date of the Make-Whole Fundamental Change
up to, and including, the Business Day immediately prior to the related Fundamental Change Repurchase Date (or, in the case of a Make-Whole Fundamental Change that would have been a Fundamental Change but for the <I>proviso</I> in clause (b)&nbsp;of
the definition thereof, the 35th Trading Day immediately following the Effective Date of such Make-Whole Fundamental Change) (such period, the &#8220;<B>Make-Whole Fundamental Change Period</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Upon surrender of Notes for conversion during a Conversion Rights Termination Period pursuant to Section&nbsp;14.01(b)(v), the Company
shall satisfy its Conversion Obligation by Physical Settlement in accordance with Section&nbsp;14.02(a)(i). Upon surrender of Notes for conversion in connection with a Make-Whole Fundamental Change, the Company shall, at its option, satisfy its
Conversion Obligation by Physical Settlement, Cash Settlement, or Combination Settlement, in accordance with Section&nbsp;14.02; <I>provided</I>, <I>however</I>, that if, at the effective time of a Make-Whole Fundamental Change described in clause
(b)&nbsp;of the definition of Fundamental Change, the Reference Property following such Make-Whole Fundamental Change is composed entirely of cash, for any conversion of Notes following the Effective Date of such Make-Whole Fundamental Change, the
Conversion Obligation shall be calculated based solely on the Stock Price for the transaction and shall be deemed to be an amount of cash per $1,000 principal amount of converted Notes equal to the Conversion Rate (including any adjustment for
Additional Shares), <I>multiplied by</I> such Stock Price. In such event, the Conversion Obligation shall be paid to Holders in cash on the second Business Day following the Conversion Date. The Company shall notify the Holders of Notes of the
Effective Date of any Make-Whole Fundamental Change and issue a press release announcing such Effective Date no later than five Business Days after such Effective Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The number of Additional Shares, if any, by which the Conversion Rate shall be increased
shall be determined by reference to the table below, based on the date on which the Make-Whole Fundamental Change occurs or becomes effective or the date the Company delivers the Notice of Termination of Conversion Rights, as the case may be (in
each case, the &#8220;<B>Effective Date</B>&#8221;) and the price (the &#8220;<B>Stock Price</B>&#8221;) paid (or deemed to be paid) per share of Class&nbsp;A Common Stock in the Make-Whole Fundamental Change or determined with respect to the Notice
of Termination of Conversion Rights, as the case may be. If the holders of the Class&nbsp;A Common Stock receive in exchange for their Class&nbsp;A Common Stock only cash in a Make-Whole Fundamental Change described in clause (b)&nbsp;of the
definition of Fundamental Change, the Stock Price shall be the cash amount paid per share. Otherwise, the Stock Price shall be the average of the Last Reported Sale Prices of the Class&nbsp;A Common Stock over the five Trading Day period ending on,
and including, the Trading Day immediately preceding the Effective Date. If a conversion during a Conversion Rights Termination Period would also be deemed to be in connection with a Make-Whole Fundamental Change, a Holder of the Notes to be
converted will be entitled to a single increase to the Conversion Rate with respect to the first to occur of the Effective Date of the Notice of Termination of Conversion Rights or the Make-Whole Fundamental Change, as applicable, and the later
event will be deemed not to have occurred for purposes of this Section&nbsp;14.03. The Board of Directors shall make appropriate adjustments to the Stock Price, in its good faith determination, to account for any adjustment to the Conversion Rate
that becomes effective, or any event requiring an adjustment to the Conversion Rate where the <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date, Effective Date (as such term is used in Section&nbsp;14.04) or expiration date of the event
occurs during such five consecutive Trading Day period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Stock Prices set forth in the column headings of the table below shall be
adjusted as of any date on which the Conversion Rate is otherwise adjusted. The adjusted Stock Prices shall equal the Stock Prices applicable immediately prior to such adjustment, <I>multiplied by</I> a fraction, the numerator of which is the
Conversion Rate immediately prior to such adjustment giving rise to the Stock Price adjustment and the denominator of which is the Conversion Rate as so adjusted. The number of Additional Shares set forth in the table below shall be adjusted in the
same manner and at the same time as the Conversion Rate as set forth in Section&nbsp;14.04. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The following table sets forth the number
of Additional Shares of Class&nbsp;A Common Stock by which the Conversion Rate shall be increased per $1,000 principal amount of Notes pursuant to this Section&nbsp;14.03 for each Stock Price and Effective Date set forth below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="54" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Stock Price</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Effective&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$9.02</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$9.50</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$10.50</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$12.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$13.53</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$15.25</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$17.59</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$20.30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$25.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$32.50</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$45.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$60.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$90.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$140.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">August&nbsp;21,&nbsp;2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36.9549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34.2284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29.4705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24.0433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.9460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.4898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.0671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.2734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.1336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.3548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.1718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.0167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.2008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">August&nbsp;15,&nbsp;2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36.9549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34.2284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29.4410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23.7858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.5528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.0151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.5492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.7557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.6672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.9932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.9449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.8855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.1569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">August&nbsp;15,&nbsp;2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36.9549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34.1084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28.8743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.6548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.0695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.6117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.8773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.9252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.4520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.6262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.7110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.1027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">August&nbsp;15,&nbsp;2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36.9549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33.5232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27.9629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.8008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.3193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.6918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.2757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.6522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.9272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.7609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.5203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">August&nbsp;15,&nbsp;2029</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36.9549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32.5853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26.5286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.9375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.2698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.6105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.3064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.9015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.5756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.8948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.8249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">August&nbsp;15,&nbsp;2030</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36.9549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31.1526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24.1429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.7283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.7472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.1180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.1666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.2951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.7788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.8911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.1597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">August&nbsp;15,&nbsp;2031</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.9549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.1526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.3286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.4233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exact Stock Prices and Effective Dates may not be set forth in the table above, in which
case: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) if the Stock Price is between two Stock Prices in the table above or the Effective Date is between two Effective
Dates in the table, the number of Additional Shares by which the Conversion Rate will be increased shall be determined by a straight-line interpolation between the number of Additional Shares set forth for the higher and lower Stock Prices and the
earlier and later Effective Dates, as applicable, based on a <FONT STYLE="white-space:nowrap">365-day</FONT> year; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) if
the Stock Price is greater than $140.00 per share (subject to adjustment in the same manner as the Stock Prices set forth in the column headings of the table above pursuant to subsection (d)&nbsp;above), no Additional Shares shall be added to the
Conversion Rate; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) if the Stock Price is less than $9.02 per share (subject to adjustment in the same manner as
the Stock Prices set forth in the column headings of the table above pursuant to subsection (d)&nbsp;above), no Additional Shares shall be added to the Conversion Rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, in no event shall the Conversion Rate per $1,000 principal amount of Notes exceed 110.8647 shares of Class&nbsp;A Common Stock,
subject to adjustment in the same manner as the Conversion Rate pursuant to Section&nbsp;14.04. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Nothing in this Section&nbsp;14.03
shall prevent an adjustment to the Conversion Rate pursuant to Section&nbsp;14.04 in respect of a Make-Whole Fundamental Change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.04<I>. Adjustment of Conversion Rate.</I> The Conversion Rate shall be adjusted from time to time by the Company if any of the
following events occurs, except that the Company shall not make any adjustments to the Conversion Rate if Holders of the Notes participate (other than in the case of (x)&nbsp;a share split or share combination or (y)&nbsp;a tender or exchange
offer), at the same time and upon the same terms as holders of the Class&nbsp;A Common Stock and solely as a result of holding the Notes, in any of the transactions described in this Section&nbsp;14.04, without having to convert their Notes, as if
they held a number of shares of Class&nbsp;A Common Stock equal to the Conversion Rate, <I>multiplied by</I> the principal amount (expressed in thousands) of Notes held by such Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If the Company exclusively issues shares of Class&nbsp;A Common Stock as a dividend or distribution on shares of the Class&nbsp;A Common
Stock, or if the Company effects a share split or share combination, the Conversion Rate shall be adjusted based on the following formula: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g72742g0821092637655.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CR<SUB STYLE="font-size:75%; vertical-align:bottom">0</SUB></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Conversion Rate in effect immediately prior to the open of business on the <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date of such dividend or distribution, or immediately prior to the open of business on the Effective
Date of such share split or share combination, as applicable;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CR&#8217;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Conversion Rate in effect immediately after the open of business on such <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date or Effective Date;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">OS<SUB STYLE="font-size:75%; vertical-align:bottom">0</SUB></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the number of shares of Class&nbsp;A Common Stock outstanding immediately prior to the open of business on such <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date or Effective Date (before giving effect to any such dividend,
distribution, split or share combination); and</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">OS&#8217;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the number of shares of Class&nbsp;A Common Stock outstanding immediately after giving effect to such dividend, distribution, share split or share combination.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any adjustment made under this Section&nbsp;14.04(a) shall become effective immediately after the open of business on the <FONT
STYLE="white-space:nowrap">Ex-Dividend</FONT> Date for such dividend or distribution, or immediately after the open of business on the Effective Date for such share split or share combination, as applicable. If any dividend or distribution of the
type described in this Section&nbsp;14.04(a) is declared but not so paid or made, the Conversion Rate shall be immediately readjusted, effective as of the date the Board of Directors determines not to pay such dividend or distribution, to the
Conversion Rate that would then be in effect if such dividend or distribution had not been declared. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If the Company issues to all or
substantially all holders of the Class&nbsp;A Common Stock any rights, options or warrants (other than a distribution of rights pursuant to a stockholders rights plan) entitling them, for a period of not more than 45 calendar days after the
announcement date of such issuance, to subscribe for or purchase shares of the Class&nbsp;A Common Stock at a price per share that is less than the average of the Last Reported Sale Prices of the Class&nbsp;A Common Stock for the 10 consecutive
Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of such issuance, the Conversion Rate shall be increased based on the following formula: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g72742g0821092637921.jpg" ALT="LOGO" STYLE="width:1.49028in;height:0.477083in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CR<SUB STYLE="font-size:75%; vertical-align:bottom">0</SUB></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Conversion Rate in effect immediately prior to the open of business on the <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date for such issuance;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CR&#8217;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Conversion Rate in effect immediately after the open of business on such <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">OS<SUB STYLE="font-size:75%; vertical-align:bottom">0</SUB></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the number of shares of Class&nbsp;A Common Stock outstanding immediately prior to the open of business on such <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the total number of shares of Class&nbsp;A Common Stock issuable pursuant to such rights, options or warrants; and</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the number of shares of Class&nbsp;A Common Stock equal to the aggregate price payable to exercise such rights, options or warrants, <I>divided by</I> the average of the Last Reported Sale Prices of the Class&nbsp;A Common Stock
over the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of the issuance of such rights, options or warrants.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any increase made under this Section&nbsp;14.04(b) shall be made successively whenever any such rights,
options or warrants are issued and shall become effective immediately after the open of business on the <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date for such issuance. To the extent that shares of Class&nbsp;A Common Stock are not
delivered after the expiration of such rights, options or warrants, the Conversion Rate shall be decreased to the Conversion Rate that would then be in effect had the increase with respect to the issuance of such rights, options or warrants been
made on the basis of delivery of only the number of shares of Class&nbsp;A Common Stock actually delivered. If such rights, options or warrants are not so issued, the Conversion Rate shall be decreased to the Conversion Rate that would then be in
effect if such <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date for such issuance had not occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this
Section&nbsp;14.04(b), and for the purpose of the Section&nbsp;14.01(b)(ii)(A), in determining whether any rights, options or warrants entitle the holders to subscribe for or purchase shares of Class&nbsp;A Common Stock at less than such average of
the Last Reported Sale Prices of the Class&nbsp;A Common Stock for the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement for such issuance, and in determining the aggregate
offering price of such shares of Class&nbsp;A Common Stock, there shall be taken into account any consideration received by the Company for such rights, options or warrants and any amount payable on exercise or conversion thereof, the value of such
consideration, if other than cash, to be determined (which determination shall be binding) by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If the Company
distributes shares of its Capital Stock, evidences of its indebtedness, other assets or property of the Company or rights, options or warrants to acquire its Capital Stock or other securities, to all or substantially all holders of the Class&nbsp;A
Common Stock, excluding (i)&nbsp;dividends, distributions or issuances as to which an adjustment was effected pursuant to Section&nbsp;14.04(a) or Section&nbsp;14.04(b), (ii) except as otherwise provided in this Section&nbsp;14.04(c) and
Section&nbsp;14.11, rights issued under a stockholders rights plan, (iii)&nbsp;distributions of Reference Property issued in exchange for, or upon conversion of, the Class&nbsp;A Common Stock in a Share Exchange Event, (iv)&nbsp;dividends or
distributions paid exclusively in cash as to which the provisions set forth in Section&nbsp;14.04(d) shall apply, and (v)&nbsp;Spin-Offs as to which the provisions set forth below in this Section&nbsp;14.04(c) shall apply (any of such shares of
Capital Stock, evidences of indebtedness, other assets or property or rights, options or warrants to acquire Capital Stock or other securities, the &#8220;<B>Distributed Property</B>&#8221;), then the Conversion Rate shall be increased based on the
following formula: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g72742g0821092638071.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CR<SUB STYLE="font-size:75%; vertical-align:bottom">0</SUB></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Conversion Rate in effect immediately prior to the open of business on the <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date for such distribution;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CR&#8217;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Conversion Rate in effect immediately after the open of business on such <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SP<SUB STYLE="font-size:75%; vertical-align:bottom">0</SUB></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the average of the Last Reported Sale Prices of the Class&nbsp;A Common Stock over the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the
<FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date for such distribution; and</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FMV</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the fair market value (as determined (which determination shall be binding) by the Board of Directors) of the Distributed Property with respect to each outstanding share of the Class&nbsp;A Common Stock on the <FONT
STYLE="white-space:nowrap">Ex-Dividend</FONT> Date for such distribution.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any increase made under the portion of this Section&nbsp;14.04(c) above shall become effective immediately after the open of
business on the <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date for such distribution. If such distribution is not so paid or made, the Conversion Rate shall be decreased to the Conversion Rate that would then be in effect if such
distribution had not been declared. Notwithstanding the foregoing, if &#8220;FMV&#8221; (as defined above) is equal to or greater than &#8220;SP<SUB STYLE="font-size:75%; vertical-align:bottom">0</SUB>&#8221; (as defined above), in lieu of the
foregoing increase, each Holder of a Note shall receive, in respect of each $1,000 principal amount thereof, at the same time and upon the same terms as holders of the Class&nbsp;A Common Stock receive the Distributed Property and without having to
convert its Note(s), the amount and kind of Distributed Property such Holder would have received if such Holder owned a number of shares of Class&nbsp;A Common Stock equal to the Conversion Rate in effect on the
<FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date for the distribution. If the Board of Directors determines the &#8220;FMV&#8221; (as defined above) of any distribution for purposes of this Section&nbsp;14.04(c) by reference to the actual or
when-issued trading market for any securities, it shall in doing so consider the prices in such market over the same period used in computing the Last Reported Sale Prices of the Class&nbsp;A Common Stock over the 10 consecutive Trading Day period
ending on, and including, the Trading Day immediately preceding the <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date for such distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to an adjustment pursuant to this Section&nbsp;14.04(c) where there has been a payment of a dividend or other distribution on the
Class&nbsp;A Common Stock of shares of Capital Stock of any class or series, or similar equity interest, of or relating to a Subsidiary or other business unit of the Company, that are, or, when issued, will be, listed or admitted for trading on a
U.S. national securities exchange (a &#8220;<B><FONT STYLE="white-space:nowrap">Spin-Off</FONT></B>&#8221;), the Conversion Rate shall be increased based on the following formula: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g72742g0821092638199.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CR<SUB STYLE="font-size:75%; vertical-align:bottom">0</SUB></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Conversion Rate in effect immediately prior to the end of the Valuation Period;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CR&#8217;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Conversion Rate in effect immediately after the end of the Valuation Period;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FMV<SUB STYLE="font-size:75%; vertical-align:bottom">0</SUB></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the average of the Last Reported Sale Prices of the Capital Stock or similar equity interest distributed to holders of the Class&nbsp;A Common Stock applicable to one share of Class&nbsp;A Common Stock (determined by reference to
the definition of Last Reported Sale Price as set forth in Section&nbsp;1.01 as if references therein to the Class&nbsp;A Common Stock were to such Capital Stock or similar equity interest) over the first 10 consecutive Trading Day period after, and
including, the <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> (the &#8220;<B>Valuation Period</B>&#8221;); and</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MP<SUB STYLE="font-size:75%; vertical-align:bottom">0</SUB></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the average of the Last Reported Sale Prices of the Class&nbsp;A Common Stock over the Valuation Period.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase to the Conversion Rate under the preceding paragraph shall occur at the close of business on the
last Trading Day of the Valuation Period; <I>provided</I> that (x)&nbsp;in respect of any conversion of Notes for which Physical Settlement is applicable, if the relevant Conversion Date occurs during the Valuation Period, references to
&#8220;10&#8221; in the preceding paragraph shall be deemed to be replaced with such lesser number of Trading Days as have elapsed from, and including, the <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date for such <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> to, and including, the Conversion Date in determining the Conversion Rate and (y)&nbsp;in respect of any conversion of Notes for which Cash Settlement or Combination Settlement is applicable, for any
Trading Day that falls within the relevant Observation Period for such conversion and within the Valuation Period, the reference to &#8220;10&#8221; in the preceding paragraph shall be deemed replaced with such lesser number of Trading Days as have
elapsed from, and including, the <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date for such <FONT STYLE="white-space:nowrap">Spin-Off</FONT> to, and including, such Trading Day in determining the Conversion Rate as of such Trading Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;14.04(c) (and subject in all respect to Section&nbsp;14.11), rights, options or warrants distributed by the
Company to all holders of the Class&nbsp;A Common Stock entitling them to subscribe for or purchase shares of the Company&#8217;s Capital Stock, including Class&nbsp;A Common Stock (either initially or under certain circumstances), which rights,
options or warrants, until the occurrence of a specified event or events (&#8220;<B>Trigger Event</B>&#8221;): (i) are deemed to be transferred with such shares of Class&nbsp;A Common Stock; (ii)&nbsp;are not exercisable; and (iii)&nbsp;are also
issued in respect of future issuances of Class&nbsp;A Common Stock, shall be deemed not to have been distributed for purposes of this Section&nbsp;14.04(c) (and no adjustment to the Conversion Rate under this Section&nbsp;14.04(c) will be required)
until the occurrence of the earliest Trigger Event, whereupon such rights, options or warrants shall be deemed to have been distributed and an appropriate adjustment (if any is required) to the Conversion Rate shall be made under this
Section&nbsp;14.04(c). If any such right, option or warrant, including any such existing rights, options or warrants distributed prior to the date of this Indenture, are subject to events, upon the occurrence of which such rights, options or
warrants become exercisable to purchase different securities, evidences of indebtedness or other assets, then the date of the occurrence of any and each such event shall be deemed to be the date of distribution and
<FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date with respect to new rights, options or warrants with such rights (in which case the existing rights, options or warrants shall be deemed to terminate and expire on such date without exercise
by any of the holders thereof). In addition, in the event of any distribution (or deemed distribution) of rights, options or warrants, or any Trigger Event or other event (of the type described in the immediately preceding sentence) with respect
thereto that was counted for purposes of calculating a distribution amount for which an adjustment to the Conversion Rate under this Section&nbsp;14.04(c) was made, (1)&nbsp;in the case of any such rights, options or warrants that shall all
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have been redeemed or purchased without exercise by any holders thereof, upon such final redemption or purchase (x)&nbsp;the Conversion Rate shall be readjusted as if such rights, options or
warrants had not been issued and (y)&nbsp;the Conversion Rate shall then again be readjusted to give effect to such distribution, deemed distribution or Trigger Event, as the case may be, as though it were a cash distribution, equal to the per share
redemption or purchase price received by a holder or holders of Class&nbsp;A Common Stock with respect to such rights, options or warrants (assuming such holder had retained such rights, options or warrants), made to all holders of Class&nbsp;A
Common Stock as of the date of such redemption or purchase, and (2)&nbsp;in the case of such rights, options or warrants that shall have expired or been terminated without exercise by any holders thereof, the Conversion Rate shall be readjusted as
if such rights, options and warrants had not been issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Section&nbsp;14.04(a), Section&nbsp;14.04(b) and this
Section&nbsp;14.04(c), if any dividend or distribution to which this Section&nbsp;14.04(c) is applicable also includes one or both of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A)
a dividend or distribution of shares of Class&nbsp;A Common Stock to which Section&nbsp;14.04(a) is applicable (the &#8220;<B>Clause A Distribution</B>&#8221;); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) a dividend or distribution of rights, options or warrants to which Section&nbsp;14.04(b) is applicable (the &#8220;<B>Clause B
Distribution</B>&#8221;), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then, in either case, (1)&nbsp;such dividend or distribution, other than the Clause A Distribution and the Clause B
Distribution, shall be deemed to be a dividend or distribution to which this Section&nbsp;14.04(c) is applicable (the &#8220;<B>Clause C Distribution</B>&#8221;) and any Conversion Rate adjustment required by this Section&nbsp;14.04(c) with respect
to such Clause C Distribution shall then be made, and (2)&nbsp;the Clause A Distribution and Clause B Distribution shall be deemed to immediately follow the Clause C Distribution and any Conversion Rate adjustment required by Section&nbsp;14.04(a)
and Section&nbsp;14.04(b) with respect thereto shall then be made, except that, if determined by the Company (I)&nbsp;the <FONT STYLE="white-space:nowrap">&#8220;Ex-Dividend</FONT> Date&#8221; of the Clause A Distribution and the Clause B
Distribution shall be deemed to be the <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date of the Clause C Distribution and (II)&nbsp;any shares of Class&nbsp;A Common Stock included in the Clause A Distribution or Clause B Distribution shall
be deemed not to be &#8220;outstanding immediately prior to the open of business on such <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date or Effective Date&#8221; within the meaning of Section&nbsp;14.04(a) or &#8220;outstanding immediately
prior to the open of business on such <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date&#8221; within the meaning of Section&nbsp;14.04(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) If any cash dividend or distribution is made to all or substantially all holders of the Class&nbsp;A Common Stock, the Conversion Rate
shall be adjusted based on the following formula: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g72742g0821092638347.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CR<SUB STYLE="font-size:75%; vertical-align:bottom">0</SUB></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Conversion Rate in effect immediately prior to the open of business on the <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date for such dividend or distribution;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CR&#8217;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Conversion Rate in effect immediately after the open of business on the <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date for such dividend or distribution;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SP<SUB STYLE="font-size:75%; vertical-align:bottom">0</SUB></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Last Reported Sale Price of the Class&nbsp;A Common Stock on the Trading Day immediately preceding the <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date for such dividend or distribution; and</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">C</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the amount in cash per share the Company distributes to all or substantially all holders of the Class&nbsp;A Common Stock.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any increase pursuant to this Section&nbsp;14.04(d) shall become effective immediately after the open of business on the <FONT
STYLE="white-space:nowrap">Ex-Dividend</FONT> Date for such dividend or distribution. If such dividend or distribution is not so paid, the Conversion Rate shall be decreased, effective as of the date the Board of Directors determines not to make or
pay such dividend or distribution, to be the Conversion Rate that would then be in effect if such dividend or distribution had not been declared. Notwithstanding the foregoing, if &#8220;C&#8221; (as defined above) is equal to or greater than
&#8220;SP<SUB STYLE="font-size:75%; vertical-align:bottom">0</SUB>&#8221; (as defined above), in lieu of the foregoing increase, each Holder of a Note shall receive, for each $1,000 principal amount of Notes, at the same time and upon the same terms
as holders of shares of the Class&nbsp;A Common Stock and without having to convert its Note(s), the amount of cash that such Holder would have received if such Holder owned a number of shares of Class&nbsp;A Common Stock equal to the Conversion
Rate on the <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date for such cash dividend or distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) If the Company or any of
its Subsidiaries make a payment in respect of a tender or exchange offer for the Class&nbsp;A Common Stock, to the extent that the cash and value of any other consideration included in the payment per share of Class&nbsp;A Common Stock exceeds the
average of the Last Reported Sale Prices of the Class&nbsp;A Common Stock over the 10 consecutive Trading Day period commencing on, and including, the Trading Day next succeeding the last date on which tenders or exchanges may be made pursuant to
such tender or exchange offer, the Conversion Rate shall be increased based on the following formula: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g72742g0821092638502.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CR<SUB STYLE="font-size:75%; vertical-align:bottom">0</SUB></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Conversion Rate in effect immediately prior to the close of business on the 10th Trading Day immediately following, and including, the Trading Day next succeeding the date such tender or exchange offer expires;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CR&#8217;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Conversion Rate in effect immediately after the close of business on the 10th Trading Day immediately following, and including, the Trading Day next succeeding the date such tender or exchange offer expires;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">AC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the aggregate value of all cash and any other consideration (as determined (which determination shall be binding) by the Board of Directors) paid or payable for shares of Class&nbsp;A Common Stock purchased in such tender or
exchange offer;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">OS<SUB STYLE="font-size:75%; vertical-align:bottom">0</SUB></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the number of shares of Class&nbsp;A Common Stock outstanding immediately prior to the date such tender or exchange offer expires (prior to giving effect to the purchase of all shares of Class&nbsp;A Common Stock accepted for
purchase or exchange in such tender or exchange offer);</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">OS&#8217;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the number of shares of Class&nbsp;A Common Stock outstanding immediately after the date such tender or exchange offer expires (after giving effect to the purchase of all shares of Class&nbsp;A Common Stock accepted for purchase or
exchange in such tender or exchange offer); and</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SP&#8217;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the average of the Last Reported Sale Prices of the Class&nbsp;A Common Stock over the 10 consecutive Trading Day period commencing on, and including, the Trading Day next succeeding the date such tender or exchange offer
expires.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase to the Conversion Rate under this Section&nbsp;14.04(e) shall be determined at the close of
business on the 10th Trading Day immediately following, and including, the Trading Day next succeeding the date such tender or exchange offer expires; <I>provided</I> that (x)&nbsp;in respect of any conversion of Notes for which Physical Settlement
is applicable, if the relevant Conversion Date occurs during the 10 Trading Days immediately following, and including, the Trading Day next succeeding the expiration date of any tender or exchange offer, references to &#8220;10&#8221; or
&#8220;10th&#8221; in the preceding paragraph shall be deemed replaced with such lesser number of Trading Days as have elapsed from, and including, the Trading Day next succeeding the date that such tender or exchange offer expires to, and
including, the Conversion Date in determining the Conversion Rate and (y)&nbsp;in respect of any conversion of Notes for which Cash Settlement or Combination Settlement is applicable, for any Trading Day that falls within the relevant Observation
Period for such conversion and within the 10 Trading Days immediately following, and including, the Trading Day next succeeding the expiration date of any tender or exchange offer, references to &#8220;10&#8221; or &#8220;10th&#8221; in the
preceding paragraph shall be deemed replaced with such lesser number of Trading Days as have elapsed from, and including, the Trading Day next succeeding the expiration date of such tender or exchange offer to, and including, such Trading Day in
determining the Conversion Rate as of such Trading Day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Notwithstanding this Section&nbsp;14.04 or any other provision of this
Indenture or the Notes, if a Conversion Rate adjustment becomes effective on any <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date, and a Holder that has converted its Notes on or after such <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT>
Date and on or prior to the related Record Date would be treated as the record holder of the shares of Class&nbsp;A Common Stock as of the related Conversion Date as described under Section&nbsp;14.02(i) based on an adjusted Conversion Rate for such
<FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date, then, notwithstanding the Conversion Rate adjustment provisions in this Section&nbsp;14.04, the Conversion Rate adjustment relating to such <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT>
Date shall not be made for such converting Holder. Instead, such Holder shall be treated as if such Holder were the record owner of the shares of Class&nbsp;A Common Stock on an unadjusted basis and participate in the related dividend, distribution
or other event giving rise to such adjustment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Except as stated herein, the Company shall not adjust the Conversion Rate for the
issuance of shares of Class&nbsp;A Common Stock or any securities convertible into or exchangeable for shares of Class&nbsp;A Common Stock or the right to purchase shares of Class&nbsp;A Common Stock or such convertible or exchangeable securities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) In addition to those adjustments required by clauses (a), (b), (c), (d) and (e)&nbsp;of this Section&nbsp;14.04, and to the extent
permitted by applicable law and subject to the applicable rules of any exchange on which any of the Company&#8217;s securities are then listed, the Company from time to time may increase the Conversion Rate by any amount for a period of at least 20
Business Days if the Board of Directors determines (which determination shall be binding) that such increase would be in the Company&#8217;s best interest. In addition, to the extent permitted by applicable law and subject to the applicable rules of
any exchange on which any of the Company&#8217;s securities are then listed, the Company may (but is not required to) increase the Conversion Rate to avoid or diminish any income tax to holders of the Class&nbsp;A Common Stock or rights to purchase
or otherwise acquire shares of the Class&nbsp;A Common Stock in connection with a dividend or distribution of shares of Class&nbsp;A Common Stock (or rights to acquire shares of Class&nbsp;A Common Stock) or similar event. Whenever the Conversion
Rate is increased pursuant to either of the preceding two sentences, the Company shall deliver to the Holder of each Note a notice of the increase at least 15 days prior to the date the increased Conversion Rate takes effect, and such notice shall
state the increased Conversion Rate and the period during which it will be in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Notwithstanding anything to the contrary in
this Article 14, the Conversion Rate shall not be adjusted: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) upon the issuance of any shares of Class&nbsp;A Common
Stock pursuant to any present or future plan providing for the reinvestment of dividends or interest payable on the Company&#8217;s securities and the investment of additional optional amounts in shares of Class&nbsp;A Common Stock under any plan;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) upon the issuance of any shares of Class&nbsp;A Common Stock or options or rights to purchase those shares pursuant
to any present or future benefit plan or program of or assumed by the Company or any of the Company&#8217;s Subsidiaries; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) upon the issuance of any shares of Class&nbsp;A Common Stock pursuant to any option, warrant, right or exercisable,
exchangeable or convertible security not described in clause (ii)&nbsp;of this subsection and outstanding as of the date the Notes were first issued; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) upon (a)&nbsp;the issuance of any Class&nbsp;B Common Units or shares of Class&nbsp;B Common Stock or (b)&nbsp;the
exchange of Class&nbsp;B Common Units or shares of Class&nbsp;B Common Stock for shares of Class&nbsp;A Common Stock in accordance with the Company&#8217;s certificate of incorporation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) for stock repurchases that are not tender offers to which the provisions of Section&nbsp;14.04(e) shall apply, including
structured or derivative transactions; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) solely for a change in the par value of the Class&nbsp;A Common Stock; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) for accrued and unpaid interest, if any. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) All calculations and other adjustments under this Article 14 shall be made by the
Company and shall be made to the nearest <FONT STYLE="white-space:nowrap">one-ten</FONT> thousandth (1/10,000th) of a share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Whenever
the Conversion Rate is adjusted as herein provided, the Company shall promptly file with the Trustee (and the Conversion Agent if not the Trustee) an Officer&#8217;s Certificate setting forth the Conversion Rate after such adjustment and setting
forth a brief statement of the facts requiring such adjustment. Unless and until a Responsible Officer of the Trustee shall have received such Officer&#8217;s Certificate, the Trustee shall not be deemed to have knowledge of any adjustment of the
Conversion Rate and may assume without inquiry that the last Conversion Rate of which it has knowledge is still in effect. Promptly after delivery of such certificate, the Company shall prepare a notice of such adjustment of the Conversion Rate
setting forth the adjusted Conversion Rate and the date on which each adjustment becomes effective and shall deliver such notice of such adjustment of the Conversion Rate to each Holder. Failure to deliver such notice shall not affect the legality
or validity of any such adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) For purposes of this Section&nbsp;14.04, the number of shares of Class&nbsp;A Common Stock at any
time outstanding shall not include shares of Class&nbsp;A Common Stock held in the treasury of the Company so long as the Company does not pay any dividend or make any distribution on shares of Class&nbsp;A Common Stock held in the treasury of the
Company, but shall include shares of Class&nbsp;A Common Stock issuable in respect of scrip certificates issued in lieu of fractions of shares of Class&nbsp;A Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.05<I>. Adjustments of Prices. </I>Whenever any provision of this Indenture requires the Company to calculate the Last Reported
Sale Prices, the Daily VWAPs, the Daily Conversion Values or the Daily Settlement Amounts over a span of multiple days (including, without limitation, an Observation Period and the period for determining the Stock Price for purposes of a Make-Whole
Fundamental Change or Notice of Termination of Conversion Rights), the Board of Directors shall make appropriate adjustments to each to account for any adjustment to the Conversion Rate that becomes effective, or any event requiring an adjustment to
the Conversion Rate where the <FONT STYLE="white-space:nowrap">Ex-Dividend</FONT> Date, Effective Date or expiration date, as the case may be, of the event occurs, at any time during the period when the Last Reported Sale Prices, the Daily VWAPs,
the Daily Conversion Values or the Daily Settlement Amounts are to be calculated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.06<I>. Shares to Be Fully Paid.</I> The
Company shall provide, free from preemptive rights, out of its authorized but unissued shares or shares held in treasury, sufficient shares of Class&nbsp;A Common Stock to provide for conversion of the Notes from time to time as such Notes are
presented for conversion (assuming delivery of the maximum number of Additional Shares pursuant to Section&nbsp;14.03 and that at the time of computation of such number of shares, all such Notes would be converted by a single Holder and that
Physical Settlement were applicable). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.07<I>. Effect of Recapitalizations, Reclassifications and Changes of the
Class</I><I></I><I>&nbsp;A Common Stock.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In the case of: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any recapitalization, reclassification or change of the Class&nbsp;A Common Stock (other than changes resulting from a
subdivision or combination), </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) any consolidation, merger or combination involving the Company, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) any sale, lease or other transfer to a third party of the consolidated assets of the Company and the Company&#8217;s
Subsidiaries substantially as an entirety or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) any statutory share exchange, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in each case, as a result of which the Class&nbsp;A Common Stock would be converted into, or exchanged for, stock, other securities, other property or assets
(including cash or any combination thereof) (any such event, a &#8220;<B>Share Exchange Event</B>&#8221;), then, at and after the effective time of such Share Exchange Event, the right to convert each $1,000 principal amount of Notes shall be
changed into a right to convert such principal amount of Notes into the kind and amount of shares of stock, other securities or other property or assets (including cash or any combination thereof) that a holder of a number of shares of Class&nbsp;A
Common Stock equal to the Conversion Rate immediately prior to such Share Exchange Event would have owned or been entitled to receive (the &#8220;<B>Reference Property</B>,&#8221; with each &#8220;<B>unit of Reference Property</B>&#8221; meaning the
kind and amount of Reference Property that a holder of one share of Class&nbsp;A Common Stock is entitled to receive) upon such Share Exchange Event and, prior to or at the effective time of such Share Exchange Event, the Company or the successor or
purchasing Person, as the case may be, shall execute with the Trustee a supplemental indenture permitted under Section&nbsp;10.01(g) providing for such change in the right to convert each $1,000 principal amount of Notes; <I>provided</I>,
<I>however</I>, that at and after the effective time of the Share Exchange Event (A)&nbsp;for any conversions of Notes other than a conversion during a Conversion Rights Termination Period, the Company or the successor or acquiring company, as the
case may be, shall continue to have the right to determine the form of consideration to be paid or delivered, as the case may be, upon conversion of Notes in accordance with Section&nbsp;14.02 and (B)(I) any amount payable in cash upon conversion of
the Notes in accordance with Section&nbsp;14.02 shall continue to be payable in cash, (II)&nbsp;any shares of Class&nbsp;A Common Stock that the Company would have been required to deliver upon conversion of the Notes in accordance with
Section&nbsp;14.02 shall instead be deliverable in the amount and type of Reference Property that a holder of that number of shares of Class&nbsp;A Common Stock would have received in such Share Exchange Event and (III)&nbsp;the Daily VWAP shall be
calculated based on the value of a unit of Reference Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Share Exchange Event causes the Class&nbsp;A Common Stock to be
converted into, or exchanged for, the right to receive more than a single type of consideration (determined based in part upon any form of stockholder election), then (i)&nbsp;the Reference Property into which the Notes will be convertible shall be
deemed to be the weighted average of the types and amounts of consideration actually received by the holders of Class&nbsp;A Common Stock and (ii)&nbsp;the unit of Reference Property for purposes of the immediately preceding paragraph shall refer to
the consideration referred to in clause (i)&nbsp;attributable to one share of Class&nbsp;A Common Stock. The Company shall notify the Holders, the Trustee and the Conversion Agent (if other than the Trustee) of such weighted average as soon as
practicable after such determination is made. If the holders of the Class&nbsp;A Common Stock receive only cash in such Share Exchange Event, then for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
all conversions for which the relevant Conversion Date occurs after the effective date of such Share Exchange Event (A)&nbsp;the consideration due upon conversion of each $1,000 principal amount
of Notes shall be solely cash in an amount equal to the Conversion Rate in effect on the Conversion Date (as may be increased by any Additional Shares pursuant to Section&nbsp;14.03), <I>multiplied by</I> the price paid per share of Class&nbsp;A
Common Stock in such Share Exchange Event and (B)&nbsp;the Company shall satisfy the Conversion Obligation by paying cash to converting Holders on the second Business Day immediately following the relevant Conversion Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such supplemental indenture described in the second immediately preceding paragraph shall provide for anti-dilution and other adjustments that
shall be as nearly equivalent as is possible to the adjustments provided for in this Article 14. If, in the case of any Share Exchange Event, the Reference Property includes shares of stock, securities or other property or assets (including cash or
any combination thereof) of a Person other than the Company or the successor or purchasing corporation, as the case may be, in such Share Exchange Event, then such supplemental indenture shall also be executed by such other Person and shall contain
such additional provisions to protect the interests of the Holders of the Notes as the Board of Directors shall determine (which determination shall be binding) to be reasonably necessary by reason of the foregoing, including the provisions
providing for the purchase rights set forth in Article 15. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) When the Company executes a supplemental indenture pursuant to subsection
(a)&nbsp;of this Section&nbsp;14.07, the Company shall promptly file with the Trustee an Officer&#8217;s Certificate briefly stating the reasons therefor, the kind or amount of cash, securities or property or asset that will comprise a unit of
Reference Property after any such Share Exchange Event, any adjustment to be made with respect thereto and that all conditions precedent have been complied with, and shall promptly deliver notice thereof to all Holders. The Company shall cause
notice of the execution of such supplemental indenture to be delivered to each Holder within 20 days after execution thereof. Failure to deliver such notice shall not affect the legality or validity of such supplemental indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company shall not become a party to any Share Exchange Event unless its terms are consistent with this Section&nbsp;14.07. None of the
foregoing provisions shall affect the right of a Holder to convert its Notes into cash, shares of Class&nbsp;A Common Stock or a combination of cash and shares of Class&nbsp;A Common Stock, as applicable, as set forth in Section&nbsp;14.01 and
Section&nbsp;14.02 prior to the effective date of such Share Exchange Event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The above provisions of this Section shall similarly
apply to successive Share Exchange Events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.08<I>. Certain Covenants.</I> (a)&nbsp;The Company covenants that all shares
of Class&nbsp;A Common Stock issued upon conversion of Notes will be fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> by the Company and free from all taxes, liens and charges with respect to the issue thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company covenants that, if any shares of Class&nbsp;A Common Stock to be provided for the purpose of conversion of Notes hereunder
require registration with or approval of any governmental authority under any federal or state law before such shares of Class&nbsp;A Common Stock may be validly issued upon conversion, the Company will, to the extent then permitted by the rules and
interpretations of the Commission, secure such registration or approval, as the case may be. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company further covenants that if at any time the Class&nbsp;A Common Stock shall be
listed on any national securities exchange or automated quotation system the Company will list and keep listed, so long as the Class&nbsp;A Common Stock shall be so listed on such exchange or automated quotation system, any Class&nbsp;A Common Stock
issuable upon conversion of the Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.09<I>. Responsibility of Trustee.</I> The Trustee and any other Conversion Agent
shall not at any time be under any duty or responsibility to any Holder to determine the Conversion Rate (or any adjustment thereto) or whether any facts exist that may require any adjustment (including any increase) of the Conversion Rate, or with
respect to the nature or extent or calculation of any such adjustment when made, or with respect to the method employed, or herein or in any supplemental indenture provided to be employed, in making the same. The Trustee and any other Conversion
Agent shall not be accountable with respect to the validity or value (or the kind or amount) of any shares of Class&nbsp;A Common Stock, or of any securities, property or cash that may at any time be issued or delivered upon the conversion of any
Note; and the Trustee and any other Conversion Agent make no representations with respect thereto. Neither the Trustee nor any Conversion Agent shall be responsible for any failure of the Company to issue, transfer or deliver any shares of
Class&nbsp;A Common Stock or stock certificates or other securities or property or cash upon the surrender of any Note for the purpose of conversion or to comply with any of the duties, responsibilities or covenants of the Company contained in this
Article. Without limiting the generality of the foregoing, neither the Trustee nor any Conversion Agent shall be under any responsibility to determine the correctness of any provisions contained in any supplemental indenture entered into pursuant to
Section&nbsp;14.07 relating either to the kind or amount of shares of stock or securities or property (including cash) receivable by Holders upon the conversion of their Notes after any event referred to in such Section&nbsp;14.07 or to any
adjustment to be made with respect thereto, but, subject to the provisions of Section&nbsp;7.01, may accept (without any independent investigation) as conclusive evidence of the correctness of any such provisions, and shall be protected in relying
upon, the Officer&#8217;s Certificate (which the Company shall be obligated to file with the Trustee prior to the execution of any such supplemental indenture) with respect thereto. Neither the Trustee nor the Conversion Agent shall be responsible
for determining whether any event contemplated by Section&nbsp;14.01(b) has occurred that makes the Notes eligible for conversion or no longer eligible therefor. The Company shall deliver to the Trustee and the Conversion Agent the notices referred
to in Section&nbsp;14.01(b) with respect to the commencement or termination of such conversion rights, on which notices the Trustee and the Conversion Agent may conclusively rely, and the Company agrees to deliver such notices to the Trustee and the
Conversion Agent immediately after the occurrence of any such event or at such other times as shall be provided for in Section&nbsp;14.01(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.10<I>. Notice to Holders Prior to Certain Actions.</I> In case of any: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) action by the Company or one of its Subsidiaries that would require an adjustment in the Conversion Rate pursuant to Section&nbsp;14.04 or
Section&nbsp;14.11; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Share Exchange Event; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) voluntary or involuntary dissolution, liquidation or
<FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then, in each case (unless notice of such event is otherwise required pursuant to
another provision of this Indenture), the Company shall cause to be filed with the Trustee and the Conversion Agent (if other than the Trustee) and to be delivered to each Holder, as promptly as possible but in any event at least 20 days prior to
the applicable date hereinafter specified, a notice stating (i)&nbsp;the date on which a record is to be taken for the purpose of such action by the Company or one of its Subsidiaries or, if a record is not to be taken, the date as of which the
holders of Class&nbsp;A Common Stock of record are to be determined for the purposes of such action by the Company or one of its Subsidiaries, or (ii)&nbsp;the date on which such Share Exchange Event, dissolution, liquidation or <FONT
STYLE="white-space:nowrap">winding-up</FONT> is expected to become effective or occur, and the date as of which it is expected that holders of Class&nbsp;A Common Stock of record shall be entitled to exchange their Class&nbsp;A Common Stock for
securities or other property deliverable upon such Share Exchange Event, dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up.</FONT> Failure to give such notice, or any defect therein, shall not affect the legality or validity of
such action by the Company or one of its Subsidiaries, Share Exchange Event, dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.11<I>. Stockholder Rights Plans.</I> If the Company has a stockholder rights plan in effect upon conversion of the Notes, each
share of Class&nbsp;A Common Stock, if any, issued upon such conversion shall be entitled to receive the appropriate number of rights, if any, and the certificates representing the Class&nbsp;A Common Stock issued upon such conversion shall bear
such legends, if any, in each case as may be provided by the terms of any such stockholder rights plan, as the same may be amended from time to time. However, if, prior to any conversion of Notes, the rights have separated from the shares of
Class&nbsp;A Common Stock in accordance with the provisions of the applicable stockholder rights plan, the Conversion Rate shall be adjusted at the time of separation as if the Company distributed to all or substantially all holders of the
Class&nbsp;A Common Stock Distributed Property as provided in Section&nbsp;14.04(c), subject to readjustment in the event of the expiration, termination or redemption of such rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.12. <I>Limitation on Beneficial Ownership</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary herein, no Person will be entitled to receive any shares of Class&nbsp;A Common Stock otherwise
deliverable upon conversion of the Notes to the extent, but only to the extent, that such receipt would cause such Person to become, directly or indirectly, a Beneficial Owner of more than 9.8% of the Class&nbsp;A Common Stock outstanding at such
time (such restriction, the &#8220;<B>Beneficial Ownership Limit</B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;14.12 only, a Person
shall be deemed the &#8220;<B>Beneficial Owner</B>&#8221; of and shall be deemed to beneficially own any shares of Class&nbsp;A Common Stock that such Person or any of such person&#8217;s Affiliates (as defined in Rule
<FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act) or associates (as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act) is deemed to beneficially own, together with any Class&nbsp;A Common Stock
beneficially owned by any other persons whose beneficial ownership would be aggregated with such Person for purposes of Section&nbsp;13(d) of the Exchange Act. Subject to the following proviso, for purposes of this Section&nbsp;14.12 only,
beneficial ownership shall be determined in accordance with Section&nbsp;13(d) of the Exchange Act and the rules and regulations promulgated thereunder as in effect on the date hereof; <I>provided</I> that the number of shares of Class&nbsp;A Common
Stock beneficially owned by such Person and its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Affiliates and associates and any other persons whose beneficial ownership would be aggregated with such Person for purposes of Section&nbsp;13(d) of the Exchange Act shall include the number of
shares of Class&nbsp;A Common Stock issuable upon exercise or conversion of any of the Company&#8217;s securities or rights to acquire the Class&nbsp;A Common Stock, whether or not such securities or rights are currently exercisable or convertible
or are exercisable or convertible only after the passage of time (including the number of shares of Class&nbsp;A Common Stock issuable upon conversion of the Notes in respect of which the beneficial ownership determination is being made), but shall
exclude the number of shares of Class&nbsp;A Common Stock that would be issuable upon (A)&nbsp;conversion of the remaining, unconverted portion of any Notes beneficially owned by such Person or any of its Affiliates or associates and any other
persons whose beneficial ownership would be aggregated with such Person for purposes of Section&nbsp;13(d) of the Exchange Act and (B)&nbsp;exercise or conversion of the unexercised or unconverted portion of any of the Company&#8217;s other
securities subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by such Person or any of its Affiliates or associates and any other persons whose beneficial ownership would be aggregated
with such Person for purposes of Section&nbsp;13(d) of the Exchange Act. For the avoidance of doubt, the term &#8220;<B>Beneficial Owner</B>&#8221; as used in this Section&nbsp;14.12 shall not include (i)&nbsp;with respect to any Global Note, the
nominee of the Depositary or any Person having an account with the Depositary or its nominee or (ii)&nbsp;with respect to any Physical Note, the Holder of such Physical Note unless, in each case, such nominee, account holder or Holder shall also be
a Beneficial Owner of such Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Any purported delivery of shares of Class&nbsp;A Common Stock upon conversion of the Notes shall be
void and have no effect to the extent, but only to the extent, that such delivery would result in any Person becoming the Beneficial Owner of Class&nbsp;A Common Stock outstanding at such time in excess of the Beneficial Ownership Limit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) When such Holder tenders Notes for conversion, that Holder must provide a certification to the Company as to whether the Person (or
Persons) receiving shares of Class&nbsp;A Common Stock upon conversion is, or would, as a result of such conversion, assuming Physical Settlement upon conversion, become the Beneficial Owner of Class&nbsp;A Common Stock outstanding at such time in
excess of any Beneficial Ownership Limit then applicable to such Person (or Persons). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) If any delivery of shares of Class&nbsp;A
Common Stock otherwise owed to any Person (or persons) upon conversion of the Notes is not made, in whole or in part, as a result of the Beneficial Ownership Limit, the Company&#8217;s obligation to make such delivery shall not be extinguished and,
such Holder may either: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) request the return of the Notes surrendered by such Holder for conversion, after which the
Company shall deliver such Notes to such Holder within two Trading Days after receipt of such request; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) certify to
the Company that the Person (or Persons) receiving shares of Class&nbsp;A Common Stock upon conversion is not, and would not, as a result of such conversion, become the Beneficial Owner of the Class&nbsp;A Common Stock outstanding at such time in
excess of the Beneficial Ownership Limit, after which the Company shall deliver any such shares of Class&nbsp;A Common Stock withheld on account of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Beneficial Ownership Limit by the later of (i)&nbsp;the date such shares were otherwise due to such Person (or Persons) and (ii)&nbsp;two Trading Days after receipt of such certification;
provided, however, until such time as the affected Holder gives such notice, no Person shall be deemed to be the stockholder of record with respect to the shares of Class&nbsp;A Common Stock otherwise deliverable upon conversion in excess of the
Beneficial Ownership Limit. Upon delivery of such notice, the provisions under Section&nbsp;14.02 shall apply to the Class&nbsp;A Common Stock to be delivered pursuant to such notice. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 15 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">R<SMALL>EPURCHASE</SMALL> <SMALL>OF</SMALL> N<SMALL>OTES</SMALL> <SMALL>AT</SMALL> O<SMALL>PTION</SMALL> <SMALL>OF</SMALL>
H<SMALL>OLDERS</SMALL> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.01<I>. </I>[<I>Intentionally Omitted</I>].<I> </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.02<I>. Repurchase</I> <I>at Option of Holders Upon a Fundamental Change.</I> (a)&nbsp;If a Fundamental Change occurs at any
time, each Holder shall have the right, at such Holder&#8217;s option, to require the Company to repurchase for cash all of such Holder&#8217;s Notes, or any portion of the principal thereof that is equal to $1,000 or an integral multiple of $1,000,
on the date (the &#8220;<B>Fundamental Change Repurchase Date</B>&#8221;) specified by the Company that is not less than 20 calendar days or more than 35 calendar days following the date of the Fundamental Change Company Notice at a repurchase price
equal to 100% of the principal amount thereof, <I>plus</I> accrued and unpaid interest thereon to, but excluding, the Fundamental Change Repurchase Date (the &#8220;<B>Fundamental Change Repurchase Price</B>&#8221;), unless the Fundamental Change
Repurchase Date falls after a Regular Record Date but on or prior to the Interest Payment Date to which such Regular Record Date relates, in which case the Company shall instead pay the full amount of accrued and unpaid interest to the Holder of
record as of such Regular Record Date, and the Fundamental Change Repurchase Price shall be equal to 100% of the principal amount of Notes to be repurchased pursuant to this Article 15. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Repurchases of Notes under this Section&nbsp;15.02 shall be made, at the option of the Holder thereof, upon: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) delivery to the Paying Agent by a Holder of a duly completed notice (the &#8220;<B>Fundamental Change Repurchase
Notice</B>&#8221;) in the form set forth in Attachment 2 to the Form of Note attached hereto as Exhibit A, if the Notes are Physical Notes, or in compliance with the Depositary&#8217;s procedures for surrendering interests in Global Notes, if the
Notes are Global Notes, in each case on or before the close of business on the Business Day immediately preceding the Fundamental Change Repurchase Date; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) delivery of the Notes, if the Notes are Physical Notes, to the Paying Agent at any time after delivery of the Fundamental
Change Repurchase Notice (together with all necessary endorsements for transfer) at the Corporate Trust Office of the Paying Agent, or book-entry transfer of the Notes, if the Notes are Global Notes, in compliance with the procedures of the
Depositary, in each case, such delivery or transfer being a condition to receipt by the Holder of the Fundamental Change Repurchase Price therefor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Fundamental Change Repurchase Notice in respect of any Notes to be repurchased shall
state: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) in the case of Physical Notes, the certificate numbers of the Notes to be delivered for repurchase; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the portion of the principal amount of Notes to be repurchased, which must be $1,000 or an integral multiple thereof; and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) that the Notes are to be repurchased by the Company pursuant to the applicable provisions of the Notes and this
Indenture; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I>, <I>however</I>, that if the Notes are Global Notes, the Fundamental Change Repurchase Notice must comply with appropriate
Depositary procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary, any Holder delivering to the Paying Agent the Fundamental Change
Repurchase Notice contemplated by this Section&nbsp;15.02 shall have the right to withdraw, in whole or in part, such Fundamental Change Repurchase Notice at any time prior to the close of business on the Business Day immediately preceding the
Fundamental Change Repurchase Date by delivery of a written notice of withdrawal to the Paying Agent in accordance with Section&nbsp;15.03. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Paying Agent shall promptly notify the Company of the receipt by it of any Fundamental Change Repurchase Notice or written notice of
withdrawal thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) On or before the 20th calendar day after the occurrence of the effective date of a Fundamental Change, the
Company shall provide to all Holders of Notes and the Trustee and the Paying Agent (in the case of a Paying Agent other than the Trustee) a notice (the &#8220;<B>Fundamental Change Company Notice</B>&#8221;) of the occurrence of the effective date
of the Fundamental Change and of the repurchase right at the option of the Holders arising as a result thereof. In the case of Physical Notes, such notice shall be by first class mail or, in the case of Global Notes, such notice shall be delivered
in accordance with the applicable procedures of the Depositary. Simultaneously with providing such notice, the Company shall publish a notice containing the information set forth in the Fundamental Change Company Notice in a newspaper of general
circulation in The City of New York or publish such information on the Company&#8217;s website or through such other public medium as the Company may use at that time. Each Fundamental Change Company Notice shall specify: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the events causing the Fundamental Change; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the date of the Fundamental Change; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the last date on which a Holder may exercise the repurchase right pursuant to this Article 15; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) the Fundamental Change Repurchase Price; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) the Fundamental Change Repurchase Date; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) the name and address of the Paying Agent and the Conversion Agent, if
applicable; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) if applicable, the Conversion Rate and any adjustments to the Conversion Rate; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) that the Notes with respect to which a Fundamental Change Repurchase Notice has been delivered by a Holder may be
converted only if the Holder withdraws the Fundamental Change Repurchase Notice in accordance with the terms of this Indenture; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) the procedures that Holders must follow to require the Company to repurchase their Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No failure of the Company to give the foregoing notices and no defect therein shall limit the Holders&#8217; repurchase rights or affect the
validity of the proceedings for the repurchase of the Notes pursuant to this Section&nbsp;15.02. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Company&#8217;s request, the
Trustee shall give such notice in the Company&#8217;s name and at the Company&#8217;s expense;<I> provided</I>,<I> however</I>, that, in all cases, the text of such Fundamental Change Company Notice shall be prepared by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding the foregoing, in the case of a Fundamental Change described in clauses (a)&nbsp;and/or (b)&nbsp;of the definition
thereof, the Company will not be required to repurchase, or to make an offer to repurchase, the Notes upon a Fundamental Change to the extent, and solely to the extent, that the other party to such Fundamental Change (or its Affiliate)&nbsp;(i)
makes such offer in the same manner, at the same time and otherwise in compliance with the requirements for an offer made by the Company as set forth in this Section&nbsp;15.02 (including, without limitation, the requirement to comply with
applicable securities laws), and (ii)&nbsp;such party purchases all Notes properly surrendered and not validly withdrawn under its offer in the same manner, at the same time and otherwise in compliance with the requirements for an offer made by the
Company as set forth above (including, without limitation, the requirement to pay the applicable Fundamental Change Repurchase Price on the later of the applicable Fundamental Change Repurchase Date and the time of book-entry transfer or delivery of
the relevant Notes); <I>provided </I>that the Company will continue to be obligated to (x)&nbsp;deliver the applicable Fundamental Change Repurchase Notice to the Holders, the Trustee and the Paying Agent (which Fundamental Change Repurchase Notice,
in addition to the requirements set forth above, will state that such party will make such an offer to repurchase the Notes), (y) comply with applicable securities laws in connection with any such repurchase and (z)&nbsp;pay the applicable
Fundamental Change Repurchase Price on the later of the applicable Fundamental Change Repurchase Date and the time of book-entry transfer or delivery of the relevant Notes in the event such party fails to make such payment in such amount at such
time. The provisions of this Section&nbsp;15.02(d) shall be limited to the matters set forth above and shall not be deemed or otherwise construed to (a)&nbsp;limit any of the Company&#8217;s obligations under this Indenture or the Notes (except
solely to the extent expressly set forth in this paragraph and subject to the conditions set forth above in this Section&nbsp;15.02(d)) or (b)&nbsp;prejudice any right, power or remedy which the Trustee or the Holders may then have or may have in
the future under or in connection with this Indenture or the Notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding the foregoing, no Notes may be repurchased by the Company on any date at
the option of the Holders upon a Fundamental Change if the principal amount of the Notes has been accelerated, and such acceleration has not been rescinded, on or prior to such date (except in the case of an acceleration resulting from a Default by
the Company in the payment of the Fundamental Change Repurchase Price with respect to such Notes). The Paying Agent will promptly return to the respective Holders thereof any Physical Notes held by it during the acceleration of the Notes (except in
the case of an acceleration resulting from a Default by the Company in the payment of the Fundamental Change Repurchase Price with respect to such Notes), or any instructions for book-entry transfer of the Notes in compliance with the procedures of
the Depositary shall be deemed to have been cancelled, and, upon such return or cancellation, as the case may be, the Fundamental Change Repurchase Notice with respect thereto shall be deemed to have been withdrawn. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.03<I>. Withdrawal of Fundamental Change Repurchase Notice.</I> (a)&nbsp;A Fundamental Change Repurchase Notice may be
withdrawn (in whole or in part) by means of a written notice of withdrawal delivered to the Corporate Trust Office of the Paying Agent in accordance with this Section&nbsp;15.03 at any time prior to the close of business on the Business Day
immediately preceding the Fundamental Change Repurchase Date, specifying: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the principal amount of the Notes with
respect to which such notice of withdrawal is being submitted, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) if Physical Notes have been issued, the certificate
number of the Note in respect of which such notice of withdrawal is being submitted, and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the principal amount, if
any, of such Note that remains subject to the original Fundamental Change Repurchase Notice, which portion must be in principal amounts of $1,000 or an integral multiple of $1,000; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I>, <I>however</I>, that if the Notes are Global Notes, the notice must comply with appropriate procedures of the Depositary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.04<I>. Deposit of Fundamental Change Repurchase Price.</I> (a)&nbsp;The Company will deposit with the Trustee (or other Paying
Agent appointed by the Company, or if the Company is acting as its own Paying Agent, set aside, segregate and hold in trust as provided in Section&nbsp;4.04) on or prior to 10:00 a.m., New York City time, on the Fundamental Change Repurchase Date an
amount of money sufficient to repurchase all of the Notes to be repurchased at the appropriate Fundamental Change Repurchase Price. Subject to receipt of funds and/or Notes by the Trustee (or other Paying Agent appointed by the Company), payment for
Notes surrendered for repurchase (and not withdrawn prior to the close of business on the Business Day immediately preceding the Fundamental Change Repurchase Date) will be made on the later of (i)&nbsp;the Fundamental Change Repurchase Date
(<I>provided</I> the Holder has satisfied the conditions in Section&nbsp;15.02) and (ii)&nbsp;the time of book-entry transfer or the delivery of such Note to the Trustee (or other Paying Agent appointed by the Company) by the Holder thereof in the
manner required </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by Section&nbsp;15.02 by mailing checks for the amount payable to the Holders of such Notes entitled thereto as they shall appear in the Note Register; <I>provided</I>, <I>however</I>, that
payments to the Depositary shall be made by wire transfer of immediately available funds to the account of the Depositary or its nominee. The Trustee shall, promptly after such payment and upon written demand by the Company, return to the Company
any funds in excess of the Fundamental Change Repurchase Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If by 10:00 a.m. New York City time, on the Fundamental Change
Repurchase Date, the Trustee (or other Paying Agent appointed by the Company) holds money sufficient to make payment on all the Notes or portions thereof that are to be repurchased on such Fundamental Change Repurchase Date, then, with respect to
the Notes that have been properly surrendered for repurchase and have not been validly withdrawn, (i)&nbsp;such Notes will cease to be outstanding, (ii)&nbsp;interest will cease to accrue on such Notes (whether or not book-entry transfer of the
Notes has been made or the Notes have been delivered to the Trustee or Paying Agent) and (iii)&nbsp;all other rights of the Holders of such Notes will terminate (other than the right to receive the Fundamental Change Repurchase Price and, if
applicable, accrued and unpaid interest). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Upon surrender of a Note that is to be repurchased in part pursuant to Section&nbsp;15.02,
the Company shall execute and the Trustee shall authenticate and deliver to the Holder a new Note in an authorized denomination equal in principal amount to the unrepurchased portion of the Note surrendered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.05. <I>Covenant to Comply with Applicable Laws Upon Repurchase of Notes</I>. In connection with any repurchase offer, the
Company shall, if required: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) comply with the provisions of Rule <FONT STYLE="white-space:nowrap">13e-4,</FONT> Rule <FONT
STYLE="white-space:nowrap">14e-1</FONT> and any other tender offer rules under the Exchange Act that may then be applicable; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) file a
Schedule TO or any other required schedule under the Exchange Act; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) otherwise comply with all federal and state securities laws in
connection with any offer by the Company to repurchase the Notes; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in each case, so as to permit the rights and obligations under this Article 15 to be
exercised in the time and in the manner specified in this Article 15. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary herein, to the extent
that, as a result of any change in any federal or state securities laws or other applicable laws or regulations after the date of this Indenture, compliance with this Article 15 would result in a violation of any such federal or state securities
laws or other applicable laws or regulations, the Company shall comply with its obligation to offer to repurchase the Notes upon a Fundamental Change in a manner that also complies with the applicable securities laws and regulations and will not be
deemed to have breached its obligations set forth in this Article 15 by virtue of such conflict. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 16 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">O<SMALL>PTIONAL</SMALL> R<SMALL>EDEMPTION</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;16.01. <I>Optional Redemption</I>. Unless and until the Company validly exercises its Termination of Conversion Rights option in
the manner specified in Section&nbsp;14.01(c), the Notes shall not be redeemable by the Company, and no sinking fund is provided for the Notes. If the Company validly exercises it Termination of Conversion Rights option pursuant to
Section&nbsp;14.01(c), the Company may redeem (an &#8220;<B>Optional Redemption</B>&#8221;) for cash all or part of the Notes, at the Company&#8217;s option, at any time or from time to time after the Conversion Rights Termination Date at the
Redemption Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;16.02. <I>Notice of </I><I>Optional Redemption; Selection of Notes</I>. (a)&nbsp;In case the Company
exercises its Optional Redemption right to redeem all or, as the case may be, any part of the Notes pursuant to Section&nbsp;16.01, it shall fix a date for redemption (each, a &#8220;<B>Redemption Date</B>&#8221;) and it or, at its written request
received by the Trustee not less than 15 calendar days prior to the date such Notice of Redemption is to be sent (or such shorter period of time as may be acceptable to the Trustee), the Trustee, in the name of and at the expense of the Company,
shall deliver or cause to be delivered a notice of such Optional Redemption (a <B>&#8220;</B><B>Notice of Redemption</B>&#8221;) not less than 10 nor more than 60 calendar days prior to the Redemption Date to each Holder of Notes so to be redeemed
as a whole or in part; <I>provided, however, </I>that, if the Company shall give such notice, it shall also give written notice of the Redemption Date to the Trustee and the Paying Agent (if other than the Trustee). The Redemption Date must be a
Business Day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Notice of Redemption, if delivered in the manner herein provided, shall be conclusively presumed to have been duly
given, whether or not the Holder receives such notice. In any case, failure to give such Notice of Redemption or any defect in the Notice of Redemption to the Holder of any Note designated for redemption as a whole or in part shall not affect the
validity of the proceedings for the redemption of any other Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each Notice of Redemption shall specify: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the Redemption Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the Redemption Price; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) that on the Redemption Date, the Redemption Price will become due and payable upon each Note to be redeemed, and that
interest thereon, if any, shall cease to accrue on and after the Redemption Date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) the place or places where such
Notes are to be surrendered for payment of the Redemption Price; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) the CUSIP, ISIN or other similar numbers, if any,
assigned to such Notes; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) in case any Note is to be redeemed in part only, the portion of the principal amount
thereof to be redeemed and on and after the Redemption Date, upon surrender of such Note, a new Note in principal amount equal to the unredeemed portion thereof shall be issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Notice of Redemption shall be irrevocable; <I>provided </I>that any Notice of Redemption may state that
such redemption shall be conditional, in the Company&#8217;s discretion, on one or more conditions precedent, and that the Redemption Date may (but shall not be required to) be delayed until such time as any or all of such conditions have been
satisfied, and that such conditional Notice of Redemption may be rescinded by the Company if the Company determines that any or all such conditions will not be satisfied by the Redemption Date, and that in such event, such Notice of Redemption shall
be of no further force or effect and the Company shall not be required to redeem the Notes on the Redemption Date or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) If
fewer than all of the outstanding Notes are to be redeemed and the Notes to be redeemed are Global Notes, the Notes to be redeemed shall be selected by the Depositary in accordance with the applicable procedures of the Depositary. If fewer than all
of the outstanding Notes are to be redeemed and the Notes to be redeemed are not Global Notes, the Trustee shall select the Notes or portions thereof to be redeemed (in principal amounts of $1,000 or multiples thereof) on a <I>pro rata</I> basis.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;16.03. <I>Payment of Notes Called for Redemption</I>. (a)&nbsp;If any Notice of Redemption has been given in respect of the
Notes in accordance with Section&nbsp;16.02, the Notes shall become due and payable on the Redemption Date at the place or places stated in the Notice of Redemption and at the applicable Redemption Price. On presentation and surrender of the Notes
at the place or places stated in the Notice of Redemption, the Notes shall be paid and redeemed by the Company at the applicable Redemption Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Prior to 10:00 a.m. New York City time on the Redemption Date, the Company shall deposit with the Paying Agent or, if the Company or a
Subsidiary of the Company is acting as the Paying Agent, shall segregate and hold in trust as provided in Section&nbsp;7.05 an amount of cash (in immediately available funds if deposited on the Redemption Date), sufficient to pay the Redemption
Price of all of the Notes to be redeemed on such Redemption Date. Subject to receipt of funds by the Paying Agent, payment for the Notes to be redeemed shall be made on the Redemption Date for such Notes. The Paying Agent shall, promptly after such
payment and upon written demand by the Company, return to the Company any funds in excess of the Redemption Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;16.04.
<I>Restrictions on Redemption</I>. The Company may not redeem any Notes on any date if the principal amount of the Notes has been accelerated in accordance with the terms of this Indenture, and such acceleration has not been rescinded, on or prior
to the Redemption Date (except in the case of an acceleration resulting from a Default by the Company in the payment of the Redemption Price with respect to such Notes). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 17 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M<SMALL>ISCELLANEOUS</SMALL> P<SMALL>ROVISIONS</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17.01<I>. Provisions Binding on Company</I><I>&#8217;</I><I>s Successors.</I> Prior to the date that it is released pursuant to
Section&nbsp;11.02, all the covenants, stipulations, promises and agreements of the Company contained in this Indenture shall bind its successors and assigns whether so expressed or not. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17.02<I>. Official Acts by Successor Corporation.</I> Any act or proceeding by any provision of this Indenture authorized or
required to be done or performed by any board, committee or Officer of the Company shall and may be done and performed with like force and effect by the like board, committee or officer of any corporation or other entity that shall at the time be
the lawful sole successor of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17.03<I>. Addresses for Notices, Etc.</I> Any notice or demand that by any
provision of this Indenture is required or permitted to be given or served by the Trustee or by the Holders on the Company shall be deemed to have been sufficiently given or made, for all purposes if given or served by being deposited postage
prepaid by registered or certified mail in a post office letter box addressed (until another address is filed by the Company with the Trustee) to Evolent Health, Inc., 1812 N. Moore Street, Suite 1705, Arlington, Virginia 22209, Attention: Jonathan
Weinberg. Any notice, direction, request or demand hereunder to or upon the Trustee shall be deemed to have been sufficiently given or made, for all purposes, if given or served by being deposited postage prepaid by registered or certified mail in a
post office letter box addressed to the Corporate Trust Office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Trustee, by notice to the Company, may designate additional or
different addresses for subsequent notices or communications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any notice or communication delivered or to be delivered to a Holder of
Physical Notes shall be mailed to it by first class mail, postage prepaid, at its address as it appears on the Note Register and shall be sufficiently given to it if so mailed within the time prescribed. Any notice or communication delivered or to
be delivered to a Holder of Global Notes shall be delivered in accordance with the applicable procedures of the Depositary and shall be sufficiently given to it if so delivered within the time prescribed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to mail or deliver a notice or communication to a Holder or any defect in it shall not affect its sufficiency with respect to other
Holders. If a notice or communication is mailed or delivered, as the case may be, in the manner provided above, it is duly given, whether or not the addressee receives it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case by reason of the suspension of regular mail service or by reason of any other cause it shall be impracticable to give such notice to
Holders by mail, then such notification as shall be made with the approval of the Trustee shall constitute a sufficient notification for every purpose hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17.04<I>. Governing Law; Jurisdiction.</I> THIS INDENTURE AND EACH NOTE, AND
ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS INDENTURE AND EACH NOTE, SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK (WITHOUT REGARD TO THE CONFLICTS OF LAWS PROVISIONS THEREOF). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company irrevocably consents and agrees, for the benefit of the Holders from time to time of the Notes and the Trustee, that any legal
action, suit or proceeding against it with respect to obligations, liabilities or any other matter arising out of or in connection with this Indenture or the Notes may be brought in the courts of the State of New York or the courts of the United
States located in the Borough of Manhattan, New York City, New York and, until amounts due and to become due in respect of the Notes have been paid, hereby irrevocably consents and submits to the <FONT STYLE="white-space:nowrap">non-exclusive</FONT>
jurisdiction of each such court<I> in personam</I>, generally and unconditionally with respect to any action, suit or proceeding for itself in respect of its properties, assets and revenues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company irrevocably and unconditionally waives, to the fullest extent permitted by law, any objection which it may now or hereafter have
to the laying of venue of any of the aforesaid actions, suits or proceedings arising out of or in connection with this Indenture brought in the courts of the State of New York or the courts of the United States located in the Borough of Manhattan,
New York City, New York and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17.05<I>. Evidence of Compliance with Conditions Precedent; Certificates and Opinions of Counsel to Trustee.</I> Upon any
application or demand by the Company to the Trustee to take any action under any of the provisions of this Indenture, the Company shall, if requested by the Trustee, furnish to the Trustee an Officer&#8217;s Certificate stating that such action is
permitted by the terms of this Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Officer&#8217;s Certificate provided for, by or on behalf of the Company in this Indenture
and delivered to the Trustee with respect to compliance with this Indenture (other than the Officer&#8217;s Certificates provided for in Section&nbsp;4.08) shall include (a)&nbsp;a statement that the person signing such certificate is familiar with
the requested action and this Indenture; (b)&nbsp;a brief statement as to the nature and scope of the examination or investigation upon which the statement contained in such certificate is based; (c)&nbsp;a statement that, in the judgment of such
person, he or she has made such examination or investigation as is necessary to enable him or her to express an informed judgment as to whether or not such action is permitted by this Indenture; and (d)&nbsp;a statement as to whether or not, in the
judgment of such person, such action is permitted by this Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary in this Section&nbsp;17.05,
if any provision in this Indenture specifically provides that the Trustee shall or may receive an Opinion of Counsel in connection with any action to be taken by the Trustee or the Company hereunder, the Trustee shall be entitled to, or entitled to
request, such Opinion of Counsel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17.06<I>. Legal Holidays.</I> In any case where any Interest Payment Date, any
Fundamental Change Repurchase Date, any Redemption Date or the Maturity Date is not a Business Day, then any action to be taken on such date need not be taken on such date, but may be taken on the next succeeding Business Day with the same force and
effect as if taken on such date, and no interest shall accrue in respect of the delay. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17.07<I>. No Security Interest
Created.</I> Nothing in this Indenture or in the Notes, expressed or implied, shall be construed to constitute a security interest under the Uniform Commercial Code or similar legislation, as now or hereafter enacted and in effect, in any
jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17.08<I>. Benefits of Indenture.</I> Nothing in this Indenture or in the Notes, expressed or implied, shall
give to any Person, other than the Holders, the parties hereto, any Paying Agent, any Conversion Agent, any authenticating agent, any Note Registrar and their successors hereunder, any benefit or any legal or equitable right, remedy or claim under
this Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17.09<I>. Table of Contents, Headings, Etc.</I> The table of contents and the titles and headings of the
articles and sections of this Indenture have been inserted for convenience of reference only, are not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17.10<I>. Authenticating Agent.</I> The Trustee may appoint an authenticating agent that shall be authorized to act on its behalf
and subject to its direction in the authentication and delivery of Notes in connection with the original issuance thereof and transfers and exchanges of Notes hereunder, including under Section&nbsp;2.04, Section&nbsp;2.05, Section&nbsp;2.06,
Section&nbsp;2.07, Section&nbsp;10.04 and Section&nbsp;15.04 as fully to all intents and purposes as though the authenticating agent had been expressly authorized by this Indenture and those Sections to authenticate and deliver Notes. For all
purposes of this Indenture, the authentication and delivery of Notes by the authenticating agent shall be deemed to be authentication and delivery of such Notes &#8220;by the Trustee&#8221; and a certificate of authentication executed on behalf of
the Trustee by an authenticating agent shall be deemed to satisfy any requirement hereunder or in the Notes for the Trustee&#8217;s certificate of authentication. Such authenticating agent shall at all times be a Person eligible to serve as trustee
hereunder pursuant to Section&nbsp;7.08. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any corporation or other entity into which any authenticating agent may be merged or converted
or with which it may be consolidated, or any corporation or other entity resulting from any merger, consolidation or conversion to which any authenticating agent shall be a party, or any corporation or other entity succeeding to the corporate trust
business of any authenticating agent, shall be the successor of the authenticating agent hereunder, if such successor corporation or other entity is otherwise eligible under this Section&nbsp;17.10, without the execution or filing of any paper or
any further act on the part of the parties hereto or the authenticating agent or such successor corporation or other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
authenticating agent may at any time resign by giving written notice of resignation to the Trustee and to the Company. The Trustee may at any time terminate the agency of any authenticating agent by giving written notice of termination to such
authenticating agent and to the Company. Upon receiving such a notice of resignation or upon such a termination, or in case at any time any authenticating agent shall cease to be eligible under this Section, the Trustee may appoint a successor
authenticating agent (which may be the Trustee), shall give written notice of such appointment to the Company and shall deliver notice of such appointment to all Holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company agrees to pay to the authenticating agent from time to time reasonable
compensation for its services although the Company may terminate the authenticating agent, if it determines such agent&#8217;s fees to be unreasonable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of Section&nbsp;7.02, Section&nbsp;7.03, Section&nbsp;7.04, Section&nbsp;8.03 and this Section&nbsp;17.10 shall be applicable
to any authenticating agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an authenticating agent is appointed pursuant to this Section&nbsp;17.10, the Notes may have endorsed
thereon, in addition to the Trustee&#8217;s certificate of authentication, an alternative certificate of authentication in the following form: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">__________________________, as Authenticating Agent, certifies that this is one of the Notes described in the within-named Indenture. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Authorized Officer</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17.11<I>. Execution in Counterparts.</I> This Indenture may be executed in any number of
counterparts, each of which shall be an original, but such counterparts shall together constitute but one and the same instrument. The exchange of copies of this Indenture and of signature pages by facsimile or PDF transmission shall constitute
effective execution and delivery of this Indenture as to the parties hereto and may be used in lieu of the original Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original
signatures for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17.12<I>. Severability.</I> In the event any provision of this Indenture or in the Notes shall
be invalid, illegal or unenforceable, then (to the extent permitted by law) the validity, legality or enforceability of the remaining provisions shall not in any way be affected or impaired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17.13<I>. Waiver of Jury Trial.</I> EACH OF THE COMPANY AND THE TRUSTEE HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT
PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE NOTES OR THE TRANSACTIONS CONTEMPLATED HEREBY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17.14<I>. Force Majeure.</I> In no event shall the Trustee be responsible or liable for any failure or delay in the performance
of its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or
natural catastrophes or acts of God, and interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services; it being understood that the Trustee shall use reasonable efforts that are consistent with
accepted practices in the banking industry to resume performance as soon as practicable under the circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17.15<I>. Calculations</I>. Except as otherwise provided herein, the Company
shall be responsible for making all calculations called for under the Notes. These calculations include, but are not limited to, determinations of the Stock Price, the Last Reported Sale Prices of the Class&nbsp;A Common Stock, the Daily VWAPs, the
Daily Conversion Values, the Daily Settlement Amounts, accrued interest payable on the Notes and the Conversion Rate of the Notes. The Company shall make all these calculations in good faith and, absent manifest error, the Company&#8217;s
calculations shall be final and binding on Holders. The Company shall provide a schedule of its calculations to each of the Trustee and the Conversion Agent, and each of the Trustee and Conversion Agent is entitled to rely conclusively upon the
accuracy of the Company&#8217;s calculations without independent verification and shall have no liability or responsibility in connection with any calculations requested under this Indenture. The Trustee will forward the Company&#8217;s calculations
to any Holder of Notes upon the written request of that Holder at the sole cost and expense of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17.16. <I>USA
PATRIOT Act. </I>The parties hereto acknowledge that in accordance with Section&nbsp;326 of the USA PATRIOT Act, the Trustee, like all financial institutions and in order to help fight the funding of terrorism and money laundering, is required to
obtain, verify, and record information that identifies each person or legal entity that establishes a relationship or opens an account with the Trustee. The parties to this Indenture agree that they will provide the Trustee with such information as
it may request in order for the Trustee to satisfy the requirements of the USA PATRIOT Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of page intentionally left
blank</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">EVOLENT HEALTH, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jonathan Weinberg</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:&#8194;Jonathan Weinberg</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:&#8195;General Counsel</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. BANK TRUST COMPANY,<BR>NATIONAL ASSOCIATION, as Trustee</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Wally Jones</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:Wally Jones</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:Vice President</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Indenture</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[FORM OF FACE OF NOTE] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[INCLUDE
FOLLOWING LEGEND IF A GLOBAL NOTE] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY,
A NEW YORK CORPORATION (&#8220;DTC&#8221;), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE&nbsp;&amp; CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN
AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT HEREUNDER IS MADE TO CEDE&nbsp;&amp; CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY
PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE&nbsp;&amp; CO., HAS AN INTEREST HEREIN.] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[INCLUDE FOLLOWING LEGEND IF A
RESTRICTED SECURITY] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[THIS SECURITY AND THE CLASS A COMMON STOCK, IF ANY, ISSUABLE UPON CONVERSION OF THIS SECURITY HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF OR OF A BENEFICIAL
INTEREST HEREIN, THE ACQUIRER: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) REPRESENTS THAT IT AND ANY ACCOUNT FOR WHICH IT IS ACTING IS A &#8220;QUALIFIED
INSTITUTIONAL BUYER&#8221; (WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT) AND THAT IT EXERCISES SOLE INVESTMENT DISCRETION WITH RESPECT TO EACH SUCH ACCOUNT, AND </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) AGREES FOR THE BENEFIT OF EVOLENT HEALTH, INC. (THE &#8220;COMPANY&#8221;) THAT IT WILL NOT OFFER, SELL, PLEDGE OR
OTHERWISE TRANSFER THIS SECURITY OR ANY BENEFICIAL INTEREST HEREIN PRIOR TO THE DATE THAT IS THE LATER OF (X)&nbsp;ONE YEAR AFTER THE LAST ORIGINAL ISSUE DATE HEREOF OR SUCH SHORTER PERIOD OF TIME AS PERMITTED BY RULE 144 UNDER THE SECURITIES ACT OR
ANY SUCCESSOR PROVISION THERETO AND (Y)&nbsp;SUCH LATER DATE, IF ANY, AS MAY BE REQUIRED BY APPLICABLE LAW, EXCEPT: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) TO
THE COMPANY OR ANY SUBSIDIARY THEREOF, OR </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) PURSUANT TO A REGISTRATION STATEMENT WHICH HAS BECOME EFFECTIVE UNDER THE
SECURITIES ACT, OR </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) TO A PERSON REASONABLY BELIEVED TO BE A QUALIFIED INSTITUTIONAL BUYER IN
COMPLIANCE WITH RULE 144A UNDER THE SECURITIES ACT, OR </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144
UNDER THE SECURITIES ACT OR ANY OTHER AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PRIOR TO THE
REGISTRATION OF ANY TRANSFER IN ACCORDANCE WITH CLAUSE (2)(D) ABOVE, THE COMPANY AND THE TRUSTEE RESERVE THE RIGHT TO REQUIRE THE DELIVERY OF SUCH LEGAL OPINIONS, CERTIFICATIONS OR OTHER EVIDENCE AS MAY REASONABLY BE REQUIRED IN ORDER TO DETERMINE
THAT THE PROPOSED TRANSFER IS BEING MADE IN COMPLIANCE WITH THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. NO REPRESENTATION IS MADE AS TO THE AVAILABILITY OF ANY EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NO AFFILIATE (AS DEFINED IN RULE 144 UNDER THE SECURITIES ACT) OF EVOLENT HEALTH, INC. OR PERSON THAT HAS BEEN AN AFFILIATE (AS DEFINED IN
RULE 144 UNDER THE SECURITIES ACT) OF EVOLENT HEALTH, INC. DURING THE IMMEDIATELY PRECEDING THREE MONTHS MAY PURCHASE, OTHERWISE ACQUIRE OR HOLD THIS SECURITY OR A BENEFICIAL INTEREST HEREIN. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EVOLENT HEALTH, INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4.50% Convertible Senior Note due 2031 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No. [_____]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;[Initially]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP>
$[_________]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CUSIP No. [_________]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Evolent Health, Inc., a corporation duly organized and validly existing under the laws of the State of
Delaware (the &#8220;<B>Company</B>,&#8221; which term includes any successor corporation or other entity under the Indenture referred to on the reverse hereof), for value received hereby promises to pay to [CEDE&nbsp;&amp; CO.]<SUP
STYLE="font-size:75%; vertical-align:top">2</SUP> [_______]<SUP STYLE="font-size:75%; vertical-align:top">3</SUP>, or registered assigns, the principal sum [as set forth in the &#8220;Schedule of Exchanges of Notes&#8221; attached hereto]<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP><SUP STYLE="font-size:75%; vertical-align:top">4</SUP> [of $[_______]]<SUP STYLE="font-size:75%; vertical-align:top">5</SUP>, which amount, taken together with the principal amounts of all other
outstanding Notes, shall not, unless permitted by the Indenture, exceed $166,750,000 in aggregate at any time, in accordance with the rules and procedures of the Depositary, on August 15, 2031, and interest thereon as set forth below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Note shall bear interest at the rate of 4.50% per year from August 21, 2025, or from the most recent date to which interest had been paid
or provided for to, but excluding, the next scheduled Interest Payment Date until August&nbsp;15, 2031. Interest is payable semiannually in arrears on each February&nbsp;15 and August&nbsp;15, commencing on February&nbsp;15, 2026, to Holders of
record at the close of business on the preceding February&nbsp;1 and August&nbsp;1 (whether or not such day is a Business Day), respectively. Additional Interest will be payable as set forth in Section&nbsp;4.06(d), Section&nbsp;4.06(e) and
Section&nbsp;6.03 of the within-mentioned Indenture, and any reference to interest on, or in respect of, any Note therein shall be deemed to include Additional Interest if, in such context, Additional Interest is, was or would be payable pursuant to
any of such Section&nbsp;4.06(d), Section&nbsp;4.06(e) or Section&nbsp;6.03, and any express mention of the payment of Additional Interest in any provision therein shall not be construed as excluding Additional Interest in those provisions thereof
where such express mention is not made. Accrued interest on the Notes shall be computed on the basis of a <FONT STYLE="white-space:nowrap">360-day</FONT> year composed of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months and, for partial
months, on the basis of the number of days actually elapsed in a <FONT STYLE="white-space:nowrap">30-day</FONT> month. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Defaulted
Amounts shall accrue interest per annum at the rate borne by the Notes <I>plus</I> one percent, subject to the enforceability thereof under applicable law, from, and including, the relevant payment date to, but excluding, the date on which such
Defaulted Amounts shall have been paid by the Company, at its election, in accordance with Section&nbsp;2.03(c) of the Indenture.
</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Include if a global note. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Include if a global note. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Include if a physical note. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Include if a global note. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Include if a physical note. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall pay the principal of and interest on this Note, if and so long as such
Note is a Global Note, in immediately available funds to the Depositary or its nominee, as the case may be, as the registered Holder of such Note. As provided in and subject to the provisions of the Indenture, the Company shall pay the principal of
any Notes (other than Notes that are Global Notes) at the office or agency designated by the Company for that purpose. The Company has initially designated the Trustee as its Paying Agent and Note Registrar in respect of the Notes and its agency in
St. Paul, Minnesota, as a place where Notes may be presented for payment or for registration of transfer and exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made
to the further provisions of this Note set forth on the reverse hereof, including, without limitation, provisions giving the Holder of this Note the right to convert this Note into cash, shares of Class&nbsp;A Common Stock or a combination of cash
and shares of Class&nbsp;A Common Stock, as applicable, on the terms and subject to the limitations set forth in the Indenture, including the right of the Company to exercise its Termination of Conversion Rights option pursuant to
Section&nbsp;14.01(c) of the Indenture. Such further provisions shall for all purposes have the same effect as though fully set forth at this place. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This Note, and any claim, controversy or dispute arising under or related to this Note, shall be construed in accordance with and governed
by the laws of the State of New York (without regard to the conflicts of laws provisions thereof). </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of any conflict
between this Note and the Indenture, the provisions of the Indenture shall control and govern. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Note shall not be valid or become
obligatory for any purpose until the certificate of authentication hereon shall have been signed manually or by facsimile by the Trustee or a duly authorized authenticating agent under the Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of page intentionally left blank</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Note to be duly executed. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">EVOLENT HEALTH, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="60%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TRUSTEE&#8217;S CERTIFICATE OF AUTHENTICATION</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION<BR>as Trustee, certifies that this is one of the Notes described in the within-named
Indenture.</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authorized Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[FORM OF REVERSE OF NOTE] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EVOLENT HEALTH, INC. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4.50%
Convertible Senior Note due 2031 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Note is one of a duly authorized issue of Notes of the Company, designated as its 4.50% Convertible
Senior Notes due 2031 (the &#8220;<B>Notes</B>&#8221;), limited to the aggregate principal amount of $166,750,000 all issued or to be issued under and pursuant to an Indenture dated as of August 21, 2025 (the &#8220;<B>Indenture</B>&#8221;), between
the Company and U.S. Bank Trust Company, National Association (the &#8220;<B>Trustee</B>&#8221;), to which Indenture and all indentures supplemental thereto reference is hereby made for a description of the rights, limitations of rights,
obligations, duties and immunities thereunder of the Trustee, the Company and the Holders of the Notes. Additional Notes may be issued in an unlimited aggregate principal amount, subject to certain conditions specified in the Indenture. Capitalized
terms used in this Note and not defined in this Note shall have the respective meanings set forth in the Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case certain
Events of Default shall have occurred and be continuing, the principal of, and interest on, all Notes may be declared, by either the Trustee or Holders of at least 25% in aggregate principal amount of Notes then outstanding, and upon said
declaration shall become, due and payable, in the manner, with the effect and subject to the conditions and certain exceptions set forth in the Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions of the Indenture, the Company will make all payments and deliveries in respect of the Fundamental Change
Repurchase Price on the Fundamental Change Repurchase Date, the Redemption Price on the Redemption Date and the principal amount on the Maturity Date, as the case may be, to the Holder who surrenders a Note to a Paying Agent to collect such payments
in respect of the Note. The Company will pay cash amounts in money of the United States that at the time of payment is legal tender for payment of public and private debts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Indenture contains provisions permitting the Company and the Trustee in certain circumstances, without the consent of the Holders of the
Notes, and in certain other circumstances, with the consent of the Holders of not less than a majority in aggregate principal amount of the Notes at the time outstanding, evidenced as in the Indenture provided, to execute supplemental indentures
modifying the terms of the Indenture and the Notes as described therein. It is also provided in the Indenture that, subject to certain exceptions, the Holders of a majority in aggregate principal amount of the Notes at the time outstanding may on
behalf of the Holders of all of the Notes waive any past Default or Event of Default under the Indenture and its consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each
Holder shall have the right to receive payment or delivery, as the case may be, of (x)&nbsp;the principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, (y)&nbsp;accrued and unpaid interest, if any,
on, and (z)&nbsp;the consideration due upon conversion of, this Note at the place, at the respective times, at the rate and in the lawful money or shares of Class&nbsp;A Common Stock, as the case may be, herein prescribed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Notes are issuable in registered form without coupons in denominations of $1,000
principal amount and integral multiples thereof. At the office or agency of the Company referred to on the face hereof, and in the manner and subject to the limitations provided in the Indenture, Notes may be exchanged for a like aggregate principal
amount of Notes of other authorized denominations, without payment of any service charge but, if required by the Company or Trustee, with payment of a sum sufficient to cover any transfer or similar tax that may be imposed in connection therewith as
a result of the name of the Holder of the new Notes issued upon such exchange of Notes being different from the name of the Holder of the old Notes surrendered for such exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Notes shall be redeemable at the Company&#8217;s option in accordance with the terms and subject to the conditions specified in the
Indenture. No sinking fund is provided for the Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the occurrence of a Fundamental Change, the Holder has the right, at such
Holder&#8217;s option, to require the Company to repurchase for cash all of such Holder&#8217;s Notes or any portion thereof (in principal amounts of $1,000 or integral multiples thereof) on the Fundamental Change Repurchase Date at a price equal to
the Fundamental Change Repurchase Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the provisions of the Indenture, including the right of the Company to exercise its
Termination of Conversion Rights option pursuant to Section&nbsp;14.01(c) of the Indenture, the Holder hereof has the right, at its option, during certain periods and upon the occurrence of certain conditions specified in the Indenture, prior to the
close of business on the Business Day immediately preceding the Maturity Date, to convert any Notes or portion thereof that is $1,000 or an integral multiple thereof, into cash, shares of Class&nbsp;A Common Stock or a combination of cash and shares
of Class&nbsp;A Common Stock, as applicable, at the Conversion Rate specified in the Indenture, as adjusted from time to time as provided in the Indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABBREVIATIONS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following abbreviations, when used in the inscription of the face of this Note, shall be construed as though they were written out in full
according to applicable laws or regulations: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEN COM = as tenants in common </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">UNIF GIFT MIN ACT = Uniform Gifts to Minors Act </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CUST =
Custodian </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEN ENT = as tenants by the entireties </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JT TEN =
joint tenants with right of survivorship and not as tenants in common </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional abbreviations may also be used though not in the above
list. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>SCHEDULE A<SUP STYLE="font-size:75%; vertical-align:top">6</SUP> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE OF EXCHANGES OF NOTES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Evolent Health, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4.50%
Convertible Senior Notes due 2031 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial principal amount of this Global Note is _______ DOLLARS ($[_________]). The following
increases or decreases in this Global Note have been made: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Date of exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Amount of</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">decrease in</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">principal amount</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">of this Global Note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Amount of</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">increase in</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">principal amount</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">of this Global Note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Principal amount</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">of this Global Note</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">following
such</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">decrease or</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Signature of</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">authorized</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">signatory of</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Trustee or</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Custodian</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;&#8195;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR></TABLE>
<DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Include if a global note. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>ATTACHMENT 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[FORM OF NOTICE OF CONVERSION] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Evolent Health, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4.50%
Convertible Senior Notes due 2031 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">To:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">U.S. Bank Trust Company, National Association </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1051 East Cary Street, Suite 600 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Richmond, Virginia 23219 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attn:
Global Corporate Trust Services </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registered owner of this Note hereby exercises the option to convert this Note, or the
portion hereof (that is $1,000 principal amount or an integral multiple thereof) below designated, into cash, shares of Class A Common Stock or a combination of cash and shares of Class A Common Stock, as applicable in accordance with the terms of
the Indenture referred to in this Note, and directs that any cash payable and any shares of Class A Common Stock issuable and deliverable upon such conversion, together with any cash for any fractional share, and any Notes representing any
unconverted principal amount hereof, be issued and delivered to the registered Holder hereof unless a different name has been indicated below. If any shares of Class A Common Stock or any portion of this Note not converted are to be issued in the
name of a Person other than the undersigned, the undersigned will pay all documentary, stamp or similar issue or transfer taxes, if any in accordance with Section 14.02(d) and Section 14.02(e) of the Indenture. Any amount required to be paid to the
undersigned on account of interest accompanies this Note. Capitalized terms used herein but not defined shall have the meanings ascribed to such terms in the Indenture. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">Signature(s)</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signature Guarantee</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Signature(s) must be guaranteed by an eligible Guarantor Institution (banks, stock brokers, savings andloan associations and credit unions) with membership in
an approved signature guarantee medallion program pursuant to Securities and Exchange Commission Rule 17Ad-15 if sharesof Class A Common Stock are to be issued, or</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Notes are to be delivered, other than to and in the name of the registered holder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fill in for registration of shares if to be issued, and Notes if to be delivered, other than to and in the name of the registered holder:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Name)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Street Address)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(City, State and Zip Code)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Please print name and address</TD></TR></TABLE> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="45%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Principal amount to be converted (if less than all):</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">$______,000</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NOTICE: The above signature(s) of the Holder(s) hereof must correspond with the name as written upon the face of the Note in every particular without alteration or enlargement or any change whatever.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Social Security or Other Taxpayer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Identification Number</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>ATTACHMENT 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[FORM OF FUNDAMENTAL CHANGE REPURCHASE NOTICE] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Evolent Health, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4.50%
Convertible Senior Notes due 2031 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">To:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">U.S. Bank Trust Company, National Association </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1051 East Cary Street, Suite 600 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Richmond, Virginia 23219 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attn:
Global Corporate Trust Services </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registered owner of this Note hereby acknowledges receipt of a notice from Evolent
Health, Inc. (the &#8220;<B>Company</B>&#8221;) as to the occurrence of a Fundamental Change with respect to the Company and specifying the Fundamental Change Repurchase Date and requests and instructs the Company to pay to the registered holder
hereof in accordance with Section&nbsp;15.02 of the Indenture referred to in this Note (1)&nbsp;the entire principal amount of this Note, or the portion thereof (that is $1,000 principal amount or an integral multiple thereof) below designated, and
(2)&nbsp;if such Fundamental Change Repurchase Date does not fall during the period after a Regular Record Date and on or prior to the corresponding Interest Payment Date, accrued and unpaid interest, if any, thereon to, but excluding, such
Fundamental Change Repurchase Date. Capitalized terms used herein but not defined shall have the meanings ascribed to such terms in the Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of Physical Notes, the certificate numbers of the Notes to be repurchased are as set forth below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: _____________________ </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="45%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature(s)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Social Security or Other Taxpayer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Identification Number</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Principal amount to be repaid (if less than all):</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">$______,000</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NOTICE: The above signature(s) of the Holder(s) hereof must correspond with the name as written upon the face of the Note in every particular without alteration or enlargement or any change whatever.</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>ATTACHMENT 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[FORM OF ASSIGNMENT AND TRANSFER] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For value
received ____________________________ hereby sell(s), assign(s) and transfer(s) unto _________________ (Please insert social security or Taxpayer Identification Number of assignee) the within Note, and hereby irrevocably constitutes and appoints
_____________________ attorney to transfer the said Note on the books of the Company, with full power of substitution in the premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with
any transfer of the within Note occurring prior to the Resale Restriction Termination Date, as defined in the Indenture governing such Note, the undersigned confirms that such Note is being transferred: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; To Evolent Health, Inc. or a subsidiary thereof; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; Pursuant to a registration statement that has become effective under the Securities Act of 1933, as amended; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; To a Person reasonably believed to be a qualified institutional buyer in compliance with Rule 144A under the Securities Act of 1933, as amended; or
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; Pursuant to and in compliance with Rule 144 under the Securities Act of 1933, as amended, or any other available exemption from the registration
requirements of the Securities Act of 1933, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="45%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: ________________________</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature(s)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature Guarantee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature(s) must be guaranteed by an eligible Guarantor Institution (banks, stock brokers, savings and loan associations and credit unions) with membership in an approved signature guarantee medallion program pursuant to Securities
and Exchange Commission Rule <FONT STYLE="white-space:nowrap">17Ad-15</FONT> if Notes are to be delivered, other than to and in the name of the registered holder.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTICE: The signature on the assignment must correspond with the name as written upon the face of the Note in every particular
without alteration or enlargement or any change whatever. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>d72742dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Execution Version</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EVOLENT HEALTH, INC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4.50%
Convertible Senior Notes due 2031 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Purchase Agreement </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">August&nbsp;18, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oppenheimer&nbsp;&amp; Co.
Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representative of the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">several Initial Purchasers
listed </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in Schedule 1 hereto </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Oppenheimer&nbsp;&amp; Co.
Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">85 Broad Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10004 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Evolent Health, Inc., a
Delaware corporation (the &#8220;Company&#8221;), proposes to issue and sell to the several initial purchasers listed in Schedule 1 hereto (the &#8220;Initial Purchasers&#8221;), for whom you are acting as representative (the
&#8220;Representative&#8221;), $145.0&nbsp;million principal amount of its 4.50% Convertible Senior Notes due 2031 (the &#8220;Firm Securities&#8221;) and, at the option of the Initial Purchasers, up to an additional $21.75&nbsp;million principal
amount of its 4.50% Convertible Senior Notes due 2031 (the &#8220;Option Securities&#8221;) if and to the extent that the Initial Purchasers shall have determined to exercise the option to purchase such 4.50% Convertible Senior Notes due 2031
granted to the Initial Purchasers in Section&nbsp;2 hereof. The Firm Securities and the Option Securities are herein referred to as the &#8220;Securities.&#8221; The Securities will be convertible into shares (the &#8220;Underlying
Securities&#8221;) of Class&nbsp;A common stock of the Company, par value $0.01 per share (the &#8220;Class&nbsp;A Common Stock&#8221;), cash or a combination thereof, at the Company&#8217;s election. The Securities will be issued pursuant to an
Indenture to be dated as of August&nbsp;21, 2025 (the &#8220;Indenture&#8221;), between the Company and U.S. Bank Trust Company, National Association, as trustee (the &#8220;Trustee&#8221;). Class&nbsp;A Common Stock of the Company, together with
the shares of Class&nbsp;B Common Stock, par value $0.01 per share, of the Company (the &#8220;Class&nbsp;B Common Stock&#8221;), is referred to herein as the &#8220;Stock.&#8221; Evolent Health LLC, a Delaware limited liability company, is referred
to herein as &#8220;Evolent Health.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent there are no additional parties listed on Schedule 1 other than you, the term
Representative as used herein shall mean you as the Initial Purchaser, and the term Initial Purchasers shall refer only to Oppenheimer&nbsp;&amp; Co. Inc., and the term shall be taken in the singular as the context requires. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreement with the several Initial Purchasers concerning the
purchase and sale of the Securities, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Offering Memorandum and Transaction Information</U>. The Securities will be sold to
the Initial Purchasers without being registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in reliance upon an exemption therefrom. The Company has prepared a preliminary offering memorandum dated
August&nbsp;18, 2025 (the &#8220;Preliminary Offering Memorandum&#8221;) and will prepare an offering memorandum dated the date hereof (the &#8220;Offering Memorandum&#8221;) setting forth information concerning the Company and the Securities.
Copies of the Preliminary Offering Memorandum have been, and copies of the Offering Memorandum will be, delivered by the Company to the Initial Purchasers pursuant to the terms of this purchase agreement (this &#8220;Agreement&#8221;). The Company
hereby confirms that it has authorized the use of the Preliminary Offering Memorandum, the other Time of Sale Information (as defined below) and the Offering Memorandum in connection with the offering and resale of the Securities by the Initial
Purchasers in the manner contemplated by this Agreement. References herein to the Preliminary Offering Memorandum, the Time of Sale Information and the Offering Memorandum shall be deemed to refer to and include any document incorporated by
reference therein, and any reference to &#8220;amend,&#8221; &#8220;amendment&#8221; or &#8220;supplement&#8221; with respect to the Preliminary Offering Memorandum or the Offering Memorandum shall be deemed to refer to and include any documents
filed after such date and incorporated by reference therein. Capitalized terms used but not defined herein shall have the meanings given to such terms in the Time of Sale Information and the Offering Memorandum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the Time of Sale (as defined below), the Company had prepared the following information (collectively, the &#8220;Time of Sale
Information&#8221;): the Preliminary Offering Memorandum, as supplemented and amended by the written communications listed on Annex A hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Time of Sale&#8221; means 10:30 p.m., New York City time, on August&nbsp;18, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase and Resale of the Securities</U>. (a)&nbsp;The Company agrees to issue and sell the Firm Securities to the several Initial
Purchasers as provided in this Agreement, and each Initial Purchaser, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase from
the Company the respective principal amount of Firm Securities set forth opposite such Initial Purchasers&#8217; name in Schedule 1 hereto at a price equal to 97.000% of the principal amount thereof (the &#8220;Purchase Price&#8221;) plus accrued
interest, if any, from August&nbsp;21, 2025 to the Closing Date (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company agrees to issue and sell the
Option Securities to the several Initial Purchasers as provided in this Agreement, and the Initial Purchasers, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, shall have
the option to purchase, severally and not jointly, from the Company the Option Securities at the Purchase Price plus accrued interest, if any, from August&nbsp;21, 2025 to the date of payment and delivery. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any Option Securities are to be purchased, the principal amount of Option Securities to
be purchased by each Initial Purchaser shall be the principal amount of Option Securities which bears the same ratio to the aggregate principal amount of Option Securities being purchased as the principal amount of Firm Securities set forth opposite
the name of such Initial Purchaser in Schedule 1 hereto (or such amount increased as set forth in Section&nbsp;10 hereof) bears to the aggregate principal amount of Firm Securities being purchased from the Company by the several Initial Purchasers,
subject, however, to such adjustments to eliminate Securities in denominations other than $1,000 as the Representative in its sole discretion shall make. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Initial Purchasers may exercise the option to purchase the Option Securities at any time in whole, or from time to time in part, on or
before the thirtieth day following the date of this Agreement, by written notice from the Representative to the Company.&nbsp;Such notice shall set forth the aggregate principal amount of Option Securities plus accrued interest as to which the
option is being exercised and the date and time when the Option Securities are to be delivered and paid for which may be the same date and time as the Closing Date (as hereinafter defined) but shall not be earlier than the Closing Date nor later
than the tenth full business day (as hereinafter defined) after the date of such notice (unless such time and date are postponed in accordance with the provisions of Section&nbsp;10 hereof).&nbsp;Any such notice shall be given at least two business
days prior to the date and time of delivery specified therein (unless such date and time of delivery is the same as the Closing Date). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company understands that the Initial Purchasers intend to offer the Securities for resale on the terms set forth in the
Time of Sale Information. Each Initial Purchaser, severally and not jointly, represents, warrants and agrees that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) it
is a qualified institutional buyer within the meaning of Rule 144A under the Securities Act (a &#8220;QIB&#8221;) and an accredited investor within the meaning of Rule 501(a) of Regulation D under the Securities Act (&#8220;Regulation D&#8221;);
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) it has not solicited offers for, or offered or sold, and will not solicit offers for, or offer or sell, the
Securities by means of any form of general solicitation or general advertising within the meaning of Rule 502(c) of Regulation D or in any manner involving a public offering within the meaning of Section&nbsp;4(a)(2) of the Securities Act; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) it has not solicited offers for, or offered or sold, and will not solicit offers for, or offer or sell, the Securities as
part of the initial offering except to persons whom it reasonably believes to be QIBs in transactions pursuant to Rule 144A under the Securities Act (&#8220;Rule 144A&#8221;) and in connection with each such sale, it has taken or will take
reasonable steps to ensure that the purchaser of the Securities is aware that such sale is being made in reliance on Rule 144A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each Initial Purchaser acknowledges and agrees that the Company and, for purposes of the &#8220;no registration&#8221;
opinions to be delivered to the Initial Purchasers pursuant to Sections 6(f) and 6(g), counsel for the Company and counsel for the Initial Purchasers, respectively, may rely upon the accuracy of the representations and warranties of the Initial
Purchasers, and compliance by the Initial Purchasers with their agreements, contained in paragraph (b)&nbsp;above and each Initial Purchaser hereby consents to such reliance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company acknowledges and agrees that the Initial Purchasers may
offer and sell Securities to or through any affiliate of an Initial Purchaser and that any such affiliate may offer and sell Securities purchased by it to or through any Initial Purchaser. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Payment for the Securities shall be made by wire transfer in immediately available funds to the account specified by the
Company to the Representative in the case of the Firm Securities, at the offices of Davis Polk&nbsp;&amp; Wardwell LLP, 450 Lexington Avenue, New York, New York 10017, at 10:00 A.M., New York City time, on August&nbsp;21, 2025, or at such other time
or place on the same or such other date, not later than the fifth business day thereafter, as the Representative and the Company may agree upon in writing or, in the case of the Option Securities, on the date and at the time and place specified by
the Representative in the written notice of the Initial Purchasers&#8217; election to purchase such Option Securities. The time and date of such payment for the Firm Securities is referred to herein as the &#8220;Closing Date&#8221; and the time and
date for such payment for the Option Securities, if other than the Closing Date, is herein referred to as the &#8220;Additional Closing Date.&#8221; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment for the Securities to be purchased on the Closing Date or the Additional Closing Date, as the case may be, shall be
made against delivery to the nominee of The Depository Trust Company (&#8220;DTC&#8221;), for the respective accounts of the several Initial Purchasers of the Securities of one or more global notes representing the Securities to be purchased on such
date (collectively, the &#8220;Global Note&#8221;), with any transfer taxes payable in connection with the sale of such Securities duly paid by the Company. The Global Note will be made available for inspection by the Representative at the office of
Davis Polk&nbsp;&amp; Wardwell LLP set forth above not later than 1:00 P.M., New York City time, on the business day prior to the Closing Date or the Additional Closing Date, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Each of the Company and Evolent Health acknowledges and agrees that each Initial Purchaser is acting solely in the capacity
of an arm&#8217;s length contractual counterparty to the Company with respect to the offering of Securities contemplated hereby (including in connection with determining the terms of the offering) and not as a financial advisor or a fiduciary to, or
an agent of, the Company or Evolent Health or any other person. Additionally, neither the Representative nor any other Initial Purchaser is advising the Company or Evolent Health or any other person as to any legal, tax, investment, accounting or
regulatory matters in any jurisdiction. The Company and Evolent Health shall consult with their own advisors concerning such matters and shall be responsible for making their own independent investigation and appraisal of the transactions
contemplated hereby, and the Initial Purchasers shall have no responsibility or liability to the Company or Evolent Health with respect thereto. Any review by the Representative or any Initial Purchaser of the Company or Evolent Health, the
transactions contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of the Representative or such Initial Purchaser and shall not be on behalf of the Company or Evolent Health. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations and Warranties</U>. Each of the Company and Evolent Health jointly and
severally represents and warrants to each Initial Purchaser that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Preliminary Offering Memorandum.</I> The
Preliminary Offering Memorandum, as of its date, did not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading; <U>provided</U> that neither the Company nor Evolent Health makes any representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Initial
Purchaser furnished to the Company and Evolent Health in writing by such Initial Purchaser through the Representative expressly for use in any Preliminary Offering Memorandum, it being understood and agreed that the only such information furnished
by any Initial Purchaser consists of the information described as such in Section&nbsp;7(b) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Time of Sale
Information</I>. The Time of Sale Information, at the Time of Sale, did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that neither the Company nor Evolent Health makes any representation or warranty with respect to
any statements or omissions made in reliance upon and in conformity with information relating to any Initial Purchaser furnished to the Company and Evolent Health in writing by such Initial Purchaser through the Representative expressly for use in
such Time of Sale Information, it being understood and agreed that the only such information furnished by any Initial Purchaser consists of the information described as such in Section&nbsp;7(b) hereof. No statement of material fact included in the
Offering Memorandum has been omitted from the Time of Sale Information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Additional Written Communications.
</I>Other than the Preliminary Offering Memorandum and the Offering Memorandum, neither the Company nor Evolent Health (including their agents and representatives, other than the Initial Purchasers in their capacity as such) has prepared, used,
authorized, approved or referred to and will not prepare, use, authorize, approve or refer to any &#8220;written communication&#8221; (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to
buy the Securities (each such communication by the Company or Evolent Health or their respective agents and representatives (other than a communication referred to in clauses (i), (ii) and (iii)&nbsp;below) an &#8220;Issuer Written
Communication&#8221;) other than (i)&nbsp;the Preliminary Offering Memorandum, (ii)&nbsp;the Offering Memorandum, (iii)&nbsp;the documents listed on Annex A hereto, including a term sheet substantially in the form of Annex B hereto, which constitute
part of the Time of Sale Information, and (iv)&nbsp;each electronic road show and any other written communications approved in writing in advance by the Representative. Each such Issuer Written Communication and each such electronic road show does
not conflict in any material respect with the information contained in the Time of Sale Information, and when taken together with the Time of Sale Information, did not, and as of the Closing Date and as of the Additional Closing Date, as the case
may be, will not, contain any untrue statement of a material fact or omit to state a material fact </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided </U>that neither the Company nor Evolent Health makes
any representation or warranty with respect to any statements or omissions made in each such Issuer Written Communication in reliance upon and in conformity with information relating to any Initial Purchaser furnished to the Company and Evolent
Health in writing by such Initial Purchaser through the Representative expressly for use in such Issuer Written Communication, it being understood and agreed that the only such information furnished by any Initial Purchaser consists of the
information described as such in Section&nbsp;7(b) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Offering Memorandum.</I> As of the date of the Offering
Memorandum and as of the Closing Date and as of the Additional Closing Date, as the case may be, the Offering Memorandum does not and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that neither the Company nor Evolent Health makes any representation or warranty with respect to any statements or omissions
made in reliance upon and in conformity with information relating to any Initial Purchaser furnished to the Company and Evolent Health in writing by such Initial Purchaser through the Representative expressly for use in the Offering Memorandum, it
being understood and agreed that the only such information furnished by any Initial Purchaser consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) [Reserved.] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) [Reserved.] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Incorporated Documents.</I> The documents incorporated by reference in the Offering Memorandum or the Time of Sale
Information, when they were filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) conformed or will conform, as the case may be, in all material respects to the requirements of the Securities Exchange Act of 1934, as
amended, and the rules and regulations of the Commission thereunder (collectively, the &#8220;Exchange Act&#8221;) and such documents did not and will not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements therein, in the light of the circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)
<I>Financial Statements of the Company.</I> The financial statements (including the related notes thereto) of the Company and its consolidated subsidiaries included or incorporated by reference in the Time of Sale Information and the Offering
Memorandum comply in all material respects with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and present fairly in all material respects the financial position of the Company and its consolidated
subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles
(&#8220;GAAP&#8221;) in the United States applied on a consistent basis throughout the periods covered thereby; the other financial information (other than the financial statements of Evolent Health) included or incorporated by reference in the Time
of Sale Information and the Offering Memorandum has been derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly in all material respects the information shown thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Financial Statements of Evolent Health. </I>The financial statements
(including the related notes thereto) of Evolent Health included in the Time of Sale Information and the Offering Memorandum comply in all material respects with the applicable requirements of the Securities Act and present fairly in all material
respects the financial position of Evolent Health as of the dates indicated and the results of its operations and the changes in its cash flows for the periods specified; such financial statements have been prepared in conformity with generally
accepted accounting principles in the United States applied on a consistent basis throughout the periods covered thereby, and any supporting schedules included in the Time of Sale Information and Offering Memorandum present fairly in all material
respects the information required to be stated therein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) [Reserved.] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>No Material Adverse Change.</I> Except as disclosed in the Time of Sale Information and the Offering Memorandum, since
the date of the most recent financial statements of the Company and Evolent Health included or incorporated by reference in the Time of Sale Information and the Offering Memorandum, (i)&nbsp;there has not been any change in the capital stock (other
than the issuance of shares of Stock upon exercise of stock options and warrants described as outstanding in, the grant and forfeiture of options and awards under existing equity incentive plans described in, the Time of Sale Information and the
Offering Memorandum), any material change in short-term debt or long-term debt of the Company, Evolent Health or the Company&#8217;s other subsidiaries or any dividend or distribution of any kind declared, set aside for payment, paid or made by the
Company or Evolent Health on any class of capital stock; (ii)&nbsp;there has not been any material adverse change with respect to the Company, Evolent Health and the Company&#8217;s other subsidiaries, taken as a whole, or any development that would
reasonably be expected to result in a material adverse change, in or affecting the business, properties, management, financial position, stockholders&#8217; or members&#8217; equity, as applicable, results of operations or prospects of the Company,
Evolent Health and the Company&#8217;s other subsidiaries, taken as a whole; (iii)&nbsp;none of the Company, Evolent Health, or the Company&#8217;s other subsidiaries has entered into any transaction or agreement (whether or not in the ordinary
course of business) that is material to the Company, Evolent Health and the Company&#8217;s other subsidiaries, taken as a whole, or incurred any liability or obligation, direct or contingent, that is material to the Company, Evolent Health, the
Company&#8217;s other subsidiaries, taken as a whole; and (iv)&nbsp;none of the Company, Evolent Health or the Company&#8217;s other subsidiaries has sustained any loss or interference with its business that is material to the Company, Evolent
Health, or the Company&#8217;s other subsidiaries, taken as a whole, and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of
any court or arbitrator or governmental or regulatory authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Organization and Good Standing.</I> The Company, Evolent Health and
the Company&#8217;s other subsidiaries have been duly organized and are validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each
jurisdiction in which their respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the
businesses in which they are engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the business, properties,
management, financial position, stockholders&#8217; or members&#8217; equity, results of operations or prospects of the Company, Evolent Health and the Company&#8217;s other subsidiaries, taken as a whole, or on the performance by the Company and
Evolent Health of their obligations under the Transaction Documents (as defined below) (a &#8220;Material Adverse Effect&#8221;). Neither the Company nor Evolent Health owns or controls, directly or indirectly, any corporation, association or other
entity other than, in the case of the Company, the subsidiaries listed on Schedule 3 hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Capitalization.</I>
The Company has an authorized capitalization as set forth in the Time of Sale Information and the Offering Memorandum; and the outstanding shares of capital stock of the Company and membership interests of Evolent Health have been duly and validly
authorized and issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and are not subject to any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> or similar rights; except as described in or expressly contemplated by
the Time of Sale Information and the Offering Memorandum and other than options in the aggregate not exceeding $1&nbsp;million in fair market value as of the date of this Agreement, there are no outstanding rights (including, without limitation, <FONT
STYLE="white-space:nowrap">pre-emptive</FONT> rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or any membership interests in Evolent
Health or the Company&#8217;s other subsidiaries or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the Company or of any membership interests of Evolent Health or the
Company&#8217;s other subsidiaries, any such convertible or exchangeable securities or any such rights, warrants or options; the capital stock of the Company and the membership interests of Evolent Health conform in all material respects to the
description thereof contained in the Time of Sale Information and the Offering Memorandum; and all the outstanding membership interests of Evolent Health and the Company&#8217;s other subsidiaries that are owned directly or indirectly by the Company
are owned free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Stock Options. </I>Except as would not reasonably be expected, individually or in the aggregate, to result in a Material
Adverse Effect, with respect to the stock options (the &#8220;Stock Options&#8221;) granted pursuant to the stock-based compensation plans of the Company and Evolent Health, including the Evolent Health Holdings, Inc. 2011 Equity Incentive Plan and
the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, as amended, each as described in the Time of Sale Information and Offering Memorandum (the &#8220;Company Stock Plans&#8221;), (i) each grant of a Stock Option was duly authorized no
later than the date on which the grant of such Stock Option was </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
by its terms to be effective (the &#8220;Grant Date&#8221;) by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted
and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and, to the knowledge of the Company (other than with respect to due execution and delivery by the Company), the award
agreement governing such grant (if any) was duly executed and delivered by each party thereto, (ii)&nbsp;each such grant was made in accordance with the terms of the Company Stock Plans, the Exchange Act and all other applicable laws and regulatory
rules or requirements and (iii)&nbsp;each such grant was properly accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company and Evolent Health. There is no and has been no policy or practice of
the Company or Evolent Health of granting Stock Options prior to, or otherwise coordinating the grant of Stock Options with, the release or other public announcement of material information regarding the Company or Evolent Health or their respective
subsidiaries or their results of operations or prospects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>Due Authorization. </I>The Company has full right, power
and authority to execute and deliver this Agreement, the Indenture, and the Securities (collectively, the &#8220;Transaction Documents&#8221;) and to perform its obligations hereunder and thereunder; and all action required to be taken for the due
and proper authorization, execution and delivery by the Company of each of the Transaction Documents and the consummation by it of the transactions contemplated hereby and thereby or by the Time of Sale Information and the Offering Memorandum has
been duly and validly taken. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>Purchase Agreement. </I>This Agreement has been duly authorized, executed and
delivered by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <I>Interests</I>. All of the membership interests of Evolent Health outstanding as of the
Closing Date have been duly authorized and when issued, fully paid and validly issued and, to the extent owned by the Company, will be owned free and clear of any liens, encumbrances or claims. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <I>The Indenture</I>. The Indenture has been duly authorized by the Company and, when duly executed and delivered in
accordance with its terms by each of the parties thereto, will constitute a valid and legally binding agreement of the Company enforceable against the Company in accordance with its terms, except as enforceability may be limited by applicable
bankruptcy, insolvency or similar laws affecting creditors&#8217; rights generally or by equitable principles relating to enforceability (collectively, the &#8220;Enforceability Exceptions&#8221;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) [Reserved.] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <I>The Securities</I>. The Securities have been duly authorized by the Company and, when duly executed, authenticated,
issued and delivered as provided in the Indenture and paid for as provided herein, will be duly and validly issued and outstanding and will constitute valid and legally binding obligations of the Company enforceable against the Company in accordance
with their terms, subject to the Enforceability Exceptions, and will be entitled to the benefits of the Indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <I>The Underlying Securities</I>. Upon issuance and delivery of the
Securities in accordance with this Agreement and the Indenture, the Securities will be convertible at the option of the holder thereof into shares of the Underlying Securities in accordance with the terms of the Indenture and the Securities; the
maximum number of shares of Class&nbsp;A Common Stock issuable upon conversion of the Securities (including the maximum number of additional shares of Class&nbsp;A Common Stock by which the Conversion Rate (as such term is defined in the Indenture)
may be increased upon conversion in connection with a Make-Whole Fundamental Change (as such term is defined in the Indenture) or a redemption of the Securities (such maximum number of shares of Class&nbsp;A Common Stock, the &#8220;Maximum Number
of Underlying Securities&#8221;)) have been duly authorized and reserved and, when issued upon conversion of the Securities in accordance with the terms of the Indenture and the Securities, will be validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable,</FONT> and the issuance of such Maximum Number of Underlying Securities will not be subject to any preemptive or similar rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Descriptions of the Transaction Documents.</I> Each Transaction Document conforms in all material respects to the
description thereof contained in the Time of Sale Information and the Offering Memorandum. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <I>No Violation or Default.
</I>None of the Company, Evolent Health or any of the Company&#8217;s other subsidiaries is (i)&nbsp;in violation of its charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents; (ii)&nbsp;in default, and no
event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other
agreement or instrument to which the Company, Evolent Health or any of the Company&#8217;s other subsidiaries is a party or by which the Company, Evolent Health or any of the Company&#8217;s other subsidiaries is bound or to which any of the
property or assets of the Company, Evolent Health or any of the Company&#8217;s other subsidiaries is subject; or (iii)&nbsp;in violation of any law or statute applicable to the Company, Evolent Health or the Company&#8217;s other subsidiaries or
any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority having jurisdiction over the Company, Evolent Health or the Company&#8217;s other subsidiaries except, in the case of clauses (ii)&nbsp;and
(iii) above, for any such default or violation that would not, individually or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <I>No Conflicts. </I>The execution and delivery by the Company and Evolent Health of this Agreement, the performance by the
Company and Evolent Health of each of the Transaction Documents to which it is a party, the issuance and sale by the Company of the Securities (including the issuance of the Maximum Number of Underlying Securities upon conversion thereof) and the
consummation by the Company of the transactions contemplated by the Transaction Documents or the Time of Sale Information and the Offering Memorandum will not (i)&nbsp;conflict with or result in a breach or violation of any of the terms or
provisions of, or constitute a default under, or result in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company, Evolent Health or the Company&#8217;s other subsidiaries pursuant to any indenture,
mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company, Evolent Health or any of the Company&#8217;s other subsidiaries is a party or by which the Company, Evolent Health or any of the Company&#8217;s other
subsidiaries is bound or to which any of the property or assets of the Company, Evolent Health or any of the Company&#8217;s other subsidiaries is subject, (ii)&nbsp;result in any violation of the provisions of the charter or <FONT
STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents of the Company, Evolent Health or the Company&#8217;s other subsidiaries or (iii)&nbsp;result in the violation of any law or statute or any judgment, order, rule or
regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i)&nbsp;and (iii) above, for any such conflict, breach, violation or default that would not, individually or in the aggregate, have a
Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <I>No Consents Required.</I> No consent, approval, authorization, order, license,
registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for performance by the Company and Evolent Health of each of the Transaction Documents to which it is a party, the issuance and sale
of the Securities by the Company (including the issuance of the Maximum Number of Underlying Securities upon conversion thereof) and the consummation of the transactions contemplated by the Transaction Documents or the Time of Sale Information and
the Offering Memorandum, except for such consents, approvals, authorizations, orders and registrations or qualifications that (i)&nbsp;have been obtained or made or (ii)&nbsp;may be required by the New York Stock Exchange (the
&#8220;Exchange&#8221;) and under applicable state securities laws in connection with the purchase and resale of the Securities by the Initial Purchasers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <I>Legal Proceedings.</I> Except as described in the Time of Sale Information and the Offering Memorandum, there are no
legal, governmental or regulatory investigations, actions, suits or proceedings, including by the Federal Trade Commission and the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) and any office contained therein, pending to which
the Company, Evolent Health or any of the Company&#8217;s other subsidiaries is or, to the knowledge of the Company or Evolent Health, may reasonably be expected to become a party or to which any property of the Company, Evolent Health or the
Company&#8217;s other subsidiaries, is or may reasonably be expected to become the subject that, individually or in the aggregate, if determined adversely to the Company, Evolent Health or the Company&#8217;s other subsidiaries, could reasonably be
expected to have a Material Adverse Effect; no such investigations, actions, suits or proceedings are, to the knowledge of the Company, Evolent Health or the Company&#8217;s other subsidiaries, threatened or contemplated by any governmental or
regulatory authority or threatened by others; (i)&nbsp;there are no material current or pending legal, governmental or regulatory actions, suits or proceedings that would be required under the Securities Act to be described in a registration
statement or prospectus to be filed with the Commission that are not so described in the Time of Sale Information and the Offering Memorandum and (ii)&nbsp;there are no statutes, regulations or contracts or other documents that would be required by
the Securities Act to be described in a registration statement to be filed with the Commission and that is not so described in the each of Time of Sale </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Information and the Offering Memorandum; and to the knowledge of the Company or Evolent Health, there is no complaint to or audit, proceeding, investigation (formal or informal) or claim
currently pending or threatened against any of the Company&#8217;s or Evolent Health&#8217;s customers (specific to the customer&#8217;s use of the products or services of the Company or Evolent Health) by the Federal Trade Commission, HHS, or any
similar authority in any jurisdiction or any other governmental entity, or by any person in respect of the collection, use or disclosure of Personal Data by the Company or Evolent Health that, individually or in the aggregate, if determined
adversely to such customer, could reasonably be expected to have a material adverse effect on such customer or a material adverse effect on the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <I>Independent Accountants</I>. Deloitte&nbsp;&amp; Touche LLP, who has audited certain financial statements of the
Company that are incorporated by reference into the Time of Sale Information and the Offering Memorandum, is an independent registered public accounting firm with respect to the Company within the applicable rules and regulations adopted by the
Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb)
<I>Title to Real and Personal Property.</I> The Company, Evolent Health and the Company&#8217;s other subsidiaries have good and marketable title in fee simple (in the case of real property) to, or have valid and marketable rights to lease or
otherwise use, all items of real and personal property and assets (other than Intellectual Property (as defined below)) that are material to the respective businesses of the Company, Evolent Health and the Company&#8217;s other subsidiaries, in each
case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i)&nbsp;do not materially interfere with the use made and currently proposed to be made of such property by the Company, Evolent Health
and the Company&#8217;s other subsidiaries or (ii)&nbsp;could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <I>Title to Intellectual Property.</I> The Company, Evolent Health and the Company&#8217;s other subsidiaries own or
possess adequate rights to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, domain names, copyrights, licenses, software and
<FONT STYLE="white-space:nowrap">know-how</FONT> (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures) and other intellectual property rights (&#8220;Intellectual
Property&#8221;) necessary for the conduct of their respective businesses as currently conducted and as currently proposed to be conducted, and, to the knowledge of the Company, Evolent Health or the Company&#8217;s other subsidiaries, the conduct
of their respective businesses does not and will not conflict in any material respect with any such rights of others. Except as could not reasonably be expected to result in a Material Adverse Effect, the Company, Evolent Health and the
Company&#8217;s other subsidiaries have not received any notice of any claim (i)&nbsp;alleging any infringement or misappropriation of, or conflict with, any Intellectual Property rights of any third party or (ii)&nbsp;challenging the validity,
scope, enforceability or ownership of any Intellectual Property owned by the Company, Evolent Health and the Company&#8217;s other subsidiaries. The Company, Evolent Health and the Company&#8217;s other subsidiaries have taken reasonable steps in
accordance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
with normal industry practice to maintain the confidentiality of all <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets and confidential information owned, used or held for use by
the Company, Evolent Health or the Company&#8217;s other subsidiaries, and no such trade secrets or confidential information have been disclosed other than to employees, representatives and agents of the Company, Evolent Health or the
Company&#8217;s other subsidiaries, or parties who are bound by written confidentiality agreements, except as could not reasonably be expected to result in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <I>No Undisclosed Relationships.</I> No relationship, direct or indirect, exists between or among the Company, Evolent
Health or the Company&#8217;s other subsidiaries on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company, Evolent Health or the Company&#8217;s other subsidiaries, on the other, that would be required by the
Securities Act to be described in a registration statement to be filed with the Commission and that is not so described in each of Time of Sale Information and the Offering Memorandum. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <I>Investment Company Act</I>. Upon the offering and sale of the Securities and the application of the proceeds thereof as
described in the Time of Sale Information and the Offering Memorandum, neither the Company nor Evolent Health will be required to register as an &#8220;investment company&#8221; or an entity &#8220;controlled&#8221; by an &#8220;investment
company&#8221; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#8220;Investment Company Act&#8221;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) <I>Taxes.</I> The Company and its subsidiaries have paid or accrued in their respective financial statements included in
the Time of Sale Information all federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes and filed all tax returns required to be paid or filed through the date hereof; and except as otherwise disclosed in the Time of Sale
Information and the Offering Memorandum, there is no tax deficiency that has been, or could reasonably be expected to be, asserted against the Company, its subsidiaries or any of their respective properties or assets, except where the failure to pay
or file or where such deficiency could not reasonably be expected to result, individually or in the aggregate, in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <I>Licenses and Permits.</I> The Company, Evolent Health and the Company&#8217;s other subsidiaries possess all licenses,
certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are necessary for the ownership or lease of their
respective properties or the conduct of their respective businesses as described in the Time of Sale Information and the Offering Memorandum, except where the failure to possess or make the same would not, individually or in the aggregate, have a
Material Adverse Effect; and except as described in the Time of Sale Information and the Offering Memorandum, none of the Company, Evolent Health or any of the Company&#8217;s other subsidiaries has received notice of any revocation or modification
of any such license, certificate, permit or authorization or has any reason to believe that any such license, certificate, permit or authorization will not be renewed in the ordinary course, except where such revocation, modification or renewal
would not reasonably be expected to result in a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) <I>No Labor Disputes.</I> No labor disturbance by or dispute with
employees of the Company, Evolent Health or the Company&#8217;s other subsidiaries exists or, to the knowledge of the Company or Evolent Health, is contemplated or threatened, and neither the Company nor Evolent Health is aware of any existing or
imminent labor disturbance by, or dispute with, the employees of any of their or their respective subsidiaries&#8217; principal suppliers, contractors or customers, except as would not have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Compliance with and Liability under Environmental Laws.</I> (i)&nbsp;The Company, Evolent Health and the
Company&#8217;s other subsidiaries (a)&nbsp;are, and at all prior times were, in compliance with any and all applicable federal, state, local and foreign laws, rules, regulations, requirements, decisions, judgments, decrees, orders and the common
law relating to pollution or the protection of the environment, natural resources or human health or safety, including those relating to the generation, storage, treatment, use, handling, transportation, Release or threat of Release of Hazardous
Materials (collectively, &#8220;Environmental Laws&#8221;), (b)&nbsp;have received and are in compliance with all permits, licenses, certificates or other authorizations or approvals required of them under applicable Environmental Laws to conduct
their respective businesses, (c)&nbsp;have not received notice of any actual or potential liability under or relating to, or actual or potential violation of, any Environmental Laws, including for the investigation or remediation of any Release or
threat of Release of Hazardous Materials, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice, (d)&nbsp;are not conducting or paying for, in whole or in part, any investigation, remediation
or other corrective action pursuant to any Environmental Law at any location, and (e)&nbsp;are not a party to any order, decree or agreement that imposes any obligation or liability under any Environmental Law, and (ii)&nbsp;there are no costs or
liabilities associated with Environmental Laws of or relating to the Company, Evolent Health or the Company&#8217;s other subsidiaries, except in the case of each of (i)&nbsp;and (ii) above, for any such matter, as would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect; and (iii)&nbsp;except as described in the Time of Sale Information and the Offering Memorandum, (a)&nbsp;there are no proceedings that are pending, or that are known to be
contemplated, against the Company, Evolent Health or the Company&#8217;s other subsidiaries under any Environmental Laws in which a governmental entity is also a party, other than such proceedings regarding which it is reasonably believed no
monetary sanctions of $300,000 or more will be imposed, (b)&nbsp;the Company, Evolent Health and the Company&#8217;s other subsidiaries are not aware of any facts or issues regarding compliance with Environmental Laws, or liabilities or other
obligations under Environmental Laws, including the Release or threat of Release of Hazardous Materials, that could reasonably be expected to have a material effect on the capital expenditures, earnings or competitive position of the Company,
Evolent Health and the Company&#8217;s other subsidiaries, and (c)&nbsp;none of the Company, Evolent Health or the Company&#8217;s other subsidiaries anticipates material capital expenditures relating to any Environmental Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <I>Hazardous Materials</I>. There has been no storage, generation,
transportation, use, handling, treatment, Release or threat of Release of Hazardous Materials by, relating to or caused by the Company, Evolent Health or the Company&#8217;s other subsidiaries (or, to the knowledge of the Company and Evolent Health,
any other entity (including any predecessor) for whose acts or omissions the Company, Evolent Health or any of the Company&#8217;s other subsidiaries is or could reasonably be expected to be liable) at, on, under or from any property or facility now
or previously owned, operated or leased by the Company, Evolent Health or the Company&#8217;s other subsidiaries, or at, on, under or from any other property or facility, in violation of any Environmental Laws or in a manner or amount or to a
location that could reasonably be expected to result in any liability under any Environmental Law, except for any violation or liability which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
&#8220;Hazardous Materials&#8221; means any material, chemical, substance, waste, pollutant, contaminant, compound, mixture, or constituent thereof, in any form or amount, including petroleum (including crude oil or any fraction thereof) and
petroleum products, natural gas liquids, asbestos and asbestos-containing materials, naturally occurring radioactive materials, brine, and drilling mud, regulated or which can give rise to liability under any Environmental Law. &#8220;Release&#8221;
means any spilling, leaking, seepage, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, dumping, disposing, depositing, dispersing, or migrating in, into or through the environment, or in, into, from or through any
building or structure. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) <I>Compliance with ERISA.</I> (i)&nbsp;Each employee benefit plan, within the meaning of
Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974, as amended (&#8220;ERISA&#8221;), for which the Company or any member of its &#8220;Controlled Group&#8221; (defined as any entity, whether or not incorporated, that is under
common control with the Company within the meaning of Section&nbsp;4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section&nbsp;414(b),(c),(m) or (o)&nbsp;of the Internal Revenue Code of 1986, as
amended (the &#8220;Code&#8221;)) has or would have any liability (each, a &#8220;Plan&#8221;) and is not a &#8220;multiemployer plan&#8221; within the meaning of Section&nbsp;3(37) of ERISA has been maintained in compliance with its terms and the
requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii)&nbsp;no prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has
occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption; (iii)&nbsp;for each Plan that is subject to the funding rules of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, no
Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards (within the meaning of Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code) applicable to such Plan; (iv)&nbsp;no Plan is, or
is reasonably expected to be, in &#8220;at risk status&#8221; (within the meaning of Section&nbsp;303(i) of ERISA) and no Plan that is a &#8220;multiemployer plan&#8221; within the meaning of Section&nbsp;4001(a)(3) of ERISA is in &#8220;endangered
status&#8221; or &#8220;critical status&#8221; (within the meaning of Sections 304 and 305 of ERISA); (v) no &#8220;reportable event&#8221; (within the meaning of Section&nbsp;4043(c) of ERISA and the regulations promulgated thereunder) has occurred
or is reasonably expected to occur; (vi)&nbsp;each Plan that is intended to be qualified under Section&nbsp;401(a) of the Code is subject to a favorable determination or opinion letter, and to the knowledge of the Company and Evolent Health, nothing
has occurred, whether by action </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or by failure to act, which would cause the loss of such qualification; (vii)&nbsp;neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any
liability under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guaranty Corporation, in the ordinary course and without default) in respect of a Plan (including a &#8220;multiemployer plan&#8221; within
the meaning of Section&nbsp;4001(a)(3) of ERISA); except in each case with respect to the events or conditions set forth in (i)&nbsp;through (vii) hereof, as would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) <I>Disclosure Controls</I>. Except as disclosed in the Time of Sale Information and the Offering
Memorandum, the Company and Evolent Health maintain an effective system of &#8220;disclosure controls and procedures&#8221; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act) that complies with the
requirements of the Exchange Act and that has been designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time
periods specified in the Commission&#8217;s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#8217;s management as appropriate to allow timely decisions
regarding required disclosure. The Company and its subsidiaries have carried out evaluations of the effectiveness of their disclosure controls and procedures as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> of the Exchange Act.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <I>Accounting Controls.</I> The Company and Evolent Health maintain systems of &#8220;internal control over financial
reporting&#8221; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the Exchange Act) that comply with the requirements of the Exchange Act and have been designed by, or under the supervision of, their respective principal
executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#8217;s general or specific
authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability; (iii)&nbsp;access to assets is permitted
only in accordance with management&#8217;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any
differences and (v)&nbsp;interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Offering Memorandum and the Time of Sale Information fairly presents the information called for in all material respects
and is prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto. Based on the Company&#8217;s most recent evaluation of its internal controls over financial reporting pursuant to Rule
<FONT STYLE="white-space:nowrap">13a-15(c),</FONT> and except as disclosed in the Time of Sale Information and the Offering Memorandum, there are no material weaknesses in the Company&#8217;s or Evolent Health&#8217;s internal controls. The
Company&#8217;s and Evolent Health&#8217;s auditors and the Audit Committee of the Board of Directors of the Company and of Evolent Health have been advised of: (i)&nbsp;all significant deficiencies and material weaknesses in the design or operation
of internal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
controls over financial reporting which have adversely affected or are reasonably likely to adversely affect the Company&#8217;s and/or Evolent Health&#8217;s ability to record, process,
summarize and report financial information; and (ii)&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s and/or Evolent Health&#8217;s internal controls over
financial reporting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) <I>eXtensible Business Reporting Language</I>. The interactive data in eXtensible Business
Reporting Language included or incorporated by reference in the Offering Memorandum fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines applicable
thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) <I>Insurance. </I>The Company, Evolent Health and the Company&#8217;s other subsidiaries have insurance
covering their respective properties, operations, personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as are adequate to protect the Company, Evolent Health and
the Company&#8217;s other subsidiaries and their respective businesses; and none of the Company, Evolent Health or any of the Company&#8217;s other subsidiaries has (i)&nbsp;received notice from any insurer or agent of such insurer that capital
improvements or other expenditures are required or necessary to be made in order to continue such insurance or (ii)&nbsp;any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to
obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) <I>No
Unlawful Payments. </I>None of the Company, Evolent Health or the Company&#8217;s other subsidiaries, nor any director or officer of the Company, Evolent Health or the Company&#8217;s other subsidiaries, nor, to the knowledge of the Company or
Evolent Health, any employee, agent, affiliate or other person associated with or acting on behalf of the Company, Evolent Health, or the Company&#8217;s other subsidiaries has (i)&nbsp;used any corporate funds for any unlawful contribution, gift,
entertainment or other unlawful expense relating to political activity; (ii)&nbsp;made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government
official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official
or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign
Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom, or any other applicable anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, agreed, requested or taken an
act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit. The Company, Evolent Health and the Company&#8217;s
other subsidiaries, taken as a whole, have instituted, maintain and enforce, and will continue to maintain and enforce policies and procedures reasonably designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption
laws. None of the Company, Evolent Health or any of the Company&#8217;s other subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance of any offer, payment, promise to pay, or authorization of the payment or giving
of money, or anything else of value, to any person in violation of any applicable anti-corruption laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) <I>Compliance with Anti-Money Laundering Laws</I>. The operations of
the Company, Evolent Health and the Company&#8217;s other subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign
Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company, Evolent Health and the Company&#8217;s other subsidiaries conduct business, the rules and regulations thereunder and any
related or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency (collectively, the &#8220;Anti-Money Laundering Laws&#8221;), and no action, suit or proceeding by or before any court or governmental
agency, authority or body or any arbitrator involving the Company, Evolent Health or the Company&#8217;s other subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company or Evolent Health, threatened.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) <I>No Conflicts with Sanctions Laws. </I>None of the Company, Evolent Health or the Company&#8217;s other
subsidiaries, nor any director or officer of the Company, Evolent Health or the Company&#8217;s other subsidiaries, nor, to the knowledge of the Company or Evolent Health, any employee, agent, affiliate or other person associated with or acting on
behalf of the Company, Evolent Health or the Company&#8217;s other subsidiaries, is currently the subject or the target of any sanctions administered or enforced by the U.S. government (including, without limitation, the Office of Foreign Assets
Control of the U.S. Department of the Treasury or the U.S. Department of State and including, without limitation, the designation as a &#8220;specially designated national&#8221; or &#8220;blocked person&#8221;), the United Nations Security Council,
the European Union, His Majesty&#8217;s Treasury or other relevant sanctions authority (collectively, &#8220;Sanctions&#8221;), nor is the Company, Evolent Health, or any of the Company&#8217;s other subsidiaries, located, organized or resident in a
country or territory that is the subject or target of Sanctions, including, without limitation, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#8217;s Republic, <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk
People&#8217;s Republic or any other Covered Region of Ukraine identified pursuant to Executive Order 14065, the Crimea Region of Ukraine, Cuba, Iran, North Korea and Syria (each, a &#8220;Sanctioned Country&#8221;); and the Company and Evolent
Health will not directly or indirectly use the proceeds of the offering of the Securities hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or
facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii)&nbsp;to fund or facilitate any activities of or business in any Sanctioned Country or
(iii)&nbsp;in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as Initial Purchaser, advisor, investor or otherwise) of Sanctions. The Company, Evolent Health and the
Company&#8217;s other subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or
with any Sanctioned Country. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) <I>No Restrictions on Subsidiaries</I>. Except as disclosed in the Time
of Sale Information and the Offering Memorandum, no subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company,
from making any other distribution on such subsidiary&#8217;s capital stock, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#8217;s properties or assets to the
Company or any other subsidiary of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) <I>No Broker&#8217;s Fees. </I>None of the Company, Evolent Health or
any of the Company&#8217;s other subsidiaries is a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company or Evolent Health or any Initial Purchaser for
a brokerage commission, finder&#8217;s fee or like payment in connection with the offering and sale of the Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) <I>Rule 144A Eligibility</I>. On the Closing Date, the Securities will not be of the same class as securities listed on a
national securities exchange registered under Section&nbsp;6 of the Exchange Act or quoted in an automated inter-dealer quotation system; and each of the Time of Sale Information, as of the Time of Sale, and the Offering Memorandum, as of its date,
contains or will contain all the information that, if requested by a prospective purchaser of the Securities, would be required to be provided to such prospective purchaser pursuant to Rule 144A(d)(4) under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) <I>No Integration</I>. Neither the Company, nor any of its affiliates (as defined in Rule 501(b) of Regulation D) has,
directly or through any agent, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act), that is or will be integrated with the sale of the Securities in a manner that
would require registration of the Securities under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) <I>No General Solicitation</I>. None of the
Company or any of its controlled affiliates or any other person acting on its or their behalf (other than the Initial Purchasers, as to which no representation is made) has solicited offers for, or offered or sold, the Securities by means of any
form of general solicitation or general advertising within the meaning of 502(c) of Regulation D or in any manner involving a public offering within the meaning of Section&nbsp;4(a)(2) of the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) <I>Securities Law Exemptions</I>. Assuming the accuracy of the representations and warranties of the Initial Purchasers
contained in Section&nbsp;2(b) and their compliance with their agreements set forth therein, it is not necessary, in connection with the issuance and sale of the Securities to the Initial Purchasers and the offer, resale and delivery of the
Securities by the Initial Purchasers in the manner contemplated by this Agreement, the Time of Sale Information and the Offering Memorandum, to register the Securities under the Securities Act or to qualify the Indenture under the Trust Indenture
Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(yy) <I>No Stabilization. </I>Neither the Company nor Evolent Health has taken, directly or indirectly, any action
designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(zz) <I>Forward-Looking Statements.</I> No forward-looking statement (within
the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act) included or incorporated by reference in any of the Time of Sale Information or the Offering Memorandum has been made or reaffirmed without a reasonable
basis or has been disclosed other than in good faith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aaa) <I>Statistical and Market Data.</I> Nothing has come to the
attention of the Company or Evolent Health that has caused the Company or Evolent Health to believe that the statistical and market-related data included or incorporated by reference in each of the Time of Sale Information and the Offering
Memorandum is not based on or derived from sources that are reliable and accurate in all material respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bbb)
<I>Sarbanes-Oxley Act</I>. There is and has been no failure on the part of the Company or Evolent Health or any of the Company&#8217;s or Evolent Health&#8217;s directors or officers, in their capacities as such, to comply with any provision of the
Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated in connection therewith (the &#8220;Sarbanes-Oxley Act&#8221;), including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications, that
are applicable to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ccc) <I>No Ratings</I>. There are (and prior to the Closing Date, will be) no debt
securities or preferred stock issued or guaranteed by the Company, Evolent Health or any of the Company&#8217;s other subsidiaries that are rated by a &#8220;nationally recognized statistical rating organization&#8221;, as such term is defined in
Section&nbsp;3(a)(62) of the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ddd) <I>Health Care Regulations. </I>The statements in (or incorporated by
reference in) the Time of Sale Information and the Offering Memorandum under the captions: &#8220;Risk Factors&#8212;Risks Relating to Our Industry and Market &#8212;The health care regulatory and political framework is uncertain and evolving&#8221;
and &#8220;Risk Factors&#8212;Risks Relating to Data Protection Privacy, Cybersecurity, Intellectual Property and Technology&#8212;We are subject to data privacy and protection laws governing the collection, use, disclosure and security of health
information, which may impose restrictions on the manner in which we access personal data and subject us to penalties if we are unable to fully comply with such laws&#8221; and &#8220;Business&#8212;Government Regulation&#8221;, insofar as such
statements describe the state, federal and foreign administrative healthcare laws, rules and regulations which are applicable to the Company (the &#8220;Healthcare Laws&#8221;), are true and correct in all material respects; and to the knowledge of
the Company or Evolent Health, there are no Healthcare Laws which as of this date are material to the businesses of the Company, Evolent Health or the Company&#8217;s other subsidiaries which are not described in the Time of Sale Information or the
Offering Memorandum. None of the Company, Evolent Health or any of the Company&#8217;s other subsidiaries is in violation of any Healthcare Laws, except for any violation that would not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect, and none have received any written notice from any governmental or regulatory authority of potential or actual material <FONT STYLE="white-space:nowrap">non-compliance</FONT> by, or liability of, the Company or
Evolent Health under any Healthcare Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(eee) <I>Cybersecurity, Data Privacy and Security Laws. </I>Except as could
not reasonably be expected to have a Material Adverse Effect or as disclosed in the Time of Sale Information and the Offering Memorandum, (i)&nbsp;(x) there has been no unauthorized access to, or unauthorized use, security breach or other compromise
of, any information technology or computer systems, networks, hardware, software, data (including the data of their respective customers, employees, suppliers, vendors and any third party data), equipment or technology used or held for use by or on
behalf of the Company&#8217;s, Evolent Health&#8217;s or the Company&#8217;s other subsidiaries&#8217; (collectively, &#8220;IT Systems and Data&#8221;) and (y)&nbsp;such IT Systems and Data are adequate for, and operate and perform in all material
respects as required in connection with, the operation of the business of the Company, Evolent Health and the Company&#8217;s other subsidiaries as currently conducted; and (ii)&nbsp;the Company, Evolent Health and the Company&#8217;s other
subsidiaries are, and since the Company&#8217;s, Evolent Health&#8217;s or such Company subsidiary&#8217;s inception have been, in compliance with all applicable state and federal data privacy and security laws and regulations, including without
limitation the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) as amended by the Health Information Technology for Economic and Clinical Health Act (the &#8220;HITECH Act&#8221;, and collectively, the &#8220;Privacy
Laws&#8221;). To ensure compliance with the Privacy Laws, the Company, Evolent Health and the Company&#8217;s other subsidiaries, taken as a whole, have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in
all material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data and have implemented backup and disaster recovery technology
consistent with industry standards and practices. &#8220;Personal Data&#8221; means (i)&nbsp;a natural person&#8217;s name, street address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number
or tax identification number, driver&#8217;s license number, passport number, credit card number, bank information, or customer or account number; (ii)&nbsp;any information which would qualify as &#8220;personally identifying information&#8221;
under the Federal Trade Commission Act, as amended; (iii)&nbsp;Protected Health Information as defined by HIPAA; and (iv)&nbsp;any other piece of information that allows the identification of such natural person, or his or her family, or permits the
collection or analysis of any data related to an identified person&#8217;s health or sexual orientation. The Company, Evolent Health and the Company&#8217;s other subsidiaries have at all times made all disclosures to users or customers required by
applicable laws and regulatory rules or requirements, and no such disclosures made or contained in any internal or external policies or procedures of the Company, Evolent Health or the Company&#8217;s other subsidiaries relating to data privacy and
security or the collection, storage, use, sharing, disposal or other processing of Personal Data have been inaccurate or in violation of any applicable laws and regulatory rules or requirements, except as could not reasonably be expected to result
in a Material Adverse Effect. None of the Company, Evolent Health or any of the Company&#8217;s other subsidiaries: (i)&nbsp;has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of
the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation, or other
corrective action pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(fff) <I>Accurate Disclosure. </I>The statements included or incorporated by
reference in the Time of Sale Information and the Offering Memorandum from the sections &#8220;Risk Factors&#8212;Risks Relating to Our Former <FONT STYLE="white-space:nowrap">Up-C</FONT> Structure&#8221;, &#8220;Risk Factors&#8212;Risks Relating to
Ownership of Our Class&nbsp;A Common Stock&#8221;, &#8220;Risk Factors&#8212;Risks Relating to the Notes&#8221;, &#8220;Description of Notes&#8221;, and &#8220;Description of Class&nbsp;A Common Stock&#8221;; and &#8220;Certain Relationships and
Related Party Transactions&#8221; in the Company&#8217;s Proxy Statement on Schedule 14A, filed with the Commission on April&nbsp;25, 2025, insofar as such statements summarize legal matters, agreements, documents or proceedings discussed therein,
are accurate and fair summaries in all material respects of such legal matters, agreements, documents or proceedings and present information required to be shown therein pursuant to the rules and regulations of the Commission. The statements
included in the Time of Sale Information and the Offering Memorandum under the caption: &#8220;Certain U.S. Federal Income Tax Considerations&#8221;, insofar as they purport to describe provisions of U.S. federal tax laws or legal conclusions with
respect thereto, fairly and accurately summarize the matters referred to therein in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Further Agreements of
the Company and Evolent Health</U>. The Company and Evolent Health jointly and severally covenant and agree with each Initial Purchaser that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Delivery of Copies. </I>The Company will deliver to the Initial Purchasers as many copies of the Preliminary Offering
Memorandum, any other Time of Sale Information, any Issuer Written Communication and the Offering Memorandum (including all amendments and supplements thereto) as the Representative may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Offering Memorandum, Amendments or Supplements</I>. Before finalizing the Offering Memorandum or making or distributing
any amendment or supplement to any of the Time of Sale Information or the Offering Memorandum or filing with the Commission any document that will be incorporated by reference therein, the Company will furnish to the Representative and counsel for
the Initial Purchasers a copy of the proposed Offering Memorandum or such amendment or supplement or document to be incorporated by reference therein for review, and will not distribute any such proposed Offering Memorandum, amendment or supplement
or file any such document with the Commission to which the Representative reasonably objects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Additional Written
Communications. </I>Before using, authorizing, approving or referring to any Issuer Written Communication, the Company will furnish to the Representative and counsel for the Initial Purchasers a copy of such written communication for review and will
not use, authorize, approve or refer to any such written communication to which the Representative reasonably objects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
<I>Notice to the Representative.</I> The Company will advise the Representative promptly, and confirm such advice in writing, (i)&nbsp;of the issuance by any governmental authority of any order preventing or suspending the use of any of the Time of
Sale Information, any Issuer Written Communication or the Offering Memorandum or the initiation or threatening of any proceeding for that purpose; (ii)&nbsp;of the occurrence or development of any event at any time prior to the completion of the
initial offering of the Securities as a result of which any of the Time of Sale Information, any Issuer Written Communication or the Offering Memorandum as then amended or supplemented would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing when such Time of
Sale Information, Issuer Written Communication or the Offering Memorandum is delivered to a purchaser, not misleading; and (iii)&nbsp;of the receipt by the Company of any notice with respect to any suspension of the qualification of the Securities
for offer and sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and the Company will use its reasonable best efforts to prevent the issuance of any such order preventing or suspending the use of any of the
Time of Sale Information, any Issuer Written Communication or the Offering Memorandum or suspending any such qualification of the Securities and, if any such order is issued, will obtain as soon as possible the withdrawal thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Ongoing Compliance of the Offering Memorandum and Time of Sale Information</I>. (1)&nbsp;If at any time prior to the
completion of the initial offering of the Securities (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Offering Memorandum as then amended or supplemented would include any untrue statement of a material
fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Offering Memorandum is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or
supplement the Offering Memorandum to comply with law, the Company will notify the Initial Purchasers thereof reasonably promptly and forthwith prepare and, subject to paragraph (b)&nbsp;above, furnish to the Initial Purchasers such amendments or
supplements to the Offering Memorandum (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Offering Memorandum as so amended or supplemented (or including such
document to be incorporated by reference therein) will not, in the light of the circumstances existing when the Offering Memorandum is delivered to a purchaser, be misleading or so that the Offering Memorandum will comply with law and (2)&nbsp;if at
any time prior to the Closing Date (i)&nbsp;any event or development shall occur or condition shall exist as a result of which any of the Time of Sale Information as then amended or supplemented would include any untrue statement of a material fact
or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading or (ii)&nbsp;it is necessary to amend or supplement any of the Time of Sale
Information to comply with law, the Company will notify the Initial Purchasers thereof reasonably promptly and forthwith prepare and, subject to paragraph (b)&nbsp;above, furnish to the Initial Purchasers such amendments or supplements to any of the
Time of Sale Information (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in any of the Time of Sale Information as so amended or supplemented will not, in light of
the circumstances under which they were made, be misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Blue Sky Compliance.</I> The Company will use
reasonable efforts to qualify the Securities for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representative shall reasonably request and will continue such qualifications in effect so long as required for
distribution of the Securities; <U>provided</U> that neither the Company nor Evolent Health shall be required to (i)&nbsp;qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not
otherwise be required to so qualify, (ii)&nbsp;file any general consent to service of process in any such jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Earnings Statement</I>. The Company will make generally available to
its security holders and the Representative as soon as practicable an earnings statement that satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering a period of at least
twelve months beginning with the first fiscal quarter of the Company occurring after the &#8220;effective date&#8221; (as defined in Rule 158) of the Company&#8217;s registration statement; <U>provided</U> that the Company will be deemed to have
furnished such reports and financial statements to the Representative to the extent they are filed on the Commission&#8217;s Electronic Data Gathering, Analysis, and Retrieval system. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Clear Market. </I>For a period of 60 days after the date of the offering of the Securities, the Company will not
(i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, or file
with the Commission a registration statement under the Securities Act relating to, any shares of Stock or any securities convertible into or exercisable or exchangeable for Stock, or publicly disclose the intention to make any offer, sale, pledge,
disposition or filing, or (ii)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or any such other securities, or any membership interest in Evolent Health,
whether any such transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise, without the prior written consent of Oppenheimer&nbsp;&amp; Co. Inc., other than in
relation to (A)&nbsp;the Securities to be sold hereunder and any Underlying Securities issued upon conversion thereof, (B) [reserved], (C) any shares of Stock of the Company issued upon the exercise or settlement of options or the vesting of
restricted stock units (&#8220;RSUs&#8221;), performance-based RSUs or leveraged stock units (&#8220;LSUs&#8221;) granted under Company Stock Plans; <U>provided</U> that if the recipient of any such shares of Stock has previously delivered a <FONT
STYLE="white-space:nowrap">&#8220;lock-up&#8221;</FONT> agreement to the Representative substantially in the form of Exhibit A hereto, such shares of Stock will be subject to the terms of such <FONT STYLE="white-space:nowrap">lock-up,</FONT>
(D)&nbsp;the grant by the Company of awards under Company Stock Plans as disclosed in the Time of Sale Information and the Offering Memorandum, (E) [reserved], (F) the filing of a registration statement on Form
<FONT STYLE="white-space:nowrap">S-8</FONT> (or equivalent form) with the Commission in connection with an employee stock compensation plan or agreement of the Company, which plan or agreement is disclosed in the Time of Sale Information and the
Offering Memorandum, (G) [reserved], (H) the issuance of, agreement to issue or public disclosure of the intent to issue, shares of Stock or other securities (including securities convertible into shares of Stock) in connection with the acquisition
by the Company or any of its subsidiaries of the securities, businesses, properties or other assets of another person or entity or pursuant to any employee benefit plan assumed by the Company in connection with any such acquisition, (I)&nbsp;the
issuance of, agreement to issue or public disclosure of the intent to issue, shares of Stock or other securities (including securities convertible into shares of Stock) in connection with joint ventures, strategic transactions or other commercial
relationships (including issuances to current or prospective customers or partners), or (J) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
any shares of Class&nbsp;A Common Stock issuable upon conversion of the Company&#8217;s 1.50% convertible senior notes due 2025 or the Company&#8217;s 3.50% convertible senior notes due 2029;
<U>provided</U> that, in the case of clauses (H)&nbsp;and (I), the aggregate number of shares of Stock issued in all such acquisitions and transactions shall not exceed 10.0% of the issued and outstanding Stock of the Company on the Closing Date and
any recipients of such shares shall deliver a <FONT STYLE="white-space:nowrap">&#8220;lock-up&#8221;</FONT> agreement to the Representative substantially in the form of Exhibit A hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Use of Proceeds.</I> The Company will apply the net proceeds from the sale of the Securities as described in each of the
Time of Sale Information and the Offering Memorandum under the heading &#8220;Use of Proceeds.&#8221; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>No
Stabilization. </I>Neither the Company nor Evolent Health will take, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Securities and will
not take any action prohibited by Regulation M under the Exchange Act in connection with the distribution of the Securities contemplated hereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Underlying Securities</I>. The Company will reserve and keep available at all times, free of pre-emptive rights, a
number of shares of Class&nbsp;A Common Stock equal to the Maximum Number of Underlying Securities. The Company will use its commercially reasonable best efforts to cause the Underlying Securities to be listed and maintain the listing of such
Maximum Number of Underlying Securities on the Exchange. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Supplying Information</I>. While the Securities remain
outstanding and are &#8220;restricted securities&#8221; within the meaning of Rule 144(a)(3) under the Securities Act, the Company will, during any period in which the Company is not subject to and in compliance with Section&nbsp;13 or 15(d) of the
Exchange Act, furnish to holders of the Securities, prospective purchasers of the Securities designated by such holders and securities analysts, in each case upon request, the information required to be delivered pursuant to Rule 144A(d)(4) under
the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>DTC</I>. The Company will assist the Initial Purchasers in arranging for the Securities to be
eligible for clearance and settlement through DTC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>No Resales by the Company</I>. The Company will not, and will
not permit any of its controlled affiliates (as defined in Rule 144 under the Securities Act) to, resell any of the Securities that have been acquired by any of them, except for Securities purchased by the Company or any of its affiliates and resold
in a transaction registered under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>No Integration</I>. Neither the Company nor any of its
affiliates (as defined in Rule 501(b) of Regulation D) will, directly or through any agent, sell, offer for sale, solicit offers to buy or otherwise negotiate in respect of, any security (as defined in the Securities Act), that is or will be
integrated with the sale of the Securities in a manner that would require registration of the Securities under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>No General Solicitation</I>. None of the Company or any of its
controlled affiliates or any other person on its or their behalf (other than the Initial Purchasers, as to which no covenant is given) will solicit offers for, or offer or sell, the Securities by means of any form of general solicitation or general
advertising within the meaning of Rule 502(c) of Regulation D without the prior written consent of the Representative or in any manner involving a public offering within the meaning of Section&nbsp;4(a)(2) of the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <I>Reports</I>. For a period of two years from the date hereof, so long as the Securities are outstanding, the Company will
furnish to the Representative, as soon as they are available, copies of all reports or other communications (financial or other) furnished to holders of the Securities, and copies of any reports and financial statements furnished to or filed with
the Commission or any national securities exchange or automatic quotation system; <U>provided</U> the Company will be deemed to have furnished such reports and financial statements to the Representative to the extent they are filed on the
Commission&#8217;s Electronic Data Gathering, Analysis, and Retrieval system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Certain Agreements of the Initial Purchasers</U>.
Each Initial Purchaser hereby represents and agrees that it has not used, authorized the use of, referred to or participated in the planning for the use of, and will not use, authorize the use of, refer to or participate in the planning for the use
of, any written communication that constitutes an offer to sell or the solicitation of an offer to buy the Securities other than (i)&nbsp;the Preliminary Offering Memorandum and the Offering Memorandum, (ii)&nbsp;a written communication that
contains no &#8220;issuer information&#8221; (as defined in Rule 433(h)(2) under the Securities Act) that was not included (including through incorporation by reference) in the Time of Sale Information or the Offering Memorandum, (iii)&nbsp;any
written communication listed on Annex A or prepared pursuant to Section&nbsp;4(c) above (including any electronic road show (as defined below) approved in advance by the Company)&nbsp;(iv) any written communication prepared by such Initial Purchaser
and approved by the Company in advance in writing or (v)&nbsp;any written communication relating to or that contains the terms of the Securities and/or other information that was included (including through incorporation by reference) in the Time of
Sale Information or the Offering Memorandum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Conditions of Initial Purchasers&#8217; Obligations.</U> The obligation of each
Initial Purchaser to purchase the Firm Securities on the Closing Date or the Option Securities on the Additional Closing Date, as the case may be, as provided herein is subject to the performance by the Company and Evolent Health, jointly and
severally, of their respective covenants and other obligations hereunder and to the following additional conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<I>Representations and Warranties.</I> The respective representations and warranties of the Company and Evolent Health contained herein shall be true and correct on the date hereof and on and as of the Closing Date or the Additional Closing Date, as
the case may be; and the statements of the Company and its officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date or the Additional Closing Date, as the case may be. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>No Material Adverse Change.</I> No event or condition of a type
described in Section&nbsp;3(k) hereof shall have occurred or shall exist, which event or condition is not described in the Time of Sale Information (excluding any amendment or supplement thereto) and the Offering Memorandum (excluding any amendment
or supplement thereto) and the effect of which in the judgment of the Representative makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the Closing Date or the Additional Closing Date, as the
case may be, on the terms and in the manner contemplated by this Agreement, the Time of Sale Information and the Offering Memorandum. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Officer&#8217;s Certificate.</I> The Representative shall have received on and as of the Closing Date or the Additional
Closing Date, as the case may be, a certificate of the Company by the chief financial officer or chief accounting officer of the Company and one additional senior executive officer of the Company who is reasonably satisfactory to the Representative
(i)&nbsp;confirming that such officers have carefully reviewed the Time of Sale Information and the Offering Memorandum and, to the knowledge of such officers, the representations of the Company and Evolent Health set forth in Sections 3(b) and 3(d)
hereof are true and correct, (ii)&nbsp;confirming that the other representations and warranties of the Company and Evolent Health in this Agreement are true and correct and that the Company and Evolent Health have complied in all material respects
with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date or the Additional Closing Date, as the case may be, and (iii)&nbsp;to the effect set forth in paragraphs (a)&nbsp;and
(b) above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Comfort Letters.</I> On the date of this Agreement and on the Closing Date or the Additional Closing
Date, as the case may be, Deloitte&nbsp;&amp; Touche LLP shall have furnished to the Representative, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Initial Purchasers, in form and
substance reasonably satisfactory to the Representative, containing statements and information of the type customarily included in accountants&#8217; &#8220;comfort letters&#8221; to initial purchasers with respect to the financial statements and
certain financial information contained in or incorporated by reference in the Time of Sale Information and the Offering Memorandum; <U>provided</U>, that the letter delivered on the Closing Date or the Additional Closing Date, as the case may be,
shall use a <FONT STYLE="white-space:nowrap">&#8220;cut-off&#8221;</FONT> date no more than three business days prior to such Closing Date or such Additional Closing Date, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel for the Company and Evolent Health.</I>
King&nbsp;&amp; Spalding LLP, counsel for the Company, shall have furnished to the Representative, at the request of the Company, their written opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement, dated the Closing Date or the
Additional Closing Date, as the case may be, and addressed to the Initial Purchasers, in form and substance reasonably satisfactory to the Representative, to the effect set forth in Annex&nbsp;C hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement
of Counsel for the Initial Purchasers.</I> The Representative shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, an opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement of Davis
Polk&nbsp;&amp; Wardwell LLP, counsel for the Initial Purchasers, with respect to such matters as the Representative may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable
them to pass upon such matters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>No Legal Impediment to Issuance and/or Sale.</I> No action shall have been taken
and no statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent
the issuance or sale of the Securities; and no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of
the Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Good Standing</I>. The Representative shall have received on and as of the Closing Date or the
Additional Closing Date, as the case may be, satisfactory evidence of the good standing of the Company and Evolent Health in their respective jurisdictions of organization and their good standing as foreign entities in such other jurisdictions as
the Representative may reasonably request, in each case in writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>DTC</I>. The Securities shall be eligible for clearance and settlement through DTC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Exchange Listing</I>. A number of shares of Class&nbsp;A Common Stock equal to the sum of the Maximum Number of
Underlying Securities shall have been approved for listing on the Exchange, subject to official notice of issuance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)
<I><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements</I>. The <FONT STYLE="white-space:nowrap">&#8220;lock-up&#8221;</FONT> agreements, each substantially in the form of Exhibit A hereto, between you and the parties listed on Schedule 2
hereto, relating to sales and certain other dispositions of shares of Stock or certain other securities, delivered to you on or before the date hereof, shall be in full force and effect on the Closing Date or the Additional Closing Date, as the case
may be. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Additional Documents.</I>On or prior to the Closing Date or the Additional Closing Date, as the case may
be, the Company shall have furnished to the Representative such further certificates and documents as the Representative may reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All opinions, letters, certificates and evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the
provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Initial Purchasers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Indemnification and Contribution</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Indemnification of the Initial Purchasers by the Company and Evolent Health. </I>Each of the Company and Evolent Health
agrees to jointly and severally indemnify and hold harmless each Initial Purchaser, its affiliates, directors and officers and each person, if any, who controls such Initial Purchaser within the meaning of Section&nbsp;15 of the Securities Act or
Section&nbsp;20 of the Exchange Act, from and against any and all losses, claims, damages and liabilities (including, without limitation, reasonable legal fees and other reasonable expenses incurred in connection with any suit, action or proceeding
or any claim asserted, as such fees and expenses are incurred), joint or several, that arise out of, or are based upon, any untrue statement or alleged untrue statement of a material fact contained in the Preliminary Offering Memorandum, any of the
other Time of Sale Information, any Issuer Written Communication, any road show as defined in Rule 433(h) under the Securities Act (a &#8220;road show&#8221;), or the Offering Memorandum (or any amendment or supplement thereto), or caused by any
omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, in each case except insofar as such losses, claims, damages or
liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any Initial Purchaser furnished to the Company in writing
by such Initial Purchaser through the Representative expressly for use therein, it being understood and agreed that the only such information furnished by any Initial Purchaser consists of the information described as such in subsection
(b)&nbsp;below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Indemnification of the Company and Evolent Health.</I> Each Initial Purchaser agrees, severally and
not jointly, to indemnify and hold harmless the Company and Evolent Health and their respective directors and officers and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20
of the Exchange Act to the same extent as the indemnity set forth in paragraph (a)&nbsp;above, but only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue statement or omission or alleged
untrue statement or omission made in reliance upon and in conformity with any information relating to such Initial Purchaser furnished to the Company in writing by such Initial Purchaser through the Representative expressly for use in the
Preliminary Offering Memorandum, any of the other Time of Sale Information (including any of the other Time of Sale Information that has subsequently been amended), any Issuer Written Communication, any road show or the Offering Memorandum (or any
amendment or supplement thereto) it being understood and agreed upon that the only such information furnished by any Initial Purchaser consists of the following information in the Offering Memorandum furnished on behalf of each Initial Purchaser:
the information contained in the twelfth and thirteenth paragraphs under the caption &#8220;Plan of Distribution.&#8221; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Notice and Procedures.</I> If any suit, action, proceeding (including any governmental or regulatory investigation),
claim or demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of this Section&nbsp;7, such person (the &#8220;Indemnified Person&#8221;) shall promptly notify
the person against whom such indemnification may be sought (the &#8220;Indemnifying Person&#8221;) in writing; <U>provided</U> that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have under the
preceding paragraphs of this Section&nbsp;7 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and <U>provided further</U> that the failure to notify the
Indemnifying Person shall not relieve it from any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs of this Section&nbsp;7. If any such proceeding shall be brought or asserted against an
Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel
to the Indemnifying Person) to represent the Indemnified Person in such proceeding and shall pay the reasonable fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the
right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless (i)&nbsp;the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary;
(ii)&nbsp;the Indemnifying Person has failed within a reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii)&nbsp;the Indemnified Person shall have reasonably concluded that there may be legal defenses available
to it that are different from or in addition to those available to the Indemnifying Person; or (iv)&nbsp;the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and
representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related
proceedings in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as they are
incurred. Any such separate firm for any Initial Purchaser, its affiliates, directors and officers and any control persons of such Initial Purchaser shall be designated in writing by Oppenheimer&nbsp;&amp; Co. Inc., and any such separate firm for
the Company, its directors, its officers and any control persons of the Company shall be designated in writing by the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but
if settled with such consent or if there be a final judgment for the plaintiff, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the
foregoing sentence, if at any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for reasonable fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall
be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into in good faith more than 60 days after receipt by the Indemnifying Person of such request and more than 30 days after
receipt of the proposed terms of such settlement and (ii)&nbsp;the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request prior to the date of such settlement. No Indemnifying Person shall, without the
written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such
Indemnified Person, unless such settlement (x)&nbsp;includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of
such proceeding and (y)&nbsp;does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Contribution.</I> If the indemnification provided for in paragraphs
(a)&nbsp;and (b) above is unavailable to an Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified
Person thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the
Company, on the one hand, and the Initial Purchasers on the other, from the offering of the Securities or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not
only the relative benefits referred to in clause (i)&nbsp;but also the relative fault of the Company on the one hand, and the Initial Purchasers on the other, in connection with the statements or omissions that resulted in such losses, claims,
damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Initial Purchasers on the other, shall be deemed to be in the same respective proportions as the
net proceeds (before deducting expenses) received by the Company from the sale of the Securities and the total discounts and commissions received by the Initial Purchasers in connection therewith, as provided in this Agreement, bear to the aggregate
offering price of the Securities. The relative fault of the Company, on the one hand, and the Initial Purchasers on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact
or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the Initial Purchasers and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent
such statement or omission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Limitation on Liability.</I> The Company, Evolent Health and the Initial Purchasers
agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;7 were determined by <U>pro</U> <U>rata</U> allocation (even if the Initial Purchasers were treated as one entity for such purpose) or by any other method of
allocation that does not take account of the equitable considerations referred to in paragraph (d)&nbsp;above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph
(d)&nbsp;above shall be deemed to include, subject to the limitations set forth above, any reasonable legal or other expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of
paragraphs (d)&nbsp;and (e) of this Section&nbsp;7, in no event shall an Initial Purchaser be required to contribute any amount in excess of the amount by which the total discounts and commissions received by such Initial Purchaser with respect to
the offering of the Securities exceeds the amount of any damages that such Initial Purchaser has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent
misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Initial Purchasers&#8217; obligations to contribute
pursuant to paragraphs (d)&nbsp;and (e) of this Section&nbsp;7 are several in proportion to their respective purchase obligations hereunder and not joint. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT>
Remedies.</I>The remedies provided for in this Section&nbsp;7 paragraphs (a)&nbsp;through (e) are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Effectiveness of Agreement</U>. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Termination</U>. This Agreement may be terminated in the absolute discretion of the Representative, by notice to the Company, if after
the execution and delivery of this Agreement and prior to the Closing Date or, in the case of the Option Securities, prior to the Additional Closing Date (i)&nbsp;trading generally shall have been suspended or materially limited on or by any of the
Exchange or The Nasdaq Stock Market; (ii)&nbsp;trading of any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; (iii)&nbsp;a general moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or
(iv)&nbsp;there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, that, in the judgment of the Representative, is material and
adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement,
the Time of Sale Information and the Offering Memorandum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Defaulting Initial Purchaser</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If, on the Closing Date or the Additional Closing Date, as the case may be, any Initial Purchaser defaults on its
obligation to purchase the Securities that it has agreed to purchase hereunder on such date, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Initial Purchasers may in their discretion arrange for the purchase of such Securities by other
persons satisfactory to the Company on the terms contained in this Agreement. If, within 36 hours after any such default by any Initial Purchaser, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Initial Purchasers do not arrange for the
purchase of such Securities, then the Company shall be entitled to a further period of 36 hours within which to procure other persons satisfactory to the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Initial Purchasers to purchase such
Securities on such terms. If other persons become obligated or agree to purchase the Securities of a defaulting Initial Purchaser, either the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Initial Purchasers or the Company may postpone the
Closing Date or the Additional Closing Date, as the case may be, for up to five full business days in order to effect any changes that in the opinion of counsel for the Company or counsel for the Initial Purchasers may be necessary in the Time of
Sale Information, the Offering Memorandum or in any other document or arrangement, and the Company agrees to promptly prepare any amendment or supplement to the Time of Sale Information or the Offering Memorandum that effects any such changes. As
used in this Agreement, the term &#8220;Initial Purchaser&#8221; includes, for all purposes of this Agreement unless the context otherwise requires, any person not listed in Schedule 1 hereto that, pursuant to this Section&nbsp;10, purchases
Securities that a defaulting Initial Purchaser agreed but failed to purchase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If, after giving effect to any arrangements for the purchase of the
Securities of a defaulting Initial Purchaser or Initial Purchasers by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Initial Purchasers and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Securities that
remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be, does not exceed <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of Securities to be purchased on such date, then the Company
shall have the right to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Initial Purchaser to purchase the number of Securities that such Initial Purchaser agreed to purchase hereunder on such date plus such Initial
Purchaser&#8217;s pro rata share (based on the number of Securities that such Initial Purchaser agreed to purchase on such date) of the Securities of such defaulting Initial Purchaser or Initial Purchasers for which such arrangements have not been
made. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If, after giving effect to any arrangements for the purchase of the Securities of a defaulting Initial Purchaser
or Initial Purchasers by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Initial Purchasers and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Securities that remain unpurchased on the Closing Date or the
Additional Closing Date, as the case may be, exceeds <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate principal amount of Securities to be purchased on such date, or if the Company shall not exercise the right described in
paragraph (b)&nbsp;above, then this Agreement or, with respect to any Additional Closing Date, the obligation of the Initial Purchasers to purchase Securities on the Additional Closing Date, as the case may be, shall terminate without liability on
the part of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Initial Purchasers. Any termination of this Agreement pursuant to this Section&nbsp;10 shall be without liability on the part of the Company, except that the Company will
continue to be liable for the payment of expenses as set forth in Section&nbsp;11 hereof and except that the provisions of Section&nbsp;7 hereof shall not terminate and shall remain in effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Nothing contained herein shall relieve a defaulting Initial Purchaser of any liability it may have to the Company or any <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Initial Purchaser for damages caused by its default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Payment of
Expenses</U><I>.</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Whether or not the transactions contemplated by this Agreement are consummated or this Agreement
is terminated, except as otherwise agreed, the Company and Evolent Health jointly and severally will pay or cause to be paid all costs and expenses incident to the performance of their obligations hereunder, including without limitation,
(i)&nbsp;the costs incident to the authorization, issuance, sale, preparation and delivery of the Securities and any taxes payable in that connection; (ii)&nbsp;the costs incident to the preparation and printing the Time of Sale Information, any
Issuer Written Communication and the Offering Memorandum (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii)&nbsp;the costs of reproducing and distributing each of the Transaction Documents; (iv)&nbsp;the
fees and expenses of the Company and Evolent Health&#8217;s counsel and the Company&#8217;s independent accountants; (v)&nbsp;the fees and expenses incurred in connection with the registration or qualification and determination of eligibility for
investment of the Securities under the state or foreign securities or blue sky laws of such jurisdictions as the Representative may designate and the preparation, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
printing and distribution of a Blue Sky Memorandum (including the related fees and expenses of counsel for the Initial Purchasers up to $5,000); (vi) any fees charged by rating agencies for
rating the Securities, if any; (vii)&nbsp;the fees and expenses of the Trustee and any paying agent (including related reasonable fees and expenses of any counsel to such parties); (viii) all expenses and application fees incurred in connection with
the approval of the Securities for book-entry transfer by DTC; (ix)&nbsp;all expenses incurred by the Company in connection with any &#8220;road show&#8221; presentation to potential investors; and (x)&nbsp;all expenses and application fees related
to the listing of the Maximum Number of Underlying Securities on the Exchange. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If (i)&nbsp;this Agreement is
terminated pursuant to Section&nbsp;9 (other than as a result of a termination pursuant to clauses (i), (iii) or (iv)&nbsp;of Section&nbsp;9), (ii) the Company for any reason fails to tender the Securities for delivery to the Initial Purchasers
(other than as a result of a termination pursuant to clauses (i), (iii) or (iv)&nbsp;of Section&nbsp;9 or Section&nbsp;10) or (iii)&nbsp;the Initial Purchasers decline to purchase the Securities for any reason permitted under this Agreement, the
Company and Evolent Health jointly and severally agree to reimburse the Initial Purchasers (or, in the case of Section&nbsp;10, solely the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Initial Purchasers) for all documented <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including the reasonable fees and expenses of their counsel) reasonably incurred by the Initial Purchasers in connection with this Agreement
and the offering contemplated hereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Persons Entitled to Benefit of Agreement</U>. This Agreement shall inure to the
benefit of and be binding upon the parties hereto and their respective successors and the officers and directors and any controlling persons referred to in Section&nbsp;7 hereof. Nothing in this Agreement is intended or shall be construed to give
any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Securities from any Initial Purchaser shall be deemed to be a successor merely by reason of such
purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Survival</U>. The respective indemnities, rights of contribution, representations, warranties and agreements of the
Company, Evolent Health and the Initial Purchasers contained in this Agreement or made by or on behalf of the Company, Evolent Health or the Initial Purchasers pursuant to this Agreement or any certificate delivered pursuant hereto shall survive the
delivery of and payment for the Securities and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company, Evolent Health or the Initial Purchasers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Certain Defined Terms</U>. For purposes of this Agreement, (a)&nbsp;except where otherwise expressly provided, the term
&#8220;affiliate&#8221; has the meaning set forth in Rule 405 under the Securities Act; (b)&nbsp;the term &#8220;business day&#8221; means any day other than a day on which banks are permitted or required to be closed in New York City; and
(c)&nbsp;the term &#8220;subsidiary&#8221; has the meaning set forth in Rule 405 under the Securities Act and with respect to the Company specifically includes Evolent Health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>USA Patriot Act.</U> In accordance with the requirements of the USA Patriot Act (Title III of Pub. L.
<FONT STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Initial Purchasers are required to obtain, verify and record information that identifies their respective clients, including the Company, which information
may include the name and address of their respective clients, as well as other information that will allow the Initial Purchasers to properly identify their respective clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Recognition of the U.S. Special Resolution Regimes</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In the event that any Initial Purchaser that is a Covered Entity becomes subject to a proceeding under a U.S. Special
Resolution Regime, the transfer from such Initial Purchaser of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution
Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event that any Initial Purchaser that is a Covered Entity or a BHC Act Affiliate of such Initial Purchaser becomes
subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Initial Purchaser are permitted to be exercised to no greater extent than such Default Rights could be exercised
under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;24, a &#8220;BHC Act Affiliate&#8221; has
the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k). &#8220;Covered Entity&#8221; means any of the following: (i)&nbsp;a &#8220;covered entity&#8221; as that term is
defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii)&nbsp;a &#8220;covered FSI&#8221; as that
term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). &#8220;Default Right&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as
applicable. &#8220;U.S. Special Resolution Regime&#8221; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and
the regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Notices.</I> All notices and other communications hereunder shall be in writing and shall be deemed to have been duly
given if mailed or transmitted and confirmed by any standard form of telecommunication. Notices to the Initial Purchasers shall be given to the Representative c/o Oppenheimer&nbsp;&amp; Co. Inc., 85 Broad Street, New York, New York 10004, Attention:
Peter Vogelsang (Peter.Vogelsang@opco.com). Notices to the Company shall be given to it at 1812 N. Moore Street, Suite 1705, Arlington, Virginia 22209 (fax: (571) <FONT STYLE="white-space:nowrap">389-6001);</FONT> Attention: Jonathan Weinberg. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Governing Law.</I> This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall
be governed by and construed in accordance with the laws of the State of New York applicable to agreements made and to be performed in such state. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Submission to Jurisdiction</I>. Each of the Company and Evolent Health submits to the exclusive jurisdiction of the U.S.
federal and New York state courts in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. Each of the Company and Evolent Health waives any
objection which it may now or hereafter have to the laying of venue of any such suit or proceeding in such courts. Each of the Company and Evolent Health agrees that final judgment in any such suit, action or proceeding brought in such court shall
be conclusive and binding upon the Company or Evolent Health, as applicable, and may be enforced in any court to the jurisdiction of which the Company or Evolent Health, as applicable, is subject by a suit upon such judgment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>WAIVER OF JURY TRIAL</I>. EACH OF THE PARTIES HERETO HEREBY WAIVES ANY RIGHT TO TRIAL BY JURY IN ANY SUIT OR PROCEEDING
ARISING OUT OF OR RELATING TO THIS AGREEMENT. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Counterparts.</I> This Agreement may be signed in counterparts (which
may include counterparts delivered by any standard form of telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail
(including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any
counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Amendments or Waivers.</I> No amendment or waiver of any provision of this Agreement, nor any consent or approval to any
departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Headings.</I> The headings herein are included for convenience of reference only and are not intended to be part of, or
to affect the meaning or interpretation of, this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please indicate
your acceptance of this Agreement by signing in the space provided below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">EVOLENT HEALTH, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jonathan Weinberg</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:Jonathan Weinberg</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:General Counsel</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Purchase Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accepted: As of the date first written above</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OPPENHEIMER&nbsp;&amp; CO. INC.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For itself and on behalf of the</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">several Initial Purchasers listed</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">in Schedule 1 hereto.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Robert Missant</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Authorized Signatory</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Purchase Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Initial Purchaser</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal&nbsp;Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oppenheimer&nbsp;&amp; Co. Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B>145,000,000</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sch. 1-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 2 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cheryl Scott </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Toyin Ajayi </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Craig Barbarosh </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peter Grua </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Richard Jelinek </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kim Keck </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seth Blackley </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Russell Glass </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brendan Springstubb </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shawn Guertin </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;16 Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seth Blackley </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John Johnson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dan McCarthy </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emily Rafferty </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aammaad Shams </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jonathan Weinberg </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sch. 2-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subsidiaries </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evolent Health LLC </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evolent Specialty Services, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EH Holding Company, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Justify Holdings, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evolent Health International Private
Ltd. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evolent Care Partners Holding Company, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evolent
Care Partners of Texas, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Accountable Care Organization Ltd. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evolent Care Partners of North Carolina, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evolent IPA of
New York, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evolent Health International Philippines, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evolent Accountable Care Organization, LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evolent Connected
Care Accountable Care Organization LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OncCare Partners, LLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Valtruis Oncology Care Partners Holdings, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OCP Management
Aggregator, LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oncology Care Partners Management, LLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OCP Management Arizona, LLC </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sch. 3-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Annex A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Time of Sale Information </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Term sheet
containing the terms of the Securities, substantially in the form of Annex B. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annex A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Annex B </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRICING TERM SHEET</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>DATED
AUGUST&nbsp;18, 2025</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>STRICTLY CONFIDENTIAL</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g72742g0821114418535.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EVOLENT HEALTH, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>$145,000,000 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4.50%
CONVERTIBLE SENIOR NOTES DUE 2031 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The information in this pricing term sheet supplements Evolent Health, Inc.&#8217;s preliminary
offering memorandum, dated August&nbsp;18, 2025 (the &#8220;Preliminary Offering Memorandum&#8221;), and supersedes the information in the Preliminary Offering Memorandum to the extent inconsistent with the information in the Preliminary Offering
Memorandum. In all other respects, this pricing term sheet is qualified in its entirety by reference to the Preliminary Offering Memorandum, including all documents incorporated by reference therein. Terms used herein but not defined herein shall
have the respective meanings as set forth in the Preliminary Offering Memorandum. All references to dollar amounts are references to U.S. dollars. The offering was upsized from the previously announced offering of $140,000,000 aggregate principal
amount of notes. The final offering memorandum relating to the offering will reflect conforming changes relating to such increase in the size of the offering. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="65%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Issuer:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Evolent Health, Inc., a Delaware corporation (the &#8220;Issuer&#8221;).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ticker/Exchange for the Issuer&#8217;s Class&nbsp;A Common Stock:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#8220;EVH&#8221;/The New York Stock Exchange.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Notes:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.50% Convertible Senior Notes due 2031 (the &#8220;Notes&#8221;).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Principal Amount:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$145,000,000, plus up to an additional $21,750,000 principal amount pursuant to the initial purchasers&#8217; option to purchase additional Notes.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominations:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$1,000 and multiples of $1,000 in excess thereof.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Maturity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">August&nbsp;15, 2031, unless earlier repurchased, redeemed or converted.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annex B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="65%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Termination of Conversion Rights:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On or after August&nbsp;20, 2026, the Issuer may terminate the rights of holders to convert their Notes if the last reported sale price of
the Issuer&#8217;s Class&nbsp;A common stock has been greater than or equal to the applicable Conversion Rights Termination Price Trigger for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period
(including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Issuer provides the &#8220;notice of termination of conversion rights&#8221; (as defined in the Preliminary
Offering Memorandum).</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Issuer will give notice of any termination of conversion
rights not less than 15 nor more than 25 scheduled trading days before the date on which holders&#8217; conversion rights will be terminated by mail or electronic delivery to the trustee, the conversion agent (if other than the trustee) and each
holder of Notes.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Issuer will be required to settle all conversions of Notes for
which the relevant conversion date occurs after its issuance of a notice of termination of conversion rights with respect to the Notes and prior to the conversion rights termination date by physical settlement, and the Issuer will describe the same
in the relevant notice of termination of conversion rights.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">See &#8220;Description
of Notes&#8212;Conversion Rights&#8212;Termination of Conversion Rights&#8221; in the Preliminary Offering Memorandum.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Conversion Rights Termination Price Trigger:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">For any trading day and in respect of any conversion rights termination date, (i)&nbsp;if the conversion rights termination date is on or after August&nbsp;20, 2026 and prior to, but not including, August&nbsp;21, 2028, 150% of the
conversion price then in effect on such trading day and (ii)&nbsp;if the conversion rights termination date is on or after August&nbsp;21, 2028, 130% of the conversion price then in effect on such trading day.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Limitation on Conversion:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A holder of Notes will not be entitled to receive any shares of Class&nbsp;A common stock otherwise deliverable upon conversion of its Notes to the extent, but solely to the extent, that such receipt would cause such holder to
become, directly or indirectly, a beneficial owner of more than 9.8% of the Class&nbsp;A common stock outstanding at such time. See &#8220;Description of Notes&#8212;Conversion Rights&#8212;Limitation on Beneficial Ownership&#8221; in the
Preliminary Offering Memorandum.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Optional Redemption:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Issuer may not redeem the Notes unless and until holders&#8217; conversion rights have been terminated at the Issuer&#8217;s election.
However, if holders&#8217; conversion rights have been terminated at the Issuer&#8217;s election, the Issuer may redeem for cash all or part of the Notes, at its option, at any time or from time to time after the conversion rights termination date
at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Issuer will give notice of any redemption not less than 10 nor more than 60
calendar days before the redemption date by mail or electronic delivery to the trustee, the paying agent (if other than the trustee) and each holder of Notes. See &#8220;Description of Notes&#8212;Optional Redemption&#8221; in the Preliminary
Offering Memorandum.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Interest Rate:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.50% per year.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Interest Payment Dates:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Interest will accrue from August&nbsp;21, 2025 and will be payable semiannually in arrears on February&nbsp;15 and August&nbsp;15 of each year, beginning on February&nbsp;15,
2026.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annex B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="65%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Interest Record Dates:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">February&nbsp;1 and August&nbsp;1 of each year, immediately preceding any February&nbsp;15 or August&nbsp;15 interest payment date, as the case may be.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Issue Price:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">100% of principal, plus accrued interest, if any, from August&nbsp;21, 2025.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Trade Date:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">August&nbsp;19, 2025.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Settlement Date:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">August&nbsp;21, 2025, which will be the second business day following the Trade Date (this settlement cycle being referred to as &#8220;T+2&#8221;). Under Rule <FONT STYLE="white-space:nowrap">15c6-1</FONT> under the Securities
Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade Notes prior to the
business day preceding the settlement date will be required, by virtue of the fact that the Notes initially will settle T+2, to specify an alternate settlement cycle at the time of any such trade to prevent a failed settlement. Purchasers of the
Notes who wish to trade the Notes prior to the business day preceding the settlement date should consult their own advisors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Last Reported Sale Price of the Issuer&#8217;s Class&nbsp;A Common Stock on August&nbsp;18,
2025:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$9.02 per share.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Initial Conversion Rate:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">73.9098 shares of the Issuer&#8217;s Class&nbsp;A common stock per $1,000 principal amount of Notes.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Initial Conversion Price:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Approximately $13.53&nbsp;per share of the Issuer&#8217;s Class&nbsp;A common stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Conversion Premium:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Approximately 50.0% above the last reported sale price of the Issuer&#8217;s Class&nbsp;A common stock on August&nbsp;18, 2025.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Settlement Method:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cash, shares of the Issuer&#8217;s Class&nbsp;A common stock, or a combination of cash and shares of the Issuer&#8217;s Class&nbsp;A common stock, at the Issuer&#8217;s election, as described under &#8220;&#8212;Conversion
Rights&#8212;Settlement upon Conversion&#8221; in the Preliminary Offering Memorandum.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Joint Book-Runners:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oppenheimer&nbsp;&amp; Co. Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Goldman
Sachs&nbsp;&amp; Co. LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CUSIP Number (144A):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">30050B AJ0</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ISIN (144A):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">US30050BAJ08</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annex B-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="65%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Issuer estimates that the net proceeds from the offering will be approximately $140.2&nbsp;million (or approximately $161.2&nbsp;million
if the initial purchasers exercise their option to purchase additional Notes in full), after deducting fees and estimated expenses payable by the Issuer.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Issuer expects to use approximately $100.2&nbsp;million of the net proceeds from the offering, plus available liquidity, to repurchase approximately
$167.4&nbsp;million aggregate principal of its 1.50% convertible senior notes due 2025 (the &#8220;2025 Notes&#8221;) for approximately $167.6&nbsp;million in cash in note repurchases entered into concurrently with the pricing of the Notes. The
Issuer also expects to use approximately $40.0&nbsp;million of the net proceeds from the offering to repurchase shares of the Issuer&#8217;s Class&nbsp;A common stock concurrently with the pricing of the offering in privately negotiated transactions
effected with or through one of the initial purchasers or its affiliate at a purchase price per share equal to the last reported sale price of the Issuer&#8217;s Class&nbsp;A common stock on August&nbsp;18, 2025. If the initial purchasers exercise
their option to purchase additional Notes, the Issuer expects to use the net proceeds from the sale of the additional Notes to reduce the amount of available liquidity required to repurchase or repay the 2025 Notes. See &#8220;Use of Proceeds&#8221;
in the Preliminary Offering Memorandum.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Increase in Conversion Rate upon Conversion upon a Make-Whole Fundamental Change or a Notice of
Termination of Conversion Rights:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the occurrence of a &#8220;make-whole fundamental change&#8221; (as defined in the Preliminary Offering Memorandum) or the delivery
of a notice of termination of conversion rights, the Issuer will increase the conversion rate for a holder who elects to convert its Notes in connection with such make-whole fundamental change or notice of termination of conversion rights, as the
case may be, in certain circumstances, as described under &#8220;Description of Notes&#8212;Conversion Rights&#8212; Increase in Conversion Rate upon Conversion upon a Make-Whole Fundamental Change or a Notice of Termination of Conversion
Rights&#8221; in the Preliminary Offering Memorandum.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The following table sets forth
the number of additional shares by which the conversion rate will be increased per $1,000 principal amount of Notes for conversions in connection with a make-whole fundamental change or notice of termination of conversion rights for each
&#8220;stock price&#8221; and &#8220;effective date&#8221; set forth below:</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="54" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Effective&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$9.02</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$9.50</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$10.50</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$12.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$13.53</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$15.25</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$17.59</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$20.30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$25.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$32.50</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$45.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$60.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$90.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$140.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">August&nbsp;21,&nbsp;2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36.9549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34.2284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29.4705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24.0433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.9460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.4898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.0671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.2734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.1336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.3548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.1718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.0167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.2008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">August&nbsp;15,&nbsp;2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36.9549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34.2284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29.4410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23.7858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.5528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.0151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.5492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.7557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.6672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.9932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.9449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.8855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.1569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">August&nbsp;15,&nbsp;2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36.9549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34.1084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28.8743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.6548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.0695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.6117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.8773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.9252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.4520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.6262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.7110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.1027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">August&nbsp;15,&nbsp;2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36.9549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33.5232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27.9629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.8008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.3193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.6918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.2757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.6522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.9272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.7609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.5203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">August&nbsp;15,&nbsp;2029</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36.9549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32.5853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26.5286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.9375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.2698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.6105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.3064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.9015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.5756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.8948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.8249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">August&nbsp;15,&nbsp;2030</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36.9549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31.1526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24.1429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.7283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.7472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.1180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.1666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.2951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.7788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.8911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.1597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">August&nbsp;15,&nbsp;2031</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36.9549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31.1526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.3286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.4233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exact stock prices and effective dates may not be set forth in the table above, in which case: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the stock price is between two stock prices in the table above or the effective date is between two effective
dates in the table above, the number of additional shares by which the conversion rate will be increased will be determined by a straight-line interpolation between the number of additional shares set forth for the higher and lower stock prices and
the earlier and later effective dates, as applicable, based on a <FONT STYLE="white-space:nowrap">365-day</FONT> year. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annex B-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the stock price is greater than $140.00 per share (subject to adjustment in the same manner as the stock
prices set forth in the column headings of the table above as described in the Preliminary Offering Memorandum), no additional shares will be added to the conversion rate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the stock price is less than $9.02 per share (subject to adjustment in the same manner as the stock prices set
forth in the column headings of the table above as described in the Preliminary Offering Memorandum), no additional shares will be added to the conversion rate. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, in no event will the conversion rate per $1,000 principal amount of Notes exceed 110.8647 shares of the Issuer&#8217;s
Class&nbsp;A common stock, subject to adjustment in the same manner as the conversion rate as set forth under &#8220;Description of Notes&#8212;Conversion Rights&#8212;Conversion Rate Adjustments&#8221; in the Preliminary Offering Memorandum. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This communication is intended for the sole use of the person to whom it is provided by the sender. This material is confidential and is for your
information only and is not intended to be used by anyone other than you. This information does not purport to be a complete description of the Notes or the offering thereof. This communication does not constitute an offer to sell or the
solicitation of an offer to buy any Notes in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Notes and the shares of the Issuer&#8217;s Class&nbsp;A common stock, if any, issuable upon conversion of the Notes have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or any other securities laws, and may not be offered or sold within the United States or any other jurisdiction, except pursuant to an exemption from,
or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. The initial purchasers are initially offering the Notes only to persons reasonably believed to be qualified
institutional buyers as defined in, and in reliance on, Rule 144A under the Securities Act. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Notes and any shares of the Issuer&#8217;s
Class&nbsp;A common stock issuable upon conversion of the Notes are not transferable except in accordance with the restrictions described under &#8220;Transfer Restrictions&#8221; in the Preliminary Offering Memorandum. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A copy of the Preliminary Offering Memorandum for the offering of the Notes may be obtained by contacting your sales representative at
Oppenheimer&nbsp;&amp; Co. Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Any legends, disclaimers or other notices that may appear below are not applicable to this communication and
should be disregarded. Such legends, disclaimers or other notices have been automatically generated as a result of this communication having been sent via Bloomberg or another system. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of Page Intentionally Blank</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annex B-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Annex C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Opinion of Counsel for the Company </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[_], 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OPPENHEIMER&nbsp;&amp; CO. INC. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representative of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the several Initial Purchasers listed in
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule 1 to the Purchase </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agreement referred to below </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Oppenheimer&nbsp;&amp; Co. Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">85 Broad Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10004 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EVOLENT HEALTH, INC. &#8212; <FONT STYLE="white-space:nowrap">Lock-up</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned
understands that you, as Representative of the several Initial Purchasers, propose to enter into a purchase agreement (the &#8220;Purchase Agreement&#8221;) with Evolent Health, Inc., a Delaware corporation (the &#8220;Company&#8221;), and Evolent
Health LLC, a Delaware limited liability company, providing for the purchase and resale (the &#8220;Placement&#8221;) by the several Initial Purchasers named in Schedule 1 to the Purchase Agreement (the &#8220;Initial Purchasers&#8221;), of
Convertible Notes of the Company (the &#8220;Securities&#8221;). To the extent there are no additional parties listed on Schedule 1 to the Purchase Agreement other than you, the term Representative as used herein shall mean you as the Initial
Purchaser, and the term Initial Purchasers shall refer only to Oppenheimer&nbsp;&amp; Co. Inc., and the term shall be taken in the singular as the context requires. Capitalized terms used herein and not otherwise defined shall have the meanings set
forth in the Purchase Agreement. References to shares of Common Stock shall be deemed to refer to shares of any class of stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the Initial Purchasers&#8217; agreement to purchase and make the Placement of the Securities, and for other good and
valuable consideration receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of Oppenheimer&nbsp;&amp; Co. Inc. on behalf of the Initial Purchasers, the undersigned will not, during the period
beginning on the date of this letter agreement (the &#8220;Letter Agreement&#8221;) and ending 60 days after the date of the offering memorandum relating to the Placement (the &#8220;Offering Memorandum&#8221;) (such period, the &#8220;Restricted
Period&#8221;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly,
any shares of Common Stock, or any securities convertible into or exercisable or exchangeable for Common Stock (including without limitation, Common Stock or such other securities which may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exh. A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise of a
stock option or warrant), or publicly disclose the intention to make any offer, sale, pledge or disposition, (2)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the
Common Stock or such other securities, whether any such transaction described in clause (1)&nbsp;or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise or (3)&nbsp;make any demand for or exercise any
right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock, in each case other than: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;(i) transfers of shares of Common Stock as a bona fide gift or gifts, (ii)&nbsp;transfers of shares of Common Stock or such other
securities as a result of the operation of law through estate, other testamentary document or intestate succession or (iii)&nbsp;transfers of shares of Common Stock or such other securities to any immediate family member of the undersigned or any
trust for the direct or indirect benefit of the undersigned or any immediate family member of the undersigned (for purposes of this Letter Agreement, &#8220;immediate family&#8221; shall mean any relationship by blood, marriage or adoption, not more
remote than first cousin); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;transfers of shares of Common Stock or other securities acquired in open market transactions after
the completion of the Placement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;the exercise or settlement of Stock Options to purchase shares of Common Stock, RSUs,
performance-based RSUs, LSUs or other equity awards outstanding on or prior to the date hereof or on the date of the Purchase Agreement, and any related transfer to the Company of shares of Common Stock (i)&nbsp;deemed to occur upon the cashless
exercise of such Stock Options or (ii)&nbsp;for the purpose of paying the exercise price of such Stock Options or for paying taxes (including estimated taxes) due as a result of the exercise of such Stock Options; provided that any such purchased
shares will be subject to the restrictions described in this Letter Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D)&nbsp;transfers to the Company of shares of Common
Stock or any security convertible into or exercisable for Common Stock in connection with the termination of service of an option to repurchase such shares; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) transfers of shares of Common Stock pursuant to a trading plan established prior to the date hereof pursuant to Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> of the Exchange Act (an &#8220;Established Plan&#8221;); <U>provided</U> that (i)&nbsp;to the extent a filing under the Exchange Act or public announcement, if any, is required or voluntarily made by or on
behalf of the undersigned or the Company regarding any such sales, the undersigned shall cause such announcement or filing to include a statement to the effect that the sale was made pursuant to an Established Plan, and (ii)&nbsp;the undersigned may
not amend, alter or modify an Established Plan during the Restricted Period; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>provided</U> that in the case of any transfer or
distribution pursuant to clause (A), each donee or distributee shall execute and deliver to the Representative a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of this Letter Agreement; and <U>provided</U>, <U>further</U>, that
in the case of any transfer or distribution pursuant to clause (A)&nbsp;through (E), no filing by any party (donor, donee, transferor or transferee) under the Securities Exchange Act of 1934, as amended, or other public announcement shall be
required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on a Form 5, Schedule 13D or Schedule 13G, in each case, in accordance with applicable law and made after the expiration of the Restricted
Period). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exh. A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, nothing in this Letter Agreement shall prohibit the undersigned from
(i)&nbsp;transferring shares of Common Stock pursuant to a liquidation, tender offer, merger, consolidation, stock exchange or similar transaction that results in all of the Company&#8217;s equity holders having the right to exchange their equity
securities in the Company for cash, securities or other property; <U>provided</U> that if such liquidation, tender offer, merger, consolidation, stock exchange or similar transaction is not completed, any Common Stock or other equity securities in
the Company subject to this Letter Agreement shall remain subject to the restrictions contained in this Letter Agreement or (ii)&nbsp;engaging in any transaction to the extent required by law, regulation or governmental order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the undersigned may, if permitted by the Company, establish a written trading plan meeting the requirements of Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act; <U>provided</U> that no sales or other transfers occur under such plan during the Restricted Period and no public disclosure of such plan shall be required or shall be made by any
person during the Restricted Period, except to the extent required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In furtherance of the foregoing, the Company, and any duly
appointed transfer agent for the registration or transfer of the securities described herein, are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Letter Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Letter Agreement. All
authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that, if (i)&nbsp;prior to entering into the Purchase Agreement, the Company notifies the Representative in
writing that the Company does not intend to proceed with the Placement; (ii)&nbsp;the Purchase Agreement has not been executed by all parties by December&nbsp;19, 2023; or (iii)&nbsp;if the Purchase Agreement (other than the provisions thereof which
survive termination) shall terminate or be terminated prior to payment for and delivery of the Securities to be sold thereunder, then this Letter Agreement shall immediately terminate and the undersigned shall be released from all obligations under
this Letter Agreement. The undersigned understands that the Initial Purchasers are entering into the Purchase Agreement and proceeding with the Placement in reliance upon this Letter Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exh. A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Letter Agreement and any claim, controversy or dispute arising under or related to this
Letter Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflict of laws principles thereof. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[NAME OF STOCKHOLDER]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>evh-20250818.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 8/22/2025 12:46:58 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:evh="http://www.evolenthealth.com/20250818"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.evolenthealth.com/20250818"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20250818_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20250818_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>evh-20250818_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 8/22/2025 12:46:58 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>evh-20250818_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 8/22/2025 12:46:58 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="evh-20250818.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g72742g0821092637655.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g72742g0821092637655.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  M '4# 2(  A$! Q$!_\0
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%** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g72742g0821092637921.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g72742g0821092637921.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  M (T# 2(  A$! Q$!_\0
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M_%E[:/#IAL;^WLY)=10K.Z@JS?W@"1N'3FIO"D]I8S:I'?W &MM+YEYN;'F
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MP'L*KZ#XAO=6U2:!M3MXKR*<I/I<T01XD'=3U;/!SR*[2@# _M?Q!_T*[_\
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M1A, .=@3'?@$[L>U;7ARY6X6?R;U[R$$%I'??MD/WESVQZ=NE;M( %Z #Z4
M<U=>!]"N=6ANVTBS9=LGFY3EF8K@_H:Z)(U@@$<$:A47")T''05)10!SOA'3
CM1TRSO8M0M+6W::\EN$^SSF0$.Y;!RJX(R!^%=%110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g72742g0821092638071.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g72742g0821092638071.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P *0# 2(  A$! Q$!_\0
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M0V]G#M*28(_>2>8V2 3P O6F!Z715'3M3345DQ!/ R'[DP4%E/1A@G@^_/J
M:O4@"BBB@ HHHH XV_AC\0?$%]%U.-9]+L].2Z%G*N8IY'D9=SJ>'"A!@$8!
M;/4#%7Q?X5TBR\):U)#81O;M ACLBH:*)D)P8D;Y4)W'I@=^YKI=6\/V^J7-
MO>I<W-CJ%N"L5Y:,HD"GJA#*RLIQT92,\C!YJK?>$UU'1I]/N=9U-I+@!9KP
M&$3.H_A_U>Q1_NJ#WZ\T 8'A32;:7Q'JUQI^F)H5B+<6=QI@"HYE^\)&2,F,
M#:<!E))R<XQ74,TOA_2K&RL=)OM2CAB6$"V>$%0H !/FR)Z=LTUO#JG4K/44
MU._CO((A#-*GE#[6@.<2KLVGG/*A2,G&,U;U+1-)UI(TU72[*_6,Y1;JW24*
M?;<#B@!NFZE=WSR"YT2_TX*,AKIX&#^P\J1_UQ7,V%A:>*O$VNMKEK%?0Z?<
M+;VMK=1!XXAL#%PK9&XY^]C.!@=ZZ;3?#^BZ*\CZ5I%A8-(,.;6V2(L/?:!F
MJE]X9BN=2;4K+4;[2[R10DTMF8R)E'3<LB.I(['&?>@#F?%?AO2[&SL-VD'5
MT.I(Z6TJI*P5L HAE( 7CH2!VK1\ 62P6^I7EK%'9Z?=7&;?3T/_ !Z[>&!4
M?*K$]57CWYK0OO"B7L=FHUC4H'MIA.98C$6FD'0ONC;\EP/:K,6@K:ZO<:C:
M7UW$;A?WUJI3R9'Q@.05R&]U(S@9S0!L5D7>K36FH+8&.-YI^;=LX4#OO[C^
MM5O#L*1S7+0VDUL"<3^9$8_-ESRPR!NX_B'!X]*UVL+5UF#PJWGG,FXDEO3G
MV[>E $.HZSIFBPQ2:OJEE8K(=JO<SK$KMWQN/Z5G?\)WX/\ ^AKT/_P8P_\
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MZ+R]I8G=\^,9!XQ7=44 <3H>G'6_AE;Z8T5U:74<"HIN;:2%XIDPRL%< G#
I'(XXZUT.@?;9=,CO-2M_L]]<JKS0[MWE< !<_K]2:U:* N%%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g72742g0821092638199.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g72742g0821092638199.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  M *P# 2(  A$! Q$!_\0
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M87@]^Y^M:- &9J-]JEK<*EEHS7L93)D%RD>#D\8;\.?>J?\ :_B#_H5W_P#
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M0!RUF-5&M_:Y/#\\:RL VZ^C9(LX#.%'.<#GUQ74T44 %%%% !1110 4444
M%%%% !1110 4444 %%%% '':AH6LZO:F0I;:;J%M?"XL[B*<RX4_*X.47&4)
M&.>H]*/[*UNQUZ]FL--L7L6T^*RMP]ZR-\A<@D>6<9WXZGI[UV-% ' :-X:M
M?"_A&R%_:V>F7<4<=M>7UK-SY> "_F$*4R0,GMGK79Z5))-I=O)*S,Q7AF'+
;#/!/N1@_C5L@,,$ @]C2T %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g72742g0821092638347.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g72742g0821092638347.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P (P# 2(  A$! Q$!_\0
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MW3V[!_8>5*YS]0*YNVLK7Q5XQ\01:Y;17MII<D-O:V5S&'B7=&':78<@L2V
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7REA2+^]F5E\ML?[#-GMD<UNT44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g72742g0821092638502.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g72742g0821092638502.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  M +P# 2(  A$! Q$!_\0
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9(@!!08^YNS[_ (UVM% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g72742g0821114418535.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g72742g0821114418535.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !N .X# 2(  A$! Q$!_\0
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M4G!_*O,/AG\7=1\=>)I-+NM+M;6-+9I]\3L22"HQS]:]%\4_\BCK7_7C/_Z
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MEWQRQG*L*'%K<#R7XB_&34O!7BZ71K;2K2YB2&.0222,#\P]J]>M93/:0S,
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MA8)>R7-FZQQ.I)!VACURIPO^%5KGXJ:1%MDMX7N+=;>.YG?S41D5QD!4)R[
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E44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 18, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001628908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 18,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Evolent Health, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">32-0454912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1812 North Moore Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Arlington<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">22209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(571)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">389-6000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Class&#160;A Common Stock of Evolent Health, Inc., par value $0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EVH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d72742d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d72742d8k.htm">d72742d8k.htm</File>
    <File>evh-20250818.xsd</File>
    <File>evh-20250818_lab.xml</File>
    <File>evh-20250818_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>21
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d72742d8k.htm": {
   "nsprefix": "evh",
   "nsuri": "http://www.evolenthealth.com/20250818",
   "dts": {
    "inline": {
     "local": [
      "d72742d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "evh-20250818.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "evh-20250818_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "evh-20250818_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-08-18_to_2025-08-18",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d72742d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-08-18_to_2025-08-18",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d72742d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.evolenthealth.com//20250818/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0001193125-25-185388-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-185388-xbrl.zip
M4$L#!!0    ( (F(%5OCE^E9YQ8  "*+   -    9#<R-S0R9#AK+FAT;>T]
M:U/CQK+?^153S@NJ_)!D \:P/D58;Y:;7=@"-LF]7U)C:6Q/5I9T1A+@_/K;
MW2/)DBUC8VS834A5%LOSZNEW]_3()_^Y'[OL5JA0^MZ;G\RZ\1,3GNT[TAN^
M^>GT^NS\_*?_='=.1A%T@ZY>V'&$?%,915'0:33N^\JMA\*N#_W;!C0T+,/:
MKR0=X[ 630(19KT'/.S7?35LI"V%[I[O>?$XZWQW=U>GZ7& $ZD&CFA IQKT
M$DK:Z;A[5WI?"L/NFC3(/#HZ:E!KVG6N9[: 91C-!C;W>2C2[N)V5.@M;GU7
M>-%(<#<:U6U_3/ ;;;.=P1+*,DA@=K/QQ\</U_9(C'E->F'$/3M;)X[40JB.
M&M":=I2AW[+,PP>VD/3(!MPOZFM"7P\V+/[X^>K#M'M4WG_:M1$I[H4#7XUY
M!"R#,^W7#*MF'>0FJ0%+%"9*6639/.U:T\QP"8O+A[8Z@T5L=698,^E\T-"-
M2=?%S()L7D%V%]R!/Y&,7-%MUWX]:>B/.R=C$7&&PVOBO[&\?5,Y\[T(F*)V
M ^Q98;9^>E.)Q'W4H.D:,*JA)V2,G?1]9](]<>0M"Z.)*]Y4'!D&+I\@_XM*
MEYW(^P[V%BKY+!U'>/HS=+G0S,\\/L:Q0G9.Q\)SX/_HG<N'"03WT9480'.L
M"+M_(I\B=LWVGY&?>ZHPZ;RIR/O;6M,P*MT!=T-QTBBL-+<RCGA/0/T)R__9
M\P UDS-87W'WW'/$_:]B4LG!MZ##X^#L&B!"!U;[R&C/P]>809,2 Z% BXD0
MGE&H.R$)'JRU39U!*Z&6>E,)Y3APL^]&"C<)VJ26ZHOZ?>BDK5S9RD=&6+Y&
M(]EL88/T'/JQTH\D-IT$NT2L%;";#A-$J^Q1.OC%0 K%"(.B5*C/SG\MTF=V
M,$)=.G\ !/2=[!'D645O>22Z4]C2D=.V*:S.@KYI2[9LMDZC@)T,FU/L-?+2
MUP IA3\Y6<51->[*H=>Q82]"58KM=]*)1IUV?5]ZQ[F^KAA$QV.NAM*KX><.
MXW'DI]\H.1PE7\U,A\JR-A+4#J8YR":)_*"3>^S[4>2/Z9N^KP#X]!LSN&>A
M[TJ'?6?0?Y7NC]^9!\9QR=[RBS67+V8]?K$@72HW<1NF8?/;8 ,@42V4?XN.
MV<Z>!WPLW4GG1HY%R"[$';ORQ]P[IK8[#7G?=YWC$C)]OCB_Z;UEUS>G-[WK
MDT:P !SCF<"Y[IU]OCJ_.>]=L].+MZSWQ]G[TXM?>NSL\N/'\^OK\\N+)\%H
M;0+&WT^OWY]?_')S>5%E;^MG=689^ZVC&;BFB[978,\I1P2/$ZP\<QZLQ9QU
M [H5^?-8BZME_C"__17%-<_@7P.;O[N\^LA.PH![F4H:R4C4X!M;@-6\4SRH
M=!?Z$F]].T97(N?,K.%*F&9%.TU%0WW20+BZKPRT)0;:B-"#6KKJ7=RPJ]ZG
MRZN;EU="GV(5QMR+6.2S:V$C"VJ4F4WF*V;N[SI[+P^E/V W(X$ QDI&$L;W
M[NT1]X:"G=H1@V;SJ-E:#.=S47>IX'\B3ZFG':A':P =SJ$6B#H.3#"&X2.'
M3R:"@[N:UQ!6I7L:#^,P2HC9KC*<:%YEO#1E$0](ORL1^"IBN^DS[,@%.D=,
MW$)/IJA9S/'BJW;;D':S6EOE?QVD7HFA##$Q$5U RQ,,8+/2[>ED$7M/V:(J
M._?L^D;9V]@$0G9[]QP4%"("N5IE"& \9&$@; S@'"8])J.0@4H#)E>O3+XZ
MDS\!-SLG$>^[@MG"==%_PY1LQ:C0<\ =)WU.5DKV:ONNRX-0=-(/#S,)*P*H
ML6$:Q@\I[I*5.T8";<=((U6 3]&_3C'\;;9^P$Q%ON%6J$C:W$W0JS<\VRD9
M;:TV.@5UKG=^FI-& J)*6P,^%+6^$OP+IF&E(SK\U@=V6!E+)I'I(?B NJ6Z
M)^^5S\KF4M4$ZL-78&-(!UU'8(7._-B+U.3,=YYDJ#%7B]F52 3*O\5EBY:Z
M!390N/P.+/A"ASYR5B%WQMM+NJ^)O[6#'HW@=](5T-:'I=;7^_N8"#-KS<.6
M6>++)-CZ!R'MAM^?)VD^F[#T9 P>5+I-JV:T]EM'IK4""K<@X>TU!7Q=2[Z1
MP'^7= *&1'XT$HK]!8%(Z$@*F,"R/\K3,+< G\SK+P)3#;DG_Z9G<BB>22)>
ME$IG_G@L0SQK?7&"H+YC6EP[SXC^)0II][Q^5;^NL]XX</V)4"=]U>@650R[
M\.M[<RH _D%G:?WX>B/N]!)U>>HX2H1A\N<#^+/F$U3E8:5KMDT+\*&B$?OH
M^TJPZT@)$<WJS>KBT\-%@%E/ *Q=Z5['8$N8>6C,F<%583F#CY?JQK_SG@#)
M4:5["G&Z-XQ0XM8#A!3KI?H$WI&DX^:M^5J64>G^)I%))5\7VD\^S._^GPS6
M\@NGH)B5KF59QM$F0];-&+IDHQBN!@HH(@/N,G$O[#B2MQC%@J(0X=[NWS*
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M!OA]0%@20^BE<RG+&.8!7O,F:=O =P%('(?V5J+?'786<E-KW03=IA)P9JZ
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M$.V6+:CV*.0Z^_*]V=JO&QIB((*+9I,/88M#M,?3LD(^1I.((_#Z6ZN^;_R
M;@K)&*DGX4G ,AAE(*$#T9-E-,T" JDIPQGLAN/TM[2,R^T2C">MG]+6;#!L
M"$Q[B+EET#SP%V1A@G4X$E!)]3-]P?X;@Z@E=_9"<+9BM-2PDWX\0=0BT0 (
M7&\LN$<E-0/MT)JMUNGB>H/$/2:"\K'V.?)@%[M/R9'W&] 9NA?C@+R4@?+'
M!4>'OE7X5B5%^PX7..I\,$ ][J#;5/!$6N"([%I[Y</J=$$[$1!PQ0 DS6)L
MRD0(H*^A0URGK!\'"?!H'1)T?F^9]</]QS 0,4(UR5/,K M843:Y8T";0>RZ
MS)_1 4=:!^A=V*X?)I2CB68Y)FW0;.G;@ >4^)DY+5//28+!88L1P$NR<7"P
MSM[8'8@KB1NLQ2-$&#W@")ND#@QM'6PM5>YR10ZJ)R+T,6TA'*(W59G=2RP9
M -X&4,RZ58 $&'  "@P".R>V2<X'0NC"0@'\C@/ATSUHI5"$=799ON<J.-!)
M69A>.N/&>60&;@SSWW+IDD?B2N!0X(-$$Z4<!4HNH:<SOXG#>NNQNL9<1=<
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M9) O0BU!@PP+MI@X!:\Q*1%-T'1E[W!+.8+T/KVT;>&DH/P O0'5MVI# JL
M\Z&,849I)/LR C5;-QGZ3F2U'%UDF]Z^@ZZ)6Y6'X4$4;J.0G1)]L*,8Y&++
M[O1-9@GS!BJM%693./+N3/9MYGTYA#M.'%IJ1OLBNA/"FV/?SWB?[6?N?6$W
M"D:E;55VP1-GXC0,?5O2$_E7$?8318!N]'<I.-OG^?R+=Q .,!+C3#PS]%2I
M?EOABU!\+^=T ,\%?*)#>#&6W/- %MP).<"@K3EJ3X^]$WT5@V GFDN[(@5E
MMI\=-NF+ GUP%CWMMLX/)T(<5+4:1EZ?JESMN@=$<B\>:X.5< 48(:Q11!:8
MU:4T91,H''LNWE_0;WU1>>N&$8>#XNDP2KB1P=8BCQDUY5#PD5HFJ1)$@K)'
M^^*S,(;-(7,]CQK+[1FBA9Q_ 7L,T*90S3U/[PTS&YHYN@^^IYW?L)HZ=TG@
MIN<(21\G+\<Y;-:/C*/VVD8=Z?2]634,8[DK#9Q&;V+E%!IK1[T$M,RXSCI+
MS?I^,V>D'PNKYJ2%"V:6+Z3 #T0A'L]#L0\>$;C%MTGHE?KWZSL$.&#!Z<YB
M?^%<C\M\TVI.GA$UR28!WKQ;2FXC3-)J'U0/VNO3?'=ZNXJB4P[8 5SINU>$
M,M"GR>04T^/B_4E!W1('\SP5-.=Z.DQ,DN P]Q=1NQOY+AI=S\%P%F.?%#^@
M(W#7*>Y!7*6773G)<SMY'_J4"3V"OI;Z@G[<2R*V&1D9<PS<(:#\*Z94A[9&
MJ:PM3I7G3?'B4_]\LGPGGU/>83O_[K3RMMZU!'/;4MGQ6+^2&ES2S\B*4[(7
M@T52OV ?D=<<X<I;O%V(AA]9!3T^S1]5"MJJ:XL4<3)\T\_S+X:!E I;;U+2
M_F4CZ( *%MF^&;N.^W_!6F0\EUHKO=?IB#+0>1_B-_#*L3F1=GVZ-B_LL ;H
M#8>BOT*2A=YIH5,3!>_0T$Y)44O0W;F\>BVQQRF>_4*@D2Y.)A@@!MQ,78G4
M=I#>ZF.&@^Y):Y64/3O 6W(,_HK4Q@>LDBUR>C>B"H1G<DDNE^"M*#<H%BM0
M*.>&#L"N[.DI*5/B34J&Y%4\;IOM%BL'BAH]2:@E/N@2J@/SI>0!YS6.Z/PV
MLW35LDBB7=UP@@"/C_L8F0#3@/J%:<U]G86;P:">G_"4]K0,S) 0=P#?8-Y)
MI9S2-'!LF-Z[SW5+3Z!G3#KM*-\-TS[H_>KN>T5&GMU?HB<GB0.88(+&+S71
M,.NN7(,/5J#T\]&L^0B:?;NTVK[*>5^FOU&S)&</!8T3Y3.920"G1Y"O20I:
MY]>])+PH<REU7I HE46DIC&E9UF0,X6M+Y (A9!3YZ0QP6#;BO+M'CJ1 9?.
M-"!/58ZXS]2-SC/-P9?;HE;[-S-*%[66#G-S<"4QL5XZDFYJG!(V*!&P$0?F
M([;.M#@=%5!N+/,?WOMW@CPB.5AORGFCD<!.)3'D .$1"WI'**HY\YI$E@E(
MVO2F^028(CFZ>C(E=;[@:63,P:-I=N&GN2(P]%_H9 0HG9X%RUPMS\!74Z"^
M@NSI- 6'^Y^BR_'A'V0]X$YZ^ZX^XJ2B)A&)-+GYQ#3K_.I869;F&:J8<)7:
M4=8)!PR%YW*NK;I)PZ?/5I*"Q?P0ODA5'U_/87LFN'O*7;?7(IE\D8Q5-YK?
M<)',&> ME1'.W@(_0_SR+BO6N\S>@_'L-3):H*67_783"T6$,A/1^2*2@&&%
M4E:3JAVBN6.(@G!2%HEZTW@DWJNH/)>H-.N&]0V+RF<O=['P&IQN4M8]<.:B
M2:X*Y*L2%)WPVXBL(/7J[#77]UI"^@B1/P*FJW_#,C^UA/1Z1ET[D'/ 5I'V
M'$36EN\2;X;Y'G&9>&='7R>F/TXC^;O*!>#YR\;Z^Z/FLUT WM#MWI78<H6;
MF2S]A4;]ZY6UONO;7S9^AS%A7'KA[85?7^/:Z8IWTOX=Z'P[#3.+BB"1C!(E
M,,>'Z<O_H*&QL 7B0]0 WIN*]9(_.%!V68PNX!P=0VRZ'4Z"=<'F<*9_W](Y
MM Y;EB/N6V9]%(US%3[5I<4SU:QZIK3&_4EE-&@)^**[P/\*\ELO0OYW219%
ME]Z<Y4ZVKG4EZ\5,U;S.0!?S*J>8MLDE6?;^K<3$HKYG):-I)'0L*T/4\EQ^
M2Z6OR]Z6"O22JR/_7D*WMDAG78R"A4:XQ;3L'4+),UU$G?[.&5;7K?I.UVKV
M4E<*=!--?T[6G>%O?>>,[\-N^&MYR]=9WK+:&U/.?[DXO?E\U7OVTM0EEX;*
M;MJG9RB%.]9.C+5M/ [I9M T&Z./'4+8K+Y%@V<,?3'B[B M0*-T3M(!T_XQ
MIFAH.B#-R%>P,>>A?.8W'W_.1IQ%KFY14+EZ#+KH)52K3E,^>G]#0+2R0'@F
MEG@&JU&^OZ>]I&2+<T[M;'-I=JKWV^4'_.79][W3#S?OP5&X.*L__$M/*[@!
M*%D+_ !J*CH"F^WV(FY%2B?\G=).::RUZ7?<;(-]R%?Y>=+9$JR/?%O5DG<X
M/-)Z-<(&^Q\(6",P2NQMG?TNI-<7:OBR;ZSZ5A0+<0:^%FEKO%%.FU>ZK!)=
MX+O+MD:8>?M!GSLR@GYVI?N+\.B- OC#F*%P*<@$-U")B*O)G"69AB*S,<1)
MH^\[$WB&\-?M_C]02P,$%     @ B8@56^!<@A'\JP  P^@# !    !D-S(W
M-#)D97@Q,#$N:'1M[+UY<]O8DB?Z/R/X'1 UMSND"-@E>:G-U8Y0V:XJS[AL
M/]O5-?TFY@^0!$640((7 "7S?OJ7ZSEYL'"1*4ONYX[;]UHD>'"6/+GG+W_^
M_<,?KY[^_/N+L^=/AX.?/[S\\.K%TQ?_^][IR?W3G[_E/^'S;^6!Z.=?WCS_
MK^B7WYZ]>?7FW7]\\]?O+S^\^"9Z_^&_7KWXCV_R;)'>FZ79^:S^Z751SI/\
MFZ?1< "_?Y8NZK1\^O/SE_^I#U]EDWKVTP_W'V>+;Z(DS\X7,$ ZK;^AU[S5
MQ^9)>9XM[M7%\J>39?TDDK]'15T7<_YH6BSJ>U7VK_2G4__W-)EG^?JG#]D\
MK:+7Z57TKI@G\*:S5R]_>_T?WY0XR6^>_OS+TQ<?9]DHJR-<<?3SM[\\_?G;
MM[CDKAF</KB1*=!;X3\O83+I>%5GQ2+ZS[2LX']__O:E?OU9)S>F _OFZ8O_
M?//JQ>L/$9S_JP^_Q]'+U\_N1SB)[B.ZD3D\NO_XY-^&@V?%XC(MZVR4I]'[
M=)$59?2ZJ.&7DU4:/3AY>/JYY_5V58YG295&9^=EFL[AT^@ST\[9ZGQ5U?^^
M&%7+)Z<_Q+ +#Q[?]"X\?;-<I@NXY?.TY#?_>S)?/HF>%?>'@Y>+\2;R.,0-
M?GI61>_299E6L.%)G5VF43&-ZEEZT^^M4B"_)(]>+K(Z@__5XR^KX2#/JCJ=
MW/0,LD7T?CQ+)RNX :?1+"W3NKCQXQY_6T2W?>0_/(Y^*8MD$KVOX:;5-_TZ
M_.=_%>5%'.F_0#J<G#RZ\>O]]%4RR>"39#&)?@/RSI&K_+1AN=_UO+1./];W
MLL4$QOCIT;_M.8D7ET6.S.SW-,GK&?!\..$X2H:#YVF>7"5E&HV+<EF4"0FJ
M([QZ__X_?GCPX.3)LV*^3!9K^NOTR7$<+<MB650P/!!J5E7 J'%I59KG^ G^
M4F]5)K=JZ6Y5))>JD^KM6]L7TD]@"E+B:E;,HW6QBG#JR;C.%N=14D5ER$1P
MQ.% A@P9C!_N'Z>/'M\_X3L FY?C!BS+;#'.EC"!9%ZL8-^ '65U%9'8BK9+
M+;N47[-R#H^-5R4L*77KP%V#$ZAIQXHE[;LPO?;BXVBUQ-U-%E$RF63X,'S_
MCP>G][]_W#/SX>#3I_Z&I]4Q^6Q*IRX'#I2)Q%7/9#GM!435+ $"F25P*I,4
M1.T<]$KZ??HQ+<<92%RS#_"QTDQ4K<:S72<_')R7R:).W<0Z)I+1>O UO'$/
MB/R*Z?WH _R@<5B\2/B\M1-$>/A+&*],IVE9\EN!",T&^N?OR];16\PP5W!N
MT0BOGU];MH"!8,. 7(/C^!,N?YFO@=:'@XXS@8-^EB=5Q>LZ@R'G<YAS51?C
M"R4MN<UPBY,RNDQRV+A_G-P_.8V6:<FO#"^_'>\9C_<>Q_/79YQ4LPA.(L'W
MC;(%<Y":-]41N.$BI]\_J:(TYS.XW[<?Q%DF2 ;5*D':0N)'R83\;P73A _@
ML4F"IPV;#NNSFM.#4]&<0J8B/_:S'Z7U59HN[!SIS/^\__Y^]$NRN(@^E#"H
MW[?7B5R^LZHJQAG]%=.IXW-IN'T?^#-]W?VH=S];YU,7YREN(FQ(/1L.B*TR
M183'_$LPS(9SC1NOZ#OG7WK..:L".A?2;Y [_L11>BASHE>OGL%&14[@Y-D\
MP\/+LV24Y5F]1@+BQ9MWP=+MR^1%X=#NC=?0FSY)JGYHL+\4A1'\_Z*P;!J.
MA$A;9%\1R+Z"#ADXYP+%64SC(7L<#AH*,2Q^5<'/92^8G\Y3_IV>0XO?Q8Z#
MX:#]C)FV&Z:6K_%P^W5#51SLH#P"7,8ZN8"KE/%MJH!-K7*@1ID:,#C<:WC3
M/U<9+.R^:E[?/G_YGV #BSMA.(CH/S\O@7&M\S0\Q73>.D3\:)F<I_=&99I<
MW!NEH!ZD/R7Y5;*NOD$#>XDO^?U=]/[E_PLT\? ;'9?<'3_]CQ_I_[Z)_GKY
M_,/O__$-*(7_YDRR9V FOWCW61P>GT:'YEHC?8SP+BVF(,LJDOV),V:1FP0Z
M6@=%P$_':;E E8KT)R>*2<]+<F><>;9-''!:Y'EQ57UVW?842.G/IV^F0,$X
MYS_2.>BQB\EJ3A/^ /^N$A(VL-@INK!J<L+\^;17^%1%CDR.V6['#N$N%JL:
M'L47ENDYWFQDC"N4T(V]B<[&I(2=_OCP(>U3 B<Q@8<M PX?-UP7M0O@D' B
MH +"$N"^@\8T7WHI.RV+.:_$D0"\!'@'\!V4C?A/Y+6+I%S#/&27YGZ72(8.
M!YV.!SO'MV:<CMVVBBWOI,P!Y]S[7MHL_)>H8:'^N>$M55J3U@\G"B2=^9-M
MT&\@UL.3N8\.J&7&,A6_VK)"5E]'H"\P!QP'/^[Z@1!4##IO#DP<SP/NIIU5
MOZ)J51_EM?*RK/+ZL;_;1_2%;)WS7WGEPY#(<-!D$Z2[9S713K("\B[A]O&&
M@=C9<8-8?+%(PVN*/WN/#,-<O.@(WC!)IZ3_CU+@&,=>R^[8PHP.=,'JHN=?
MCJ#PMR!..MF2;K;L[G 0V@'X%7"0!<R6I--\F1-)TJ]@*]T>WH_>H7Q,@:XJ
M%<!R*COM2.]>;%JX$ZL3G 0I72RE215&&WJ<KR9XN];1I!BOB ;@0['C:1W#
M0:D39V:1">GBC\Q7A9(-\:98]2G[H:$E5/?EJVJU7.:6SOB$X$"6<&([;A*.
M=\A=J(:#:98C[YO6J/ZB!4DL1GY@=RAJ;1!HZ<DRJT&:TP6@6T>:UP@X_J*H
M'?$&FABQ!B(H4,E@#55T#A>>R(3>S^,(T5V''NY?RU/U28+UK,:3699H:,M)
M!C-OW^0XX&VS9.+E$'[!&@*NR_+KHS%\C/?[,LW7L;4G[-O0]G._4:;VTVYW
M$.;I"17I F^ 2&%A$5? ,4"+)Z-YM<C&]!JKLY\!G_@8G8FSZA9.HV-/],XA
MS571Z<E/#T^BY?WY?>/D?(:&50V_B6D1'3+^%I;R@#2VMU:O?-?#PEE/.TJ.
M>=)6S2')U^F&['#D-%R371*!M*;B,INP@S(4 <PVTP2N<H>1Q;I8-$JJS.D#
MUA<)I!1'8/6B=TK=2DYP5ZC+B!ZCEBXN937ZV_!0D%!L4;8?CV4K8EU>SMH.
M,JN_BVQ1T[4R/C54&5FY=6H(39B8-AJ;7?[/YH[Z613+95&!+<^<KMMU>_K]
MDV@!=Z[;]0NZ!^JI&7!A, \3\B3_^/W]$S#&=#M;4ZH[%$9'4F]Q+*<K+O,5
M[/EX7*Y0T<W0C$LK.%+R8L+>X'YTNX]D\Y_E!=JST7.4(FVV=ZWPZ2?=H)?>
M$1SRW$V78CAHNS&[[T6TW[7H<UK?]K7PHIFIO>U>WGAEB"R:MZ3#$\PNSI#V
M IJ+KD%RI+# GBV3-6EV.#NQ(M9";^AC6/;X&%H$%UD*^V%9@T"A]]YLW*T9
M7W^@,__J^#D(&R!JZHE.L(=<*7T2=[-1(+$NKC <V-^BEM0M^XSW;^?1KV89
M##5*DY)=@Q7*!0H]*O$GY\ %SO$&[#8B.V+\=,7G>#TQQKR"A!4\WRW3>B*8
MA5@;\CIX.]"F3,B_J!F".CT1Y\>Q;LHNN]!<2',/6MQ+--U^5A\/!\)=XVA6
M7.%SL3-@DLG?P*N8,6/8CC7N.C"W86% Q\5<HD"5]6[_XS0&<:XGTW!NPP_1
M3UD5L)N3K()=HQ,6)W=RD=Z"DOJAVRTS3]9;8Y:]<H*$2,9:T-4,5ANCA<4G
MA1_CP<O7&#4@"5J4>!>1N;$;:)9A.*%&DW9M+"HK,YHR&DY>[1L0<"B=''$T
M#D+U'2:9^TR?[_'\Y8=\))Z6KW-;.T4C448AO(&4%=G83$E;=WWB= YGU-.F
M7<TDD+>)'7I''/YNF603R2? U^+9"B<CGA2.+Z3;T@59VV!?@^B%Q^0LX+U"
ME0(&A8N=9WH96N,L8 [H?"J1^<@#&%2:1=,5LM<5/)I6%9UY[SOY3TL(E3FY
MH]4BQR'8'4$+0I6"E@C; [RO7A8+5O+@<(IR0EYGYW$C);#B:SWM8V!",6=
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MG]8I/$%5_)9WG[:?8@](.Z &9&/:"R)D(ET2E/0G?EQ2B"[VH2;SL\X?T4_
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M*26,$2K3'#V8J4?UXZ,3%QI(KRIM^+LF!7<2DI7G:X]'ZG7@5<5=AWAR7@V
M327\<5:<V4DF&8'N=)K52>%N<3G@7H$%%RH^"/3&G4^9&'-_=\<,.LGZH'R
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M+.%?LQNQW0NRVJ613U&6<NI2 -BL36]M?23Z<5[8#IU':6/&6ODCPTBUJ#8
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MU8.3DP?[-*:WH)FA_DFZ*KW?XA^WW^K3&GSLL $[]R#26X"HZT4B>KC!#WU
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MS2PVK9MZS[3Q!4DU"\C8-R=C,88N$I\MP!HD)AXOE^EBE@+O*'EF_Y[,ET^
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M\:)!^+\>BZJ7:^"Q3\+ 'UC6 "K(MEUX?^\'/3IT*Z%)"HH,CH&S/.YT)W5
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M^X[NA,@DD?^E9!&4U#(YH?*OW)?'*]4O<X0WAVO<K[7XP*?WF(I3HL5Z.N.
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M\U#(&GO+KPZ]71,JBVCN#MF#?=LCT<&V &Q8N(F#T?%=4MVR91O$@\$<C^I
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M8)H*9H5I'F_2QA ".9\[]^ZQ#'0!C2>[Z&+)MB-F2C!25C#F$#-?(D-%*U#
MAI%5L1.,/I*P0LD/OHB"P@_(J_!?OG WNZ;S.6R.!L.$(^Y>9=A!"ZT<SY('
M3Q^G0+:2IGSA%+2&0T+KY?V;68[ D[?1^"+D&(*=C2PKVEA&A+E[!1J@,_V.
MS.1FCF)9$ % R5"&2-W-OW@)]<?K,QO8-K152!@QB@DC1KT(@IWE8F$4?\EX
MD5C,IY@B9@QBN[D9(GFS;WH1I;"QU9I9JG%KKYKM,FI,GMLN$-*VHT=F0"\+
MV_+W,L*N=^_:6E!BYYFUU2 @U3XQ-&;[?#>E:'XUXA72U <,AD3TP)XXUG0Z
ME\EQE@];XI,:^<D>^',X]=*I3._'_<S(38C[(!G!Q6+#.C*0XO+KA7P.=>J_
MF8>YO/<P[SW,>P_SLZ\WPCK>-G],L*!E!I;@7^D^190,EWBAYR=9H1*Q9X+9
MLV728G?C$./G&)AZ?]WN,L2>[=7;HR&IBRD]+*%DR6TG)9;J :V\@/<;OZM
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MEP6=0E<]S"W>^NA?BIXJ&*0<X\-PY?G6--&P)&'B-=*K@-^.G( N>.\&[;E
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MNA&RO#=";MF7)1VLI%:.D6Y7R9'BP !GX8#!Y/6!B27YW$'2&D#WPT:"B^O
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M:D)=]ZME )98R-J"J98/=:KR[!XDKH>B)'<6G2 D/4YANY$RH\Q6CQ&*M.:
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MT+7?Q<]M5-B<!3PC7=+[\/:D<_87?'G>_W+Y\?\#4$L#!!0    ( (F(%5M
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MS;_4'W/WL+CAI3U%BJ,AMM_+'R=F(+ TH"*>F%^^R=T\53-D=:'[@-<O[_F
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MP_&JL>/#PRW%WI5B7VT,Q7;#T21)@86N'%ENS;4[D^7KC2'+XV#<#^/8M=+
M2(N G4JR*'+69M[?6R&2W=IC=R;9-YM#LE\[K0OO;#KJA>DJ\=$M4=Z5* _V
M-X8H&X,!):\$L;&G)M,43+!LI83]PXET<Z-I&QY85CD#SU<U3KO=VOMN;4?%
M\KNMSL?&\8(P?[VFL@E:G>//C;8)]*\J96PNSUD)<G+E\O--BN!WP++)AD'?
M^.NC#(1RBO4**R.47VR%\O]6SJV$\M&JLM[MUMYW:R^4Y,4M_GK::&N1?*R2
MY[XUSQIGW<[L/#N8.O_1_=PLWTX%WEO9O97=6G8?;9+LEE01=$M>I-&X'TW
MND89OGJY^(\@PO_7$>KF).)]"2*@R#&ZTI%8SX?#"/]*O<9E..ZO4-!\2Z9W
M)]/-2<UK3"8)$"JGW^6)]S&*8^];T >ZC>#B:*P06O[M7UX?'KQZFPDEKQ#]
M;I,^[DR_FY.(=Y$FUU%&^4D!$3 H"-'XDKCL*ND"6R*],Y%N3MK=?Z%R.N90
M4'SCG8^B/ \'_W>%R//5ECSO2IZ;DSC7GL:A=W!TU  C:HB0B^08;8?_,XW2
MD*PMJG,:CZ=@:[7#29*N4B+^EG;O3KN;DT+7R8,;WVO^ OZ:*7?^UVR:WGBG
MP<]5HM(W6RJ]*Y5N4$9=,IK$$?D"CA%J<8C5(N%;#Z@W#]GV8NU5"IZVA+O6
MA+LY>74?IVE^%::@&&1Y.A5*166@O_8T"A?_2:B)=-_&0G?BFFRQ(>_T@/E_
MO]N"%3Y-N/O%JD8KMUM[WZT]U3EE\P+:WF?UU2FPF$XISFVCT6CPFHOS=OF9
M'_XN?K,X1EZ%>5-Q<U>^0QSUYC8Y;FD!=D?7>L&A[?77LTZCC.$//B?Q8*5*
M&)[OK[+^7Z2&PXV@AHLTS,+T.G 2%.,DFZ842R9BV2@*V5QVM>$"7NEN+U=5
M$&ZW]N% TXVOIV55RZD=T%K9E^9):PO^MR+:T<M-T8Z:UPH=2ORC&R7\?B,Y
M;(9ZU.CWPSADX!K"J.E'F0[^8)@R'JU4\L?SE88,+]+(\\V@$5-[NWJ9P<]7
M&O6E2!!'&T$0-L8@ UH PQ!Q\M;K3*/<ZUX!G0R3=(4(9:5Q6(J$\F(C"*4Q
MF<0*S ]HY4LRQD38XR2.8;KAP.O=J)38%:*3E<:9*-+)RXV@DXLTZ8?A(!I?
M9D@3J^>X6^F\_B)-O-I$FE@]/K'2:<A%FGB]$331#D= $2A"IJ,I@FI=,_SF
M,=P7C:= *UOZN!]]O-D(^CB)4IX7US0:!H)$\CU (&'+\T%\Y4OPWTD:Y3>K
M&3!:Z7S< @T1VM3ZTQ 8-!'7&:Y> N%ZT<-F.$R_POUI'OS 2BBNB0)QLUI!
MPX=3Q>9Z\3<\LJ2"AJ]6-3ZTW=K[;JU.L3H[;K;/6F>?YJ14U6O;G*K5X#>.
M$'RU*5'#DVF.9A>W.L@F"2Q:+XHC^I+:':R:<?YZ;12E5YL22FR'4I:#P8"D
MSQ4.OG<^B<984[YJ(-='ZQ-M?K4ID<2SQ&4?-W!'"E_UHSR(MQ3R( K9C-"B
M2!+?P9[(%%8^92:HKS[ .G:2.$+BR?4/" N$,4G=DB?UOH#)=OYS7*^M6&>(
MH_7)97BU*1%)"4&B(M.Y"E)67X[C(,MX!@V@M-$(B*F3)_T?:/!_"+W/83S0
M\#U;^KD?_6Q&I!*KC\-Q9M+)F[_P\XJJP>M%(9L1MV1,KU1C?%E%ZEB8WKR&
M-1RO$NC7T?ID4+W:E$!F,XXNE0J\DHQCK6AB,X*7;:L9.EE%H^0ZB+?D\5#R
MV)"X)&9J3W)RL/1NO,X4/F89T,GJ$<?Z)%J^VI0@I9 #L@[,:0C3RS!=.7?*
M^B16 EULAD^V"#AK)^2BZXVQ:*0I\3!-1EY^%:()/ G&*X2K_ BDL[D1IPT/
M@ZH(]^M5C65NM_;W1+BKD4U6E2HVE]\XDO+UID2X&YPWNHK5!T?K4WWP>E."
MV1=I H8W_-?\%?:G6])X%-+8C"#V!5  JLO?KQ*OD8;>28A5"5ZCER7Q- \Q
MU+BED7O3R&:$L<6">H:T,) :V9,H2\/+(!V$@Q4BCO6I4GF]*3'H=GB=F*+8
M8^ EF-#PUOLXS1&52H2,]R&9CM>=4NHV,*SW;J(VP%W_MZ75]^Q5?8WDH9Y\
M8>]CX3%5N_@0^R2*/'HA@<5N46U7#M7VX*&HMB^VJ+;KX"=0+J WJVKL;[?V
MOEM;[=01?[7W16&A-;O A+8^G]7P^;S9%)_/Q32=)!G5>GX)PQPKA==<WUH:
M06R&U^<XB&.;&E82>.)H?8J WVR*SZ>*,,3&QUR=U?,+KA6-;(;/YS^G8%D-
M);J>47C]6Y*O%";)>I'%IGA[+@FJ!FAB2PCW(X3-*!U8.6:P/C6R;S:E.. ,
MV]+% 25]MW$;&(.(M8J-(HW-M84WW".CG&T'^ZOJ9MGN[7WWMB/^M*\7%Z?-
M+\VS;N-4IURUY+>S$_C^:WO;>6!%O&T'^YOB;NM,)Y.86K02DC@^;(H5N-^C
M_"J9YBH2NI)(?$<KW;JU1#";X8Z;13 _@6"VU/)XU+(9/KKF< @30WJ803>K
M0Q\OUJ<N&^EC,_QS9XG@A,!_*X8$LF;TL!F..56)STE8NJG\3/XA8" ?I^DX
MRJ["P>I%AAZ!C#97J=YPTTZ;[0>K:J]M]_;A=5*=\]/62:/;.C]3UKEODF3:
MGYIM_76]IHS]QFG37&P>]:WY=^/LN#FO=;-J.=UL=+:(HBOB#3C8%&^ "I]_
M(4#M<9;$T2#(0ZY:1QT-@7,"1-T*T]%65[LOL6R*)T#!71PGZ23A?H6BD'6F
MO2R/\FF^2G45+]8'(06I9#,\  (URPK]=)R%L9#(I^@Z)')9/97]X72RN9)O
MP]4ZK;(?KJI2M=W;^^ZMBJ9]^?+UK-7]NZAEGW\TN 8Z\'9\WKXX;S>ZYR81
MWO>4%M\]/_Z/SVZ6O.^=RX\?/[:.K1^J='G5@KS5;A[;;UA5TMM<KN8*W\--
MT>>-GPQA4;GDM9/$87RC=;;0.^_%T>6J)<.]>#A@V>92ZX;S:2V#GZ\J(]SN
M[7WW]K^T9.TVS]!G!G\;2:QDYY=6M]O4<O+_KBH9;#G,FE*AYC!'JTI:V[U]
MN&/^&ZC?EE>^2L\_4]]UM[EUJZ)]'VV*]FWU1[E(H^LH#B]7R<NU/I# 2!*;
MX3-W2"+IAP.PS=YZG3#/.;?!^SK!*(N^:H7(97VJDY!<-L-YWAKW8;FR<&#W
M6FJCT2Z@P;V84F!46$XL_&F:AM@A-Z0..7#K6#IP4Y+FE^!'^.S[51*']=K'
MZ7@02%+-\54POL2F*:EW,DVQT5/@O)9+8S#R%PDB_D681LD*!7A>KE& YVA3
M4O@:@_^>9OE(TGX+=+I"M+$^2.=(&YN1SF=H@WHQ@1;47Z44SU?KI0)M1LFM
MM'A3B9MQ?.-=!-$*29%[445]S4'UMJAZ6U2]=4#5*S'%S:A!-W4R[; ?3+#U
M;O3_.";GXU?8#-/",<%HGE;7A]P?I-POLUZCAIDKQ%G72P?;C+9VRC8\3J[#
M<0":V K1P_J@8",];$Q+.[O9]RJVLGNU/C![0!<;TLON+,G!.D.]7(%=@[F6
MI+9[B?MQK!(#62]"V8RP!BD55T0CRBEX$0<K119KY:O>D+9VI]$H,L6\'\)Q
M"/IJ%,32>^,JFFP4@6QN-';#\P-T[L>+50WT;_?VOGO;5L61%U_;QY^M"LER
M[H=7E?H!TY8L[6XI)^VB.S>7Q-NVPEL-]N6*UQ<;D4SR7Q0+SN$!,+, 7>;G
M(&REN.[>Z9&/+%/7"%_GQ:;DD[3#R33M7P59Z 6Y=SY1#8R4"4?I)(%7#O.O
MD"ZV7G2S&8DE".\V2(.? 2&HE\G#LPB+'0.K0S"OURC+X\6F9'F<A),DB_+%
MU$(Q_BVQW)-8-B/M0X4:R'>(*$XWG'EF):V=!C]%.EFT \2U8B!@K[=E:/]K
MC4GM*'BYJD;<=F_ON[>.46\!+FL'PDGSBV/PKRH);"YW<67CRXVPXPD/A6UX
MD'N#<$0?5DC<K5&"QLM-L>$E\ K*3P5M8'%(+-G[*Z@>K1>];(;M?A'<J&Q[
MKO? 1FCAP,/F5BO)5-8HR^?EIMCK[3#+P1+G=$&RLC:2,#97_=EP!5P;5Z]6
M5;/>[NU]]U:!W[8ZF%??.&N>?S4P6!?R8_O\6PNK\[>1TA6QL%YMBH5UD2;7
M44:"[P,\"PM9J:::H&VEBSD6R0IZZ2JITVN4SOAJ4\RO\Z'DJ37ZW/FO$M=V
M2R3W))+-L+D:@T$*-!%R"V&VV#.&Q=Y2QCTI8S,,K4_)=9B.4<B<!C_?>O]G
MFD;9@ VO%:*,-4J(?K4I4= 9O6Q4H[1!Q,;Y11KV0WS36ZJSX"J_D&O\!#P[
M<]&SZ[65J]A9,P+;C$KZT_ 2U);/U*3A9I74V/5I8HW$L!D5Q&>)!S,#Z9/?
M>)@J"NI*[AW#"JY4"X8U(XW-J #F6AR&8-&(T%N:N"=-;$85<)>RL!BP"?/*
MP9CY' ;H+%D]LV:MZ&-#JH$;T_P*RPT0<0)LF\8E?-B2Q#U)8C/\JLU?H%]0
M(@*A24Q1R9@$Z2H!2KQ>HUJ"5YM2^-L)K\,T8#B)+2G<DQ0VPTWZ/8B %E"M
M^#_3],;KIE$0;TGBGB2Q&?[1CTG:#[TOP7^'JV5TK!<M;(9']#B(^]-XU5H-
MO=E?*U+8#-_EUT[#NVATVZWS+@9>UYP:ZNN-_GG]OP'\\[<MY[L/[YO__-SZ
MT.K"=#^\+^RE]>1#0Q(S*<2A"*3)M<0O??U ^-*C^\*7EA_P[K=#EJX&SVW^
MNHIZ4>XU'IIGMT)S MURI-+@'RE]L" -WGT\/^MJ]G(5Y>&S;!+TP[_&R<\T
M@(5H/#MX]R=>]'Y3I,%6&!17TR;4HW^](XVVSDY@I%_;36^ H3@OH#!,8WHY
MS7+O\,#W#O</7WB],/\9AF.O^>W\%"[W/C<;I]W/OM<Z.][SO< [">/@9Y"&
M7M^DI/GU&CPLRK(IF-P[B &,R8V'^V]! $FV(\H?G[X]>(MO'L'Z>T/"7,_"
M''.9\BOTYKE*YM[^P2ZE'WS=Z^QY'QIG_^%UVU\[7>_X_,M%X^QOWSMK<-VD
MU^ATSH];] F'R7U!@MCK!>,?U$$DRY)^Q,/% >2<N% <KLYGN-5PZ[7R>/>\
MV:?D\.@)CLEWK^5UO3.OZ77@_YOP]^>_: Q C56#(&G_Z-3U_7.SW6QT?$I+
MPQ ?D DLF":3T)M,X:\,D]4()9KIPKN"U1U,85V#:7Z5I/"V ?V.U!1(S@H^
M[FCOQ?Z_2E.//,*042<<1YP"%^(C0J#?YP>TG_6:V5"I4_OP7G9SUX=]B_*(
ML(N X +X[_(R#2]IB&DT[D<3()M@A&YE;YP0=$#XJQ_"N/YQ\/*E_^K%OK^_
MO^\37<(#DA3A)^&B"6;[#D(:/6S,B!-G^B:_9HH@ \"Z^U=T#0\<CQ+<W MI
M 230$0Y\/DX#>L8@C-&;A=\N6+IZ#2\(M7_<NON&\;FCS$1>W]+OL\GUB2D%
MAVH+3OZF;U*/\ =K57!"O%2])!V'F"$;!K"8="_/W'I<I/*=5!L8]X6W09JA
MY;%O:F09<&^J><.?NFDPSH:\^_:HJG8WF_:R/!@;PL.+X*P F5S!UD;C8 A$
MHXAH8+9F.:<81ND%F(;,2X#16&\<8C9R )0$4QH%/T(S41_H&H0&$QY0K2R"
MHE1\B$/>+EFKRX7Y8M^GH%XK<H7 #00&& @D5DZ+:=.U7D7>\FN0N?!G3U+P
M\=4Q)2PEIM^T!J_G$?MJWO93 WX2O#D-N4=:T ?V1@^%%4$N1>?>AY-Y#82
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M]KV+JYLLZF.BAYZ!7]#S!-V$60:.-,,H=%6>#YN@P4PC 6;(,2"2N>I/Y3X
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MU>HZRF;I1#.2<"2I>>Z00+>B,?F48,Z"21[J1.XT.F)2%"F5S-(]^EK0^T[
MT 2^2LGP$^QU(R:7JP\NNYP >-(1!:W0I(0_FBHYQ/<:Y;C-B94Q:#(WJ]*
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MB^'6T,MV>W,ZG/K&U:13M5G5(6#OD1ITH4X(#0+C!H&G972:284+4],Z]3K
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MGUS@%].S2P*\4C KO@\S?VS!O+;.ZQ=;Y_53JM_/.4K/R>[LJ@3:^X@<^EN
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M$2SRUS'K_O[[P7ZVOX__'W,*L*M@%9CIX.!T? O0[?(FGYFG[LN^<E+7_IA
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M).#RYLS<GN,Z#B"1&BZ\;CK%YO$2&1]XZ&3&!_X09WP ^Q#A&3P4I]4]Q94
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M;BO0TYZ52BYB_<?5&85U8#])BCM;1M8D#WY3#G$Q,(DB'%5=KA.Y,QO)VIG
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MP,2 ??O]R;8H]ZRML\IS(8O!I)CB*XSM(W5C\^1-B2E5!E>;'F4#II#C\=Z
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MTR;R1^!#8H;F@9SM)L*$M?&PK"K4=3MR-GIT,>0#4W8?RDC][J</?O>S/I?
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M;GH\?LD"/>FY<M,/:82Y) *6>TT]H-V==02!J+[[!,?'>E%BTM7Q?QN_GQX
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M($K$XM]E-?K#N=XS/C0D) ">9Z_)/XDW,R)DW%9&Y5GD]-9)HK:F#9@W8*W
M\O!:[P9N[=3\M.ENZOPF#+&QQ)_O=)SA<O$T/&#(F#&-^2G=:DN (1F8!E3D
M"$=U?(2H+8*U:D<>P4Z$2R:XO*A:G,AO1XDS*.^G)-+N8MJJE&+:'7[OZ;X)
M907U8KLUU2&S9L:/H32-/:)6/S3=AG8+W,QLD+L\M)VJT@2C-Q6ZA5N<,3EY
MR9@\>2;^/+_;OF(0+QG3>PE(/#K6=+WSJE-:]]EPAG2P &\C^D*J!KPZ8>,"
M=(:;]*!!DS3A5)[F&WC1-_RB5B?>2Y#I"/OQDV&[.P_-U73)?3_/^+WE\0L@
M)Y9K$$#(R'! .@=N !O5XX-]N_IU220>I2_\(E2(?G(PI^G=<FLII79.]R\7
M=\]0FGCH]\O;IC1ACXD*A='A&UC?YWUWQD] _)+XHG 'FI&5M##XJ%2LUPDF
MFPG^!E[DY]AZ,I2"F"]M<HFLSWP))2F8^S/6,(.9(= [TUI/)H[A.;RLET79
MW4FG40Z)?HL4@H+P\,$KU$G:;'38?^%A_^/3N]^SWKM/[]Y;9$"O*<V/3(A/
M8TV^.D;&><-LVJ)^LSH5]#1Y6'-?F#I1ZH.G XS$A;75YL=U7M]R*)$]P7GG
MU0V?/Q,=L\C$C%AL&KY7EHO4<=VWB"WK^=ED\KZOAQ9I"Q$O3KPU@8<&YC'Z
MRRMSS2PE3.'X&..H_!KROS6T)S-%?DH%PZTIW[IFFHM2"NMK]#$C/$ (NC*X
MUV5O3^4$X=]NQOP$X!I,2?# %Q3VHGF#ZT>FU#SYK"R66'KBEY>,^K0FF*YY
M=FKFZ+I9*BVM>4[^Y+I^E120@DG6KYXX:KWD%P*!Q]752!E8'#Z&#:P_-&SZ
MN\:F]TT-S1OUUFV+@Y.[6-;$=I7<)S+#^R38S Z^ 416OQ?:=-AS$")?5%A\
M05T'Y66"V^[@;L"G>0/9^Z2SR4A2KQ#SE*YFQ+.V1K[/Z;S@[$Y:7$^2IKC3
M0$ XXD:B,YF8Q8\!P0Y-!HI;J*/D-[.3JLD6)W=>O21WGKQ =T["%);>^<X[
MV!Q1:@M_T\&BL/C?WTRIS0DM$YW=UK13ETW1L3EIW .#X6M%!4]"V-5T_0)S
M[#Z;-@S/BD<(!SEZE$DY!;W5^<(#A<##=,J$/&L'4^CKP2B$<[@GO.A4LYSX
MLB\P1F7MDPBR\!BFC."@-A<&V?6Y^7;#-'Z!-]IOZ;BWY4I;E Q5:]V\T ;Q
M':NIOSSC6?1?GV'=\?O[\*(5CY_!@>SXP&W)UB_ DNA3^/@JG>$\\@8C-(=4
MZ4S;M2$Y_-Z&UAU+33>!WLY:FS]:YK+[;:>.WT*$V+UOPDG)2,;F;NGZ/0;!
MQ&O*^AH)/Z?OM6FL<%K\68^^T!^$L$S;YX$;"+KGHH=C),2DR"<S@%('CG0;
M[MLCX'%2QV)$)7_@<T!CL;WU2=(%98^,!R\GC(OP79$A7FV.1;I&$@)8#X^W
MFU=T664LL \JVALV,*%UDHIGLM8K>X]AK#DI]F#Z'9^I-"_^UNS<O.Z=4<2]
M#K%1M# @[3^S=C7]D-$0YFK\=G?@_+3KBZ^GP.QQDI:-KX+1M;P2@WZ[7MIV
M'JL<"*:N0NXF&9FU!FG3"(///I@2T_(^OZG8?VO0$E;"5:2!M/<KC6.X=EFK
M7F\!XXG1LDX51'!&KL$&+A8TN+AV,OHR#KV'H;M+H40Z1[7ULX>"9Q&*^<1#
M,IC3R<)=L@Y2\2PXLGJJ87AW1W70K(,.SJ*-06=?PKIK=&$?LY:HACZ'5D.\
M"&$_X.YNG@-6!;/KJ N3#4V[R0O3(+:9H]0IF +2@):,=D$D^$R2;RV7>8QU
MEU&<;)1F2F(F,L]/[PP=X>;18)I_!LVXE;0#K[_[7T(W4)&^8"."(M)P2?,6
M+-=+A,]-&,G"HP>2I(\R?+WTZ-E3:>V1B]W&P:KDT+SRWFG-%;&[<\]W4M@6
MMS1X2;/TKG^(6@/B]#UE7,!K]BPS_Z$?'S.<R(Z9I5,9O0X$,).0 C=_XD4P
M'PK+1"6#7&,G/%3%$>)<1).O"G110KDDZVMF#D4=$4 K<OP.D81]P.!>&%/Q
M#P$>+OPSP2R!.61V$1LYOJPJ$H!EX6X6UIL#:9UY5E(.\#9'(+NQQ5FMUR]9
MK2>'+'TF^W2Y5D$&(<1QT8*:3-?Y?9QZ\"M<R4X197W(-_0"?H6HO+I>,JTH
M1;[-MP&I*I.-=& MRZ8E\ND[29I;K(0DA312J0PUGJ/;W9V$QY(ZT"5#T58@
M?(SZ("1T+.1AG<7BM>8DX ^L#5_-@R]0E6#SP*.?VJ;^4>:V%U17DV$Z5(6?
M=$ZQ9HE2@?)5;]::Y94$A6_S<N9E&O\)S'J-D]_@[QUU]+4K-YZY3'9W/HR:
MHK[1WKO#I6QR]M\\[<;?W5FQ.CJR$BGD0*\3./ H\  O(W2VSFJ)OH_+97?G
M_NNE%R^7S6?F^1AN?>>]<FJ.6)M4<6HK;7MJS\,!]'6>+22N5,U\%-+Y26/L
M,9PXBHBN8?S=4NQ@?)^@@EXUN>QIX]^]W#*]5WIMRF"X]8=&R2SKG'D0'@,#
MT<&1J#+^]^-RT,/B99=3XQ)/]R,.2S@DW2>TR L]X-6=-,?N#NK>-M<@%<K2
MHU)KC9?2!AJF1Q[0*PY4]Z F1($%/G2+9B+$H,BQC,;?8N_D2UZ* CG-,ZVI
MR!>Q"H9A:KKWRZP:F=DCF!C*0]YZTI""L94U5UQ73;D @*'SJ'*FVZ-&18:O
M"EXZPP-CNH0\G;7>5@U9EE>EE"W>R1]_9YEE*H;;K)I^/=9]L",49FP2PW[9
M#^0+HS&Q3C".L"76Q-$I8)S,!"^1EAA H22D*$5(/[/@IVJCE1ZCE I*A-&A
M2'4FS[#M(1!LFH\1J:H4*ULZ+-U/O2"(,P 5BB,GV@Z=7@.H"^/NAU9%MO+8
MHT;KH^TP#\4X9;-3,VJ-_PL%,DS_3B:0R"L:I?]&HE \R5_*YI+;QH%@H9Q2
M":2J]3\;M_O7B!7"CE9$3RKAPGA(/GB5_Q$<;1=E RO5+''+9^H:+1Q*.*/&
M//-Q53<:H&U%H$&>8Y;/_T)V*1#2&./?2CIVM?X77^1*I@?)1:<@-5V-E_!I
M0VBX>':W-JMS^I+5>9AF5KBOS7(]="2 SDY/E_6\;"[;UEO3LN#(FAZEKO@H
MEA]/O4>R_+X'@EQNT(TK,)PL:0?[L?MF]VZ4E(HRU$Z2-<X\!)S)NA;]OD)>
MH,B,M^;&+3^ ,VI:Z5)R^$(.JKA[L1U=-_=W\WV^#\XT42.*T@\.; %W@<G"
M/EUV,"9U_F4>$>>:U=IVPY4T(,=(C*-ICIKEZ*ID$BK7\F8[N1P?<:9*J38?
M;@$*\KAT/J\S./#2BM-&#D5PDB!P4 2)[AD F&U6F>VS%S/^4!Y5BRE83>/Z
M_%[R.^/>. Z':EX$KF\W_S!\'YU.#DX1AR<M"NWG=Q(($L@]V>PP#_8H;TKK
M!><7%\")O4A[0&["$1=F\0I,2-;(7D27%KYL!K @V(;4TN$+(U#FK/0(;(;U
MZ2R8DB 1A<P#SM'SUV&BB11@(OXZQJ)^.SU,R 7CJKO*AI&P?3%QL0OO<CJB
MO)/!5Z-EW!E$3@/![*X\2PY1MCS9B9/LT1D>9#X7TOJI-,[%-J5Y55J^DV41
MF-OVI<Y#;-ZW,H_5:C'60_Y%3"=K92A;B@K0<W>?AVLC([4/':>:DFA%RC D
M0/WOIFM'$6#+)RRUE.B22DTY(2"$6H=#"?QPDGF19)B3:XLA:8>I,SWKB3\1
MG&?S"C)Y%'[1?S*QZ'0)WLV=:BW)8%Q,Q.Z.>&4X\CIFFV)T2Q%/5?WUG?EB
MC7F;*R32F7,N.Q_K_%]8J$XN]0T8QXECX0H)2A)'%R@6E+G&0:5RA%*VEX!9
M?%7&6"S-9T"DS8W"82'.Q]61W?:.$"BJF3? OU3" P">E;EP5:.DM1F,2M)F
MC=1JV@\\\>QIL2_G[BA0!)R4K7=/0>DF051<L[?/.Q.V+ZKVF75X8<_VN!XU
M6BZ\3%.8HA;B%P%7$[Q*W0L+",T2PN2RF#-$_X;%[26^R6L@QEKD5]>XK[A!
M6+:Q>6L)B!;Y5_V-"[C2G-TM?A7]I#/C3U;,X<F>>WEU736$ 3%O.Q?@%3@#
ME"B)>[.%W"N>?)GFAJT+ISC"R@\676P 1-W"W1<V_Q#*TG")1U',LV_)HI\,
M #A9ZGN0;<6MUMDWFSN8_IXW^W 4\)G&7UC_* G:=S.MFP[7AO-UB;3UN72=
M6#XG9+)KA#Y.$0+PS,,>Y@GUT^KA 9%?4>V.3+O0"]H\G*H1HPN6?Q4.[N!,
M@O5<%U,^X*R-\O-W@-P#!!_8,^FS6V.@:,7>X\T\"60RJI8**V4*KH'W'I'1
M^=>> %)Q#F[]1$2*.'L52'Y[458G^R_YN$<U6=.^"CNTOG$47APAW#.?_&E6
MK\(2CPK"MDY1&(M$N1H4,5C7^.@3PIVU(8U K+_LI;<V8.TO^L3J$#TSO+I+
M-:*5\ I=GE_ ?L(;\\_*[-BY)%XF*,VH/)B@30M5J['KS,9::!?4G3"BJS@^
M >U?1NHDBR?6'+H,0(?LC;9CKCR#M 9M.#DJU^'5J?<LZ.7C@")9>MW [%[R
M[.I3,?=C#4@JLA'GU5X8-QO\5"E>6TU+8Z/K)5>BEO/KO)S8!>)H7HI$_#\J
M3/3I380]5N*"$892Z5 \D4"QP)TY_1!<%;_#E [;[CP3P2G7>K]%15VN<Q2\
M]^B=VX+^0>_,N9W9D]VF16B=;T##8R96EB;0\9IC=(8QIEEEYOI+J!).8#>;
M>9L6Y0(29G_$K"@2\W#0_@!*C8ZQ2+<>X5>F96W^#G$/SR$OU3+MHD<= !1H
MJ1: 4MX)TA&JY.IT;E(9Y+SWL;A8@C/[L0#OA3,\JLU$)_%MZC-Y+?QFXG(T
M"KQ!W?YP2SA5#5*W)=,.F(>:D![H0Z6K1/-$GT0PBHF(12V-6#7'!D/I 33F
M)O7.;.^KZV*>RMJG,ULMF ?+M.M7A(.:F@_;::NP\0!4;HEXS,9(AX1NKK24
MB/6T.].&KQ82X0]A$Z3J4J.S6N]-X+BVIAXD'2'=ZY+JZS,*ET*DD%SY/=)U
MHK8BE;9>,RNYQ@K]WBN[!F]D0DOU2FL([GTCKP2MRE+Z]:L9[(=P)Y)Y+0:G
MR2EAICG\D_EI"8$L^U^D+#GU&SI;*C=X/M<8/ZSH^O-;Z6H:+MXB]UNP^OR*
M;)W>C21MOP1BCWGB"N6<CH*TW.I"$7>F"B]N\MJL\09<.&;'_MV,-J.0OUR"
M*<5X?-V(WQ$K Q4 6+20Z\Q^8X%J'1/*E#7PZTN;N^*I7G&4=?HH>_=$:)O=
MS9X>7QX?,NTFILF/^A*EW*/\T?;8R@%=Z['2$/%^NFT1':_<(Y,7WXL!BKPH
M0GX Y)5W&4==FVT]N[<XFS)\R:8\JL7YLY\.F:7U^,Y<=F!KPF7LW"FGVE?.
M39B<3S!BDRZ7QR'3:[-ZH[QQ^ 3">O_S7V>_V^.OPXSYY= 6>[.[L^H.]S-&
M_LU;K JU\19,D-XML1C[A])BW-75DJYZ@E^EBG@Z,^:1!1":ZJYPD:XVE94C
M)R1;,>B^+J[R<NYXI3F$A$<*<@\23\,*W0![;0RD0.[6=ZR/YAT^V+9WYJA!
MS''UAN75:.]]4DNB1&I7*9FAF]BIN][@^G[+:EIKD3P08>Q>SM[N.Q+NADD[
MMSWB;YFT*.^^>U*8WG<&<;+;Y?H<HLTO%C+7YGC%ZQL/M.[Y<MV.V:-9%G>4
M]5O[85?RHM^9>",JX8D4']H8+<,')!?298\Y/5^7+UIZOBQ?4$8/3! B+9TM
MR1U!]SH.;H!]BNB] ZY331? R<FS9([+X3'8->57:I!( 6K-4BCDF\=KB6^[
MQI(2,VPM6!*]BD3ZON)6E(!N%:&,]QGMF\Z%OKS&=&3B<AWX2;4MQ2U>(R9/
M$J.M&#4BRZF6LXF*ZI(9 $BHRIJ4O$U3H5%2-!XCR^)!><*8QH->_O#8[,3U
MB.#B85^]&OJ]/8\0SU_AW4,2*VYNX*2"]JT_*!TK'1UV7Z43A^N=(JO4]D;]
MO1N?*U"\D=5=ONG0<2W]Q -SKNV!?.*:[YPX=5:L]*2I9MYF8A[)]"MZ;0LK
MWS&+N]O-\[9Y?VL-2)0<S> #5G^C?U,.;FH;;AQ7C*2N5NU^C_>%MO#NCMK#
MO6 +FT_:1O9C@1">,4B<5F;;+6[#E- *\TT@6@0@ 22C!D/ )9$LP6*KE\9#
MK87E(NBLFYDI'R_)&%-@TIBKP4,R,1R>I22T*G82X3D,)G2A6EB6<60$MNNU
MFQS.9=VXL-K%/*%46&$$5?D>>].CT[Z/"^UJ.5N4!&D>W:*1)S90]Y*HV88?
M@IATW+N2&D)T_\US2@944HX=2%Q_=J/B8&=]6B5:N:##=&,)C]G\OGN!X@G.
M_&&MS%\X'L'5?8[,*7RNW[#109/_TRW.*QV\Y)4>NQ$"EGJ'"(\K?YLSRG'?
MAN; I18DZ%7I!I]OH;8FG4T+J;YR\.(E9R(9S_4"T KRK<;L6W (K/RJA6O1
M2KYS5+2VX&6<'P:CR+0<8]M^Y?Q#?Q?ZG<N,B[ZN4U3/SCIZ/T*S%]'-P:=]
M-/7K25JL,:JUGL$6 N)R3+KW]QDWR]IZZ2PK3E'K<TM!"KKUOS))()^.9=W%
MW#6?N3SF/=R87N#%>!23'6Z,/L5=64=0$GP$XWS:B1OT/D!H\Z5L5EW#!%AU
M?F$CQS9Y^#6&M1) Z[1%>]UIJ1,\YUYBZN%IA-#F>T<>%&5BMV?H =W'G<\3
MW0:<3[ L%;@+(A(+J,V9YYX5*@&3]IU26XCP,^8?:,/D[NG<P-TT:U=N<-R2
M6C!'K!'Z%\:@@2,60G^0#)EK@I3HDH80R<%4;3HXA^1?_53E-2J!OT5$8E5+
M:H<0B*I=VSF7%G>H-@-&/A!O752 ;LE1@D"SI! %L F-A% Y<%C3LP2)AGP1
M'R29Z #3L!!ZA-S@U1>%NG=-NW8E*^SYU^_>,NY5V&$)S!0LBKV<0?+PRA#P
M+)LVI"W66XNOUZ7TW*E%A:]CQ3EX#^)UT1BTL$NQ8=A,F])G?R$D:$?&U6QY
M->]=%CG))O.[*H]#I1-I]@HIIN<I'?&8@:\A:"G8Z9Y<@1:XO9[_C-001;%5
M^ **,SR9NB/:4[O*6F*JW!93K,8B=%E6-2$OX%6(Z=H+3C_&N)#T74$]&Z:_
M+IV)TX>3^J98$MM]%3]#-*(YIJ7]H>Q2B8PF/36[;C)*1M]A5S4+E&.FG[(=
M^#%1_K0_7F<7[28@XP5M!A75XAB8!VWX21=V%-%-BX>QNSWE;K[_6C3T:] >
M'SI>1&^!F>D*C&  ;(XI3]5X'K@ MS7>]>);<YW/9S_]>MY[<_[KKY]^/WOS
M[OTO__6W_;_AOW\_>_M6_NW%@C]]^/CV_"-^SL] GWQG LA?SW[_=/YW^8_.
MV=5+X=0\6!@30XB)3_CQ1_Z/M_(<!P?_\3<3(7]^Z_[R3_XUO:E[8ODB?:W[
MOU\N]G*QEXO]#[B8^3\?Z8./8L)4QJQ$]H:_(QRUM[8)P]QA^AFMR;6/T?*-
ME=_K&<MJ[+3YX/@H-)CR)J.J-F&>F/SA8!^RG$TU,R_S;_OX__[F9UY6/=4F
MAJSW_L._/IYYSD;//]IZ26]C]<M_WYN4S?4LO_T[NA+?05=*\% K7L L-)7S
MHC&2Q!<<JX\ZSP</F6;SG/]^"HK+^&1KS?,W]-S'^]OXW,/];7WP _.GK7SP
MP\'QX58^^/'@X'@K'_S5X/AT&Q_\8']PN)5K_.!X2S?GX<&6FL.C;1WQD_TM
M??#3;7WPX=$=GQR=:9??Z/WT"];>_^MO_P8RN]/IWQ[-Q3Y-N-C&@?[;G1UK
M+8D (P$H YW:^TX^].Z](KUWMKQ8-@L:F(-AQO^Q#X?B_=QHBAK66#3I+\HZ
M0"K1O_UX>#(X/3XZO=<--O3$1X.#@]='6_3$!Z>#HU?[Q]OTQ) */SS<HB<>
MG@Y.CT[VM^F)3P9'KT]?;],3'P[V3UX-M^F)]P<'KPZWR5:\&@P/#T^VZ(&/
M!H?'1]NTB@\&PU?#;7I@XW4,3UYMT0.;3;>_OTTC#*[M_AW/CJ=(%F^/)SL\
M=I[LR8LG^S_)DST:;I.7=7 X>/7Z>)N,D?%DCX\/MNJ)3\P)=;Q5?N'!P)B*
M@RUZXM/!J^/C;7("3@8G)Z^V:80/!Z>GA]OTP$,3\6[5>;<_>/WZ>)O2(/N#
MX?')=HWPPQS9ER2M[]J^>G%M[^W:#O>WR[5]/7C]ZFB;4I[&M;W[;M_LB?5Z
M<+)=R2)0<#LYW:8S:S@<G R'V^0IPL9[M4T;[WAP>G"\39[BX>#H^&"K#,7@
MY.!DFT9X?_!JN%5Y$>/:HGNS10_\DJ.]OR/[^L61O><3'PZ.#[8J+7#P:G!Z
M<K!-8WPP'+S>KH+1\-7@<'BZ33[+\'!P<KI=94^HW6]5RO.5B6X.MLE4'!E'
M=JMRM >#5R?[VV3:AH.#H]-MJHSLF^-N?YL,F_$+CUYOV0._Y&@?T;4]?7%M
M[_G$!X/CU\?;M'4.3HQU>KU-Z#B I1Z^VJK\X?'@X&2[8*F0\=PJ>/7KP>'^
MR3851XX'I_O#;1IA$[6_.MXJ0S%X?;I5E9']P>N#K3KN]@>'AUME)<!1?+5-
M5N(E1?L /Q9Z=E_\V'L]\7 P/#[8)F-_<#08'FU5BG9X,GAUL%5AMO$*7QUM
M57+K]6 X?+U--<3CP?#D9)OVW>'@X'2[<,J#5Z]>;YE7>#K<IA$V7N'IT78Y
M6</CTVVJBMS'*]RZ!]Y<@E8>YIOV;8>/Q!FV>HULP)M]\#,^@__ZT&<\& X.
MGSKS^M!G/!T<'3PQ9\%#'_$9;.'+([X\XLLCOCSBRR-N_A%_( XL\S_ 0 Z_
MVS[5KL,7U:['9/L'IO_B:SY>!-H1$2M^@_I*H-0R*MID$O)1=4,2*DCPO[L#
MNDQ_[U P.&EY)1T,P"L]3-"@[(ORKB;^+QOS)HLO(":[^%+YKQ^_E8C?!%(!
MP47L7W=W:,STA3*EFY!6G^A41A#-'">,T**)EIME6N=@);Z;F<_,#\Q?KZL9
MJX/*XZZMA"%*D9?FDJQO,:N^F/^*5@QJ811Y/2OE>R@J&"RD2"+(RK3EJX5L
M#D^.OYODMR)B<VON]OWF%QBN,%(3#I;8A9DK*ZS(K(5*4&VO68[^9.4F)77"
MR\:3%6EBA9>[2=30.M9"&>;F#0M:[4U8BPR_U<] $C*Q*)P"RH1TJE+"+]_C
MW&]^4EKW_0QT+6E&@*K[GO,1S?>W,B&AZ;B?-O2=1OM]M0 A,M"1M])L<)I>
M5*CG9D;#/#Z)7-$CIRS<6D(OQ==Q8=YT.-P?O#XY>K6.>GRVNW/7;18]6I<D
M]29$>J9]&(]+&&M\BZ3BC<AF7M<T]&NIBG6_*MQ-U.96JS=O0)4\?N0?WOTX
M,%O'OG>@;0<;!)6N/G?)$5G)IVE=79&F$XP?_._HUM, )8E3J^/K9)1P#AK6
M%<UP(5\O2"$[TOU&1XNTZSQ]N:9MULQ=_^$+7K(N4EXO2MA)(.Z&XF)D^,0^
M@;*@^<'>5[$V; @;<SPOP.FA?XZ53KCY<._6?GW!*NBU%<\$3:AI4?>SA R6
M.1>6UY7:=N"X-+#KUI;K1)%JDK4&/P)6XW*&LPJ7$..#;T\ZYG8RM-9UXRMR
MIC?048;RBM5R =J$>.E*E*U9'I3O8YZ$'8!;8^Q!0U(Y5VN8J$Y][!9E-M9X
M]>WD7O$5E9_EM:IE8P:LZ3L#BH]GUBP*L=&:V< VW<O[(M0J"]^LG]FR,6ZB
MF5E4L6[6&CE<!!,6-T1]V=+XO^5H28MUKB[2LK!V=^B8@!^7P3.AZPIW6+4M
M(G'Q%OOA:1([XV .2S/#>10L/4!JK&4^T[]+*8&9"[S[[9?>IX]O_NMO%Z\.
M7AT=7.R_/ACNGQZ<'+XZ.3X>_'E] 3_\_%]_^_7#+Q\H<KW[07BG=8.:E]DC
MCA(F3[X)0;9AVSQ0'2]29#NZIR";571[X.]/[05^"+C5'ZN^B".21,Z]^?C#
MIS]^BJ?_U;$Q1&">36PY^P[3*G^71-C^#_]I?O.@LA_>^[\>?(7D 3YG8Y.6
MS82?5-<%*O..C)6<0PC#5N2^ZJ]X-L$IT&8]R2+>]7&")(B]RVH+ZN4%5,IR
MJQ.61_\3$I8O1O1QC*AO0-5K*4/XC_-WO_S#G+FO_0NZC[7,QMI?81O^C!;\
M__HWXTR\>E#QY-GM<3Y=L*I]ROJAF;N_-0XSI:V(]&=?%\^V*CY\VO9S_6YA
MGPDM;<[L3@?M(R^UWAX=)B+'S4L?TF7S6]])R'9W?!^A_43O8R;X?^(J_K9L
MV^.L2;)]T0+Q%T?@/Z[R^0;)NO03QH]G7CK-7&Y2]):8P6I) 4&B0J)X\^ %
MOSELG/4/!N>E[^[<8[M"!>YNCOKJQPGVO[W%';WT 61QP$:T9V X$;JXO2[6
M2KK!B)>0GQO/S+TGYLD7F YM*N/\EG@#F+85"1<]&F:3<_HE4].7VYS0!'X)
M__%3E=<3^/1M69MO577C:JL-/L0"'N)VU6RT%,8HV?NE6LZP5CJG<J[U,U9$
M8[W+?,(%>/-3&9X-U!Y&4>J.TW7_7WMOVM3&EJ4+?U>$_D-&]1 0D:8 S_;I
M$R% MM6-@49@UWDK*FXD4@JR+)2J3 E,__IW37O,01*3X%@=-VX="RES#VNO
MO89G/0NO"UC]-*.$"RJ120(?W-"G"P1X8<<P?9V#6(\Y6 M+<1UE6801<#N,
M'15DC7_I9#$P(0X/5@-0WQA&H_4 5B"9#"5J?!G2.8@P$Y6D) @4A\>+D5[W
MZG4 ]@?L301; TZ7.6?-1C0:I=-1+R:]TK<=7UR="/X2JA0?'0%Z%?P_&&GO
M L/P,^.4:GTF.$+*99K$)4F6D]K$AT0@?7#-J6?N1_DD.([':8:1R"[,1"4N
M9[Y4@0"V-C$ GL>]*7OX)QEE-D&)W*A5B_GJ(%4QPH/>&T[[E ;$!]@_<"V>
MN!?K\+U:/V=12]:S5@-HH,0\,5<[6GJ7<.)#QES?;V_Y,5?7.]_:>/5^<_M=
M,OIX$:.4?]C<>/7V[>:[E_#)*CS[O"(++V?]OC2<L#4C)OOG-;I7(>'[" EK
M.U IV5\P"+$*37E2\0O*P"H0]1B!J%]0L/[V1,1CDB),:S$AH3L!D8LN9A$$
MH,9?^T5C@'\\D7V^ PPI.C_/XG/"!+*W&=W0[L.?XY]QUDO0:9VQ^X1=XHB&
M URZ-\^TV4BOXC+?-'ADUQ3_IHPF[:K6K$QYZ/,Y9KA?_PH9[@=;3@I)JUC%
M/ 'I,Q.0YJ^#I,%)$>0<>."C^(KJ+VX<&82#4A),P]@11>_Z#*R\OTCW?3@?
M&\$)JZ+XYX0@RQCEF@L4"-,:I9-FHQ\/80(81C;CCG^.DRQ2 </9&JPVRM2/
M592I IE;&_/%D"XI#K7_B#?5 &MYXB):A8+#S0;)A6S'690GM%RR%@2'34?#
MFV#Q^R'J3:84T=7K2@F F:.2_< 8/DO;@ZQJL^&%TN]/$G7PG>#;2XF[?^)@
M\3C-U;68Y,U&J8+@ZTW%;.5'ZI(J_&(+?H$U3&NM=4),JY0'WGB@3B87HDWJ
M-ICCZ)Q%48'V.:/=M9%N$\^F[3!F U??W'M$^U&MAH*4J1<X6^"88@*NQ\_9
M*'/0=3/J8/!1F77*)M&/&$L!,$?2ZQ%^'/<9EP..A*A(G 8L3-^O<]"#KSWW
MHSY7,# Z75F0\%AM0<+7>^9PTPC3 2_M532<ZADV&\ZX0CSD5B:H%^47E&!Q
MZR'7N*!2?<)3T@MPEM#6KJNY%?-_2TBO]?STF@6X<##Q"2SP;C1.T)&3#8Y)
ME_7,WW$49W V\'X.9;U /.()[=,X@SL\F^@"";6W\*>Z725Y^=<T0=O!'P-^
MD5^#1RI+)@G61^C,8+!08A SJ+;\4HD G:FU1"I05+8T=Z$'-&!UK*C !(;
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M]977J!-U(K=,3&X<\(B(0F U+F#PMVDI?S=.CA8X2G5=)N>#Z>I5J&QZ8"V
MEVN!ITY!:%L&90P/<!,N,*K'[^.YLU[;?K/6BJQ=D+/Y%F2GV:A:D0(:[=Y!
M;WA)D9$M89<>:31M!<[JV3'1[#424BKNL!P]_5=ONL6@ _M.-5NR^%$L7_C=
M2DG4K#^%4*.QM943S^&VFGB%XP.H;&O9"&R[07Q_[W*I7V2UP&4/=9;7]EL8
M)VIOT&[QR0LL1:EBP-X2_8HCXEH%XB.5K835;IK4M9MAM\*/P5K'6J^9;K;(
M186WK8+T)FJZL(C71 ?NFO^NWK*UCEH$:<D]FQN7KRKMW99/%7,NU7(&SKT?
M/#S3)^^IM I36VJE;2[CB-(+568%/J1^%LW&PTYCX4&?K2^C*79_7<4BQ>6H
MT.%)[MCEB])J%5GA?/W4;"RS<_6#XN-?OGJ[PL>O\(TK?/R?@\6G7$/^68#:
M[W^%4.I*D=V7(EO5>-R!4N?1--*O@H5]_IP[E<#R>=E%'J^NND+J?DT4]NX3
MD1])."L.6[M=IXFWV.3.]^'0+9>!9IXB^OXS:*EL4\]4>^$6#<V\]#/WT8+X
M,OH14Z9UOE[$9W'IV!ZD&_'<W#>[MV.^T?CR1Z&^"6[-?(,"5LMWHQ#:\Q/>
M-!LNX\W<#8/+J&V"6<PV!*7)+R3%ND06FV:#I/7>++3:T-H2^/[C0CMMP58A
MOQ;NCB;J0(8,.OJ&;<0K H"AC 14H*DTJ&&$INZIBP,6>^U(,OZ"9$BW8Z#!
M<<++:17AQ\#5(,V]5[__/WMQW,\9?KT4ND.XC6# O3F)<D:P4MQ\R9AR5.K3
M%WF5/!MM26[O22YP$X[B6E<F-D[7/RGNXKV2F3R#6.WKS>U5K'85XEC%:A\O
M5EM5Q0C:<W)1Z<]J%7,KI4GZLE;Q"; K_P6C*,\]U+82J"<F4*TG$QW1_66-
M90F&C+8WJ\S,>Z<;5BRRJCT9N0IS."P&D:WH'[6X-1NNO/U)$E)O-U<)J96U
MMF(.\M798?>YFXJ+A6KF J/-?PL':_J'YPD%J$QU!P425!V%7!'SM:I%P",7
MB#4;Y@G6& I:VQO>^B]H'1QVGY:Y>3]R:<S11822?_4@$FD]P+859DODKYG0
MZQX]+:E\IM')V<*/LDC2_ZPXFLK3C/&ZG7[3_H)'UU3L8?$T'-.'YX)"UHL[
MDD&!T#J$.?>W4K0,[,N9WMDW-9%QAX6J2!.$:E9_.+EX1/:@V:Q4<TF-R</-
MO+B$&:C %_C<&*>"VQ%.-1OS,TX])P$.*N47RR>>L@"7K$6]),_';=5LW(7<
MZE&3O(/U$F1$Z;6EL[\4^=)-J!513+.AF6("2>D*C !K<.OJS!ALDUOP$SH.
M-[=.J?,612KI3P?T@I@Y"%F 83'!%M#5BO,B@_JVE3S-QIY225)$;GN;U-P"
MWGD,T\SZPO5"4 5BE(HC(2[@[])W+C2&@X 6\YCPVJ)3K_-U*L4F%=,)VR>%
M/=Y&UBN=HM4D).[3CFW00O/6?#=,S!,B5*> RZD1%JOY>76S\_)TM%/::!J.
MW''769DQX(C3YIYVI_>P*"()#BQGU \=5(K6AY8T>,"5:VGMHB0$@2P+"0CO
MYW1D5TTES < BGF2( 2(;UY;B!0:)72P*,V&QZ<CGFB6Y(9YV*SV1O!<&6/>
M;OT*4>6%EO-NM\WY>M#F>E]DP)Z0C#&OM3JR##0RAXK%J/0\"W*(.?(BH?*:
MZRSX_;3T2<4D2S)B<)^Z^1?*O,C-1]P"#HW9G#]V] :^V!^(&?1&L_'HUL+%
MNDWCQ3<<>JOFL.=.V7B/:HHQ8K4>!FMG^/\A*P<";<F C\6 K^89Y+O<08"!
M48FVU41(,2U"@&%T'=@,G*K-FOE&-AWR+J  &-MNI'FW-(&93WII28L I4?2
M4\H57;1%&2V);\?_O8PL&'*9( OAB\4"%JG0"HYT M8PQG&V-YN-'1428*=@
MG@9W<Z8AC1NGQZJM%%4Z[BW)&3(P*@9YC^#-Q>S=?<.0:^"!=@SW9PUN-H6;
MU@(\2=?K-PY1\11))+ FFOLYCPA^A?CQ2?1SH9X$V J-N?PLU6%NVVN\7Z,>
MC6YND"WU]1N-^&"QAW5WPI@U9Z3%(57^<MWI07!%UL%WV)A811L+\-HDM^"#
M-HA?J$UD :S"E>M4D_7E9==*/QXF]#H6-@.8)E@T8:8C% 2KGD9+@3Z,6Z_!
M8X0C6$PLV=\O&LZ3Z(=V=4*1?7BKO$[8%NAFG/$@14XABD)B7WPHD"$L4=!+
M>=D2?,NDZ%O"+F"(XURCNN !&7;Z0Z>9KH 6&J-P\+<JK'C'WE;6[&V(E^0C
M-(-H;G>>JT;&V_;(3)J.9D-C-K1HXX] H'.)30G=[W@(%CQ'7@4S*[9Z BLD
MC@U1DO+9)F"O;I.B("1IN2JW=:4(EOM4I=FQ7>E8_H,O+.XQ.H?28*>3Y@8S
M^5AGOCS2GMUZTXR^MMBCBJI;K"-YE-IAX@LJW^(ST(0#.+VTU11(2,^SZ!)'
MD1*C[?2RR(NC4?FE.VN#]#_648<\UIK?==']@\([$!H^9#:^R7#6E,*AR65&
M8E;;5K:(_PWI%8<0EBU8B[Y;F:I8!R>7*@5^K 1O2?44!YO(B^?^.DRW]Q0V
MY$KV VQT0Z_D;XRU'3MJ.TY'&$:K<HQV"D<%['_] @>&=O>GS^N>(25_#P,H
M-#<RALK.#%+2)P.P0#DDC-9<-DXY4/P$M@QVC"8L#<25MA'62<4OKV+8&+>V
M&.W86-)!M'*6(9VA1$O\QJ(81]LDF_906;'Q"-8')C>NA!P_HD>)HEFF;K\"
M-9.G0TZ7H$-E@ Q< 909<&>M 3V+OO"QII/PIH/X9HJM=CHB@*CIILQLE\\X
MWK:]BK?=JP7^S_6@1<AEH1Y7%+#"D&]%;2S$@K' O8X%?@<2\EZ<;XA5/XHC
M,CIG1M734?P"])3N''.13G-X*JCEM:V_;FUB@>KD8ITK"$F_+\&+ 9]5>:C<
MXZ]0:) '-@&U].E3$(DR#Q3^=CF>H&I*AM8U=)+A0V+NJ^&]J75.Z>@!JW;S
M90RD!8<#N*SBS#1HL>ZO/)Y,Q%W0MYWG29KDEY4BH<WEWS8;_.,H. ,K<L"!
M6^484"$?J'T5^-.\SG8"X'2$"5U16MC6(PJ.XWR,Z'DTOV3\ZG%J'2S^9%W0
M2X^NF6]8\@1Q%KU&'S] "(=Q_]QT@#"3YX&@I!>=;@P7L26NBY>3$<Y<H "Z
MVM+_L>Z)D7 ZT@P S<D).NR6MWZD9(2W1X(6-SIMW//G[(M8/*8N,E8DP]]B
M[3'X%'L%D:G, RI)=2M+*9!2F^$UJD-%8^PPR-QCI3B0J7K?"#Y%R7#*_2_+
M'FSE%00UB9L5GX.*GMQ0H V, O"6)C?:(RG-93VF_AFN!W-VH&(Y6 R8B@8C
MME"C2+7MQ)BEDNKIN1YW$0]UE35F,_-IYGNFR$LQ3-E-LC_NI\(C@=P1/FDW
M5Y?[34+2^0(/-8/2EUD88 28)[W(A,E1XK21C4%"#W)LG]$\,)V<%(_#(!-S
M><[-6@+S9T'(7O_6^7TC:%F6 XR8,:4XO,[O.IK+$0X/)6+:":DPNRL$R/\@
MQDI<1+ V&Q:$E:5]#P[\3?#M>^O(^<#2$]B[+\Y59H[_;"&\6A+$(KPK]@V+
M:+"7T^$D&0]CCO*N67@?I?2'R64RB3CV@'=PL;&@%Z(=D+_DXH)8B)B[R6\8
M$P5?0>I??+\ -Z;9^ 066H0CCH;!KGC.&<851&&>6-D=%")+45)<2D@T2G)%
M+/1\PDJ;7.5:S5*POV?25.ZM60&&I5NQ< 7H3CT,(3#&@]_[IMSHHE)X>MWM
M 2@N?S!'C!P\6'DG#E%GTKN(H*>AZ%%.^%DX5-GZ:]6#JA*0791FGO=MQ3GB
M2_ L-N=I"<T="NKC#:F/+NLZ&-].''R:(I'4$7BR&P0G/K%=#&TOX_Z%H#'!
MJ*,,*]@WU+7C*C9$_E-2O1@VBJ9P1C,89)_4^G0DRE<I61TMTE>#7 L(S$'C
M,I'V7_.T3I#1T8EP<:<F\E?,"B, 8BKY)MHNPDI2XJKO/\IT3+'-0'SZ9?0S
MN9Q>6I=^RP3JNV[<N:P#Y>9+T5(HOVP.L24P0%3_>#K1"H7-*,^V"+G&Q,Q#
MIXP-UHYZRN0P^*'.M:E7-AMEG8"YN8U. :\_XWC&RU4\XT'5R5M2)ZS'42J/
MXQ[W)DW^CZ,=(7Z$AY?-,!T V16Z&VT%XG=0_< #Y7\J*.PZOS^^"Q 1[$9?
M1*K1S'+S!NMTX67>BB-<W%UPRK7H4'\]6&'-:CVB&(E S: MAOXH*M$(J8C.
MT#?(U<,-=+^VM<KC)16E B%/P9>45;F,LW-&E%O#Q1QK.KPRL%=Q19:_N6H6
M>81E#\-8*E1E>Z0-+IF#:-9G#"+5MY*9.X7$L ^G[P2:$)>3>@$+WR85\\@F
M\>Q2'^,LGMRHN/Q2-_M*E@GNR2D8TY+!U#BEVJV\'TXH#!E%TO.3[-5(3HR)
M-]6?N9(K&R&0H0T])(LDY(R3Z@]DMV/5-0%@[_+.\*XW&\9S8OX,,?KM0S"1
M%J$8]U3]:Z4/GM7=AXP91(^R*BFT;%9X\HA#EZ:PU@2=E&5#KRA[7NB"-Q43
MX5QTB3H2WFRH-2,D:51\'KV_^D'T,QS(CV0D[8?U-XQ)6K$7YI06=R-89#/8
M)+1*$6:S)GK]]BIH$R5H7E:<7[DQ-K<C<SBFTDB/NYIS6%>"Q'Y?J&-5OX0Q
M55H2E)O0;KW"6VQ^ @Z#V!-E/U6_5)U:R((HV:SBKXNKB@WDYJ @1.+1XDS7
MK4::I<L6(71?+R]N]^1V9\+"FE#% 991Y7G*C#*2@,:E.((]IH!(B=_,!R3^
MB97$)5D/<!*F8/3'$N-(=*#(@$?+RE8V-S:W$%?N J,X1.ZD?&]WK OEKB$2
M _Y^D5YCD(L^T-[3++U# 9^R;5IK"3)BH$^D.BVYT0N6;139WJ&$&Z)BS,<)
M"G%0:N9V"IJ3=(2R1R+AOBS93@3P):-IK-,JSE)K&#*GB=+LDCU+FS6)HQ2*
MZD@<7,R;E<D0R7M9<6<)LJ-8WL2@\YWUM<ZZC;A6V#A%AUU\"<=B%GE3<75H
MDLZ+PENT\](I)K6%EF:4SKP:O:Q3("6K5C>?DFZ:VSHT3O5+G$ZCAZL)49J(
MUY-L.VRM/:<.I \62UN4<OW.T(2XVG8+.1-LL^]N'2USN4H-$UA0?3D\?H"M
M4Z-5>EQ[46_]D6#"M&?:?LZY5C?M94I!6-)($N)1&^]1H]EM_10S&?H,+)M4
M."':@0P;$8YXR((HUAT8,-;^E8@6F4[&Z)68E$"A'<"?WO!"\[[K&&>)CHO+
MI8$3RZT;/B_.,NI-IN2IV V5\;=S-5(F$4WL&59+6B%90*"]TD8.?MTUE7/K
MN+H[ ?J;* \;_*B4U(1S;W3FT:"8RWC9P)!NL;0K&?#:<$PP=Q/WE0B(M63@
M]R?52 AEQA1V$&.M*>Y/CD%63+I)+U^#?'#+8Z2/W88BP)Z[@D,=C'0TE%YY
M=5I)I'J@/-GG&.)\M0IQWL5];S;$3M#VGJ&I8'1_/>=)F;WI4!G4&YQ%%="'
M:Z[$7J@SEIN-@A.LL)?J". -P<9!O5>H.5MUG8([:Z38%(IRBU2<\0*+9CXP
M6-CY71*]"3U'^&P0(8MI53)**TGB/7=WMOFQ8_?[==1A#FN?#V[\*1^>@1SR
MML <P7K4GKMQ8TQUN>8)RF/X6S^P:P7+^4-J)6P9: -<OPHOT$'E6[.<[]*S
M<W083WS13X:FJVX1#LG9*=-K-"=,([P"K6NP!6E/$=,1P W,(#95NV@]1?F-
M]%I%5V#@E7B]A&HZ/47:!D)1[8>7VCS2B[X0&[IU5(B++4O#0F0!LY=?Z!->
MXU1:(0(+2U_NX\UQ8^8U@B+ ]6%.%IV$&TA)T*]XT#(# T-#3RW"(C0!?&E5
M8F'E.=<[4;@QA;O69L$7UTJ0S&Y>C[LP+O*\A;HT+U1],+ZS(1+;X#IC$=W9
MC7RN@9E6@QN]R1.G @ M(K^D3-<O24D3B(F  6%OM/R^7@(8[HS!N(Z\R1;G
M-1$DZQXP=3O-ABYYJ<34O;T%?'<&()<PM$/.&1@=C+N6\S'3[A:%%/&<.HUO
M_'-=.-'L3Y/7@Q$<8N707FNS4:)"V(C0T??R@U<$^RC4=VFO=P,KX-/%!RH7
M'8U/,#$+'";=P/BDT#J5>J55)$-PG**.5%LR.7AEC@8YP<V&6\[+$F,#&RH$
MAR>I8U(>W%3Q=6UO,DJ,E]$\7$9Y-U1JX(%2:X:[C,[@O?5R[TZU4(LD,RC%
M>J7&T931X0C<H7Y2!%XBJS0G]@ Y8:7G$QM[C=3&$E!=VF)9>EMN!+.V4B$X
ML#BBBGVG)!$C1VY.6A'GTI0#J^1YU@,X>V>QS46>YBW,?HO9]$JB=4Y9^@*>
MP1)4>I\EB/J<>95I]IXK2YFY X8W8*-@;9JDC? &Q F6S2E_ KBW=P14P6L
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M4CCZ#VRPB@UZN!;+9[KT<X,>J+U<9I;*R<%SW#WM=H["H-/M')@P5)[ C\!
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MSX?$]$*U-JO@?,D)Q?1L5QT]'$$5Q;-4<7QBI!1XOFIH%5&HN?987)72^92
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MS%[\G$-\[U<AO@=5>%RWL1L->XJ/B?GOVLP(%]EY((U_U\TD3=1.]>#Q-.&
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MTG.TAWR1M@\H*%#Q.I#SV[]O#[Z%I0SPD\[7K^T]?#[(&&SC+M<_G'P!8S@
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M=8"UNXZ'5W-T]GSI/.82Y.,BYXI?5%Y4SH,<-_R'L#!24F6*]PA/9XZ\#*R
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M?8875T(Z0U9V ^Z(<3(!Z_;_\,%T9*@'.FXV3.-L.J'%[\>#!)\->PBK0YV
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M,]N.6]YV5>LFF6V.\O*F/_+M5;MRZ.?_4$L#!!0    ( (F(%5NEXP4N>P8
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MLH5SR@(6TB"&FZ+A%W#!PCZ<Q#%\TFE2=2F)N"-1/U>-*?MOI/^:ZM[A^3,
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MA":Q]3V._;RNEC95!KCYN-.RQJB%M:C)Q4&I0RKOOJ9II=^=%4V#IMU G8A
M?]+\9KN8<NLE^(.DCA UM\X-!UW@- @AD9DK0R;M3&4+C9:1M.T6Y[IYM@GG
MRBUI\F$&<V['UT^C$5X=@W$=W=?#OI86%7 ^S-!>W\9KJF7S&,_WSA9$S-34
M_";X.IFKQ<@R8 T_R%LAT>D3OGI;_&"H^S.^&EDDUO,'8T4AR"I!7@KI&5^+
M-@P/^6R]E'=<JBW]*U?R733[Q2-JS_]02P,$%     @ B8@56W3EE07$!
M1RP  !0   !E=F@M,C R-3 X,3A?<')E+GAM;-6:78_B-A2&[U?:_^"F-ZW4
M$,C,[,Z@85>4F:E0YTO ME5O5B8Y@%7'1K;Y^O<]#K@E$&9A=EO%7/#A^#U^
M?1['Q$ZN/RXS3N:@-).B%31J]8" 2&3*Q+@5S'1(=<)80+2A(J5<"F@%*]#!
MQP]OWUQ_%X;DYJ[[2$(R,6:JFU&T6"QJZ8@)+?G,8$A=2V06D3!T]3N#3^2W
M=7--T@,.5 .)+QHQ^7G&>-J,Z_%%_7T<UQK;(@741B,I-= DEU$<1[8B:<3-
M\W?-BTO2?B"W5!M0@@Q8!MM:.5TI-IX8\D/R(\E5-U((X!Q6Y(X)*A)&.>D[
MPS^1KDAJI,TYZ5F91I<:U!S2VB8J9^*OIGT;6N_D[1N"+TRCT'EI*[#)V.1B
M.52\)M48[=;/(B<*MC7+/='B+)<TKJZNHOQHL;YF9;6Q@4;TQ\-]/YE 1D-$
M@,B2G:;036K^46^;NXC6!UU]S9HZCW0ODSSW1W2+'*QA?X6N6FB+PD8<GC5J
M2YT&'VR3ZZPJR:$'(V(_/_6ZA39ACH7"3(!R,\F'53X&ZI>-R\C0I10R6T56
M&-W(9)9A5??9%NFM,,RLNF(D599W)R!Y9IL3!:-6 /-)Z()93]_W,,[G4^*8
MU11/#<VR*8> 1%M]FBH</\+DM>^QH"" I0&10NK"6/__9:\_K/%NQK!,"EEP
M)W'.3D-2&\MYE ++6[1?\ASE^<$?GSL2YXWV4!M%$U/, [>#1BI7R.D0>"LH
M$47?TE ;NYW:KM]Q.C[6T(ZH:&B;75LEA9!4)2X<?MT#5SP!-C6B*548+TPF
M.-<Y]4C)K#0YF]9DJ5&I4E"M &=*//$#,E5,*H2-)0&9:?0BI]8UY?88C$ I
M2._7W3[H,K>(DZB&O.8WQK,>C1WL@:*\BZ-^^2NLCL5T0%Q=7 <,.VQGWF!S
M\\D TW@LK:*FNI"*/AV;"^_8/ -ZQ>D^O<$+I%,A[8BK3VO'L,/VSAMLZ[FA
M!V-F.RK,(\V.IE:NK2ZT<K^.V7O/F.':0*JI5'EJ^YAAZ,@93O&KCDQ/1/B%
M4%4G^@7[#O"E9X#O&(?'638$=1K-;5W5T6U[=9RN/.,TH,MNBFE@([9>G[X&
MVL$@52=XT/@&YUG=,YSM-,4DZ\T'+I.A<1K*T@!5QUAJVB%L>(\P_EJ$L8\(
MXW\1^K8VW_2B@U^?U$ NQ*L ;LL]P;=MV<'S9X5>Z$I^*?:DGI6<,[O_^QJ"
M>S$\P;CGV[$\]Y/EL]2&\C_9]/3517D$3SCNN'84_=F7L?-)6P$]A5M14UU2
M19^.C3^;+_:&%G^>2''B.F]?5UU&^UX=)W\V7'Y'?P9$1V;93&R6.?I86 ?$
MU25VP+##YL\V2E]REC##Q/@!_XP5L]:.8U:FK"ZP,K>.EC^;*<\*[) #O%K*
M[X/8F]'J:30Z?EI\*4)UZ;WD>D/QW)\]E)W>=+6>@?IZEB5QO"%:XMUQ]6=C
MI0_)S%ILQ,,!,_SH2\E]776Y[7MUG/S9/1DH:A^8ZZ^RH3SZ[VY'5%U".T8=
M'G_V1]P0NUTF$RK&<,KMUG)M=6&5^W7,?-L'N<U C7'L_:+DPDQP?I]2<>(C
M0P="5)?@B[8=R/]A*^0ZVDO-/1;8)V#71^R;?9X32_X&4$L! A0#%     @
MB8@56^.7Z5GG%@  (HL   T              ( !     &0W,C<T,F0X:RYH
M=&U02P$"% ,4    " ")B!5;X%R"$?RK  ##Z , $               @ $2
M%P  9#<R-S0R9&5X,3 Q+FAT;5!+ 0(4 Q0    ( (F(%5M FJLAA6H! !F=
M"0 /              "  3S#  !D-S(W-#)D97@T,2YH=&U02P$"% ,4
M" ")B!5;#5DSGT$#  !7"P  $               @ 'N+0( 979H+3(P,C4P
M.#$X+GAS9%!+ 0(4 Q0    ( (F(%5NEXP4N>P8  +A&   4
M  "  5TQ @!E=F@M,C R-3 X,3A?;&%B+GAM;%!+ 0(4 Q0    ( (F(%5MT
MY94%Q 0  $<L   4              "  0HX @!E=F@M,C R-3 X,3A?<')E
:+GAM;%!+!08     !@ & '@!    /0(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>d72742d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="evh-20250818.xsd" xlink:type="simple"/>
    <context id="duration_2025-08-18_to_2025-08-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2025-08-18</startDate>
            <endDate>2025-08-18</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-300">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-08-18_to_2025-08-18"
      id="Hidden_dei_EntityCentralIndexKey">0001628908</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-311">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-312">2025-08-18</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-313">Evolent Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-314">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-315">001-37415</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-316">32-0454912</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-317">1812 North Moore Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-318">Suite 1705</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-319">Arlington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-320">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-321">22209</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-322">(571)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-323">389-6000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-324">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-325">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-326">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-327">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-328">Class&#160;A Common Stock of Evolent Health, Inc., par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-329">EVH</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-330">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-08-18_to_2025-08-18" id="ixv-331">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
